Dec. 31 2024 | Dec. 31 2025 | Dec. 31 2025 | ||||||||||
Translation into U.S. dollars (Note 3) | ||||||||||||
(In millions of Korean won) | (In thousands) | |||||||||||
ASSETS | ||||||||||||
Cash and due from financial institutions | ₩ | ₩ | US$ | |||||||||
Financial assets at fair value through profit or loss | ||||||||||||
Derivative financial assets | ||||||||||||
Loans measured at amortized cost | ||||||||||||
Financial investments | ||||||||||||
Investments in associates and joint ventures | ||||||||||||
Insurance contract assets | ||||||||||||
Reinsurance contract assets | ||||||||||||
Property and equipment | ||||||||||||
Investment property | ||||||||||||
Intangible assets | ||||||||||||
Net defined benefit assets | ||||||||||||
Current income tax assets | ||||||||||||
Deferred income tax assets | ||||||||||||
Assets held for sale | ||||||||||||
Assets included in disposal groups classified as held for sale | ||||||||||||
Other assets | ||||||||||||
Total assets | ₩ | ₩ | US$ | |||||||||
LIABILITIES | ||||||||||||
Financial liabilities at fair value through profit or loss | ₩ | ₩ | US$ | |||||||||
Derivative financial liabilities | ||||||||||||
Deposits | ||||||||||||
Borrowings | ||||||||||||
Debentures | ||||||||||||
Insurance contract liabilities | ||||||||||||
Reinsurance contract liabilities | ||||||||||||
Provisions | ||||||||||||
Net defined benefit liabilities | ||||||||||||
Current income tax liabilities | ||||||||||||
Deferred income tax liabilities | ||||||||||||
Liabilities included in disposal groups classified as held for sale | ||||||||||||
Other liabilities | ||||||||||||
Total liabilities | ||||||||||||
Dec. 31 2024 |
Dec. 31 2025 |
Dec. 31 2025 |
||||||||||
|
Translation into
U.S. dollars
(Note 3)
|
||||||||||||
(In millions of Korean won) |
(In thousands) |
|||||||||||
|
TOTAL EQUITY
|
||||||||||||
|
Share capital
|
||||||||||||
|
Hybrid securities
|
||||||||||||
|
Capital surplus
|
||||||||||||
|
Accumulated other comprehensive income
|
( |
) | ( |
) | ||||||||
|
Retained earnings
|
||||||||||||
|
Treasury shares
|
( |
) | ( |
) | ( |
) | ||||||
|
|
|
|
|
|
|
|||||||
|
Equity attributable to shareholders of the Parent Company
|
||||||||||||
|
Non-controlling interests |
||||||||||||
|
|
|
|
|
|
|
|||||||
|
Total equity
|
||||||||||||
|
|
|
|
|
|
|
|||||||
|
Total liabilities and equity
|
₩ | ₩ | US$ | |||||||||
|
|
|
|
|
|
|
|||||||
2023 | 2024 | 2025 | 2025 | |||||||||||||
Translation into U.S. dollars (Note 3) | ||||||||||||||||
(In millions of Korean won, except per share amounts) | (In thousands, except per share amounts) | |||||||||||||||
Interest income | ₩ | ₩ | ₩ | US$ | ||||||||||||
Interest income from financial instruments at fair value through other comprehensive income and amortized cost | ||||||||||||||||
Interest income from financial instruments at fair value through profit or loss | ||||||||||||||||
Insurance finance interest income | ||||||||||||||||
Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Insurance finance interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Net interest income | ||||||||||||||||
Fee and commission income | ||||||||||||||||
Fee and commission expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Net fee and commission income | ||||||||||||||||
Insurance income | ||||||||||||||||
Insurance income | ||||||||||||||||
Reinsurance income | ||||||||||||||||
Insurance expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Insurance service expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Reinsurance expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Net insurance income | ||||||||||||||||
Net gains (losses) on financial instruments at fair value through profit or loss | ||||||||||||||||
Other insurance finance income (expenses) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Net other operating expenses | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
General and administrative expenses | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Operating income before provision for credit losses | ||||||||||||||||
Provision for credit losses | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Net operating income | ||||||||||||||||
2023 |
2024 |
2025 |
2025 |
|||||||||||||
|
Translation into
U.S. dollars
(Note 3)
|
||||||||||||||||
|
(In millions of Korean won,
except per share amounts)
|
(In thousands,
except per share
amounts) |
|||||||||||||||
|
Share of profit (loss) of associates and joint ventures
|
( |
) | ||||||||||||||
|
Net other
non-operating income (expenses) |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Net
non-operating income (expenses) |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Profit before income tax expense
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Income tax expense
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Profit for the year
|
₩ | ₩ | ₩ | US$ | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Items that will not be reclassified to profit or loss
|
||||||||||||||||
|
Remeasurements of net defined benefit liabilities
|
₩ | ( |
) | ₩ | ( |
) | ₩ | US$ | ||||||||
|
Share of other comprehensive income (loss) of associates and joint ventures
|
( |
) | ||||||||||||||
|
Gains (losses) on equity securities at fair value through other comprehensive income
|
( |
) | ||||||||||||||
|
Fair value changes on financial liabilities designated at fair value through profit or loss due to own credit risk
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ( |
) | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Items that may be reclassified subsequently to profit or loss
|
||||||||||||||||
|
Currency translation differences
|
( |
) | ( |
) | ||||||||||||
|
Gains (losses) on debt securities at fair value through other comprehensive income
|
( |
) | ( |
) | ||||||||||||
|
Shares of other comprehensive income (loss) of associates and joint ventures
|
||||||||||||||||
|
Gains (losses) on cash flow hedging instruments
|
( |
) | ( |
) | ||||||||||||
|
Gains (losses) on hedging instruments of net investments in foreign operations
|
( |
) | ( |
) | ||||||||||||
|
Insurance finance incomes(expenses)
|
( |
) | ( |
) | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ( |
) | ( |
) | ( |
) | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
2023 |
2024 |
2025 |
2025 |
|||||||||||||
|
Translation into
U.S. dollars
(Note 3)
|
||||||||||||||||
|
(In millions of Korean won,
except per share amounts)
|
(In thousands,
except per share
amounts) |
|||||||||||||||
|
Other comprehensive income for the year, net of tax
|
( |
) | ( |
) | ( |
) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Total comprehensive income for the year
|
₩ | ₩ | ₩ | US$ | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Profit attributable to:
|
||||||||||||||||
|
Shareholders of the Parent Company
|
|
|
|
|
||||||||||||
|
Non-controlling interests |
( |
) | ( |
) | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | ₩ | ₩ | US$ | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Total comprehensive income for the year attributable to:
|
||||||||||||||||
|
Shareholders of the Parent Company
|
||||||||||||||||
|
Non-controlling interests |
( |
) | ( |
) | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | ₩ | ₩ | US$ | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Earnings per share
|
||||||||||||||||
|
Basic earnings per share
|
₩ | ₩ | ₩ | US$ | ||||||||||||
|
Diluted earnings per share
|
||||||||||||||||
Equity attributable to shareholders of the Parent Company | ||||||||||||||||||||||||||||||||||||
Share capital | Hybrid securities | Capital surplus | Accumulated other comprehensive income | Accumulated other comprehensive income relating to assets of a disposal group held for sale | Retained earnings | Treasury shares | Non-controlling interests | Total equity | ||||||||||||||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||||||||||||||
Balance as of January 1, 2023 | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | |||||||||||||||||||||||||
Comprehensive income for the year | ||||||||||||||||||||||||||||||||||||
Profit for the year | ( | ) | ||||||||||||||||||||||||||||||||||
Remeasurements of net defined benefit liabilities | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Currency translation differences | ( | ) | ||||||||||||||||||||||||||||||||||
Gains on financial instruments at fair value through other comprehensive income and transfer to retained earnings | ||||||||||||||||||||||||||||||||||||
Share of other comprehensive income of associates and joint ventures | ||||||||||||||||||||||||||||||||||||
Gains on cash flow hedging instruments | ||||||||||||||||||||||||||||||||||||
Losses on hedging instruments of net investments in foreign operations | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Insurance finance expenses | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Fair value changes of financial liabilities designated at fair value through profit or loss due to own credit risk | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Total comprehensive income for the year | ( | ) | ||||||||||||||||||||||||||||||||||
Transactions with shareholders | ||||||||||||||||||||||||||||||||||||
Annual dividends paid to shareholders of the Parent Company | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Quarterly dividends paid to shareholders of the Parent Company | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Issuance of hybrid securities | ||||||||||||||||||||||||||||||||||||
Dividends on hybrid securities | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Acquisition of treasury shares | — | — | — | — | — | — | ( | ) | — | ( | ) | |||||||||||||||||||||||||
Retirement of treasury shares | ( | ) | ||||||||||||||||||||||||||||||||||
Ownership changes in subsidiaries | — | — | ( | ) | — | — | — | — | ||||||||||||||||||||||||||||
Total transactions with shareholders | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||
Balance as of December 31, 2023 | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | |||||||||||||||||||||||||
Equity attributable to shareholders of the Parent Company | ||||||||||||||||||||||||||||||||||||
Share capital | Hybrid securities | Capital surplus | Accumulated other comprehensive income | Accumulated other comprehensive income relating to assets of a disposal group held for sale | Retained earnings | Treasury shares | Non-controlling interests | Total equity | ||||||||||||||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||||||||||||||
Balance as of January 1, 2024 | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | |||||||||||||||||||||||||
Comprehensive income for the year | ||||||||||||||||||||||||||||||||||||
Profit for the year | ( | ) | ||||||||||||||||||||||||||||||||||
Remeasurements of net defined benefit liabilities | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Currency translation differences | ||||||||||||||||||||||||||||||||||||
Gains (losses) on financial instruments at fair value through other comprehensive income and transfer to retained earnings | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Share of other comprehensive income of associates and joint ventures | ||||||||||||||||||||||||||||||||||||
Gains (losses) on cash flow hedging instruments | ( | ) | ||||||||||||||||||||||||||||||||||
Losses on hedging instruments of net investments in foreign operations | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Insurance finance expenses | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Fair value changes of financial liabilities designated at fair value through profit or loss due to own credit risk | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Total comprehensive income for the year | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Transactions with shareholders | ||||||||||||||||||||||||||||||||||||
Annual dividends paid to shareholders of the Parent Company | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Quarterly dividends paid to shareholders of the Parent Company | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Issuance of hybrid securities | ||||||||||||||||||||||||||||||||||||
Dividends on hybrid securities | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Repayment on hybrid securities | — | ( | ) | — | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||
Acquisition of treasury shares | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Disposal of treasury shares | — | — | — | — | — | — | ||||||||||||||||||||||||||||||
Retirement of treasury shares | ( | ) | ||||||||||||||||||||||||||||||||||
Ownership changes in subsidiaries | ||||||||||||||||||||||||||||||||||||
Others | — | — | ( | ) | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||
Total transactions with shareholders | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
Balance as of December 31, 2024 | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | |||||||||||||||||||||||||
Equity attributable to shareholders of the Parent Company | ||||||||||||||||||||||||||||||||||||
Share capital | Hybrid securities | Capital surplus | Accumulated other comprehensive income | Accumulated other comprehensive income relating to assets of a disposal group held for sale | Retained earnings | Treasury shares | Non-controlling interests | Total equity | ||||||||||||||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||||||||||||||
Balance as of January 1, 2025 | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | ||||||||||||||||||||||||||
Comprehensive income for the year | ||||||||||||||||||||||||||||||||||||
Profit for the year | — | |||||||||||||||||||||||||||||||||||
Remeasurements of net defined benefit liabilities | ( | ) | ||||||||||||||||||||||||||||||||||
Currency translation differences | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Gains (losses) on financial instruments at fair value through other comprehensive income and transfer to retained earnings | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Share of other comprehensive income of associates and joint ventures | ||||||||||||||||||||||||||||||||||||
Losses on cash flow hedging instruments | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Gains on hedging instruments of net investments in foreign operations | ||||||||||||||||||||||||||||||||||||
Insurance finance income | ||||||||||||||||||||||||||||||||||||
Fair value changes of financial liabilities designated at fair value through profit or loss due to own credit risk | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Total comprehensive income for the year | ( | ) | ||||||||||||||||||||||||||||||||||
Transactions with shareholders | ||||||||||||||||||||||||||||||||||||
Annual dividends paid to shareholders of the Parent Company | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Quarterly dividends paid to shareholders of the Parent Company | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Issuance of hybrid securities | ||||||||||||||||||||||||||||||||||||
Dividends on hybrid securities | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Redemption of hybrid securities | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Acquisition of treasury shares | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Retirement of treasury share | ( | ) | ||||||||||||||||||||||||||||||||||
Ownership changes in subsidiaries | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Others | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Total transactions with shareholders | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||
Balance as of December 31, 2025 | ₩ | ₩ | ₩ | ₩ | ( | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | ||||||||||||||||||||||||
Equity attributable to shareholders of the Parent Company | ||||||||||||||||||||||||||||||||||||
Share capital | Hybrid securities | Capital surplus | Accumulated other comprehensive income | Accumulated other comprehensive income relating to assets of a disposal group held for sale | Retained earnings | Treasury shares | Non-controlling interests | Total equity | ||||||||||||||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||||||||||||||
Balance as of January 1, 2025 | US$ | US$ | US$ | US$ | US$ | US$ | US$ | ( | US$ | US$ | ||||||||||||||||||||||||||
Comprehensive income for the year | ||||||||||||||||||||||||||||||||||||
Profit for the year | ||||||||||||||||||||||||||||||||||||
Remeasurements of net defined benefit liabilities | ( | ) | ||||||||||||||||||||||||||||||||||
Currency translation differences | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Gains(losses) on financial instruments at fair value through other comprehensive income and transfer to retained earnings | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Share of other comprehensive income of associates and joint ventures | ||||||||||||||||||||||||||||||||||||
Losses on cash flow hedging instruments | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Gains on hedging instruments of net investments in foreign operations | ||||||||||||||||||||||||||||||||||||
Insurance finance expenses | ||||||||||||||||||||||||||||||||||||
Fair value changes of financial liabilities designated at fair value through profit or loss due to own credit risk | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Total comprehensive income for the year | ( | ) | ||||||||||||||||||||||||||||||||||
Transactions with shareholders | ||||||||||||||||||||||||||||||||||||
Annual dividends paid to shareholders of the Parent Company | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Quarterly dividends paid to shareholders of the Parent Company | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Issuance of hybrid securities | ||||||||||||||||||||||||||||||||||||
Dividends on hybrid securities | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Redemption of hybrid securities | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Acquisition of treasury shares | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Retirement of treasury shares | ( | ) | ||||||||||||||||||||||||||||||||||
Ownership changes in subsidiaries | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Others | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Total transactions with shareholders | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||
Balance as of December 31, 2025 | US$ | US$ | US$ | US$ | ( | ) | US$ | US$ | US$ | ( | ) | US$ | US$ | |||||||||||||||||||||||
2023 | 2024 | 2025 | 2025 | |||||||||||||
Translation into U.S. dollars (Note 3) | ||||||||||||||||
(In millions of Korean won) | (In thousands) | |||||||||||||||
Cash flows from operating activities: | ||||||||||||||||
Profit for the year | ₩ | ₩ | ₩ | US$ | ||||||||||||
Adjustment for non-cash items | ||||||||||||||||
Net losses (gains) on financial assets at fair value through profit or loss | ( | ) | ( | ) | ( | ) | ||||||||||
Net losses on derivative financial instruments for hedging purposes | ||||||||||||||||
Provision for credit losses | ||||||||||||||||
Net losses (gains) on financial investments | ( | ) | ( | ) | ||||||||||||
Share of loss (profit) of associates and joint ventures | ( | ) | ( | ) | ( | ) | ||||||||||
Depreciation and amortization expense | ||||||||||||||||
Other net losses (gains) on property and equipment/intangible assets | ( | ) | ( | ) | ||||||||||||
Share-based payments | ||||||||||||||||
Post-employment benefits | ||||||||||||||||
Net interest expense | ||||||||||||||||
Losses on foreign currency translation | ||||||||||||||||
Insurance finance income | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Reinsurance finance expense | ||||||||||||||||
Other expenses | ||||||||||||||||
| ( | ) | ( | ) | ( | ) | ( | ) | |||||||||
Changes in operating assets and liabilities | ||||||||||||||||
Financial asset at fair value through profit or loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Derivative financial instruments | ( | ) | ( | ) | ||||||||||||
Loans measured at fair value through other comprehensive income | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Loans measured at amortized cost | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Current income tax assets | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Deferred income tax assets | ( | ) | ||||||||||||||
Other assets | ( | ) | ( | ) | ( | ) | ||||||||||
Financial liabilities at fair value through profit or loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Deposits | ||||||||||||||||
Current income tax liabilities | ( | ) | ||||||||||||||
Deferred income tax liabilities | ||||||||||||||||
Other liabilities | ( | ) | ||||||||||||||
Insurance contract assets | ( | ) | ( | ) | ||||||||||||
Reinsurance contract assets | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Insurance contract liabilities | ||||||||||||||||
Reinsurance contract liabilities | ( | ) | ( | ) | ||||||||||||
Investment contract liabilities | ||||||||||||||||
Net cash inflow from operating activities | ₩ | | ₩ | ₩ | US$ | |||||||||||
2023 |
2024 |
2025 |
2025 |
|||||||||||||
|
Translation into
U.S. dollars
(Note 3)
|
||||||||||||||||
(In millions of Korean won) |
(In thousands) |
|||||||||||||||
|
Cash flows from investing activities:
|
||||||||||||||||
|
Net cash flows from derivative financial instruments for hedging purposes
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | US$ | ( |
) | ||||
|
Disposal of financial asset at fair value through profit or loss
|
||||||||||||||||
|
Acquisition of financial asset at fair value through profit or loss
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Disposal of financial investments
|
||||||||||||||||
|
Acquisition of financial investments
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Disposal of investments in associates and joint ventures
|
||||||||||||||||
|
Acquisition of investments in associates and joint ventures
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Disposal of property and equipment
|
||||||||||||||||
|
Acquisition of property and equipment
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Disposal of investment property
|
||||||||||||||||
|
Acquisition of investment property
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Disposal of intangible assets
|
||||||||||||||||
|
Acquisition of intangible assets
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Net cash flows from changes in ownership of subsidiaries
|
( |
) | ( |
) | ||||||||||||
|
Others
|
( |
) | ( |
) | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Net cash outflow from investing activities
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Cash flows from financing activities:
|
||||||||||||||||
|
Net cash flows from derivative financial instruments for hedging purposes
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Net increase (decrease) in borrowings
|
( |
) | ( |
) | ||||||||||||
|
Increase in debentures
|
||||||||||||||||
|
Decrease in debentures
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Increase in other payables to trust accounts
|
||||||||||||||||
|
Dividends paid to shareholders of the Parent Company
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Issuance of hybrid securities
|
||||||||||||||||
|
Repayment on hybrid securities
|
( |
) | ( |
) | ( |
) | ||||||||||
|
Dividends paid on hybrid securities
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Acquisition of treasury shares
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Redemption of principal of lease liabilities
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Increase (decrease) in
non-controlling interests |
( |
) | ( |
) | ||||||||||||
|
Others
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Net cash inflow (outflow) from financing activities
|
( |
) | ( |
) | ||||||||||||
|
Effect of exchange rate changes on cash and cash equivalents
|
( |
) | ( |
) | ( |
) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Net increase (decrease) in cash and cash equivalents
|
( |
) | ( |
) | ||||||||||||
|
Cash and cash equivalents at the beginning of the year
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Cash and cash equivalents at the end of the year
|
₩ | ₩ | ₩ | US$ | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| • |
Amendment of International Accounting Standard (“IAS”) No. 21 “The Effects of Changes in Foreign Exchange Rates” and IFRS No.01 “First-time Adoption of International Financial Reporting Standards”—Lack of exchangeability |
• |
Amendment of IFRS No.09 “Financial Instruments” and No.07 “Financial Instruments: Disclosures” |
• |
clarify the date of recognition and derecognition of some financial assets and liabilities, with a new exception for some financial liabilities settled through an electronic cash transfer system; |
• |
clarify and add further guidance for assessing whether a financial asset meets the solely payments of principal and interest (SPPI) criterion; |
• |
add new disclosures of impact on the entity and the extent to which the entity is exposed for each type of financial instruments if the timing or amount of contractual cash flow changes due to amendment of contract term; and |
• |
update the disclosures for equity instruments designated at fair value through other comprehensive income (FVOCI). |
• |
IFRS Accounting Standards Annual Improvements Volume 11 |
• |
IFRS No.01 “First-time adoption of International Financial Reporting Standards”: Hedge accounting by a first-time adopter |
• |
IFRS No.07 “Financial Instruments: Disclosures”: Gain or loss on derecognition, Application guidance |
• |
IFRS No.09 “Financial Instruments”: Derecognition of lease liabilities, Definition of transaction price |
• |
IFRS No.10 “Consolidated Financial Statements”: Determination of a ‘de facto agent’ |
• |
IAS No.07 “Statement of Cash Flows”: Cost method |
• |
IFRS No.18 Presentation and Disclosures in Financial Statements |
(In millions of Korean won) | Before the effects of change in accounting policy | After the effects of change in accounting policy | Net increase (decrease) | |||||||||
Net Interest income | ₩ | ₩ | ₩ | |||||||||
Insurance finance interest income | ( | ) | ||||||||||
Insurance finance interest expense | ( | ) | ( | ) | ||||||||
Net insurance income | ||||||||||||
Insurance income | ||||||||||||
Insurance income | ||||||||||||
Insurance expense | ( | ) | ( | ) | ( | ) | ||||||
Insurance service expense | ( | ) | ( | ) | ( | ) | ||||||
Reinsurance expense | ( | ) | ( | ) | ( | ) | ||||||
Other insurance finance expenses | ( | ) | ( | ) | ( | ) | ||||||
Net operating income | ( | ) | ||||||||||
Net non-operating expenses | ( | ) | ( | ) | ||||||||
Profit before income tax expense | ( | ) | ||||||||||
Income tax expense | ( | ) | ( | ) | ||||||||
Profit for the period | ( | ) | ||||||||||
Other comprehensive income (loss), net of tax | ||||||||||||
Net Financial Income (Expense) of Insurance Contract Assets (Liabilities) | ( | ) | ( | ) | ||||||||
Total comprehensive income | ₩ | ₩ | ₩ | |||||||||
• | Loss ratio: The loss ratio refers to the ratio of insurance claims paid to policyholders to the premiums received by the insurance company for providing risk coverage services to policyholders. The loss ratio, which is an estimation of future premiums and claims payable, is estimated based on objective and reliable data, using the best available methods to suit the intended application. Objective and reliable data refers to the most recent measured results made using the Group’s experience statistics, insurance industry statistics, or national statistics, and others. It also means the best method that reasonably distinguishes characteristics such as the policyholder’s gender, contract type, risk characteristics by distribution channel, and others. |
• | Expense ratio: Expense ratio refers to the costs incurred by insurance companies for the sale and management of insurance contracts. Expense ratio is calculated primarily considering the ongoing costs incurred by the insurance company, taking into account the going concern, and includes the allocation of both fixed and variable indirect expenses directly related to insurance contracts. Expense ratio also considers costs such as contract acquisition expense (regardless of whether premiums are paid or not), contract maintenance expense, and claims expense, distributed in order to manage cost by product and distribution channel. |
• | Lapse ratio: The lapse ratio is an estimate of future cancelations or lapses of insurance contracts among current customers of the insurance company. It is calculated for the purpose of predicting the level of future current premium payments and cancelation refunds. The statistics used for estimation primarily rely on experience statistics of the Group, and lapse ratio is calculated based on characteristics such as product type, distribution channel, payment method, and others, which can significantly affect lapse ratio. |
Level 1: | Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Group can access at the measurement date | |
Level 2: | Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly | |
Level 3: | Unobservable inputs for the asset or liability | |
| • | Debt instruments that are held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets, and where the assets’ cash flows represent solely payments of principal and interest on the principal amount outstanding and; |
| • | Equity instruments that are not held for short-term trading but held for strategic investment, and designated as financial assets at fair value through other comprehensive income |
• | General approach: for financial assets and unused loan commitments not subject to the below 2 approaches |
• | Simplified approach: for trade receivables, contract assets, and lease receivables |
• | Credit-impaired approach: for financial assets that are credit-impaired at the time of acquisition |
• | More than 30 days past due |
• | Decline in credit rating at the end of the reporting period by certain notches or more compared to the time of initial recognition |
• | Subsequent managing ratings below certain level in the early warning system |
• | Debt restructuring (except for impaired financial assets) and |
• | 90 days or more past due |
• | Legal proceedings related to collection |
• | A borrower registered on the credit management list of Korea Federation of Banks |
• | A corporate borrower with the credit rating C and D |
• | Refinancing and |
• | Debt restructuring, etc. |
Key macroeconomic variables | Correlation between the major macroeconomic variables and the credit risk | |
Benchmark interest rate | () | |
AA- rated corporate bond (3-year) | () | |
BBB- rated corporate bond (3-year) | () | |
Composite stock index | () | |
Rate of increase in housing transaction price index (Whole Country) | () | |
Rate of increase in housing transaction price index (Metropolitan Area) | () | |
WTI crude oil price | () | |
Growth rate of private consumption | () | |
Rate of increase or decrease in facilities investments | () | |
Rate of increase or decrease in construction investments | () | |
Unemployment rate | () | |
Household loan growth rate | () | |
CD distribution yield | () |
Property and equipment | Depreciation method | Estimated useful life | ||
Buildings | ||||
Leasehold improvements | Straight-line | |||
Equipment and vehicles |
Investment properties | Depreciation method | Estimated useful life | ||
| Buildings |
Intangible assets | Amortization method | Estimated useful life | ||
| Industrial property rights | ||||
| Software | ||||
| Others |
| • | The contractual terms specify that the policyholder participates in a share of a clearly identified pool of underlying items |
| • | The Group expects to pay to the policyholder an amount equal to a substantial share of the fair value returns on the underlying items |
| • | the Group expects a substantial proportion of any change in the amounts to be paid to the policyholder to vary with the change in fair value of the underlying items |
| • | a group of contracts that are onerous at initial recognition |
| • | a group of contracts that at initial recognition have no significant possibility of becoming onerous subsequently |
| • | a group of the remaining contracts in the portfolio |
| • | the beginning of the coverage period of the group of contracts |
| • | the date when the first payment from a policyholder in the group becomes due |
| • | for a group of onerous contracts, when the group becomes onerous. |
| • | The Group has the practical ability to reassess the risks of the particular policyholder and, as a result, can set a price or level of benefits that fully reflects those risks |
| • | The Group has the practical ability to reassess the risks of the portfolio of insurance contracts that contains the contract and, as a result, can set a price or level of benefits that fully reflects the risk of that portfolio; and the pricing of the premiums up to the date when the risks are reassessed does not take into account the risks that relate to periods after the reassessment date. |
| • | The estimated expected cash flows at the beginning of reporting period and the actual cash flows received during the reporting period (including premiums received, cash flows related to insurance acquisition, and premium taxes paid) |
| • | The estimated expected cash flows at the beginning of reporting period and the actual insurance service expenses incurred during the reporting period (excluding insurance acquisition costs) |
| • | the effect of any new contracts added to the group |
| • | interest accreted on the carrying amount of the contractual service margin during the reporting period, measured at the discount rates determined at initial recognition |
| • | the changes in fulfillment cash flows relating to future service, except to the extent that: |
| (i) | such increases in the fulfillment cash flows exceed the carrying amount of the contractual service margin, giving rise to a loss |
| (ii) | such decreases in the fulfillment cash flows are allocated to the loss component of the liability for remaining coverage |
| • | the effect of any currency exchange differences on the contractual service margin |
| • | the amount recognized as insurance revenue because of the transfer of insurance contract services in the period, determined by the allocation of the contractual service margin remaining at the end of the reporting period. |
| • | the effect of any new contracts added to the group |
| • | the change in the amount of the Group’s share of the fair value of the underlying items except to the extent that |
| (i) | The amount of contractual service margin recognized in profit or loss due to the offsetting effect of risk mitigation instruments |
| (ii) | the decrease in the amount of the Group’s share of the fair value of the underlying items exceeding the carrying amount of the contractual service margin, giving rise to a loss |
| (iii) | the increase in the amount of the Group’s share of the fair value of the underlying items that causes reversal of loss component of an onerous group |
| • | the changes in fulfillment cash flows relating to future service, except to the extent that: |
| (i) | The amount of contractual service margin recognized in profit or loss due to the offsetting effect of risk mitigation instruments |
| (ii) | The increases in the fulfillment cash flows that exceeds the carrying amount of the contractual service margin, giving rise to a loss |
| (iii) | The decreases in the fulfillment cash flows that causes reversal of loss component of an onerous group |
| • | the effect of any currency exchange differences arising on the contractual service margin |
| • | the amount recognized as insurance revenue because of the transfer of insurance contract services in the period, determined by the allocation of the contractual service margin remaining at the end of the reporting period (before any allocation) over the current and remaining coverage period |
| • | changes in the effect of currency risk and the effect of financial risk not arising from underlying items, such as the impact of financial guarantees |
| • | experience adjustments arising from premiums received during the period related to future services |
| • | changes in estimated future cash flows of liability for remaining coverage |
| • | differences in the payment timing of investment components |
| • | changes in risk adjustment for non-financial risk related to future services |
| • | The amount determined in accordance with IFRS No.09 Financial Instruments and |
| • | The amount initially recognized less, when appropriate, the cumulative amount of income recognized in accordance with IFRS No.15 Revenue from Contracts with Customers. |
| • | Step 1: Identify the contract with a customer. |
| • | Step 2: Identify the performance obligations in the contract. |
| • | Step 3: Determine the transaction price. |
| • | Step 4: Allocate the transaction price to the performance obligations in the contract. |
| • | Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. |
| • | Gains or losses relating to financial instruments at fair value through profit or loss (excluding interest income using the effective interest rate method) |
| • | Gains or losses relating to derivative financial instruments for trading (including derivative financial instruments for hedging purpose but do not qualify for hedge accounting) |
| • |
Fixed payments (including
in-substance fixed payments), less any lease incentives receivable |
| • |
Variable lease payments that depend on an index or a rate
|
| • |
Amounts expected to be payable by the lessee under residual value guarantees
|
| • |
The exercise price of a purchase option if the lessee is reasonably certain to exercise that option, and
|
| • |
Payments of penalties for terminating the lease, if the lease term reflects the lessee exercising an option to terminate the lease
|
| • |
The amount of the initial measurement of the lease liability
|
| • |
Any lease payments made at or before the commencement date, less any lease incentives received
|
| • |
Any initial direct costs incurred by the lessee, and
|
| • |
An estimate of restoration costs
|
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Financial assets | ||||||||
Due from financial institutions measured at amortized cost * | ₩ | ₩ | ||||||
Financial assets at fair value through profit or loss: | ||||||||
Due from financial institutions measured at fair value through profit or loss | ||||||||
Securities measured at fair value through profit or loss | ||||||||
Loans measured at fair value through profit or loss | ||||||||
Derivatives | ||||||||
Loans measured at amortized cost * | ||||||||
Financial investments: | ||||||||
Securities measured at fair value through other comprehensive income | ||||||||
Securities measured at amortized cost * | ||||||||
Loans measured at fair value through other comprehensive income | ||||||||
Other financial assets * | ||||||||
Off-balance sheet items | ||||||||
Acceptances and guarantees contracts | ||||||||
Financial guarantee contracts | ||||||||
Commitments | ||||||||
| ₩ | | ₩ | | |||||
| * | After netting of allowance |
December 31, 2024 | ||||||||||||||||||||
12-month expected credit losses | Lifetime expected credit losses | Not applying expected credit losses | Total | |||||||||||||||||
Non-impaired | Impaired | |||||||||||||||||||
Loans measured at amortized cost * | ||||||||||||||||||||
Corporate | ||||||||||||||||||||
Grade 1 | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
Grade 2 | ||||||||||||||||||||
Grade 3 | ||||||||||||||||||||
Grade 4 | ||||||||||||||||||||
Grade 5 | ||||||||||||||||||||
Retail | ||||||||||||||||||||
Grade 1 | ||||||||||||||||||||
Grade 2 | ||||||||||||||||||||
Grade 3 | ||||||||||||||||||||
Grade 4 | ||||||||||||||||||||
Grade 5 | ||||||||||||||||||||
Credit card | ||||||||||||||||||||
Grade 1 | ||||||||||||||||||||
Grade 2 | ||||||||||||||||||||
Grade 3 | ||||||||||||||||||||
Grade 4 | ||||||||||||||||||||
Grade 5 | ||||||||||||||||||||
Loans measured at fair value through other comprehensive income | ||||||||||||||||||||
Corporate | ||||||||||||||||||||
Grade1 | ||||||||||||||||||||
Grade2 | ||||||||||||||||||||
Grade3 | ||||||||||||||||||||
Grade4 | ||||||||||||||||||||
Grade5 | ||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||
December 31, 2025 |
||||||||||||||||||||
12-month expected credit losses |
Lifetime expected credit losses |
Not applying expected credit losses |
Total |
|||||||||||||||||
Non-impaired |
Impaired |
|||||||||||||||||||
|
Loans measured at amortized cost *
|
|
|||||||||||||||||||
|
Corporate
|
||||||||||||||||||||
|
Grade 1
|
₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
|
Grade 2
|
||||||||||||||||||||
|
Grade 3
|
||||||||||||||||||||
|
Grade 4
|
||||||||||||||||||||
|
Grade 5
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Retail
|
||||||||||||||||||||
|
Grade 1
|
||||||||||||||||||||
|
Grade 2
|
||||||||||||||||||||
|
Grade 3
|
||||||||||||||||||||
|
Grade 4
|
||||||||||||||||||||
|
Grade 5
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Credit card
|
||||||||||||||||||||
|
Grade 1
|
||||||||||||||||||||
|
Grade 2
|
||||||||||||||||||||
|
Grade 3
|
||||||||||||||||||||
|
Grade 4
|
||||||||||||||||||||
|
Grade 5
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Loans measured at fair value through other comprehensive income
|
|
|||||||||||||||||||
|
Corporate
|
||||||||||||||||||||
|
Grade1
|
||||||||||||||||||||
|
Grade2
|
||||||||||||||||||||
|
Grade3
|
||||||||||||||||||||
|
Grade4
|
||||||||||||||||||||
|
Grade5
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| * |
Before netting of allowance
|
Range of probability of default (%) |
Retail |
Corporate |
||||
|
Grade 1
|
||||||
|
Grade 2
|
||||||
|
Grade 3
|
||||||
|
Grade 4
|
|
|||||
|
Grade 5
|
(In millions of Korean won) |
December 31, 2024 |
|||||||||||||||
12-month expected credit losses |
Lifetime expected credit losses |
Total |
||||||||||||||
Non-impaired |
Impaired |
|||||||||||||||
|
Guarantees
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
Deposits and savings
|
||||||||||||||||
|
Property and equipment
|
||||||||||||||||
|
Real estate
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
(In millions of Korean won) |
December 31, 2025 |
|||||||||||||||
12-month expected credit losses |
Lifetime expected credit losses |
Total |
||||||||||||||
Non-impaired |
Impaired |
|||||||||||||||
|
Guarantees
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
Deposits and savings
|
||||||||||||||||
|
Property and equipment
|
||||||||||||||||
|
Real estate
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
December 31, 2024 | ||||||||||||||||||||
12-month expected credit losses | Lifetime expected credit losses | Not applying expected credit losses | Total | |||||||||||||||||
Non-impaired | Impaired | |||||||||||||||||||
Securities measured at amortized cost * | ||||||||||||||||||||
Grade 1 | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
Grade 2 | ||||||||||||||||||||
Grade 3 | ||||||||||||||||||||
Grade 4 | ||||||||||||||||||||
Grade 5 | ||||||||||||||||||||
Securities measured at fair value through other comprehensive income | ||||||||||||||||||||
Grade 1 | ||||||||||||||||||||
Grade 2 | ||||||||||||||||||||
Grade 3 | ||||||||||||||||||||
Grade 4 | ||||||||||||||||||||
Grade 5 | ||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||
December 31, 2025 | ||||||||||||||||||||
12-month expected credit losses | Lifetime expected credit losses | Not applying expected credit losses | Total | |||||||||||||||||
Non-impaired | Impaired | |||||||||||||||||||
Securities measured at amortized cost * | ||||||||||||||||||||
Grade 1 | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
Grade 2 | ||||||||||||||||||||
Grade 3 | ||||||||||||||||||||
Grade 4 | ||||||||||||||||||||
Grade 5 | ||||||||||||||||||||
Securities measured at fair value through other comprehensive income | ||||||||||||||||||||
Grade 1 | ||||||||||||||||||||
Grade 2 | ||||||||||||||||||||
Grade 3 | ||||||||||||||||||||
Grade 4 | ||||||||||||||||||||
Grade 5 | ||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||
| * | Before netting of allowance |
Domestic | Foreign | |||||||||||||||||||||||||||
Credit quality | KIS | NICE P&I | KAP | FnPricing Inc. | S&P | Fitch-IBCA | Moody’s | |||||||||||||||||||||
Grade 1 | t o | t o | t o | t o | t | |||||||||||||||||||||||
Grade 2 | t | |||||||||||||||||||||||||||
Grade 3 | t | t o | t o | t o | ||||||||||||||||||||||||
Grade 4 | t o | t o | ||||||||||||||||||||||||||
Grade 5 | ||||||||||||||||||||||||||||
December 31, 2024 | ||||||||||||||||||||
12-month expected credit losses | Lifetime expected credit losses | Not applying expected credit losses | Total | |||||||||||||||||
Non-impaired | Impaired | |||||||||||||||||||
Due from financial institutions measured at amortized cost * | ||||||||||||||||||||
Grade 1 | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
Grade 2 | ||||||||||||||||||||
Grade 3 | ||||||||||||||||||||
Grade 4 | ||||||||||||||||||||
Grade 5 | ||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||
December 31, 2025 | ||||||||||||||||||||
12-month expected credit losses | Lifetime expected credit losses | Not applying expected credit losses | Total | |||||||||||||||||
Non-impaired | Impaired | |||||||||||||||||||
Due from financial institutions measured at amortized cost * | ||||||||||||||||||||
Grade 1 | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
Grade 2 | ||||||||||||||||||||
Grade 3 | ||||||||||||||||||||
Grade 4 | ||||||||||||||||||||
Grade 5 | ||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||
| * | Before netting of allowance |
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Deposits, savings, securities, and others | ₩ | ₩ | ||||||
(In millions of Korean won) | ||||||||||||||||||||||||||
December 31, 2024* | ||||||||||||||||||||||||||
Retail | Corporate | Credit card | Total | % | Allowances | Carrying amount | ||||||||||||||||||||
Korea | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | ||||||||||||||||||
Europe | ( | ) | ||||||||||||||||||||||||
China | ( | ) | ||||||||||||||||||||||||
Japan | ( | ) | ||||||||||||||||||||||||
United States | ( | ) | ||||||||||||||||||||||||
Cambodia | ( | ) | ||||||||||||||||||||||||
Indonesia | ( | ) | ||||||||||||||||||||||||
Others | ( | ) | ||||||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | |||||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||||
December 31, 2025* | ||||||||||||||||||||||||||
Retail | Corporate | Credit card | Total | % | Allowances | Carrying amount | ||||||||||||||||||||
Korea | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | ||||||||||||||||||
Europe | ( | ) | ||||||||||||||||||||||||
China | ( | ) | ||||||||||||||||||||||||
Japan | ( | ) | ||||||||||||||||||||||||
United States | ( | ) | ||||||||||||||||||||||||
Cambodia | ( | ) | ||||||||||||||||||||||||
Indonesia | ( | ) | ||||||||||||||||||||||||
Others | ( | ) | ||||||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | |||||||||||||||||||
| * | Amount includes loans measured at fair value through profit or loss, other comprehensive income, and amortized cost. |
December 31, 2024 | ||||||||||||||||
Loans | % | Allowances | Carrying amount | |||||||||||||
Financial institutions | ₩ | ₩ | ( | ) | ₩ | |||||||||||
Manufacturing | ( | ) | ||||||||||||||
Service | ( | ) | ||||||||||||||
Wholesale and retail | ( | ) | ||||||||||||||
Construction | ( | ) | ||||||||||||||
Public sector | ( | ) | ||||||||||||||
Others | ( | ) | ||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ||||||||||||
December 31, 2025 | ||||||||||||||||
Loans | % | Allowances | Carrying amount | |||||||||||||
Financial institutions | ₩ | ₩ | ( | ) | ₩ | |||||||||||
Manufacturing | ( | ) | ||||||||||||||
Service | ( | ) | ||||||||||||||
Wholesale and retail | ( | ) | ||||||||||||||
Construction | ( | ) | ||||||||||||||
Public sector | ( | ) | ||||||||||||||
Others | ( | ) | ||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ||||||||||||
December 31, 2024 | ||||||||||||||||
Loans | % | Allowances | Carrying amount | |||||||||||||
Housing loan | ₩ | ₩ | ( | ) | ₩ | |||||||||||
General loan | ( | ) | ||||||||||||||
Credit card | ( | ) | ||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ||||||||||||
December 31, 2025 | ||||||||||||||||
Loans | % | Allowances | Carrying amount | |||||||||||||
Housing loan | ₩ | ₩ | ( | ) | ₩ | |||||||||||
General loan | ( | ) | ||||||||||||||
Credit card | ( | ) | ||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ||||||||||||
December 31, 2024 | ||||||||||||||||
Amount | % | Allowances | Carrying amount | |||||||||||||
Due from financial institutions measured at amortized cost | ||||||||||||||||
Finance and insurance | ₩ | ₩ | ( | ) | ₩ | |||||||||||
| ( | ) | |||||||||||||||
Due from financial institutions measured at fair value through profit or loss | ||||||||||||||||
Finance and insurance | ||||||||||||||||
Securities measured at fair value through profit or loss | ||||||||||||||||
Government and government funded institutions | ||||||||||||||||
Finance and insurance | ||||||||||||||||
Others | ||||||||||||||||
Derivative financial assets | ||||||||||||||||
Government and government funded institutions | ||||||||||||||||
Finance and insurance | ||||||||||||||||
Others | ||||||||||||||||
Securities measured at fair value through other comprehensive income | ||||||||||||||||
Government and government funded institutions | ||||||||||||||||
Finance and insurance | ||||||||||||||||
Others | ||||||||||||||||
Securities measured at amortized cost | ||||||||||||||||
Government and government funded institutions | ( | ) | ||||||||||||||
Finance and insurance | ( | ) | ||||||||||||||
Others | ( | ) | ||||||||||||||
| ( | ) | |||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ||||||||||||
December 31, 2025 | ||||||||||||||||
Amount | % | Allowances | Carrying amount | |||||||||||||
Due from financial institutions measured at amortized cost | ||||||||||||||||
Government and government funded institutions | ₩ | ₩ | ₩ | |||||||||||||
Finance and insurance | ( | ) | ||||||||||||||
| ( | ) | |||||||||||||||
Due from financial institutions measured at fair value through profit or loss | ||||||||||||||||
Finance and insurance | ||||||||||||||||
Securities measured at fair value through profit or loss | ||||||||||||||||
Government and government funded institutions | ||||||||||||||||
Finance and insurance | ||||||||||||||||
Others | ||||||||||||||||
Derivative financial assets | ||||||||||||||||
Government and government funded institutions | ||||||||||||||||
Finance and insurance | ||||||||||||||||
Others | ||||||||||||||||
Securities measured at fair value through other comprehensive income | ||||||||||||||||
Government and government funded institutions | ||||||||||||||||
Finance and insurance | ||||||||||||||||
Others | ||||||||||||||||
Securities measured at amortized cost | ||||||||||||||||
Government and government funded institutions | ( | ) | ||||||||||||||
Finance and insurance | ( | ) | ||||||||||||||
Others | ( | ) | ||||||||||||||
| ( | ) | |||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ||||||||||||
December 31, 2024 | ||||||||||||||||
Amount | % | Allowances | Carrying amount | |||||||||||||
Due from financial institutions measured at amortized cost | ||||||||||||||||
Korea | ₩ | ₩ | ( | ) | ₩ | |||||||||||
United States | ( | ) | ||||||||||||||
Others | ( | ) | ||||||||||||||
| ( | ) | |||||||||||||||
Due from financial institutions measured at fair value through profit or loss | ||||||||||||||||
Korea | ||||||||||||||||
Securities measured at fair value through profit or loss | ||||||||||||||||
Korea | ||||||||||||||||
United States | ||||||||||||||||
Others | ||||||||||||||||
Derivative financial assets | ||||||||||||||||
Korea | ||||||||||||||||
United States | ||||||||||||||||
France | ||||||||||||||||
Singapore | ||||||||||||||||
Japan | ||||||||||||||||
Others | ||||||||||||||||
Securities measured at fair value through other comprehensive income | ||||||||||||||||
Korea | ||||||||||||||||
United States | ||||||||||||||||
Others | ||||||||||||||||
Securities measured at amortized cost | ||||||||||||||||
Korea | ( | ) | ||||||||||||||
United States | ( | ) | ||||||||||||||
Others | ( | ) | ||||||||||||||
| ( | ) | |||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ||||||||||||
December 31, 2025 | ||||||||||||||||
Amount | % | Allowances | Carrying amount | |||||||||||||
Due from financial institutions measured at amortized cost | ||||||||||||||||
Korea | ₩ | ₩ | ( | ) | ₩ | |||||||||||
United States | ||||||||||||||||
Others | ( | ) | ||||||||||||||
| ( | ) | |||||||||||||||
Due from financial institutions measured at fair value through profit or loss | ||||||||||||||||
Korea | ||||||||||||||||
Others | ||||||||||||||||
Securities measured at fair value through profit or loss | ||||||||||||||||
Korea | ||||||||||||||||
United States | ||||||||||||||||
Others | ||||||||||||||||
Derivative financial assets | ||||||||||||||||
Korea | ||||||||||||||||
United States | ||||||||||||||||
France | ||||||||||||||||
Singapore | ||||||||||||||||
Japan | ||||||||||||||||
Others | ||||||||||||||||
Securities measured at fair value through other comprehensive income | ||||||||||||||||
Korea | ||||||||||||||||
United States | ||||||||||||||||
Others | ||||||||||||||||
Securities measured at amortized cost | ||||||||||||||||
Korea | ( | ) | ||||||||||||||
United States | ( | ) | ||||||||||||||
Others | ( | ) | ||||||||||||||
| ( | ) | |||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ||||||||||||
December 31, 2024 | ||||||||||||||||||||||||||||
On demand | Up to 1 month | 1-3 months | 3-12 months | 1-5 years | Over 5 years | Total | ||||||||||||||||||||||
Financial liabilities | ||||||||||||||||||||||||||||
Financial liabilities at fair value through profit or loss 1 | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
Financial liabilities designated at fair value through profit or loss 1 | ||||||||||||||||||||||||||||
Derivatives held for trading 1 | ||||||||||||||||||||||||||||
Derivatives held for hedging 2 | ( | ) | ||||||||||||||||||||||||||
Deposits 3 | ||||||||||||||||||||||||||||
Borrowings | ||||||||||||||||||||||||||||
Debentures | ||||||||||||||||||||||||||||
Lease liabilities | ||||||||||||||||||||||||||||
Other financial liabilities | ||||||||||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||
Off-balance sheet items | ||||||||||||||||||||||||||||
Commitments 4 | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
Acceptances and guarantees contracts 5 | ||||||||||||||||||||||||||||
Financial guarantee contracts 5 | ||||||||||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||
December 31, 2025 | ||||||||||||||||||||||||||||
On demand | Up to 1 month | 1-3 months | 3-12 months | 1-5 years | Over 5 years | Total | ||||||||||||||||||||||
Financial liabilities | ||||||||||||||||||||||||||||
Financial liabilities at fair value through profit or loss 1 | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
Financial liabilities designated at fair value through profit or loss 1 | ||||||||||||||||||||||||||||
Derivatives held for trading 1 | ||||||||||||||||||||||||||||
Derivatives held for hedging 2 | ( | ) | ||||||||||||||||||||||||||
Deposits 3 | ||||||||||||||||||||||||||||
Borrowings | ||||||||||||||||||||||||||||
Debentures | ||||||||||||||||||||||||||||
Lease liabilities | ||||||||||||||||||||||||||||
Other financial liabilities | ||||||||||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||
Off-balance sheet items | ||||||||||||||||||||||||||||
Commitments 4 | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
Acceptances and guarantees contracts 5 | ||||||||||||||||||||||||||||
Financial guarantee contracts 5 | ||||||||||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||
1 | Financial liabilities measured or designated at fair value through profit or loss and derivatives held for trading are not managed by contractual maturity because they are expected to be traded or redeemed before maturity. Therefore, the carrying amounts of those financial instruments are included in the ‘On demand’ category. |
2 | Cash flows of derivatives held for hedging are shown at net amount of cash inflows and outflows by remaining contractual maturity. |
3 | Deposits that are contractually repayable on demand or on short notice are included in the ‘On demand’ category. |
4 | Unused lines of credit within commitments are included in the ‘On demand’ category because payments can be requested at any time. |
5 | Cash flows under acceptances and financial guarantee contracts are classified based on the earliest period that the contract can be executed. |
(In millions of Korean won) | December 31, 2024 | |||||||||||||||||||||||
Up to 1 month | 1-3 months | 3-12 months | 1-5 years | Over 5 years | Total | |||||||||||||||||||
Cash flow to be received (paid) of net-settled derivatives | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||
Cash flow to be received of gross-settled derivatives | ||||||||||||||||||||||||
Cash flow to be paid of gross-settled derivatives | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||||||||||||||
Up to 1 month | 1-3 months | 3-12 months | 1-5 years | Over 5 years | Total | |||||||||||||||||||
Cash flow to be received (paid) of net-settled derivatives | ₩ | ( | ) | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||
Cash flow to be received of gross-settled derivatives | ||||||||||||||||||||||||
Cash flow to be paid of gross-settled derivatives | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||
| • | The target position has no restrictions on the sale, and the daily fair value assessment should be made, and the embedded significant risk can be hedged in the market. |
| • | The trading position classification criteria should be clearly defined in the Trading Policy and Guidelines, and the trading position should be managed by a separate trading department. |
| • | The target position must be operated according to the documented trading strategy and the management of position limit must be carried out. |
| • | The specialized dealer or operating department shall have the authority to execute the transaction without prior approval from the Risk Management Department, etc. within the predetermined limits of the target position. |
| • | The target positions should be periodically reported to management for risk management of the Group. |
| Sensitivities-based risk | Interest rate risk group | GIRR | The risk associated with risk-free interest rates (typically OIS rates) defined by currency and maturity. | |||
| CSR | The risk associated with the issuer’s interest rate credit spread, defined by creditworthiness and sector. | |||||
| Equity risk group | The risk factors associated with equity, defined by market capitalization, economic conditions, and sector | |||||
| Foreign exchange risk group | The risk factors associated with exchange rate, defined by currency pairs | |||||
| Commodity risk group | The risk factors associated with commodities, defined by commodity types. | |||||
| Default risk | Issuer default risk in securities (bonds, etc.) and derivatives. | |||||
| Residual risk | Additional risks imposed on non-standard underlying asset products, etc. | |||||
(In millions of Korean won) | 2024 | |||||||||||||||
Sensitivities-based risk | Default risk | Residual risk | Dec. 31, 2024 | |||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||
Sensitivities-based risk | Default risk | Residual risk | Dec. 31, 2025 | |||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | 2024 | |||||||||||||||
Sensitivities-based risk | Default risk | Residual risk | Dec. 31, 2024 | |||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||
Sensitivities-based risk | Default risk | Residual risk | Dec. 31, 2025 | |||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | 2024 | |||||||||||||||
Sensitivities-based risk | Default risk | Residual risk | Dec. 31, 2024 | |||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||
Sensitivities-based risk | Default risk | Residual risk | Dec. 31, 2025 | |||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | 2024 | |||||||||||||||
Sensitivities-based risk | Default risk | Residual risk | Dec. 31, 2024 | |||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||
Sensitivities-based risk | Default risk | Residual risk | Dec. 31, 2025 | |||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | 2024 | |||||||||||||||
Sensitivities-based risk | Default risk | Residual risk | Dec. 31, 2024 | |||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||
Sensitivities-based risk | Default risk | Residual risk | Dec. 31, 2025 | |||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | 2024 | |||||||||||||||
Sensitivities-based risk | Default risk | Residual risk | Dec. 31, 2024 | |||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||
Sensitivities-based risk | Default risk | Residual risk | Dec. 31, 2025 | |||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | 2024 | |||||||||||||||
Sensitivities-based risk | Default risk | Residual risk | Dec. 31, 2024 | |||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||
Sensitivities-based risk | Default risk | Residual risk | Dec. 31, 2025 | |||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
| • | Scenario 1 : Parallel shock up |
| • | Scenario 2 : Parallel shock down |
| • | Scenario 3 : Steepener shock (short rates down and long rates up) |
| • | Scenario 4 : Flattener shock (short rates up and long rates down) |
| • | Scenario 5 : Short rates shock up |
| • | Scenario 6 : Short rates shock down |
Time bucket intervals (D:Day M:Months Y:Years t cf :Repricing date) | ||||||||||||||||
Short-term rates | (0.0028Y) | cf ≤1M (0.0417Y) | cf ≤3M (0.1667Y) | cf ≤6M (0.375Y) | cf ≤9M (0.625Y) | cf ≤1Y (0.875Y) | cf ≤1.5Y (1.25Y) | cf ≤2Y (1.75Y) | ||||||||
Medium-term rates | cf ≤3Y (2.5Y) | cf ≤4Y (3.5Y) | cf ≤5Y (4.5Y) | cf ≤6Y (5.5Y) | cf ≤7Y (6.5Y) | |||||||||||
Long-term rates | cf ≤8Y (7.5Y) | cf ≤9Y (8.5Y) | cf ≤10Y (9.5Y) | cf ≤15Y (12.5Y) | cf ≤20Y (17.5Y) | cf >20Y (25Y) | ||||||||||
| * | The number in brackets is the time bucket’s midpoint. |
Cap on proportion of core deposits (%) | Cap on average maturity of core deposits (years) | |||||||
Retail/transactional | ||||||||
Retail/non-transactional | ||||||||
Wholesale | ||||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||||||||||
Changes in the economic value of equity capital Δ EVE | Changes in net interest income Δ NII | Changes in the economic value of equity capital Δ EVE | Changes in net interest income Δ NII | |||||||||||||
Scenario 1 (Parallel shock up) | ₩ | | ₩ | | ₩ | | ₩ | |||||||||
Scenario 2 (Parallel shock down) | ||||||||||||||||
Scenario 3 (Short rates down, long rates up) | ||||||||||||||||
Scenario 4 (Short rates up, long rates down) | ||||||||||||||||
Scenario 5 (Short rates shock up) | ||||||||||||||||
Scenario 6 (Short rates shock down) | ||||||||||||||||
Maximum out of six scenarios | ||||||||||||||||
Basic capital | ||||||||||||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||||||||||
| Δ EVE | Δ NII | Δ EVE | Δ NII | |||||||||||||
KB Securities Co., Ltd. | ₩ | ₩ | ₩ | ₩ | ||||||||||||
KB Kookmin Card Co., Ltd. | ||||||||||||||||
KB Capital Co., Ltd. | ||||||||||||||||
KB Savings Bank Co., Ltd. | ||||||||||||||||
(In millions of Korean won) | December 31, 2024 | |||||||||||||||||||||||||||
USD | JPY | EUR | GBP | CNY | Others | Total | ||||||||||||||||||||||
Financial assets | ||||||||||||||||||||||||||||
Cash and due from financial institutions | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
Financial assets at fair value through profit or loss | ||||||||||||||||||||||||||||
Derivatives held for trading | ||||||||||||||||||||||||||||
Derivatives held for hedging | ||||||||||||||||||||||||||||
Loans measured at amortized cost | ||||||||||||||||||||||||||||
Financial assets at fair value through other comprehensive income | ||||||||||||||||||||||||||||
Financial assets at amortized cost | ||||||||||||||||||||||||||||
Other financial assets | ||||||||||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||
Financial liabilities | ||||||||||||||||||||||||||||
Financial liabilities at fair value through profit or loss | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
Derivatives held for trading | ||||||||||||||||||||||||||||
Derivatives held for hedging | ||||||||||||||||||||||||||||
Deposits | ||||||||||||||||||||||||||||
Borrowings | ||||||||||||||||||||||||||||
Debentures | ||||||||||||||||||||||||||||
Other financial liabilities | ||||||||||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||||||||||||||||||
USD | JPY | EUR | GBP | CNY | Others | Total | ||||||||||||||||||||||
Financial assets | ||||||||||||||||||||||||||||
Cash and due from financial institutions | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
Financial assets at fair value through profit or loss | ||||||||||||||||||||||||||||
Derivatives held for trading | ||||||||||||||||||||||||||||
Derivatives held for hedging | ||||||||||||||||||||||||||||
Loans measured at amortized cost | ||||||||||||||||||||||||||||
Financial assets at fair value through other comprehensive income | ||||||||||||||||||||||||||||
Financial assets at amortized cost | ||||||||||||||||||||||||||||
Other financial assets | ||||||||||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||
Financial liabilities | ||||||||||||||||||||||||||||
Financial liabilities at fair value through profit or loss | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
Derivatives held for trading | ||||||||||||||||||||||||||||
Derivatives held for hedging | ||||||||||||||||||||||||||||
Deposits | ||||||||||||||||||||||||||||
Borrowings | ||||||||||||||||||||||||||||
Debentures | ||||||||||||||||||||||||||||
Other financial liabilities | ||||||||||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||
| • | Common Equity Tier 1 Capital: Common equity Tier 1 Capital is the first to take losses of the Group and is the last to be compensated in liquidation of the Group and not repaid except for liquidation. It includes capital, capital surplus, retained earnings, non-controlling interests of the consolidated subsidiaries, accumulated other comprehensive income, and other capital surplus, etc. |
| • | Additional Tier 1 Capital: Additional Tier 1 Capital includes capital, capital surplus, etc. related to the issuance of capital securities of a permanent nature that meets the conditional capital securities requirements. |
| • | Tier 2 Capital: Tier 2 Capital means capital that can compensate for losses of the Group upon liquidation, including (a) the amount of subordinated bonds with maturity of not less than 5 years that meet the conditional capital securities requirements, and (b) the allowances for credit losses accumulated on the loans which are classified as normal or precautionary in accordance with Regulations on Supervision of Financial Holding Companies, and others. |
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Total Capital: | ₩ | ₩ | ||||||
Tier 1 Capital | ||||||||
Common Equity Tier 1 Capital | ||||||||
Additional Tier 1 Capital | ||||||||
Tier 2 Capital | ||||||||
Risk-Weighted Assets: | ||||||||
Total Capital ratio (%): | ||||||||
Tier 1 Capital ratio (%) | ||||||||
Common Equity Tier 1 Capital ratio (%) | ||||||||
Banking business | Corporate banking | Loans, deposit products, and other related financial services to large, small and medium-sized enterprises and SOHOs | ||
Retail banking | Loans, deposit products, and other related financial services to individuals and households | |||
Other banking services | Trading activities in securities and derivatives, funding, and other supporting activities | |||
Securities business | Investment banking, brokerage services, and other supporting activities | |||
Non-life insurance business | Non-life insurance and other supporting activities | |||
Credit card business | Credit sale, cash advance, card loan, and other supporting activities | |||
Life insurance business | Life insurance and other supporting activities | |||
(In millions of Korean won) | ||||||||||||||||||||||||||||||||||||||||||||
2024 | ||||||||||||||||||||||||||||||||||||||||||||
Banking business | ||||||||||||||||||||||||||||||||||||||||||||
Corporate banking | Retail banking | Other banking services | Sub-total | Securities | Non-life insurance | Credit card | Life insurance | Others | Consolidation adjustments | Total | ||||||||||||||||||||||||||||||||||
Net operating revenues (expenses) from external customers | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||||||||||||
Intersegment net operating revenues (expenses) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | ||||||||||||||||||||||||||||||||
Net interest income (expenses) | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | ( | ) | ₩ | ₩ | ( | ) | ₩ | |||||||||||||||||||||||||||
Interest income | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||
Net fee and commission income (expenses) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
Fee and commission income | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
Fee and commission expense | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||
Net Insurance income (expenses) | ||||||||||||||||||||||||||||||||||||||||||||
Insurance income | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
Insurance expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
Net gains on financial instruments at fair value through profit or loss | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
Net other insurance finance expense | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||
Net other operating income (expenses) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
General and administrative expenses | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ( | ) | |||||||||||||
Operating income (expenses) before provision for credit losses | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
Reversal (provision) of credit losses | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||
Net operating income (expenses) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
Share of profit (loss) of associates and joint ventures | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
Net other non-operating income (expenses) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Segment profit (loss) before income tax expense | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
Income tax benefit (expense) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
Profit (loss) for the year | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | |||||||||||||||||||||||||||||
Profit (loss) attributable to shareholders of the Parent Company | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | |||||||||||||||||||||||||||||
Profit (loss) attributable to non-controlling interests | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||
Total assets* | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
Total liabilities* | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||||||||||||||||||||||
2025 | ||||||||||||||||||||||||||||||||||||||||||||
Banking business | Securities | Non-life insurance | Credit card | Life insurance | Others | Consolidation adjustments | Total | |||||||||||||||||||||||||||||||||||||
Corporate banking | Retail banking | Other banking services | Sub-total | |||||||||||||||||||||||||||||||||||||||||
Net operating revenues (expenses) from external customers | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||||||||||||
Intersegment net operating revenues (expenses) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | ||||||||||||||||||||||||||||||||
Net interest income (expenses) | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | ( | ) | ₩ | ₩ | ( | ) | ₩ | |||||||||||||||||||||||||||
Interest income | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||
Net fee and commission income (expenses) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
Fee and commission income | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
Fee and commission expense | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||
Net insurance income (expenses) | ||||||||||||||||||||||||||||||||||||||||||||
Insurance income | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
Insurance expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
Net gains (losses) on financial instruments at fair value through profit or loss | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
Net other insurance finance expense | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||
Net other operating income (expenses) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
General and administrative expenses | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ( | ) | |||||||||||||
Operating income (expenses) before provision for credit losses | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
Reversal (provision) of credit losses | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||
Net operating income (expenses) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
Share of profit (loss) of associates and joint ventures | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||
Net other non-operating income (expenses) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Segment profit (loss) before income tax expense | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
Income tax benefit (expense) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||
Profit (loss) for the year | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | |||||||||||||||||||||||||||||||
Profit (loss) attributable to shareholders of the Parent Company | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | |||||||||||||||||||||||||||||||
Profit (loss) attributable to non-controlling interests | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||
Total assets* | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
Total liabilities* | ( | ) | ||||||||||||||||||||||||||||||||||||||||||
| * | Assets and liabilities of the reporting segments are amounts before intersegment transactions. |
(In millions of Korean won) | 2023 | 2024 | 2025 | |||||||||
Banking service | ₩ | ₩ | ₩ | |||||||||
Securities service | ||||||||||||
Non-life insurance service | ||||||||||||
Credit card service | ||||||||||||
Life insurance service | ||||||||||||
Others | ||||||||||||
| ₩ | ₩ | ₩ | ||||||||||
(In millions of Korean won) | Net operating revenues from external customers | Major non-current assets | ||||||||||||||||||
2023 | 2024 | 2025 | December 31, 2024 | December 31, 2025 | ||||||||||||||||
Domestic | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
United States | ||||||||||||||||||||
New Zealand | ||||||||||||||||||||
China | ||||||||||||||||||||
Cambodia | ||||||||||||||||||||
United Kingdom | ||||||||||||||||||||
Indonesia | ||||||||||||||||||||
Others | ||||||||||||||||||||
Consolidation | ||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||
(In millions of Korean won) | December 31, 2024 | |||||||
Carrying amount | Fair value | |||||||
Financial assets | ||||||||
Cash and due from financial institutions | ₩ | ₩ | ||||||
Financial assets at fair value through profit or loss: | ||||||||
Due from financial institutions | ||||||||
Debt securities | ||||||||
Equity securities | ||||||||
Loans | ||||||||
Others | ||||||||
Derivatives held for trading | ||||||||
Derivatives held for hedging | ||||||||
Loans measured at amortized cost | ||||||||
Securities measured at amortized cost | ||||||||
Financial assets at fair value through other comprehensive income: | ||||||||
Debt securities | ||||||||
Equity securities | ||||||||
Loans | ||||||||
Other financial assets | ||||||||
| ₩ | ₩ | |||||||
Financial liabilities | ||||||||
Financial liabilities at fair value through profit or loss | ₩ | ₩ | ||||||
Financial liabilities designated at fair value through profit or loss | ||||||||
Derivatives held for trading | ||||||||
Derivatives held for hedging | ||||||||
Deposits | ||||||||
Borrowings | ||||||||
Debentures | ||||||||
Other financial liabilities | ||||||||
| ₩ | ₩ | |||||||
(In millions of Korean won) | December 31, 2025 | |||||||
Carrying amount | Fair value | |||||||
Financial assets | ||||||||
Cash and due from financial institutions | ₩ | ₩ | ||||||
Financial assets at fair value through profit or loss: | ||||||||
Due from financial institutions | ||||||||
Debt securities | ||||||||
Equity securities | ||||||||
Loans | ||||||||
Others | ||||||||
Derivatives held for trading | ||||||||
Derivatives held for hedging | ||||||||
Loans measured at amortized cost | ||||||||
Securities measured at amortized cost | ||||||||
Financial assets at fair value through other comprehensive income: | ||||||||
Debt securities | ||||||||
Equity securities | ||||||||
Loans | ||||||||
Other financial assets | ||||||||
| ₩ | ₩ | |||||||
Financial liabilities | ||||||||
Financial liabilities at fair value through profit or loss | ₩ | ₩ | ||||||
Financial liabilities designated at fair value through profit or loss | ||||||||
Derivatives held for trading | ||||||||
Derivatives held for hedging | ||||||||
Deposits | ||||||||
Borrowings | ||||||||
Debentures | ||||||||
Other financial liabilities | ||||||||
| ₩ | ₩ | |||||||
Cash and due from financial institutions | ||
Securities | ||
Loans | ||
Derivatives and financial instruments at fair value through profit or loss | ||
Deposits | ||
Borrowings | ||
Debentures | ||
Other financial assets and other financial liabilities | ||
(In millions of Korean won) | December 31, 2024 | |||||||||||||||
Fair value hierarchy | Total | |||||||||||||||
Level 1 | Level 2 | Level 3 | ||||||||||||||
Financial assets | ||||||||||||||||
Financial assets at fair value through profit or loss: | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Due from financial institutions | ||||||||||||||||
Debt securities | ||||||||||||||||
Equity securities | ||||||||||||||||
Loans | ||||||||||||||||
Others | ||||||||||||||||
Derivatives held for trading | ||||||||||||||||
Derivatives held for hedging | ||||||||||||||||
Financial assets at fair value through other comprehensive income: | ||||||||||||||||
Debt securities | ||||||||||||||||
Equity securities | ||||||||||||||||
Loans | ||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
Financial liabilities | ||||||||||||||||
Financial liabilities at fair value through profit or loss | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Financial liabilities designated at fair value through profit or loss | ||||||||||||||||
Derivatives held for trading | ||||||||||||||||
Derivatives held for hedging | ||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||||||
Fair value hierarchy | Total | |||||||||||||||
Level 1 | Level 2 | Level 3 | ||||||||||||||
Financial assets | ||||||||||||||||
Financial assets at fair value through profit or loss: | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Due from financial institutions | ||||||||||||||||
Debt securities | ||||||||||||||||
Equity securities | ||||||||||||||||
Loans | ||||||||||||||||
Others | ||||||||||||||||
Derivatives held for trading | ||||||||||||||||
Derivatives held for hedging | ||||||||||||||||
Financial assets at fair value through other comprehensive income: | ||||||||||||||||
Debt securities | ||||||||||||||||
Equity securities | ||||||||||||||||
Loans | ||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
Financial liabilities | ||||||||||||||||
Financial liabilities at fair value through profit or loss | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Financial liabilities designated at fair value through profit or loss | ||||||||||||||||
Derivatives held for trading | ||||||||||||||||
Derivatives held for hedging | ||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
December 31, 2024 | ||||||||
Fair value | Valuation techniques | Inputs | ||||||
Financial assets | ||||||||
Financial assets at fair value through profit or loss: | ₩ | |||||||
Debt securities | ||||||||
Equity securities | ||||||||
Derivatives held for trading | ||||||||
Derivatives held for hedging | ||||||||
Financial assets at fair value through other comprehensive income: | ||||||||
Debt securities | ||||||||
Equity securities | ||||||||
Loans | ||||||||
| ₩ | ||||||||
Financial liabilities | ||||||||
Financial liabilities designated at fair value through profit or loss | ₩ | DCF Model, Closed Form, MonteCarlo Simulation, Black-Scholes Model, Hull-white Model, and others | Price of underlying asset, Interest rate, Dividend yield, Volatility, Discount rate | |||||
Derivatives held for trading | ||||||||
Derivatives held for hedging | ||||||||
| ₩ | ||||||||
December 31, 2025 | ||||||||
Fair value | Valuation techniques | Inputs | ||||||
Financial assets | ||||||||
Financial assets at fair value through profit or loss: | ₩ | |||||||
Debt securities | ||||||||
Equity securities | ||||||||
Derivatives held for trading | ||||||||
Derivatives held for hedging | ||||||||
Financial assets at fair value through other comprehensive income: | ||||||||
Debt securities | ||||||||
Equity securities | ||||||||
Loans | ||||||||
| ₩ | ||||||||
Financial liabilities | ||||||||
Financial liabilities designated at fair value through profit or loss | ₩ | |||||||
Derivatives held for trading | ||||||||
Derivatives held for hedging | ||||||||
| ₩ | ||||||||
(In millions of Korean won) | December 31, 2024 | |||||||||||||||
Fair value hierarchy | Total | |||||||||||||||
Level 1 | Level 2 | Level 3 | ||||||||||||||
Financial assets | ||||||||||||||||
Cash and due from financial institutions 1 | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Loans measured at amortized cost | ||||||||||||||||
Securities measured at amortized cost 2 | ||||||||||||||||
Other financial assets 2 | ||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
Financial liabilities | ||||||||||||||||
Deposits 1 | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Borrowings 3 | ||||||||||||||||
Debentures | ||||||||||||||||
Other financial liabilities 2 | ||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||||||
Fair value hierarchy | Total | |||||||||||||||
Level 1 | Level 2 | Level 3 | ||||||||||||||
Financial assets | ||||||||||||||||
Cash and due from financial institutions 1 | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Loans measured at amortized cost | ||||||||||||||||
Securities measured at amortized cost 2 | ||||||||||||||||
Other financial assets 2 | ||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
Financial liabilities | ||||||||||||||||
Deposits 1 | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Borrowings 3 | ||||||||||||||||
Debentures | ||||||||||||||||
Other financial liabilities 2 | ||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
1 | The amounts included in Level 2 are the carrying amounts which are reasonable approximations of fair value. |
2 | The amounts included in Level 3 are the carrying amounts which are reasonable approximations of fair value. |
3 | Borrowings of ₩ |
(In millions of Korean won) | December 31, 2024 | |||||||||||
Fair value | Valuation techniques | Inputs | ||||||||||
Financial assets | ||||||||||||
Loans measured at amortized cost | ₩ | |||||||||||
Securities measured at amortized cost | Simulation | | Interest rate | | ||||||||
| ₩ | ||||||||||||
Financial liabilities | ||||||||||||
Borrowings | ₩ | |||||||||||
Debentures | ||||||||||||
| ₩ | ||||||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||
Fair value | Valuation techniques | Inputs | ||||||||||
Financial assets | ||||||||||||
Loans measured at amortized cost | ₩ | |||||||||||
Securities measured at amortized cost | Simulation | | Interest rate | | ||||||||
| ₩ | ||||||||||||
Financial liabilities | ||||||||||||
Borrowings | ₩ | |||||||||||
Debentures | ||||||||||||
| ₩ | ||||||||||||
(In millions of Korean won) | December 31, 2024 | |||||||
Fair value | Valuation techniques | Inputs | ||||||
Financial assets | ||||||||
Cash and due from financial institutions | ₩ | |||||||
Loans measured at amortized cost | ||||||||
| ₩ | ||||||||
Financial liabilities | ||||||||
Deposits | ₩ | |||||||
Borrowings | ||||||||
Debentures | ||||||||
| ₩ | ||||||||
(In millions of Korean won) | December 31, 2025 | |||||||
Fair value | Valuation techniques | Inputs | ||||||
Financial assets | ||||||||
Cash and due from financial institutions | ₩ | |||||||
Loans measured at amortized cost | ||||||||
| ₩ | ||||||||
Financial liabilities | ||||||||
Deposits | ₩ | |||||||
Borrowings | ||||||||
Debentures | ||||||||
| ₩ | ||||||||
(In millions of Korean won) |
2024 |
|||||||||||||||||||||||
Financial assets at fair value through profit or loss |
Financial investments |
Financial liabilities at fair value through profit or loss |
Net derivative financial instruments |
|||||||||||||||||||||
Due from financial institutions measured at fair value through profit or loss |
Securities measured at fair value through profit or loss |
Loans measured at fair value through profit or loss |
Equity securities measured at fair value through other comprehensive income |
Financial liabilities designated at fair value through profit or loss |
Derivatives held for trading |
|||||||||||||||||||
|
Beginning
|
₩ | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ||||||||||||||
|
Total gains or losses:
|
||||||||||||||||||||||||
|
Profit or loss
|
( |
) | ( |
) | ||||||||||||||||||||
|
Other comprehensive income (loss)
|
( |
) | ( |
) | ||||||||||||||||||||
|
Purchases
|
||||||||||||||||||||||||
|
Sales
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
|
Issues
|
( |
) | ( |
) | ||||||||||||||||||||
|
Settlements
|
||||||||||||||||||||||||
|
Transfers into Level 3 *
|
||||||||||||||||||||||||
|
Transfers out of Level 3 *
|
( |
) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Ending
|
₩ | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
(In millions of Korean won) |
2025 |
|||||||||||||||||||||||
Financial assets at fair value through profit or loss |
Financial investments |
Financial liabilities at fair value through profit or loss |
Net derivative financial instruments |
|||||||||||||||||||||
Due from financial institutions measured at fair value through profit or loss |
Securities measured at fair value through profit or loss |
Loans measured at fair value through profit or loss |
Equity securities measured at fair value through other comprehensive income |
Financial liabilities designated at fair value through profit or loss |
Derivatives held for trading |
|||||||||||||||||||
|
Beginning
|
₩ | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ||||||||||||||
|
Total gains or losses:
|
||||||||||||||||||||||||
|
Profit or loss
|
( |
) | ( |
) | ||||||||||||||||||||
|
Other comprehensive income (loss)
|
( |
) | ||||||||||||||||||||||
|
Purchases
|
||||||||||||||||||||||||
|
Sales
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
|
Issues
|
( |
) | ( |
) | ||||||||||||||||||||
|
Settlements
|
||||||||||||||||||||||||
|
Transfers into Level 3 *
|
||||||||||||||||||||||||
|
Transfers out of Level 3 *
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Ending
|
₩ | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| * |
|
2023 |
2024 |
|||||||||||||||||||||||
Net gains on financial instruments at fair value through profit or loss |
Other operating income (expense) |
Net interest income |
Net gains on financial instruments at fair value through profit or loss |
Other operating income (expense) |
Net interest income |
|||||||||||||||||||
|
Total gains (losses) recognized in profit or loss for the period
|
₩ | ( |
) | ₩ | ₩ | ₩ | ( |
₩ | ₩ | |||||||||||||||
|
Total gains (losses) recognized in profit or loss from financial instruments held at the end of the reporting period
|
( |
|||||||||||||||||||||||
2025 |
||||||||||||
Net gains on financial instruments at fair value through profit or loss |
Other operating income (expense) |
Net interest income |
||||||||||
|
Total gains(losses) recognized in profit or loss for the period
|
₩ | ₩ | ( |
) | ₩ | |||||||
|
Total gains (losses) recognized in profit or loss from financial instruments held at the end of the reporting period
|
( |
) | ||||||||||
(In millions of Korean won) | December 31, 2024 | |||||||||||||
Fair value | Valuation techniques | Unobservable inputs | Range of unobservable inputs (%) | Relationship of unobservable inputs to fair value | ||||||||||
Financial assets | ||||||||||||||
Financial assets at fair value through profit or loss: | ||||||||||||||
Due from financial institutions | ₩ | Volatility | ||||||||||||
Debt securities | Growth rate | |||||||||||||
| Volatility | ||||||||||||||
| Discount rate | ||||||||||||||
| Volatility of Stock price | ||||||||||||||
| Correlation coefficient | ||||||||||||||
| Liquidation value | - | |||||||||||||
| Recovery rate | ||||||||||||||
| Rate of real estate price fluctuation | - | |||||||||||||
Equity securities | Growth rate | |||||||||||||
| Discount rate | ||||||||||||||
| Volatility | ||||||||||||||
Loans | Discount rate | |||||||||||||
Derivatives held for trading: | ||||||||||||||
Stock and index | ₩ | Volatility of underlying asset | ||||||||||||
| Correlation coefficient | - | |||||||||||||
(In millions of Korean won) | December 31, 2024 | |||||||||||||
Fair value | Valuation techniques | Unobservable inputs | Range of unobservable inputs (%) | Relationship of unobservable inputs to fair value | ||||||||||
Currency, interest rate, and others | Volatility | |||||||||||||
| Correlation coefficient | - | |||||||||||||
Financial assets at fair value through other comprehensive income: | ||||||||||||||
Equity securities | Growth rate | |||||||||||||
| Discount rate | ||||||||||||||
| Volatility | ||||||||||||||
| ₩ | ||||||||||||||
(In millions of Korean won) | December 31, 2024 | |||||||||||||
Fair value | Valuation techniques | Unobservable inputs | Range of unobservable inputs (%) | Relationship of unobservable inputs to fair value | ||||||||||
Financial liabilities | ||||||||||||||
Financial liabilities designated at fair value through profit or loss: | ||||||||||||||
Derivative-linked securities | ₩ | Volatility of underlying asset | ||||||||||||
| Correlation coefficient | - | |||||||||||||
Derivatives held for trading: | ||||||||||||||
Stock and index | Volatility of underlying asset | |||||||||||||
| Correlation coefficient | - | |||||||||||||
Others | Discount rate | |||||||||||||
| Volatility of underlying asset | ||||||||||||||
| Correlation coefficient | - | |||||||||||||
| ₩ | ||||||||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||||
Fair value | Valuation techniques | Unobservable inputs | Range of unobservable inputs (%) | Relationship of unobservable inputs to fair value | ||||||||||
Financial assets | ||||||||||||||
Financial assets at fair value through profit or loss: | ||||||||||||||
Due from financial institutions | ₩ | Volatility | ||||||||||||
Debt securities | Growth rate | |||||||||||||
| Volatility | ||||||||||||||
| Discount rate | ||||||||||||||
| Volatility of Stock price | ||||||||||||||
| Correlation coefficient | - | |||||||||||||
| Liquidation value | - | |||||||||||||
| Recovery rate | ||||||||||||||
| Rate of real estate price fluctuation | ||||||||||||||
Equity securities | Growth rate | |||||||||||||
| Discount rate | ||||||||||||||
| Volatility | ||||||||||||||
Loans | Discount rate | |||||||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||
Fair value | Valuation techniques | Unobservable inputs | Range of unobservable inputs (%) | Relationship of unobservable inputs to fair value | ||||||||
Derivatives held for trading: | ||||||||||||
Stock and index | ₩ | Volatility of underlying asset | ||||||||||
| Correlation coefficient | - | |||||||||||
Currency, interest rate, and others | Volatility | |||||||||||
| Correlation coefficient | ||||||||||||
Financial assets at fair value through other comprehensive income: | ||||||||||||
Equity securities | | Growth rate | ||||||||||
| Discount rate | ||||||||||||
| Volatility | ||||||||||||
| ₩ | ||||||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||||
Fair value | Valuation techniques | Unobservable inputs | Range of unobservable inputs (%) | Relationship of unobservable inputs to fair value | ||||||||||
Financial liabilities | ||||||||||||||
Financial liabilities designated at fair value through profit or loss: | ||||||||||||||
Derivative-linked securities | ₩ | Volatility of underlying asset | ||||||||||||
| Correlation coefficient | - | |||||||||||||
Derivatives held for trading: | ||||||||||||||
Stock and index | Volatility of underlying asset | |||||||||||||
| Correlation coefficient | - | |||||||||||||
Others | Discount rate | |||||||||||||
| Volatility of underlying asset | ||||||||||||||
| Correlation coefficient | - | |||||||||||||
| ₩ | ||||||||||||||
(In millions of Korean won) | December 31, 2024 | |||||||||||||||
Profit or loss | Other comprehensive income or loss | |||||||||||||||
Favorable changes | Unfavorable changes | Favorable changes | Unfavorable changes | |||||||||||||
Financial assets | ||||||||||||||||
Financial assets at fair value through profit or loss: 1 | ||||||||||||||||
Due from financial institutions | ₩ | ₩ | ( | ) | ₩ | ₩ | ||||||||||
Debt securities 4 | ( | ) | ||||||||||||||
Equity securities 3 | ( | ) | ||||||||||||||
Loans 5 | ( | ) | ||||||||||||||
Derivatives held for trading 2 | ( | ) | ||||||||||||||
Financial assets at fair value through other comprehensive income: | ||||||||||||||||
Equity securities 3 | ( | ) | ||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ₩ | ( | ) | |||||||||
Financial liabilities | ||||||||||||||||
Financial liabilities designated at fair value through profit or loss 1 | ₩ | ₩ | ( | ) | ₩ | ₩ | ||||||||||
Derivatives held for trading 2 | ( | ) | ||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ₩ | |||||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||||||
Profit or loss | Other comprehensive income or loss | |||||||||||||||
Favorable changes | Unfavorable changes | Favorable changes | Unfavorable changes | |||||||||||||
Financial assets | ||||||||||||||||
Financial assets at fair value through profit or loss: 1 | ||||||||||||||||
Due from financial institutions | ₩ | ₩ | ( | ) | ₩ | ₩ | ||||||||||
Debt securities 4 | ( | ) | ||||||||||||||
Equity securities 3 | ( | ) | ||||||||||||||
Loans 5 | ( | ) | ||||||||||||||
Derivatives held for trading 2 | ( | ) | ||||||||||||||
Financial assets at fair value through other comprehensive income: | ||||||||||||||||
Equity securities 3 | ( | ) | ||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ₩ | ( | ) | |||||||||
Financial liabilities | ||||||||||||||||
Financial liabilities designated at fair value through profit or loss 1 | ₩ | ₩ | ( | ) | ₩ | ₩ | ||||||||||
Derivatives held for trading 2 | ( | ) | ||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ₩ | |||||||||||
1 | For financial instruments at fair value through profit or loss, changes in fair value are calculated by shifting principal unobservable input parameters such as discount rate, recovery rate, liquidation value, growth rate by ±1%p and volatility of underlying asset by ±1%p or ±10% and correlation coefficient by ±10%. |
2 | For derivative financial instruments, changes in fair value are calculated by shifting principal unobservable input parameters such as price of underlying asset and volatility by +3% or ± 10%. |
3 | For equity securities, changes in fair value are calculated by shifting principal unobservable input parameters such as discount rate (-1%p~1%p) and growth rate (-1%p~1%p). |
4 | For beneficiary certificates, it is practically impossible to analyze sensitivity of changes in unobservable inputs. However, for beneficiary certificates whose underlying assets are real estates, changes in fair value are calculated by shifting rate of real estate price fluctuation by -1%p~1%p, and for beneficiary certificates whose underlying assets are equity investments, changes in fair value are calculated by shifting principal unobservable input parameters such as liquidation value by -1%p~1%p and discount rate by -1%p~1%p. There is no significant correlation among major unobservable inputs. |
5 | For loans, changes in fair value are calculated by shifting principal unobservable input parameters such as discount rate by -1%p~1%p. |
(In millions of Korean won) | 2024 | 2025 | ||||||
Balance at the beginning of the year | ₩ | ₩ | ||||||
New transactions | ||||||||
Changes during the year | ( | ) | ( | ) | ||||
Balance at the end of the year | ₩ | ₩ | ||||||
December 31, 2024 | ||||||||||||||||||||||||
Financial instruments at fair value through profit or loss | Financial instruments at fair value through other comprehensive income | Financial instruments designated at fair value through other comprehensive income | Financial instruments at amortized cost | Derivatives held for hedging | Total | |||||||||||||||||||
Financial assets | ||||||||||||||||||||||||
Cash and due from financial institutions | ₩ | — | ₩ | — | ₩ | — | ₩ | ₩ | — | ₩ | ||||||||||||||
Financial assets at fair value through profit or loss | — | — | — | — | ||||||||||||||||||||
Derivative financial assets | — | — | — | |||||||||||||||||||||
Loans measured at amortized cost | — | — | — | — | ||||||||||||||||||||
Financial investments | — | — | ||||||||||||||||||||||
Other financial assets | — | — | — | — | ||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||
December 31, 2024 | ||||||||||||||||||||
Financial instruments at fair value through profit or loss | Financial instruments designated at fair value through profit or loss | Financial instruments at amortized cost | Derivatives held for hedging | Total | ||||||||||||||||
Financial liabilities | ||||||||||||||||||||
Financial liabilities at fair value through profit or loss | ₩ | ₩ | ₩ | — | ₩ | — | ₩ | |||||||||||||
Derivative financial liabilities | — | — | ||||||||||||||||||
Deposits | — | — | — | |||||||||||||||||
Borrowings | — | — | — | |||||||||||||||||
Debentures | — | — | — | |||||||||||||||||
Other financial liabilities* | — | — | — | |||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||
December 31, 2025 | ||||||||||||||||||||||||
Financial instruments at fair value through profit or loss | Financial instruments at fair value through other comprehensive income | Financial instruments designated at fair value through other comprehensive income | Financial instruments at amortized cost | Derivatives held for hedging | Total | |||||||||||||||||||
Financial assets | ||||||||||||||||||||||||
Cash and due from financial institutions | ₩ | — | ₩ | — | ₩ | — | ₩ | ₩ | — | ₩ | ||||||||||||||
Financial assets at fair value through profit or loss | — | — | — | — | ||||||||||||||||||||
Derivative financial assets | — | — | — | |||||||||||||||||||||
Loans measured at amortized cost | — | — | — | — | ||||||||||||||||||||
Financial investments | — | — | ||||||||||||||||||||||
Other financial assets | — | — | — | — | ||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||
December 31, 2025 | ||||||||||||||||||||
Financial instruments at fair value through profit or loss | Financial instruments designated at fair value through profit or loss | Financial instruments at amortized cost | Derivatives held for hedging | Total | ||||||||||||||||
Financial liabilities | ||||||||||||||||||||
Financial liabilities at fair value through profit or loss | ₩ | ₩ | ₩ | — | ₩ | — | ₩ | |||||||||||||
Derivative financial liabilities | — | — | ||||||||||||||||||
Deposits | — | — | — | |||||||||||||||||
Borrowings | — | — | — | |||||||||||||||||
Debentures | — | — | — | |||||||||||||||||
Other financial liabilities* | — | — | — | |||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||
| * | Other financial liabilities include lease liabilities and other liabilities that are not included in the category of financial instruments measured at amortized cost. |
(In millions of Korean won) |
December 31, 2024
|
|||||||||||
|
Type of continuing
involvement |
Classification of financial
instruments |
Carrying amount of continuing involvement |
Fair value of continuing involvement |
|||||||||
|
Discovery 2
nd Securitization Specialty Co., Ltd. |
Subordinated bond
|
Financial assets at fair value through profit or loss
|
₩ | ₩ | ||||||||
|
AP 4D ABS Ltd.
|
Subordinated bond
|
Financial assets at fair value through profit or loss
|
||||||||||
|
|
|
|
|
|||||||||
| ₩ | ₩ | |||||||||||
|
|
|
|
|
|||||||||
(In millions of Korean won) |
December 31, 2025
|
|||||||||||
|
Type of continuing
involvement |
Classification of financial
instruments |
Carrying amount of continuing involvement |
Fair value of continuing involvement |
|||||||||
|
Discovery 2
nd Securitization Specialty Co., Ltd. |
Subordinated bond |
Financial assets at fair value through profit or loss
|
₩ | ₩ | ||||||||
|
AP 4D ABS Ltd.
|
Subordinated bond |
Financial assets at fair value through profit or loss
|
||||||||||
|
|
|
|
|
|||||||||
| ₩ | ₩ | |||||||||||
|
|
|
|
|
|||||||||
(In millions of Korean won) |
December 31, 2024 |
|||||||||||||||
Carrying amount of underlying assets |
Fair value of underlying assets |
Carrying amount of senior debentures |
Fair value of senior debentures |
|||||||||||||
|
KB Kookmin Card 8
th Securitization Co., Ltd. 1 |
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
KB Kookmin Card 9
th Securitization Co., Ltd. 1 |
||||||||||||||||
|
KB Kookmin Card 10
th Securitization Co., Ltd. 1 |
||||||||||||||||
|
KB Kookmin Card 11
th Securitization Co., Ltd. 1 |
||||||||||||||||
|
KB Kookmin Card 12
th Securitization Co., Ltd. 1 |
||||||||||||||||
|
KB Kookmin Card 13
th Securitization Co., Ltd. 1 |
|
|
||||||||||||||
|
KB Auto Fifth Asset Securitization Specialty Co., Ltd.
2 |
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | |
₩ | |
₩ | |
₩ | |
|||||||||
|
|
|
|
|
|
|
|
|
|||||||||
(In millions of Korean won) |
December 31, 2025 |
|||||||||||||||
Carrying amount of underlying assets |
Fair value of underlying assets |
Carrying amount of senior debentures |
Fair value of senior debentures |
|||||||||||||
|
KB Kookmin Card 9
th Securitization Co., Ltd. 1 |
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
KB Kookmin Card 10
th Securitization Co., Ltd. 1 |
||||||||||||||||
|
KB Kookmin Card 11
th Securitization Co., Ltd. 1 |
||||||||||||||||
|
KB Kookmin Card 12
th Securitization Co., Ltd. 1 |
||||||||||||||||
|
KB Kookmin Card 13
th Securitization Co., Ltd. 1 |
||||||||||||||||
|
KB Kookmin Card 14
th Securitization Co., Ltd. 1 |
||||||||||||||||
|
KB Auto Fifth Asset Securitization Specialty Co., Ltd.
2 |
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | ₩ | |
₩ | ₩ | |
|||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
1 |
|
2 |
|
(In millions of Korean won) |
December 31, 2024 |
|||||||
Carrying amount of transferred assets |
Carrying amount of related liabilities |
|||||||
|
Bonds sold under repurchase agreements
|
₩ | ₩ | ||||||
|
Loaned securities:
|
||||||||
|
Government and public bonds
|
— | |||||||
|
Stock
|
— | |||||||
|
Others
|
— | |||||||
|
|
|
|
|
|||||
| ₩ | ₩ | |||||||
|
|
|
|
|
|||||
(In millions of Korean won) |
December 31, 2025 |
|||||||
Carrying amount of transferred assets |
Carrying amount of related liabilities |
|||||||
|
Bonds sold under repurchase agreements
|
₩ | ₩ | ||||||
|
Loaned securities:
|
||||||||
|
Government and public bonds
|
— | |||||||
|
Stock
|
— | |||||||
|
Others
|
— | |||||||
|
|
|
|
|
|||||
| ₩ | ₩ | |||||||
|
|
|
|
|
|||||
(In millions of Korean won) |
December 31, 2024 |
December 31, 2025 |
||||||||
|
Underlying assets
|
Financial assets at fair value through profit or loss
|
₩ | ₩ | |||||||
| Loans measured at amortized cost * | ||||||||||
|
|
|
|
|
|||||||
|
|
|
|
|
|||||||
|
Associated liabilities
|
Debentures | ₩ | ₩ | |||||||
(In millions of Korean won) | ||||||||||||||||||||||||
December 31, 2024 | ||||||||||||||||||||||||
Gross assets | Gross liabilities offset | Net amount in the statement of financial position | Non-offsetting amount | Net amount | ||||||||||||||||||||
Financial instruments | Cash collateral | |||||||||||||||||||||||
| Derivatives held for trading and derivative-linked securities | ₩ | ₩ — | ₩ | ₩( | ₩( | ₩ | ||||||||||||||||||
Derivatives held for hedging | — | |||||||||||||||||||||||
Unsettled spot exchange receivable | — | ( | ) | — | ||||||||||||||||||||
Bonds purchased under repurchase agreements | — | ( | ) | — | ||||||||||||||||||||
Securities borrowing agreements | — | ( | ) | — | — | |||||||||||||||||||
Domestic exchange settlement debits | ( | ) | ( | ) | — | |||||||||||||||||||
Other financial instruments | ( | ) | — | — | ||||||||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | |||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||
December 31, 2025 | ||||||||||||||||||||||||
Gross assets | Gross liabilities offset | Net amount in the statement of financial position | Non-offsetting amount | Net amount | ||||||||||||||||||||
Financial instruments | Cash collateral | |||||||||||||||||||||||
Derivatives held for trading and derivative-linked securities | ₩ | ₩ | — | ₩ | ||||||||||||||||||||
Derivatives held for hedging | — | ₩ | ( | ) | ₩ | ( | ) | ₩ | ||||||||||||||||
Unsettled spot exchange receivable | — | ( | ) | — | ||||||||||||||||||||
Bonds purchased under repurchase agreements | — | ( | ) | — | — | |||||||||||||||||||
Domestic exchange settlement debits | ( | ) | ( | ) | — | |||||||||||||||||||
Other financial instruments | ( | ) | — | — | ||||||||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | |||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||
December 31, 2024 | ||||||||||||||||||||||||
Gross liabilities | Gross assets offset | Net amount in the statement of financial position | Non-offsetting amount | Net amount | ||||||||||||||||||||
Financial instruments | Cash collateral | |||||||||||||||||||||||
Derivatives held for trading and derivative-linked securities | ₩ | ₩ | — | ₩ | ||||||||||||||||||||
Derivatives held for hedging | — | ₩ | ( | ) | ₩ | ( | ) | ₩ | ||||||||||||||||
Unsettled spot exchange payable | — | ( | ) | — | ||||||||||||||||||||
Bonds sold under repurchase agreements * | — | ( | ) | — | — | |||||||||||||||||||
Securities borrowing agreements | — | ( | ) | — | — | |||||||||||||||||||
Domestic exchange settlement credits | ( | ) | ( | ) | — | |||||||||||||||||||
Other financial instruments | ( | ) | — | — | ||||||||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | |||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||
December 31, 2025 | ||||||||||||||||||||||||
Gross liabilities | Gross assets offset | Net amount in the statement of financial position | Non-offsetting amount | Net amount | ||||||||||||||||||||
Financial instruments | Cash collateral | |||||||||||||||||||||||
Derivatives held for trading and derivative-linked securities | ₩ | ₩ | — | ₩ | ||||||||||||||||||||
Derivatives held for hedging | — | ₩ | ( | ) | ₩ | ( | ) | ₩ | ||||||||||||||||
Unsettled spot exchange payable | — | ( | ) | — | ||||||||||||||||||||
Bonds sold under repurchase agreements * | — | ( | ) | — | — | |||||||||||||||||||
Securities borrowing agreements | — | ( | ) | — | ||||||||||||||||||||
Domestic exchange settlement credits | ( | ) | ( | ) | — | |||||||||||||||||||
Other financial instruments | ( | ) | — | — | ||||||||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | |||||||||||||
| * | Includes bonds sold under repurchase agreements to customers. |
(In millions of Korean won) | Financial institutions | Interest rate (%) as of December 31, 2025 | December 31, 2024 | December 31, 2025 | ||||||||||||
Due from financial institutions in Korean won | Due from the Bank of Korea | The Bank of Korea | ₩ | ₩ | ||||||||||||
Due from banks | KEB Hana Bank and others | |||||||||||||||
Due from others | Korea Securities Finance Corporation and others | |||||||||||||||
Due from financial institutions in foreign currencies | Due from banks in foreign currencies | The Bank of Korea. and others | ||||||||||||||
Time deposits in foreign currencies | Industrial and Commercial Bank of China and others | |||||||||||||||
Due from others | Yuanta Bank (Taiwan) and others | |||||||||||||||
| ₩ | ₩ | |||||||||||||||
| * | Before netting of allowance |
(In millions of Korean won) | Financial institutions | December 31, 2024 | December 31, 2025 | Reasons of restriction | ||||||||||
Due from financial institutions in Korean won | Due from the Bank of Korea | The Bank of Korea | ₩ | ₩ | ||||||||||
Due from banks | KEB Hana Bank and others | |||||||||||||
Due from others | Korea Securities Finance Corporation and others | |||||||||||||
Due from financial institutions in foreign currencies | Due from banks in foreign currencies | The Bank of Korea and others | ||||||||||||
Time deposits in foreign currencies | Industrial and Commercial Bank of China and others | |||||||||||||
Due from others | Yuanta Bank (Taiwan) and others | |||||||||||||
| ₩ | ₩ | |||||||||||||
| * | Before netting of allowance. |
(In millions of Korean won) |
2024 |
|||||||||||
12-month expectedcredit losses |
Lifetime expected credit losses |
|||||||||||
Non- impaired |
Impaired |
|||||||||||
|
Beginning
|
₩ | ₩ | ₩ | |||||||||
|
Transfer between stages:
|
||||||||||||
|
Transfer to
12-month expected credit losses |
||||||||||||
|
Transfer to lifetime expected credit losses
|
||||||||||||
|
Impairment
|
||||||||||||
|
Provision (reversal) of credit losses
|
||||||||||||
|
Business Combination
|
||||||||||||
|
Others
|
||||||||||||
|
|
|
|
|
|
|
|||||||
|
Ending
|
₩ | ₩ | ₩ | |||||||||
|
|
|
|
|
|
|
|||||||
(In millions of Korean won) |
2025 |
|||||||||||
12-month expected credit losses |
Lifetime expected credit losses |
|||||||||||
Non-impaired |
Impaired |
|||||||||||
|
Beginning
|
₩ | ₩ | ₩ | |||||||||
|
Transfer between stages:
|
||||||||||||
|
Transfer to
12-month expected credit losses |
||||||||||||
|
Transfer to lifetime expected credit losses
|
||||||||||||
|
Impairment
|
||||||||||||
|
Provision (reversal) of credit losses
|
( |
) | ||||||||||
|
Business Combination
|
||||||||||||
|
Others
|
( |
) | ||||||||||
|
|
|
|
|
|
|
|||||||
|
Ending
|
₩ | ₩ | ₩ | |||||||||
|
|
|
|
|
|
|
|||||||
(In millions of Korean won) |
||||||||
December 31, 2024 |
||||||||
|
Assets pledged
|
Pledgee
|
Carrying amount |
Reasons of pledge
|
|||||
|
Due from financial institutions
|
KEB Hana Bank and others
|
₩ |
|
|||||
|
Financial assets at fair value through profit or loss
|
The Korea Securities Depository and others
|
|||||||
|
The Korea Securities Depository and others
|
Securities borrowing transactions |
|||||||
|
Samsung Futures Inc. and others
|
|
|||||||
|
|
|
|||||||
|
|
|
|||||||
|
Financial assets at fair value through other comprehensive income
|
The Bank of Korea and others
|
|||||||
|
The Korea Securities Depository and others
|
||||||||
|
The Bank of Korea
|
|
|||||||
|
The Bank of Korea
|
Settlement risk of the Bank of Korea |
|||||||
|
Samsung Futures Inc. and others
|
|
|||||||
|
Others
|
Others |
|||||||
|
|
|
|||||||
|
|
|
|||||||
|
Securities measured at amortized cost
|
The Bank of Korea and others
|
|
||||||
|
The Bank of Korea
|
|
|||||||
|
The Bank of Korea
|
|
|||||||
|
Samsung Futures Inc. and others
|
|
|||||||
|
The Bank of Korea and others
|
||||||||
|
|
|
|||||||
|
|
|
|||||||
|
Loans
|
Others
|
|
||||||
|
Real estate
|
Hanwha Life Insurance Co., Ltd. and others
|
|||||||
|
|
|
|||||||
| ₩ | ||||||||
|
|
|
|||||||
(In millions of Korean won) |
||||||||
December 31, 2025 |
||||||||
|
Assets pledged
|
Pledgee
|
Carrying amount |
Reasons of pledge
|
|||||
|
Due from financial institutions
|
KEB Hana Bank and others
|
₩ |
|
|||||
|
Financial assets at fair value through profit or loss
|
The Korea Securities Depository and others
|
|||||||
|
The Korea Securities Depository and others
|
|
|||||||
|
The Bank of Korea
|
Borrowings from the Bank of Korea |
|||||||
|
Korea Exchange (“KRX”) and others
|
Derivatives transactions |
|||||||
|
Others
|
Others |
|||||||
|
|
|
|||||||
|
|
|
|||||||
|
Financial assets at fair value through other comprehensive income
|
The Korea Securities Depository and others
|
|
||||||
|
The Korea Securities Depository and others
|
|
|||||||
|
The Bank of Korea
|
|
|||||||
|
The Bank of Korea
|
|
|||||||
|
The Korea Securities Depository and others
|
Derivatives transactions |
|||||||
|
Mitsui Sumitomo Bank, Seoul Branch and others
|
||||||||
|
|
|
|||||||
|
|
|
|||||||
|
Securities measured at amortized cost
|
The Bank of Korea and others
|
|
||||||
|
The Bank of Korea
|
|
|||||||
|
The Bank of Korea
|
|
|||||||
|
Samsung Futures Inc. and others
|
||||||||
|
The Bank of Korea and others
|
|
|||||||
|
|
|
|||||||
|
|
|
|||||||
|
Loans
|
Others
|
|
||||||
|
Real estate
|
Shinhan Bank and others
|
|||||||
|
|
|
|||||||
| ₩ | ||||||||
|
|
|
|||||||
(In millions of Korean won) | ||||||||||||
December 31, 2024 | ||||||||||||
Fair value of collateral held | Fair value of collateral sold or repledged | Total | ||||||||||
Securities | ₩ | ₩ | ₩ | |||||||||
(In millions of Korean won) | ||||||||||||
December 31, 2025 | ||||||||||||
Fair value of collateral held | Fair value of collateral sold or repledged | Total | ||||||||||
Securities | ₩ | ₩ | ₩ | |||||||||
| • | Interest rate swaps relating to interest rate risk in Korean won |
| • | Cross-currency swaps, forwards, and options relating to currency risk |
| • | Stock index options linked with the Korea Composite Stock Price Index (“KOSPI”) |
(In millions of Korean won) | ||||||||||||||||||||||||
December 31, 2024 | December 31, 2025 | |||||||||||||||||||||||
Notional amount | Assets | Liabilities | Notional amount | Assets | Liabilities | |||||||||||||||||||
Interest rate | ||||||||||||||||||||||||
Forwards | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||
Futures* | ||||||||||||||||||||||||
Swaps | ||||||||||||||||||||||||
Options | ||||||||||||||||||||||||
Currency | ||||||||||||||||||||||||
Forwards | ||||||||||||||||||||||||
Futures* | ||||||||||||||||||||||||
Swaps | ||||||||||||||||||||||||
Options | ||||||||||||||||||||||||
Stock and index | ||||||||||||||||||||||||
Futures* | ||||||||||||||||||||||||
Swaps | ||||||||||||||||||||||||
Options | ||||||||||||||||||||||||
Credit | ||||||||||||||||||||||||
Swaps | ||||||||||||||||||||||||
Commodity | ||||||||||||||||||||||||
Futures* | ||||||||||||||||||||||||
Swaps | ||||||||||||||||||||||||
Options | ||||||||||||||||||||||||
Others | ||||||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||
| * | Gains or losses arising from some daily mark-to-market |
(In millions of Korean won) | December 31, 2024 | |||||||||||||||||||||||||||
1 year | 2 years | 3 years | 4 years | 5 years | Over 5 years | Total | ||||||||||||||||||||||
Fair value hedge | ||||||||||||||||||||||||||||
Nominal amount of the hedging instrument | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
Average price condition (%) | ||||||||||||||||||||||||||||
Average price condition (USD/KRW) | ||||||||||||||||||||||||||||
Average price condition (EUR/KRW) | ||||||||||||||||||||||||||||
Average price condition (AUD/KRW) | ||||||||||||||||||||||||||||
Average price condition (GBP/KRW) | ||||||||||||||||||||||||||||
Cash flow hedge | ||||||||||||||||||||||||||||
Nominal amount of the hedging instrument | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
Average price condition (%) | ||||||||||||||||||||||||||||
Average price condition (USD/KRW) | ||||||||||||||||||||||||||||
Average price condition (EUR/KRW) | ||||||||||||||||||||||||||||
Average price condition (AUD/KRW) | ||||||||||||||||||||||||||||
Hedge of net investments in foreign operations | ||||||||||||||||||||||||||||
Nominal amount of the hedging instrument | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
Average price condition (USD/KRW) | ||||||||||||||||||||||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||||||||||||||||||
1 year | 2 years | 3 years | 4 years | 5 years | Over 5 years | Total | ||||||||||||||||||||||
Fair value hedge | ||||||||||||||||||||||||||||
Nominal amount of the hedging instrument | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
Average price condition (%) | ||||||||||||||||||||||||||||
Average price condition (USD/KRW) | ||||||||||||||||||||||||||||
Average price condition (EUR/KRW) | ||||||||||||||||||||||||||||
Average price condition (AUD/KRW) | ||||||||||||||||||||||||||||
Average price condition (GBP/KRW) | ||||||||||||||||||||||||||||
Cash flow hedge | ||||||||||||||||||||||||||||
Nominal amount of the hedging instrument | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
Average price condition (%) | ||||||||||||||||||||||||||||
Average price condition (USD/KRW) | ||||||||||||||||||||||||||||
Average price condition (EUR/KRW) | ||||||||||||||||||||||||||||
Average price condition (AUD/KRW) | ||||||||||||||||||||||||||||
Hedge of net investments in foreign operations | ||||||||||||||||||||||||||||
Nominal amount of the hedging instrument | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
Average price condition (USD/KRW) | ||||||||||||||||||||||||||||
(In millions of Korean won) | December 31, 2024 | 2024 | ||||||||||||||||||||
Carrying amount | Accumulated amount of hedge adjustments | Changes in fair value | ||||||||||||||||||||
Assets | Liabilities | Assets | Liabilities | |||||||||||||||||||
Hedge accounting | ||||||||||||||||||||||
Interest rate | Debt securities in Korean won | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | ||||||||||||||
Debt securities in foreign currencies | ( | ) | ||||||||||||||||||||
Deposits in Korean won | ( | ) | ||||||||||||||||||||
Deposits in foreign currencies | ( | ) | ||||||||||||||||||||
Debentures in Korean won | ( | ) | ( | ) | ||||||||||||||||||
Debentures in foreign currencies | ( | ) | ( | ) | ||||||||||||||||||
| ( | ) | ( | ) | |||||||||||||||||||
Currency | Debt securities in foreign currencies | |||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ( | ₩ | |||||||||||||||||
(In millions of Korean won) | December 31, 2025 | 2025 | ||||||||||||||||||||
Carrying amount | Accumulated amount of hedge adjustments | Changes in fair value | ||||||||||||||||||||
Assets | Liabilities | Assets | Liabilities | |||||||||||||||||||
Hedge accounting | ||||||||||||||||||||||
Interest rate | Debt securities in Korean won | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | ( | ) | ||||||||||||
Debt securities in foreign currencies | ( | ) | ||||||||||||||||||||
Deposits in Korean won | ( | ) | ||||||||||||||||||||
Deposits in foreign currencies | ( | ) | ( | ) | ||||||||||||||||||
Debentures in Korean won | ( | ) | ||||||||||||||||||||
Debentures in foreign currencies | ( | ) | ( | ) | ||||||||||||||||||
| ( | ) | ( | ) | ( | ) | |||||||||||||||||
Currency | Debt securities in foreign currencies | ( | ) | |||||||||||||||||||
| ( | ) | |||||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ( | ₩ | ( | ||||||||||||||||
December 31, 2024 | 2024 | |||||||||||||||
Notional amount | Assets | Liabilities | Changes in fair value | |||||||||||||
Interest rate | ||||||||||||||||
Futures | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Swaps | ( | ) | ||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ( | ) | |||||||||||
Currency | ||||||||||||||||
Forwards | ( | ) | ||||||||||||||
| ₩ | | ₩ | | ₩ | | ₩ | ( | ) | ||||||||
December 31, 2025 | 2025 | |||||||||||||||
Notional amount | Assets | Liabilities | Changes in fair value | |||||||||||||
Interest rate | ||||||||||||||||
Futures | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Swaps | ( | ) | ||||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
Currency | ||||||||||||||||
Forwards | ( | ) | ||||||||||||||
| ₩ | | ₩ | | ₩ | | ₩ | ( | ) | ||||||||
2023 | 2024 | 2025 | ||||||||||
Hedge accounting | ||||||||||||
Interest rate | ₩ | ₩ | ₩ | ( | ) | |||||||
Currency | ( | ) | ( | ) | ||||||||
| ₩ | ₩ | ₩ | ( | ) | ||||||||
(In millions of Korean won) | 2023 | 2024 | 2025 | |||||||||
Gains (losses) on hedging instruments | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | |||
Gains (losses) on hedged items attributable to the hedged risk | ( | ) | ||||||||||
| ₩ | ( | ) | ₩ | ₩ | ( | ) | ||||||
Cash flow hedge reserve | Changes in fair value | |||||||||||||||
December 31, 2024 | December 31, 2025 | 2024 | 2025 | |||||||||||||
Hedge accounting | ||||||||||||||||
Interest rate risk | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ||||||||
Currency risk | ( | ) | ( | ) | ( | ) | ||||||||||
| ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | |||||||||
December 31, 2024 | 2024 | |||||||||||||||
Notional amount | Assets | Liabilities | Changes in fair value | |||||||||||||
Interest rate | ||||||||||||||||
Forwards | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Swaps | ( | ) | ||||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
Currency | ||||||||||||||||
Swaps | ||||||||||||||||
| ₩ | | ₩ | | ₩ | | ₩ | ||||||||||
December 31, 2025 | 2025 | |||||||||||||||
Notional amount | Assets | Liabilities | Changes in fair value | |||||||||||||
Interest rate | ||||||||||||||||
Forwards | ₩ | ₩ | ₩ | ₩ | ( | ) | ||||||||||
Swaps | ( | ) | ||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ( | ) | |||||||||||
Currency | ||||||||||||||||
Swaps | ( | ) | ||||||||||||||
| ₩ | ₩ | | ₩ | | ₩ | ( | ) | |||||||||
(In millions of Korean won) | 2023 | 2024 | 2025 | |||||||||
Gains (losses) on hedging instruments: | ₩ | ₩ | ₩ | ( | ) | |||||||
Effective portion of gains (losses) on cash flow hedging instruments (recognized in other comprehensive income or loss) | ( | ) | ||||||||||
Ineffective portion of gains (losses) on cash flow hedging instruments (recognized in profit or loss) | ||||||||||||
(In millions of Korean won) | 2023 | 2024 | 2025 | |||||||||
Other comprehensive income (loss) | ₩ | ₩ | ₩ | ( | ) | |||||||
Reclassification to profit or loss | ( | ) | ||||||||||
Income tax effect | ( | ) | ( | ) | ||||||||
| ₩ | ₩ | ₩ | ( | ) | ||||||||
Foreign currency translation reserve | Changes in fair value | |||||||||||||||
December 31, 2024 | December 31, 2025 | 2024 | 2025 | |||||||||||||
Hedge accounting | ||||||||||||||||
Currency risk | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ( | ) | ||||||
December 31, 2024 | 2024 | |||||||||||||||
Notional amount | Assets | Liabilities | Changes in fair value | |||||||||||||
Currency | ||||||||||||||||
Forwards | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Debentures in foreign currencies | ( | ) | ||||||||||||||
| ₩ | ₩ | | ₩ | ₩ | ( | ) | ||||||||||
December 31, 2025 | 2025 | |||||||||||||||
Notional amount | Assets | Liabilities | Changes in fair value | |||||||||||||
Currency | ||||||||||||||||
Forwards | ₩ | ₩ | | ₩ | ₩ | | ||||||||||
Debentures in foreign currencies | ||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Debentures in foreign currencies | ₩ | ₩ | ||||||
(In millions of Korean won) | 2023 | 2024 | 2025 | |||||||||
Gains (losses) on hedging instruments: | ₩ | ( | ) | ₩ | ( | ) | ₩ | |||||
Effective portion of gains (losses) on hedge of net investments in foreign operations (recognized in other comprehensive income or loss) | ( | ) | ( | ) | ||||||||
Ineffective portion of gains (losses) on hedge of net investments in foreign operations (recognized in profit or loss) | ||||||||||||
(In millions of Korean won) | 2023 | 2024 | 2025 | |||||||||
Other comprehensive income (loss) | ₩ | ( | ) | ₩ | ( | ) | ₩ | |||||
Reclassification to profit or loss | ||||||||||||
Income tax effect | ( | ) | ||||||||||
| ₩ | ( | ) | ₩ | ( | ) | ₩ | ||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Loans measured at amortized cost | ₩ | ₩ | ||||||
Deferred loan origination fees and costs | ||||||||
Less: Allowances for credit losses | ( | ) | ( | ) | ||||
| ₩ | ₩ | |||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Loans measured at amortized cost | ₩ | ₩ | ||||||
Less: Allowances for credit losses | ( | ) | ( | ) | ||||
| ₩ | ₩ | |||||||
(In millions of Korean won) | December 31, 2024 | |||||||||||||||
Retail | Corporate | Credit card | Total | |||||||||||||
Loans in Korean won | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Loans in foreign currencies | ||||||||||||||||
Domestic import usance bills | ||||||||||||||||
Off-shore funding loans | ||||||||||||||||
Bills bought in Korean won | ||||||||||||||||
Bills bought in foreign currencies | ||||||||||||||||
Guarantee payments under acceptances and guarantees | ||||||||||||||||
Credit card receivables in Korean won | ||||||||||||||||
Credit card receivables in foreign currencies | ||||||||||||||||
Bonds purchased under repurchase agreements | ||||||||||||||||
Privately placed bonds | ||||||||||||||||
Factored receivables | ||||||||||||||||
Lease receivables | ||||||||||||||||
Loans for installment credit | ||||||||||||||||
Proportion (%) | ||||||||||||||||
Less: Allowances for credit losses | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||||||
Retail | Corporate | Credit card | Total | |||||||||||||
Loans in Korean won | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Loans in foreign currencies | ||||||||||||||||
Domestic import usance bills | ||||||||||||||||
Off-shore funding loans | ||||||||||||||||
Call Loans | ||||||||||||||||
Bills bought in Korean won | ||||||||||||||||
Bills bought in foreign currencies | ||||||||||||||||
Guarantee payments under acceptances and guarantees | ||||||||||||||||
Credit card receivables in Korean won | ||||||||||||||||
Credit card receivables in foreign currencies | ||||||||||||||||
Bonds purchased under repurchase agreements | ||||||||||||||||
Privately placed bonds | ||||||||||||||||
Factored receivables | ||||||||||||||||
Lease receivables | ||||||||||||||||
Loans for installment credit | ||||||||||||||||
Proportion (%) | ||||||||||||||||
Less: Allowances for credit losses | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
2024 | ||||||||||||||||||||
Beginning | Increase | Decrease | Others | Ending | ||||||||||||||||
Deferred loan origination costs | ||||||||||||||||||||
Loans in Korean won | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | |||||||||||||
Others | ( | ) | ||||||||||||||||||
| ( | ) | |||||||||||||||||||
Deferred loan origination fees | ||||||||||||||||||||
Loans in Korean won | ( | ) | ||||||||||||||||||
Others | ( | ) | ||||||||||||||||||
| ( | ) | |||||||||||||||||||
| ₩ | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ||||||||||||
2025 | ||||||||||||||||||||
Beginning | Increase | Decrease | Others | Ending | ||||||||||||||||
Deferred loan origination costs | ||||||||||||||||||||
Loans in Korean won | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | |||||||||||||
Others | ( | ) | ( | ) | ||||||||||||||||
| ( | ) | ( | ) | |||||||||||||||||
Deferred loan origination fees | ||||||||||||||||||||
Loans in Korean won | ( | ) | ||||||||||||||||||
Others | ( | ) | ( | ) | ||||||||||||||||
| ( | ) | ( | ) | |||||||||||||||||
| ₩ | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ||||||||||||
(In millions of Korean won) |
2024 |
|||||||||||||||||||||||||||||||||||
Retail |
Corporate |
Credit card |
||||||||||||||||||||||||||||||||||
12-month expected credit losses |
Lifetime expected credit losses |
12-month expected credit losses |
Lifetime expected credit losses |
12-month expected credit losses |
Lifetime expected credit losses |
|||||||||||||||||||||||||||||||
Non- impaired |
Impaired |
Non- impaired |
Impaired |
Non-impaired |
Impaired |
|||||||||||||||||||||||||||||||
|
Beginning
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||||||
|
Transfer between stages:
|
||||||||||||||||||||||||||||||||||||
|
Transfer to
12-month expected credit losses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
|
Transfer to lifetime expected credit losses
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
|
Impairment
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
|
Write-offs
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Sales
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
|
Provision (reversal) for credit losses
1,2 |
( |
) | ||||||||||||||||||||||||||||||||||
|
Others (exchange differences, etc.)
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
|
Ending
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
(In millions of Korean won) |
2025 |
|||||||||||||||||||||||||||||||||||
Retail |
Corporate |
Credit card |
||||||||||||||||||||||||||||||||||
12-month expected credit losses |
Lifetime expected credit losses |
12-month expected credit losses |
Lifetime expected credit losses |
12-month expected credit losses |
Lifetime expected credit losses |
|||||||||||||||||||||||||||||||
Non-impaired |
Impaired |
Non-impaired |
Impaired |
Non-impaired |
Impaired |
|||||||||||||||||||||||||||||||
|
Beginning
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||||||
|
Transfer between stages:
|
||||||||||||||||||||||||||||||||||||
|
Transfer to
12-month expected credit losses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
|
Transfer to lifetime expected credit losses
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
|
Impairment
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
|
Write-offs
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
|
Sales
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||
|
Provision (reversal) for credit losses
1,2 |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
|
Others (exchange differences, etc.)
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
|
Ending
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
1 |
Provision for credit losses in the consolidated statements of comprehensive income also includes provision (reversal) for credit losses of due from financial institutions (Note 7.3), provision (reversal) for credit losses of financial investments (Note 12.5), provision (reversal) for credit losses of unused commitments, acceptances and guarantees (Note 24.2), provision (reversal) for credit losses of financial guarantee contracts (Note 24.3), and provision (reversal) for credit losses of other financial assets (Note 19.2).
|
2 |
Includes ₩
written-off loans for the years ended December 31, 2024 and 2025, respectively. |
(In millions of Korean won) | 2024 | |||||||||||
12-month expected credit losses | Lifetime expected credit losses | |||||||||||
Non-impaired | Impaired | |||||||||||
Beginning | ₩ | ₩ | ₩ | |||||||||
Transfer between stages: | ||||||||||||
Transfer to 12-month expected credit losses | ( | ) | ( | ) | ||||||||
Transfer to lifetime expected credit losses (non-impaired) | ( | ) | ( | ) | ||||||||
Transfer to lifetime expected credit losses (impaired) | ( | ) | ( | ) | ||||||||
Write-offs | ( | ) | ( | ) | ||||||||
Sales | ( | ) | ( | ) | ( | ) | ||||||
Net increase (decrease) (execution, repayment, and others) | ( | ) | ( | ) | ||||||||
Ending | ₩ | ₩ | ₩ | |||||||||
(In millions of Korean won) | 2025 | |||||||||||
12-month expected credit losses | Lifetime expected credit losses | |||||||||||
Non-impaired | Impaired | |||||||||||
Beginning | ₩ | ₩ | ₩ | |||||||||
Transfer between stages: | ||||||||||||
Transfer to 12-month expected credit losses | ( | ) | ( | ) | ||||||||
Transfer to lifetime expected credit losses (non-impaired) | ( | ) | ( | ) | ||||||||
Transfer to lifetime expected credit losses (impaired) | ( | ) | ( | ) | ||||||||
Write-offs | ( | ) | ( | ) | ||||||||
Sales | ( | ) | ( | ) | ( | ) | ||||||
Net increase (decrease) (execution, repayment, and others) | ( | ) | ||||||||||
Ending | ₩ | ₩ | ₩ | |||||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Financial assets at fair value through profit or loss | ||||||||
Debt securities: | ||||||||
Government and public bonds | ₩ | ₩ | ||||||
Financial bonds | ||||||||
Corporate bonds | ||||||||
Asset-backed securities | ||||||||
Beneficiary certificates | ||||||||
Derivative-linked securities | ||||||||
Other debt securities | ||||||||
Equity securities: | ||||||||
Stocks | ||||||||
Other equity securities | ||||||||
Loans: | ||||||||
Privately placed bonds | ||||||||
Other loans | ||||||||
Due from financial institutions: | ||||||||
Other due from financial institutions | ||||||||
Others | ||||||||
| ₩ | ₩ | |||||||
Financial investments | ||||||||
Financial assets at fair value through other comprehensive income | ||||||||
Debt securities: | ||||||||
Government and public bonds | ₩ | ₩ | ||||||
Financial bonds | ||||||||
Corporate bonds | ||||||||
Asset-backed securities | ||||||||
Other debt securities | ||||||||
Equity securities: | ||||||||
Stocks | ||||||||
Equity investments | ||||||||
Other equity securities | ||||||||
Loans: | ||||||||
Privately placed bonds | ||||||||
Financial assets at amortized cost | ||||||||
Debt securities: | ||||||||
Government and public bonds | ||||||||
Financial bonds | ||||||||
Corporate bonds | ||||||||
Asset-backed securities | ||||||||
Other debt securities | ||||||||
Less: Allowances for credit losses | ( | ) | ( | ) | ||||
| ₩ | ₩ | |||||||
(In millions of Korean won) | 2024 | 2025 | ||||||||||||||||
From the equity securities derecognized | From the equity securities held | From the equity securities derecognized | From the equity securities held | |||||||||||||||
Equity securities measured at fair value through other comprehensive income: | ||||||||||||||||||
Stocks | Listed | ₩ | ₩ | ₩ | ₩ | |||||||||||||
| Unlisted | ||||||||||||||||||
Equity investments | ||||||||||||||||||
Other equity securities | ||||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||||
(In millions of Korean won) | 2024 | 2025 | ||||||||||||||||
Disposal price | Accumulated other comprehensive income (loss) as of disposal date | Disposal price | Accumulated other comprehensive income (loss) as of disposal date | |||||||||||||||
Equity securities measured at fair value through other comprehensive income: | ||||||||||||||||||
Stocks | Listed | ₩ | ₩ | ( | ) | ₩ | ₩ | ( | ) | |||||||||
| Unlisted | ||||||||||||||||||
Other equity securities | ||||||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | 2023 | |||||||||||
Provision | Reversal | Total | ||||||||||
Securities measured at fair value through other comprehensive income | ₩ | ₩ | ( | ) | ₩ | |||||||
Loans measured at fair value through other comprehensive income | ( | ) | ||||||||||
Securities measured at amortized cost | ( | ) | ||||||||||
| ₩ | ₩ | ( | ) | ₩ | ||||||||
(In millions of Korean won) | 2024 | |||||||||||
Provision | Reversal | Total | ||||||||||
Securities measured at fair value through other comprehensive income | ₩ | ₩ | ( | ) | ₩ | |||||||
Loans measured at fair value through other comprehensive income | ( | ) | ||||||||||
Securities measured at amortized cost | ( | ) | ( | ) | ||||||||
| ₩ | ₩ | ( | ) | ₩ | ( | ) | ||||||
(In millions of Korean won) | 2025 | |||||||||||
Provision | Reversal | Total | ||||||||||
Securities measured at fair value through other comprehensive income | ₩ | ₩ | ( | ) | ₩ | |||||||
Loans measured at fair value through other comprehensive income | ( | ) | ||||||||||
Securities measured at amortized cost | ( | ) | ( | ) | ||||||||
| ₩ | ₩ | ( | ) | ₩ | ||||||||
(In millions of Korean won) | 2024 | |||||||||||
12-month expected credit losses | Lifetime expected credit losses | |||||||||||
Non-impaired | Impaired | |||||||||||
Beginning | ₩ | ₩ | ₩ | |||||||||
Transfer between stages: | ||||||||||||
Transfer to 12-month expected credit losses | ||||||||||||
Transfer to lifetime expected credit losses | ||||||||||||
Sales | ( | ) | ||||||||||
Provision (reversal) for credit losses | ( | ) | ||||||||||
Others (exchange differences, etc.) | ||||||||||||
Ending | ₩ | ₩ | ₩ | |||||||||
(In millions of Korean won) | 2025 | |||||||||||
12-month expected credit losses | Lifetime expected credit losses | |||||||||||
Non-impaired | Impaired | |||||||||||
Beginning | ₩ | ₩ | ₩ | |||||||||
Transfer between stages: | ||||||||||||
Transfer to 12-month expected credit losses | ||||||||||||
Transfer to lifetime expected credit losses | ||||||||||||
Sales | ( | ) | ||||||||||
Provision (reversal) for credit losses | ( | ) | ||||||||||
Others (exchange differences, etc.) | ||||||||||||
Ending | ₩ | ₩ | ₩ | |||||||||
(In millions of Korean won) | December 31, 2024 | |||||||||||||||||||
Ownership (%) | Acquisition cost | Share of net asset amount | Carrying amount | Industry | Location | |||||||||||||||
KB-KDBC Pre-IPO New Technology Business Investment Fund 2 | ₩ | ₩ | ₩ | |||||||||||||||||
Balhae Infrastructure Company 1 | ||||||||||||||||||||
Aju Good Technology Venture Fund | ||||||||||||||||||||
Incheon Bridge Co., Ltd. 1 | ( | ) | ||||||||||||||||||
Big Dipper Co., Ltd. 1 | ||||||||||||||||||||
Food Factory Co., Ltd. | ||||||||||||||||||||
KBSP Private Equity Fund No.4 1 | ||||||||||||||||||||
Korea Credit Bureau Co., Ltd. 1 | ||||||||||||||||||||
KB Social Impact Investment Fund | ||||||||||||||||||||
KB-Solidus Global Healthcare Fund 2 | ||||||||||||||||||||
POSCO-KB Shipbuilding Fund | ||||||||||||||||||||
KB-TS Technology Venture Private Equity Fund 2 | ||||||||||||||||||||
KB-SJ Tourism Venture Fund 1 | ||||||||||||||||||||
UNION Media Commerce Fund | ||||||||||||||||||||
KB-Stonebridge Secondary Private Equity Fund 1 | ||||||||||||||||||||
KB SPROTT Renewable Private Equity Fund No.1 2 | ||||||||||||||||||||
KB-UTC Inno-Tech Venture Fund 2 | ||||||||||||||||||||
WJ Private Equity Fund No.1 | ||||||||||||||||||||
All Together Korea Fund No.2 3 | ||||||||||||||||||||
KB-NAU Special Situation Corporate Restructuring Private Equity Fund 1 | ||||||||||||||||||||
2020 KB Fintech Renaissance Fund 1 | ||||||||||||||||||||
FineKB Private Equity Fund No.1 | ||||||||||||||||||||
G payment Joint Stock Company | ||||||||||||||||||||
KB-GeneN Medical Venture Fund No.1 | ||||||||||||||||||||
DA-Friend New Technology Investment Fund No.2 | ||||||||||||||||||||
Cornerstone Pentastone Fund No.4 | ||||||||||||||||||||
Star-Lord General Investors Private Real Estate Investment Company No.10 | ||||||||||||||||||||
KB-Badgers Future Mobility ESG Fund No.1 | ||||||||||||||||||||
JS Private Equity Fund No.3 | ||||||||||||||||||||
Mirae Asset Mobility Investment Fund No.1 | ||||||||||||||||||||
KB-FT Green Growth 1st Technology Investment Association 1 | ||||||||||||||||||||
Glenwood Credit Private Equity Fund No.2 | ||||||||||||||||||||
THE CHAEUL FUND NO.1 | ||||||||||||||||||||
Smart Korea KB Future9-Sejong Venture Fund | ||||||||||||||||||||
KB-KTB Technology Venture Fund 2 | ||||||||||||||||||||
KB-SOLIDUS Healthcare InvestmentFund 2 | ||||||||||||||||||||
Paramark KB Fund No.1 1 | ||||||||||||||||||||
(In millions of Korean won) | December 31, 2024 | |||||||||||||||||||
Ownership (%) | Acquisition cost | Share of net asset amount | Carrying amount | Industry | Location | |||||||||||||||
KB Co-Investment Private Equity Fund No.11 | ₩ | ₩ | ₩ | |||||||||||||||||
POSITIVE Sobujang Venture Fund No.1 | ||||||||||||||||||||
History 2022 Fintech Fund | ||||||||||||||||||||
KB-NP Green ESG New Technology Venture Capital Fund | ||||||||||||||||||||
TMAP Mobility Co., Ltd. 1 | ||||||||||||||||||||
Nextrade Co., Ltd. 1 | ||||||||||||||||||||
Shinhan Global Mobility Fund No.1 | ||||||||||||||||||||
SKB Next Unicorn K-Battery Fund No.1 | ||||||||||||||||||||
MW-Pyco NewWave New Technology Investment Fund 4th 2 | ||||||||||||||||||||
Bitgoeul Cheomdan Green 1st Co., Ltd. 1 | ||||||||||||||||||||
KB-SUSUNG 1st Investment Fund 1 | ||||||||||||||||||||
Shinhan-Eco Venture Fund 2nd | ||||||||||||||||||||
Leading H2O Fund 1 | ||||||||||||||||||||
2023 JB Newtech No.2 Fund | ||||||||||||||||||||
U-KB Credit No.1S Private Equity | ||||||||||||||||||||
KB-BridgePole Venture Investment Fund No.2 1 | ||||||||||||||||||||
Sirius Silicon Valley I New Technology Fund | ||||||||||||||||||||
FineKB Private Equity Fund No.2 1 | ||||||||||||||||||||
Timefolio Athleisure Investment Fund | ||||||||||||||||||||
VIG Private Equity Fund V-3 | ||||||||||||||||||||
COMPA Global Scale-Up Fund No.3 | ||||||||||||||||||||
AKK Robotech Valueup New Technology Investment Fund 1 | ||||||||||||||||||||
YG MCE PROJECT NO.1 Fund | ||||||||||||||||||||
HI YG Win-win Fund No.2 | ||||||||||||||||||||
KB-CJ Venture Fund 1st | ||||||||||||||||||||
Elohim-Bilanx aerospace No.1 Fund | ||||||||||||||||||||
KB-SUSUNG 2st Investment Fund 1 | ||||||||||||||||||||
IMM global Secondary 1-1 Equity Private Fund | ||||||||||||||||||||
LIB Material Investment Fund | ||||||||||||||||||||
NOVORSEC-SJG Consumer Secondary Fund | ||||||||||||||||||||
Allra Fintech Corp. 1 | ||||||||||||||||||||
Reboot Private Equity Fund | ||||||||||||||||||||
KB-SBI Global Strategic Capital Fund | ||||||||||||||||||||
KB-Cyrus Tourism Venture Fund 1 | ||||||||||||||||||||
IBKS Design Fund | ||||||||||||||||||||
NICE DATA INTELLIGENCE VENTURE FUND | ||||||||||||||||||||
Pectus Hanhwa Fund 2 | ||||||||||||||||||||
KB-IMM New Star Real Estate Private Fund I 2 | ||||||||||||||||||||
(In millions of Korean won) | December 31, 2024 | |||||||||||||||||||
Ownership (%) | Acquisition cost | Share of net asset amount | Carrying amount | Industry | Location | |||||||||||||||
Korea Environment Technology Co.,Ltd. | ₩ | ₩ | ₩ | Non-designated waste treatment | ||||||||||||||||
Others | ||||||||||||||||||||
| ₩ | ₩ | ₩ | ||||||||||||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||||||||||
Ownership (%) | Acquisition cost | Share of net asset amount | Carrying amount | Industry | Location | |||||||||||||||
KB-KDBC Pre-IPO New Technology Business Investment Fund 2 | ₩ | ₩ | ₩ | |||||||||||||||||
Balhae Infrastructure Company 1 | ||||||||||||||||||||
Aju Good Technology Venture Fund | ||||||||||||||||||||
Incheon Bridge Co., Ltd. 1 | ||||||||||||||||||||
Big Dipper Co., Ltd. 1 | ( | ) | ||||||||||||||||||
Food Factory Co., Ltd. | ||||||||||||||||||||
Korea Credit Bureau Co., Ltd. 1 | ||||||||||||||||||||
KB Social Impact Investment Fund | ||||||||||||||||||||
KB-Solidus Global Healthcare Fund 2 | ||||||||||||||||||||
POSCO-KB Shipbuilding Fund | ||||||||||||||||||||
KB-TS Technology Venture Private Equity Fund 2 | ||||||||||||||||||||
KB-SJ Tourism Venture Fund 1 | ||||||||||||||||||||
UNION Media Commerce Fund | ||||||||||||||||||||
KB-Stonebridge Secondary Private Equity Fund 1 | ||||||||||||||||||||
KB SPROTT Renewable Private Equity Fund No.1 2 | ||||||||||||||||||||
KB-UTC Inno-Tech Venture Fund 2 | ||||||||||||||||||||
WJ Private Equity Fund No.1 | ||||||||||||||||||||
All Together Korea Fund No.2 3 | ||||||||||||||||||||
KB-NAU Special Situation Corporate Restructuring Private Equity Fund 1 | ||||||||||||||||||||
2020 KB Fintech Renaissance Fund 1 | ||||||||||||||||||||
FineKB Private Equity Fund No.1 | ||||||||||||||||||||
G payment Joint Stock Company | ||||||||||||||||||||
KB-GeneN Medical Venture Fund No.1 | ||||||||||||||||||||
DA-Friend New Technology Investment Fund No.2 | ||||||||||||||||||||
Cornerstone Pentastone Fund No.4 | ||||||||||||||||||||
Star-Lord General Investors Private Real Estate Investment Company No.10 | ||||||||||||||||||||
KB-Badgers Future Mobility ESG Fund No.1 | ||||||||||||||||||||
JS Private Equity Fund No.3 | ||||||||||||||||||||
Mirae Asset Mobility Investment Fund No.1 | ||||||||||||||||||||
KB-FT Green Growth 1st Technology Investment Association 1 | ||||||||||||||||||||
Glenwood Credit Private Equity Fund No.2 | ||||||||||||||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||||||||||
Ownership (%) | Acquisition cost | Share of net asset amount | Carrying amount | Industry | Location | |||||||||||||||
Smart Korea KB Future9-Sejong Venture Fund | ₩ | ₩ | ₩ | |||||||||||||||||
KB-KTB Technology VentureFund 2 | ||||||||||||||||||||
KB-SOLIDUS Healthcare Investment Fund 2 | ||||||||||||||||||||
Paramark KB Fund No.1 1 | ||||||||||||||||||||
KB Co-Investment Private Equity Fund No.11 | ||||||||||||||||||||
KB-NP Green ESG New Technology Venture Capital Fund | ||||||||||||||||||||
TMAP Mobility Co., Ltd. 1 | ||||||||||||||||||||
Nextrade Co., Ltd. 1 | ||||||||||||||||||||
Shinhan Global Mobility Fund No.1 | ||||||||||||||||||||
SKB Next Unicorn K-Battery Fund No.1 | ||||||||||||||||||||
MW-Pyco NewWave New Technology Investment Fund 4th 2 | ||||||||||||||||||||
Bitgoeul Cheomdan Green 1st Co., Ltd. 1 | ||||||||||||||||||||
KB-SUSUNG 1st InvestmentFund 1 | ||||||||||||||||||||
Shinhan-Eco Venture Fund 2nd | ||||||||||||||||||||
Leading H2O Fund 1 | ||||||||||||||||||||
U-KB Credit No.1S Private Equity | ||||||||||||||||||||
KB-BridgePole Venture Investment Fund No.2 1 | ||||||||||||||||||||
Sirius Silicon Valley I New Technology Fund | ||||||||||||||||||||
FineKB Private Equity Fund No.2 1 | ||||||||||||||||||||
Timefolio Athleisure Investment Fund | ||||||||||||||||||||
VIG Private Equity Fund V-3 | ||||||||||||||||||||
COMPA Global Scale-Up Fund No.3 | ||||||||||||||||||||
YG MCE PROJECT NO.1 Fund | ||||||||||||||||||||
HI YG Win-win Fund No.2 | ||||||||||||||||||||
KB-CJ Venture Fund 1st | ||||||||||||||||||||
Elohim-Bilanx aerospace No.1 Fund | ||||||||||||||||||||
KB-SUSUNG 2st InvestmentFund 1 | ||||||||||||||||||||
IMM global Secondary 1-1 Equity Private Fund | ||||||||||||||||||||
LIB Material Investment Fund | ||||||||||||||||||||
Allra Fintech Corp. 1 | ||||||||||||||||||||
Reboot Private Equity Fund | ||||||||||||||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||||||||||
Ownership (%) | Acquisition cost | Share of net asset amount | Carrying amount | Industry | Location | |||||||||||||||
KB-SBI Global Strategic Capital Fund | ₩ | ₩ | ₩ | |||||||||||||||||
KB-Cyrus Tourism VentureFund 1 | ||||||||||||||||||||
IBKS Design Fund | ||||||||||||||||||||
KB-IMM New Star Real Estate Private Fund I 2 | ||||||||||||||||||||
KB-LB Middle Market Enterprises Innovation Private Equity Fund | ||||||||||||||||||||
YG AI Industrial Automation Solutions FUND | ||||||||||||||||||||
Semicolon Susong REITs Co., Ltd. | ||||||||||||||||||||
KB-Novus Genesis Private Equity Fund 1 | ||||||||||||||||||||
ATP TP VC Fund No.1 | ||||||||||||||||||||
AIM-KB-DOUBLE 1 | ||||||||||||||||||||
KB-IMM New Star Real Estate Private Fund II 2 | ||||||||||||||||||||
K-1 23rd yeoksam Real Estate Investment Trust company Ltd. | ||||||||||||||||||||
IMM Korea Beauty Co-Invest Private Equity Fund 2 | ||||||||||||||||||||
VP Inc. 1 | ||||||||||||||||||||
DAILY Fountainhead Blind Private Equity Fund II | ||||||||||||||||||||
KB-ANDA Deep Tech Venture Fund | ||||||||||||||||||||
Others | ||||||||||||||||||||
| ₩ | | ₩ | | ₩ | | |||||||||||||||
1 |
2 | co-operative members; the Group has applied the equity method as the Group cannot control the investee by itself. |
3 |
(In millions of Korean won) | ||||||||||||||||||||||||||||
December 31, 2024* | ||||||||||||||||||||||||||||
Total assets | Total liabilities | Paid-in capital | Equity | Share of net asset amount | Unrealized gains (losses) and others | Consolidated carrying amount | ||||||||||||||||||||||
KB-KDBC Pre-IPO New Technology Business Investment Fund | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
Balhae Infrastructure Company | ||||||||||||||||||||||||||||
Aju Good Technology Venture Fund | ||||||||||||||||||||||||||||
Incheon Bridge Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||||||||||
Big Dipper Co., Ltd. | ||||||||||||||||||||||||||||
Food Factory Co., Ltd. | ||||||||||||||||||||||||||||
KBSP Private Equity Fund No.4 | ||||||||||||||||||||||||||||
Korea Credit Bureau Co., Ltd. | ||||||||||||||||||||||||||||
KB Social Impact Investment Fund | ||||||||||||||||||||||||||||
KB-Solidus Global Healthcare Fund | ||||||||||||||||||||||||||||
POSCO-KB Shipbuilding Fund | ||||||||||||||||||||||||||||
KB-TS Technology Venture Private Equity Fund | ||||||||||||||||||||||||||||
KB-SJ Tourism Venture Fund | ||||||||||||||||||||||||||||
UNION Media Commerce Fund | ||||||||||||||||||||||||||||
KB-Stonebridge Secondary Private Equity Fund | ||||||||||||||||||||||||||||
KB SPROTT Renewable Private Equity Fund No.1 | ||||||||||||||||||||||||||||
KB-UTC Inno-Tech Venture Fund | ||||||||||||||||||||||||||||
WJ Private Equity Fund No.1 | ||||||||||||||||||||||||||||
All Together Korea Fund No.2 | ||||||||||||||||||||||||||||
KB-NAU Special Situation Corporate Restructuring Private Equity Fund | ||||||||||||||||||||||||||||
2020 KB Fintech Renaissance Fund | ||||||||||||||||||||||||||||
FineKB Private Equity Fund No.1 | ||||||||||||||||||||||||||||
G payment Joint Stock Company | ||||||||||||||||||||||||||||
KB-GeneN Medical Venture Fund No.1 | ||||||||||||||||||||||||||||
DA-Friend New Technology Investment Fund No.2 | ||||||||||||||||||||||||||||
Cornerstone Pentastone Fund No.4 | ||||||||||||||||||||||||||||
Star-Lord General Investors Private Real Estate Investment Company No.10 | ( | ) | ||||||||||||||||||||||||||
KB-Badgers Future Mobility ESG Fund No.1 | ||||||||||||||||||||||||||||
JS Private Equity Fund No.3 | ||||||||||||||||||||||||||||
Mirae Asset Mobility Investment Fund No.1 | ||||||||||||||||||||||||||||
KB-FT Green Growth 1st Technology Investment Association | ||||||||||||||||||||||||||||
Glenwood Credit Private Equity Fund No.2 | ||||||||||||||||||||||||||||
THE CHAEUL FUND NO.1 | ||||||||||||||||||||||||||||
Smart Korea KB Future9-Sejong Venture Fund | ||||||||||||||||||||||||||||
KB-KTB Technology Venture Fund | ||||||||||||||||||||||||||||
KB-SOLIDUS Healthcare Investment Fund | ( | ) | ||||||||||||||||||||||||||
Paramark KB Fund No.1 | ||||||||||||||||||||||||||||
KB Co-Investment Private Equity Fund No.1 | ||||||||||||||||||||||||||||
POSITIVE Sobujang Venture Fund No.1 | ||||||||||||||||||||||||||||
History 2022 Fintech Fund | ||||||||||||||||||||||||||||
KB-NP Green ESG New Technology Venture Capital Fund | ||||||||||||||||||||||||||||
TMAP Mobility Co., Ltd. | ||||||||||||||||||||||||||||
Nextrade Co., Ltd. | ||||||||||||||||||||||||||||
Shinhan Global Mobility Fund No.1 | ||||||||||||||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||||||
December 31, 2024* | ||||||||||||||||||||||||||||
Total assets | Total liabilities | Paid-in capital | Equity | Share of net asset amount | Unrealized gains (losses) and others | Consolidated carrying amount | ||||||||||||||||||||||
SKB Next Unicorn K-Battery Fund No.1 | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
MW-Pyco NewWave New Technology Investment Fund 4th | ||||||||||||||||||||||||||||
Bitgoeul Cheomdan Green 1st Co., Ltd. | ||||||||||||||||||||||||||||
KB-SUSUNG 1st Investment Fund | ||||||||||||||||||||||||||||
Shinhan-Eco Venture Fund 2nd | ||||||||||||||||||||||||||||
Leading H2O Fund 1 | ||||||||||||||||||||||||||||
2023 JB Newtech No.2 Fund | ||||||||||||||||||||||||||||
U-KB Credit No.1 Private Equity | ||||||||||||||||||||||||||||
KB-BridgePole Venture Investment Fund No.2 | ||||||||||||||||||||||||||||
Sirius Silicon Valley I New Technology Fund | ||||||||||||||||||||||||||||
FineKB Private Equity Fund No.2 | ||||||||||||||||||||||||||||
Timefolio Athleisure Investment Fund | ||||||||||||||||||||||||||||
VIG Private Equity Fund V-3 | ( | ) | ||||||||||||||||||||||||||
COMPA Global Scale-Up Fund No.3 | ||||||||||||||||||||||||||||
AKK Robotech Valueup New Technology Investment Fund | ||||||||||||||||||||||||||||
YG MCE PROJECT NO.1 Fund | ||||||||||||||||||||||||||||
HI YG Win-win Fund No.2 | ||||||||||||||||||||||||||||
KB-CJ Venture Fund 1st | ||||||||||||||||||||||||||||
Elohim-Bilanx aerospace No.1 Fund | ||||||||||||||||||||||||||||
KB-SUSUNG 2st Investment Fund | ||||||||||||||||||||||||||||
IMM global Secondary 1-1 Equity Private Fund | ||||||||||||||||||||||||||||
LIB Material Investment Fund | ||||||||||||||||||||||||||||
NOVORSEC-SJG Consumer Secondary Fund | ||||||||||||||||||||||||||||
Allra Fintech Corp. | ||||||||||||||||||||||||||||
Reboot Private Equity Fund | ||||||||||||||||||||||||||||
KB-SBI Global Strategic Capital Fund | ||||||||||||||||||||||||||||
KB-Cyrus Tourism Venture Fund | ||||||||||||||||||||||||||||
IBKS Design Fund | ||||||||||||||||||||||||||||
NICE DATA INTELLIGENCE VENTURE FUND | ||||||||||||||||||||||||||||
Pectus Hanhwa Fund 2 | ||||||||||||||||||||||||||||
KB-IMM New Star Real Estate Private Fund I | ||||||||||||||||||||||||||||
Korea Environment Technology Co.,Ltd. | ||||||||||||||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||
2024* | ||||||||||||||||||||
Operating revenue | Net profit (loss) | Other comprehensive income (loss) | Total comprehensive income (loss) | Dividends | ||||||||||||||||
KB-KDBC Pre-IPO New Technology Business Investment Fund | ₩ | ₩ | ( | ) | ₩ | ₩ | ( | ) | ₩ | |||||||||||
Balhae Infrastructure Company | ||||||||||||||||||||
Aju Good Technology Venture Fund | ( | ) | ( | ) | ||||||||||||||||
Incheon Bridge Co., Ltd. | ||||||||||||||||||||
Big Dipper Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||
Food Factory Co., Ltd. | ||||||||||||||||||||
KBSP Private Equity Fund No.4 | ||||||||||||||||||||
Korea Credit Bureau Co., Ltd. | ||||||||||||||||||||
KB Social Impact Investment Fund | ( | ) | ( | ) | ||||||||||||||||
KB-Solidus Global Healthcare Fund | ( | ) | ( | ) | ||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||
2024* | ||||||||||||||||||||
Operating revenue | Net profit (loss) | Other comprehensive income (loss) | Total comprehensive income (loss) | Dividends | ||||||||||||||||
POSCO-KB Shipbuilding Fund | ₩ | ₩ | ( | ) | ₩ | ₩ | ( | ) | ₩ | |||||||||||
KB-TS Technology Venture Private Equity Fund | ||||||||||||||||||||
KB-SJ Tourism Venture Fund | ||||||||||||||||||||
UNION Media Commerce Fund | ( | ) | ( | ) | ||||||||||||||||
KB-Stonebridge Secondary Private Equity Fund | ( | ) | ( | ) | ||||||||||||||||
KB SPROTT Renewable Private Equity Fund No.1 | ( | ) | ( | ) | ||||||||||||||||
KB-UTC Inno-Tech Venture Fund | ( | ) | ( | ) | ( | ) | ||||||||||||||
WJ Private Equity Fund No.1 | ( | ) | ( | ) | ||||||||||||||||
All Together Korea Fund No.2 | ||||||||||||||||||||
KB-NAU Special Situation Corporate Restructuring Private Equity Fund | ( | ) | ( | ) | ||||||||||||||||
2020 KB Fintech Renaissance Fund | ||||||||||||||||||||
FineKB Private Equity Fund No.1 | ||||||||||||||||||||
G payment Joint Stock Company | ( | ) | ( | ) | ||||||||||||||||
KB-GeneN Medical Venture Fund No.1 | ( | ) | ( | ) | ||||||||||||||||
DA-Friend New Technology Investment Fund No.2 | ( | ) | ( | ) | ||||||||||||||||
Cornerstone Pentastone Fund No.4 | ( | ) | ( | ) | ||||||||||||||||
Star-Lord General Investors Private Real Estate Investment Company No.10 | ( | ) | ( | ) | ||||||||||||||||
KB-Badgers Future Mobility ESG Fund No.1 | ( | ) | ( | ) | ||||||||||||||||
JS Private Equity Fund No.3 | ( | ) | ( | ) | ||||||||||||||||
Mirae Asset Mobility Investment Fund No.1 | ( | ) | ( | ) | ||||||||||||||||
KB-FT Green Growth 1st Technology Investment Association | ( | ) | ( | ) | ||||||||||||||||
Glenwood Credit Private Equity Fund No.2 | ||||||||||||||||||||
THE CHAEUL FUND NO.1 | ( | ) | ( | ) | ||||||||||||||||
Smart Korea KB Future9-Sejong Venture Fund | ( | ) | ( | ) | ||||||||||||||||
KB-KTB Technology Venture Fund | ( | ) | ( | ) | ||||||||||||||||
KB-SOLIDUS Healthcare Investment Fund | ( | ) | ( | ) | ||||||||||||||||
Paramark KB Fund No.1 | ||||||||||||||||||||
KB Co-Investment Private Equity Fund No.1 | ||||||||||||||||||||
POSITIVE Sobujang Venture Fund No.1 | ||||||||||||||||||||
History 2022 Fintech Fund | ( | ) | ( | ) | ||||||||||||||||
KB-NP Green ESG New Technology Venture Capital Fund | ( | ) | ( | ) | ||||||||||||||||
TMAP Mobility Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||
Nextrade Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||
Shinhan Global Mobility Fund No.1 | ( | ) | ( | ) | ||||||||||||||||
SKB Next Unicorn K-Battery Fund No.1 | ( | ) | ( | ) | ||||||||||||||||
MW-Pyco NewWave New Technology Investment Fund 4th | ( | ) | ( | ) | ||||||||||||||||
Bitgoeul Cheomdan Green 1st Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||
KB-SUSUNG 1st Investment Fund | ||||||||||||||||||||
Shinhan-Eco Venture Fund 2nd | ( | ) | ( | ) | ||||||||||||||||
Leading H2O Fund 1 | ( | ) | ( | ) | ||||||||||||||||
2023 JB Newtech No.2 Fund | ||||||||||||||||||||
U-KB Credit No.1 Private Equity | ||||||||||||||||||||
KB-BridgePole Venture Investment Fund No.2 | ( | ) | ( | ) | ||||||||||||||||
Sirius Silicon Valley I New Technology Fund | ( | ) | ( | ) | ||||||||||||||||
FineKB Private Equity Fund No.2 | ( | ) | ( | ) | ||||||||||||||||
Timefolio Athleisure Investment Fund | ( | ) | ( | ) | ||||||||||||||||
VIG Private Equity Fund V-3 | ( | ) | ( | ) | ||||||||||||||||
COMPA Global Scale-Up Fund No.3 | ( | ) | ( | ) | ||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||
2024* | ||||||||||||||||||||
Operating revenue | Net profit (loss) | Other comprehensive income (loss) | Total comprehensive income (loss) | Dividends | ||||||||||||||||
AKK Robotech Valueup New Technology Investment Fund | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
YG MCE PROJECT NO.1 Fund | ( | ) | ( | ) | ||||||||||||||||
HI YG Win-win Fund No.2 | ( | ) | ( | ) | ||||||||||||||||
KB-CJ Venture Fund 1st | ( | ) | ( | ) | ||||||||||||||||
Elohim-Bilanx aerospace No.1 Fund | ( | ) | ( | ) | ||||||||||||||||
KB-SUSUNG 2st Investment Fund | ( | ) | ( | ) | ||||||||||||||||
IMM global Secondary 1-1 Equity Private Fund | ||||||||||||||||||||
LIB Material Investment Fund | ( | ) | ( | ) | ||||||||||||||||
NOVORSEC-SJG Consumer Secondary Fund | ( | ) | ( | ) | ||||||||||||||||
Allra Fintech Corp. | ||||||||||||||||||||
Reboot Private Equity Fund | ( | ) | ( | ) | ||||||||||||||||
KB-SBI Global Strategic Capital Fund | ( | ) | ( | ) | ||||||||||||||||
KB-Cyrus Tourism Venture Fund | ( | ) | ( | ) | ||||||||||||||||
IBKS Design Fund | ( | ) | ( | ) | ||||||||||||||||
NICE DATA INTELLIGENCE VENTURE FUND | ( | ) | ( | ) | ||||||||||||||||
Pectus Hanhwa Fund 2 | ( | ) | ( | ) | ||||||||||||||||
KB-IMM New Star Real Estate Private Fund I | ||||||||||||||||||||
Korea Environment Technology Co.,Ltd. | ||||||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||||||
December 31, 2025* | ||||||||||||||||||||||||||||
Total assets | Total liabilities | Paid-in capital | Equity | Share of net asset amount | Unrealized gains (losses) and others | Consolidated carrying amount | ||||||||||||||||||||||
KB-KDBC Pre-IPO New Technology Business Investment Fund | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | |||||||||||||||||||
Balhae Infrastructure Company | ||||||||||||||||||||||||||||
Aju Good Technology Venture Fund | ||||||||||||||||||||||||||||
Incheon Bridge Co., Ltd. | ||||||||||||||||||||||||||||
Big Dipper Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||||||||||
Food Factory Co., Ltd. | ( | ) | ||||||||||||||||||||||||||
Korea Credit Bureau Co., Ltd. | ||||||||||||||||||||||||||||
KB Social Impact Investment Fund | ||||||||||||||||||||||||||||
KB-Solidus Global Healthcare Fund | ||||||||||||||||||||||||||||
POSCO-KB Shipbuilding Fund | ||||||||||||||||||||||||||||
KB-TS Technology Venture Private Equity Fund | ||||||||||||||||||||||||||||
KB-SJ Tourism Venture Fund | ||||||||||||||||||||||||||||
UNION Media Commerce Fund | ||||||||||||||||||||||||||||
KB-Stonebridge Secondary Private Equity Fund | ||||||||||||||||||||||||||||
KB SPROTT Renewable Private Equity Fund No.1 | ||||||||||||||||||||||||||||
KB-UTC Inno-Tech Venture Fund | ||||||||||||||||||||||||||||
WJ Private Equity Fund No.1 | ||||||||||||||||||||||||||||
All Together Korea Fund No.2 | ||||||||||||||||||||||||||||
KB-NAU Special Situation Corporate Restructuring Private Equity Fund | ||||||||||||||||||||||||||||
2020 KB Fintech Renaissance Fund | ||||||||||||||||||||||||||||
FineKB Private Equity Fund No.1 | ||||||||||||||||||||||||||||
G payment Joint Stock Company | ||||||||||||||||||||||||||||
KB-GeneN Medical Venture Fund No.1 | ||||||||||||||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||||||
December 31, 2025* | ||||||||||||||||||||||||||||
Total assets | Total liabilities | Paid-in capital | Equity | Share of net asset amount | Unrealized gains (losses) and others | Consolidated carrying amount | ||||||||||||||||||||||
DA-Friend New Technology Investment Fund No.2 | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
Cornerstone Pentastone Fund No.4 | ||||||||||||||||||||||||||||
Star-Lord General Investors Private Real Estate Investment Company No.10 | ||||||||||||||||||||||||||||
KB-Badgers Future Mobility ESG Fund No.1 | ||||||||||||||||||||||||||||
JS Private Equity Fund No.3 | ||||||||||||||||||||||||||||
Mirae Asset Mobility Investment Fund No.1 | ||||||||||||||||||||||||||||
KB-FT Green Growth 1st Technology Investment Association | ||||||||||||||||||||||||||||
Glenwood Credit Private Equity Fund No.2 | ||||||||||||||||||||||||||||
Smart Korea KB Future9-Sejong Venture Fund | ||||||||||||||||||||||||||||
KB-KTB Technology Venture Fund | ||||||||||||||||||||||||||||
KB-SOLIDUS Healthcare Investment Fund | ( | ) | ||||||||||||||||||||||||||
Paramark KB Fund No.1 | ||||||||||||||||||||||||||||
KB Co-Investment Private Equity Fund No.1 | ||||||||||||||||||||||||||||
KB-NP Green ESG New Technology Venture Capital Fund | ||||||||||||||||||||||||||||
TMAP Mobility Co., Ltd. | ||||||||||||||||||||||||||||
Nextrade Co., Ltd. | ||||||||||||||||||||||||||||
Shinhan Global Mobility Fund No.1 | ||||||||||||||||||||||||||||
SKB Next Unicorn K-Battery Fund No.1 | ||||||||||||||||||||||||||||
Bitgoeul Cheomdan Green 1st Co., Ltd. | ||||||||||||||||||||||||||||
KB-SUSUNG 1st Investment Fund | ||||||||||||||||||||||||||||
Shinhan-Eco Venture Fund 2nd | ||||||||||||||||||||||||||||
Leading H2O Fund 1 | ||||||||||||||||||||||||||||
U-KB Credit No.1S Private Equity | ( | ) | ||||||||||||||||||||||||||
KB-BridgePole Venture Investment Fund No.2 | ||||||||||||||||||||||||||||
Sirius Silicon Valley I New Technology Fund | ||||||||||||||||||||||||||||
FineKB Private Equity Fund No.2 | ||||||||||||||||||||||||||||
Timefolio Athleisure Investment Fund | ||||||||||||||||||||||||||||
VIG Private Equity Fund V-3 | ( | ) | ||||||||||||||||||||||||||
COMPA Global Scale-Up Fund No.3 | ||||||||||||||||||||||||||||
HI YG Win-win Fund No.2 | | | | |||||||||||||||||||||||||
KB-CJ Venture Fund 1st | ||||||||||||||||||||||||||||
Elohim-Bilanx aerospace No.1 Fund | ||||||||||||||||||||||||||||
KB-SUSUNG 2st Investment Fund | ||||||||||||||||||||||||||||
IMM global Secondary 1-1 Equity Private Fund | ||||||||||||||||||||||||||||
LIB Material Investment Fund | ||||||||||||||||||||||||||||
Allra Fintech Corp. | ||||||||||||||||||||||||||||
Reboot Private Equity Fund | ||||||||||||||||||||||||||||
KB-SBI Global Strategic Capital Fund | ||||||||||||||||||||||||||||
KB-Cyrus Tourism Venture Fund | ||||||||||||||||||||||||||||
IBKS Design Fund | ||||||||||||||||||||||||||||
KB-IMM New Star Real Estate Private Fund I | ||||||||||||||||||||||||||||
KB-LB Middle Market Enterprises Innovation Private Equity Fund | ( | ) | ||||||||||||||||||||||||||
YG AI Industrial Automation Solutions FUND | ||||||||||||||||||||||||||||
Semicolon Susong REITs Co., Ltd. | ( | ) | ||||||||||||||||||||||||||
KB-Novus Genesis Private Equity Fund | ||||||||||||||||||||||||||||
ATP TP VC Fund No.1 | ||||||||||||||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||||||
December 31, 2025* | ||||||||||||||||||||||||||||
Total assets | Total liabilities | Paid-in capital | Equity | Share of net asset amount | Unrealized gains (losses) and others | Consolidated carrying amount | ||||||||||||||||||||||
AIM-KB-DOUBLE | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
KB-IMM New Star Real Estate Private Fund II | ||||||||||||||||||||||||||||
K-1 23rd yeoksam Real Estate Investment Trust company Ltd. | | | | | | |||||||||||||||||||||||
IMM Korea Beauty Co-Invest Private Equity Fund | ||||||||||||||||||||||||||||
VP Inc. | ||||||||||||||||||||||||||||
DAILY Fountainhead Blind Private Equity Fund II | ||||||||||||||||||||||||||||
KB-ANDA Deep Tech Venture Fund | ||||||||||||||||||||||||||||
(In millions of Korean won) | 2025* | |||||||||||||||||||
Operating revenue | Net profit (loss) | Other comprehensive income (loss) | Total comprehensive income (loss) | Dividends | ||||||||||||||||
KB-KDBC Pre-IPO New Technology Business Investment Fund | ₩ | ₩ | ( | ) | ₩ | ₩ | ( | ) | ₩ | |||||||||||
Balhae Infrastructure Company | ( | ) | ( | ) | ||||||||||||||||
Aju Good Technology Venture Fund | ||||||||||||||||||||
Incheon Bridge Co., Ltd. | ||||||||||||||||||||
Big Dipper Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||
Food Factory Co., Ltd. | ||||||||||||||||||||
Korea Credit Bureau Co., Ltd. | ||||||||||||||||||||
KB Social Impact Investment Fund | ||||||||||||||||||||
KB-Solidus Global Healthcare Fund | ||||||||||||||||||||
POSCO-KB Shipbuilding Fund | ( | ) | ( | ) | ||||||||||||||||
KB-TS Technology Venture Private Equity Fund | ( | ) | ( | ) | ||||||||||||||||
KB-SJ Tourism Venture Fund | ||||||||||||||||||||
UNION Media Commerce Fund | ( | ) | ( | ) | ||||||||||||||||
KB-Stonebridge Secondary Private Equity Fund | ( | ) | ( | ) | ||||||||||||||||
KB SPROTT Renewable Private Equity Fund No.1 | ( | ) | ( | ) | ||||||||||||||||
KB-UTC Inno-Tech Venture Fund | ( | ) | ( | ) | ||||||||||||||||
WJ Private Equity Fund No.1 | ||||||||||||||||||||
All Together Korea Fund No.2 | ||||||||||||||||||||
KB-NAU Special Situation Corporate Restructuring Private Equity Fund | ||||||||||||||||||||
2020 KB Fintech Renaissance Fund | ( | ) | ( | ) | ||||||||||||||||
FineKB Private Equity Fund No.1 | ||||||||||||||||||||
G payment Joint Stock Company | ||||||||||||||||||||
KB-GeneN Medical Venture Fund No.1 | ( | ) | ( | ) | ||||||||||||||||
DA-Friend New Technology Investment Fund No.2 | ( | ) | ( | ) | ||||||||||||||||
Cornerstone Pentastone Fund No.4 | ( | ) | ( | ) | ||||||||||||||||
Star-Lord General Investors Private Real Estate Investment Company No.10 | ||||||||||||||||||||
KB-Badgers Future Mobility ESG Fund No.1 | ( | ) | ( | ) | ||||||||||||||||
JS Private Equity Fund No.3 | ||||||||||||||||||||
Mirae Asset Mobility Investment Fund No.1 | ( | ) | ( | ) | ||||||||||||||||
KB-FT Green Growth 1st Technology Investment Association | ( | ) | ( | ) | ||||||||||||||||
(In millions of Korean won) | 2025* | |||||||||||||||||||
Operating revenue | Net profit (loss) | Other comprehensive income (loss) | Total comprehensive income (loss) | Dividends | ||||||||||||||||
Glenwood Credit Private Equity Fund No.2 | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
Smart Korea KB Future9-Sejong Venture Fund | ( | ) | ( | ) | ||||||||||||||||
KB-KTB Technology Venture Fund | ( | ) | ( | ) | ||||||||||||||||
KB-SOLIDUS Healthcare Investment Fund | ||||||||||||||||||||
Paramark KB Fund No.1 | ( | ) | ( | ) | ||||||||||||||||
KB Co-Investment Private Equity Fund No.1 | ||||||||||||||||||||
KB-NP Green ESG New Technology Venture Capital Fund | ||||||||||||||||||||
TMAP Mobility Co., Ltd. | ||||||||||||||||||||
Nextrade Co., Ltd. | ||||||||||||||||||||
Shinhan Global Mobility Fund No.1 | ( | ) | ( | ) | ||||||||||||||||
SKB Next Unicorn K-Battery Fund No.1 | ( | ) | ( | ) | ||||||||||||||||
Bitgoeul Cheomdan Green 1st Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||
KB-SUSUNG 1st Investment Fund | ||||||||||||||||||||
Shinhan-Eco Venture Fund 2nd | ( | ) | ( | ) | ||||||||||||||||
Leading H2O Fund 1 | ( | ) | ( | ) | ||||||||||||||||
U-KB Credit No.1S Private Equity | ( | ) | ( | ) | ||||||||||||||||
KB-BridgePole Venture Investment Fund No.2 | ( | ) | ( | ) | ||||||||||||||||
Sirius Silicon Valley I New Technology Fund | ( | ) | ( | ) | ||||||||||||||||
FineKB Private Equity Fund No.2 | ( | ) | ( | ) | ||||||||||||||||
Timefolio Athleisure Investment Fund | ( | ) | ( | ) | ||||||||||||||||
VIG Private Equity Fund V-3 | ( | ) | ( | ) | ||||||||||||||||
COMPA Global Scale-Up Fund No.3 | ( | ) | ( | ) | ||||||||||||||||
HI YG Win-win Fund No.2 | ||||||||||||||||||||
KB-CJ Venture Fund 1st | ||||||||||||||||||||
Elohim-Bilanx aerospace No.1 Fund | ( | ) | ( | ) | ||||||||||||||||
KB-SUSUNG 2st Investment Fund | ( | ) | ( | ) | ||||||||||||||||
IMM global Secondary 1-1 Equity Private Fund | ||||||||||||||||||||
LIB Material Investment Fund | ( | ) | ( | ) | ||||||||||||||||
Allra Fintech Corp. | ||||||||||||||||||||
Reboot Private Equity Fund | ( | ) | ( | ) | ||||||||||||||||
KB-SBI Global Strategic Capital Fund | ( | ) | ( | ) | ||||||||||||||||
KB-Cyrus Tourism Venture Fund | ( | ) | ( | ) | ||||||||||||||||
IBKS Design Fund | ||||||||||||||||||||
KB-IMM New Star Real Estate Private Fund I | ||||||||||||||||||||
KB-LB Middle Market Enterprises Innovation Private Equity Fund | ( | ) | ( | ) | ||||||||||||||||
YG AI Industrial Automation Solutions FUND | ( | ) | ( | ) | ||||||||||||||||
Semicolon Susong REITs Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||
KB-Novus Genesis Private Equity Fund | ( | ) | ( | ) | ||||||||||||||||
ATP TP VC Fund No.1 | ( | ) | ( | ) | ||||||||||||||||
AIM-KB-DOUBLE | ( | ) | ( | ) | ||||||||||||||||
KB-IMM New Star Real Estate Private Fund II | ||||||||||||||||||||
K-1 23rd yeoksam Real Estate Investment Trust company Ltd. | ||||||||||||||||||||
IMM Korea Beauty Co-Invest Private Equity Fund | ( | ) | ( | ) | ||||||||||||||||
DAILY Fountainhead Blind Private Equity Fund II | ( | ) | ( | ) | ||||||||||||||||
| * | The condensed financial information of the associates and joint ventures is adjusted to reflect adjustments, such as fair value adjustments recognized at the time of acquisition and adjustments for differences in accounting policies. |
(In millions of Korean won) | 2024* | |||||||||||||||||||||||||||||||
Beginning | Acquisition and others | Disposal and others | Dividends | Gains (losses) on equity- method accounting | Other compre- hensive income (loss) | Others | Ending | |||||||||||||||||||||||||
KB-KDBC Pre-IPO New Technology Business Investment Fund | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | ( | ) | ₩ | ₩ | ₩ | ||||||||||||||||||||
Balhae Infrastructure Company | | ( | ) | ( | ) | | | |||||||||||||||||||||||||
Aju Good Technology Venture Fund | | ( | ( | ) | ||||||||||||||||||||||||||||
Big Dipper Co., Ltd. | | ( | ) | |||||||||||||||||||||||||||||
Food Factory Co., Ltd. | ||||||||||||||||||||||||||||||||
KBSP Private Equity Fund No.4 | ||||||||||||||||||||||||||||||||
Korea Credit Bureau Co., Ltd. | ( | ) | ||||||||||||||||||||||||||||||
KB Social Impact Investment Fund | ( | ) | ||||||||||||||||||||||||||||||
KB-Solidus Global Healthcare Fund | ( | ) | ( | ) | ||||||||||||||||||||||||||||
POSCO-KB Shipbuilding Fund | ( | ) | ||||||||||||||||||||||||||||||
KB-TS Technology Venture Private Equity Fund | ( | ) | ||||||||||||||||||||||||||||||
KB-Brain KOSDAQ Scale-up New Technology Business Investment Fund | ( | ) | ( | ) | ||||||||||||||||||||||||||||
KB-SJ Tourism Venture Fund | ( | ) | ( | ) | ||||||||||||||||||||||||||||
UNION Media Commerce Fund | ( | ) | ||||||||||||||||||||||||||||||
KB-Stonebridge Secondary Private Equity Fund | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
KB SPROTT Renewable Private Equity Fund No.1 | ( | ) | ||||||||||||||||||||||||||||||
KB-UTC Inno-Tech Venture Fund | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
WJ Private Equity Fund No.1 | ( | ) | ||||||||||||||||||||||||||||||
All Together Korea Fund No.2 | ||||||||||||||||||||||||||||||||
KB-NAU Special Situation Corporate Restructuring Private Equity Fund | ( | ) | ( | ) | ||||||||||||||||||||||||||||
2020 KB Fintech Renaissance Fund | ||||||||||||||||||||||||||||||||
KB Material and Parts No.1 PEF | ( | ) | ||||||||||||||||||||||||||||||
FineKB Private Equity Fund No.1 | ( | ) | ( | ) | | | ||||||||||||||||||||||||||
G payment Joint Stock Company | ( | ) | | ( | ) | |||||||||||||||||||||||||||
KB-GeneN Medical Venture Fund No.1 | | | | ( | ) | |||||||||||||||||||||||||||
KB-BridgePole Venture Investment Fund | ( | ) | | |||||||||||||||||||||||||||||
KB-Kyobo New Mobility Power Fund | ( | ) | | |||||||||||||||||||||||||||||
DA-Friend New Technology Investment Fund No.2 | ( | ) | ||||||||||||||||||||||||||||||
Cornerstone Pentastone Fund No.4 | ( | ) | ||||||||||||||||||||||||||||||
KB-Badgers Future Mobility ESG Fund No.1 | ( | ) | ( | ) | ||||||||||||||||||||||||||||
JS Private Equity Fund No.3 | ( | ) | ( | ) | ||||||||||||||||||||||||||||
Mirae Asset Mobility Investment Fund No.1 | ( | ) | ||||||||||||||||||||||||||||||
KB-FT Green Growth 1st Technology Investment Association | ( | ) | ||||||||||||||||||||||||||||||
Glenwood Credit Private Equity Fund No.2 | ( | ) | ||||||||||||||||||||||||||||||
THE CHAEUL FUND NO.1 | ( | ) | ||||||||||||||||||||||||||||||
Smart Korea KB Future9-Sejong Venture Fund | ( | ) | ||||||||||||||||||||||||||||||
KB-KTB Technology Venture Fund | ( | ) | ||||||||||||||||||||||||||||||
KB-SOLIDUS Healthcare Investment Fund | ( | ) | ||||||||||||||||||||||||||||||
(In millions of Korean won) | 2024* | |||||||||||||||||||||||||||||||
Beginning | Acquisition and others | Disposal and others | Dividends | Gains (losses) on equity- method accounting | Other compre- hensive income (loss) | Others | Ending | |||||||||||||||||||||||||
Paramark KB Fund No.1 | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||
KB Co-Investment Private Equity Fund No.1 | ( | ) | ||||||||||||||||||||||||||||||
POSITIVE Sobujang Venture Fund No.1 | ( | ) | ( | ) | ||||||||||||||||||||||||||||
History 2022 Fintech Fund | ( | ) | ||||||||||||||||||||||||||||||
KB-NP Green ESG New Technology Venture Capital Fund | ( | ) | ||||||||||||||||||||||||||||||
TMAP Mobility Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||||||||||||||
Nextrade Co., Ltd. | ( | ) | ||||||||||||||||||||||||||||||
Shinhan Global Mobility Fund No.1 | ( | ) | ||||||||||||||||||||||||||||||
SKB Next Unicorn K-Battery Fund No.1 | | | | ( | ) | | ||||||||||||||||||||||||||
Lakewood-AVES Fund No.1 | ( | ) | ||||||||||||||||||||||||||||||
MW-Pyco NewWave New Technology Investment Fund 4th | ( | ) | ||||||||||||||||||||||||||||||
Bitgoeul Cheomdan Green 1st Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||||||||||||||
KB-SUSUNG 1st Investment Fund | ( | ) | ||||||||||||||||||||||||||||||
Friend 55 New Technology Business Investment Fund | ( | ) | | |||||||||||||||||||||||||||||
KY Global Cell & Gene Private Equity Fund 2nd | ( | ) | ||||||||||||||||||||||||||||||
DSIP-Pharos Bioenergy Fund | ( | ) | ||||||||||||||||||||||||||||||
Shinhan-Eco Venture Fund 2nd | ( | ) | | |||||||||||||||||||||||||||||
Leading H2O Fund 1 | ( | ) | ||||||||||||||||||||||||||||||
2023 JB Newtech No.2 Fund | ( | ) | ( | |||||||||||||||||||||||||||||
U-KB Credit No.1 Private Equity | ||||||||||||||||||||||||||||||||
KB-BridgePole Venture Investment Fund No.2 | ( | ) | ||||||||||||||||||||||||||||||
Sirius Silicon Valley I New Technology Fund | ( | ) | ||||||||||||||||||||||||||||||
FineKB Private Equity Fund No.2 | ( | ) | ||||||||||||||||||||||||||||||
Timefolio Athleisure Investment Fund | ( | ) | ||||||||||||||||||||||||||||||
VIG Private Equity Fund V-3 | ||||||||||||||||||||||||||||||||
COMPA Global Scale-Up Fund No.3 | ( | ) | ||||||||||||||||||||||||||||||
AKK Robotech Valueup New Technology Investment Fund | ||||||||||||||||||||||||||||||||
YG MCE PROJECT NO.1 Fund | ( | ) | ||||||||||||||||||||||||||||||
HI YG Win-win Fund No.2 | ( | ) | ||||||||||||||||||||||||||||||
KB-CJ Venture Fund 1st | ( | |||||||||||||||||||||||||||||||
Elohim-Bilanx aerospace No.1 Fund | ( | ) | ||||||||||||||||||||||||||||||
KB-SUSUNG 2st Investment Fund | | ( | ) | | ||||||||||||||||||||||||||||
IMM global Secondary 1-1 Equity Private Fund | ||||||||||||||||||||||||||||||||
LIB Material Investment Fund | ( | ) | ||||||||||||||||||||||||||||||
NOVORSEC-SJG Consumer Secondary Fund | ( | ) | ||||||||||||||||||||||||||||||
Allra Fintech Corp. | ||||||||||||||||||||||||||||||||
Reboot Private Equity Fund | ( | ) | ||||||||||||||||||||||||||||||
KB-SBI Global Strategic Capital Fund | | | | ( | ) | |||||||||||||||||||||||||||
KB-Cyrus Tourism Venture Fund | ( | ) | ||||||||||||||||||||||||||||||
IBKS Design Fund | ( | ) | | |||||||||||||||||||||||||||||
(In millions of Korean won) | 2024* | |||||||||||||||||||||||||||||||
Beginning | Acquisition and others | Disposal and others | Dividends | Gains (losses) on equity- method accounting | Other compre- hensive income (loss) | Others | Ending | |||||||||||||||||||||||||
NICE DATA INTELLIGENCE VENTURE FUND | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | | ₩ | | ₩ | ||||||||||||||||||||
Pectus Hanhwa Fund 2 | ( | ) | ||||||||||||||||||||||||||||||
KB-IMM New Star Real Estate Private Fund I | | |||||||||||||||||||||||||||||||
Korea Environment Technology Co.,Ltd. | ||||||||||||||||||||||||||||||||
Others | | ( | ) | ( | ) | |||||||||||||||||||||||||||
| ₩ | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ₩ | |||||||||||||||||||
(In millions of Korean won) | 2025* | |||||||||||||||||||||||||||||||
Beginning | Acquisition and others | Disposal and others | Dividends | Gains (losses) on equity- method accounting | Other compre- hensive income (loss) | Others | Ending | |||||||||||||||||||||||||
KB-KDBC Pre-IPO New Technology Business Investment Fund | ₩ | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||
Balhae Infrastructure Company | | | ( | ) | ( | ) | ( | ) | | |||||||||||||||||||||||
Aju Good Technology Venture Fund | ( | ) | ||||||||||||||||||||||||||||||
Incheon Bridge Co., Ltd. | ||||||||||||||||||||||||||||||||
Big Dipper Co., Ltd. | | ( | ) | |||||||||||||||||||||||||||||
Food Factory Co., Ltd. | | ( | ) | |||||||||||||||||||||||||||||
KBSP Private Equity Fund No.4 | ( | ) | ||||||||||||||||||||||||||||||
Korea Credit Bureau Co., Ltd. | ( | ) | ||||||||||||||||||||||||||||||
KB Social Impact Investment Fund | | |||||||||||||||||||||||||||||||
KB-Solidus Global Healthcare Fund | ( | ) | ( | ) | ||||||||||||||||||||||||||||
VIG Private Equity Fund V-3 | ( | ) | ||||||||||||||||||||||||||||||
KB-Badgers Future Mobility ESG Fund No.1 | ( | ) | ( | ) | ||||||||||||||||||||||||||||
POSCO-KB Shipbuilding Fund | ( | ) | ( | ) | ||||||||||||||||||||||||||||
KB-TS Technology Venture Private Equity Fund | ( | ) | ||||||||||||||||||||||||||||||
KB-KTB Technology Venture Fund | ( | ) | ||||||||||||||||||||||||||||||
KB-SOLIDUS Healthcare Investment Fund | ||||||||||||||||||||||||||||||||
KB Co-Investment Private Equity Fund No.1 | ( | ) | ( | ) | ||||||||||||||||||||||||||||
KB-SJ Tourism Venture Fund | ( | ) | ( | ) | ||||||||||||||||||||||||||||
UNION Media Commerce Fund | ( | ) | ||||||||||||||||||||||||||||||
KB-Stonebridge Secondary Private Equity Fund | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
KB SPROTT Renewable Private Equity Fund No.1 | ( | ) | ( | ) | ||||||||||||||||||||||||||||
KB-UTC Inno-Tech Venture Fund | ( | ) | ( | ) | ||||||||||||||||||||||||||||
WJ Private Equity Fund No.1 | ||||||||||||||||||||||||||||||||
All Together Korea Fund No.2 | ||||||||||||||||||||||||||||||||
KB-NAU Special Situation Corporate Restructuring Private Equity Fund | ( | ) | ||||||||||||||||||||||||||||||
2020 KB Fintech Renaissance Fund | ( | ) | ( | ) | ||||||||||||||||||||||||||||
FineKB Private Equity Fund No.1 | ( | ) | ( | ) | ||||||||||||||||||||||||||||
FineKB Private Equity Fund No.2 | ( | ) | ||||||||||||||||||||||||||||||
Paramark KB Fund No.1 | ( | ) | ( | ) | ||||||||||||||||||||||||||||
(In millions of Korean won) | 2025* | |||||||||||||||||||||||||||||||
Beginning | Acquisition and others | Disposal and others | Dividends | Gains (losses) on equity- method accounting | Other compre- hensive income (loss) | Others | Ending | |||||||||||||||||||||||||
G payment Joint Stock Company | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | ||||||||||||||||||||||
TMAP Mobility Co., Ltd. | | ( | ) | |||||||||||||||||||||||||||||
KB-GeneN Medical Venture Fund No.1 | | | ( | ) | ||||||||||||||||||||||||||||
DA-Friend New Technology Investment Fund No.2 | ( | ) | | | ||||||||||||||||||||||||||||
Cornerstone Pentastone Fund No.4 | ( | ) | ||||||||||||||||||||||||||||||
JS Private Equity Fund No.3 | ( | ) | ||||||||||||||||||||||||||||||
Mirae Asset Mobility Investment Fund No.1 | ( | ) | | |||||||||||||||||||||||||||||
KB-FT Green Growth 1st Technology Investment Association | | ( | ) | |||||||||||||||||||||||||||||
THE CHAEUL FUND NO.1 | ( | ) | | |||||||||||||||||||||||||||||
Glenwood Credit Private Equity Fund No.2 | ( | ) | ||||||||||||||||||||||||||||||
POSITIVE Sobujang Venture Fund No.1 | ( | ) | ||||||||||||||||||||||||||||||
History 2022 Fintech Fund | ( | ) | ||||||||||||||||||||||||||||||
Nextrade Co., Ltd. | ||||||||||||||||||||||||||||||||
KB-NP Green ESG New Technology Venture Capital Fund | ( | ) | ||||||||||||||||||||||||||||||
MW-Pyco NewWave New Technology Investment Fund 4th | ( | ) | ||||||||||||||||||||||||||||||
KB-SUSUNG 1st Investment Fund | ( | ) | ||||||||||||||||||||||||||||||
Bitgoeul Cheomdan Green 1st Co., Ltd. | ( | ) | ||||||||||||||||||||||||||||||
Shinhan-Eco Venture Fund 2nd | ( | ) | ( | ) | ||||||||||||||||||||||||||||
Leading H2O Fund 1 | ( | ) | ||||||||||||||||||||||||||||||
2023 JB Newtech No.2 Fund | ( | ) | ( | ) | ||||||||||||||||||||||||||||
KB-BridgePole Venture Investment Fund No.2 | ( | ) | | | ||||||||||||||||||||||||||||
Sirius Silicon Valley I New Technology Fund | ( | ) | ||||||||||||||||||||||||||||||
Timefolio Athleisure Investment Fund | ( | ) | ||||||||||||||||||||||||||||||
COMPA Global Scale-Up Fund No.3 | ( | ) | | |||||||||||||||||||||||||||||
AKK Robotech Valueup New Technology Investment Fund | ( | ) | ||||||||||||||||||||||||||||||
YG MCE PROJECT NO.1 Fund | ( | ) | ||||||||||||||||||||||||||||||
HI YG Win-win Fund No.2 | ||||||||||||||||||||||||||||||||
KB-CJ Venture Fund 1st | ||||||||||||||||||||||||||||||||
Elohim-Bilanx aerospace No.1 Fund | ( | ) | ||||||||||||||||||||||||||||||
KB-SUSUNG 2st Investment Fund | ( | ) | ||||||||||||||||||||||||||||||
IMM global Secondary 1-1 Equity Private Fund | ( | ) | ( | ) | ||||||||||||||||||||||||||||
LIB Material Investment Fund | ( | ) | ||||||||||||||||||||||||||||||
NOVORSEC-SJG Consumer Secondary Fund | | ( | ) | |||||||||||||||||||||||||||||
U-KB Credit No.1S Private Equity | | ( | ) | |||||||||||||||||||||||||||||
Smart Korea KB Future9-Sejong Venture Fund | ( | ) | ||||||||||||||||||||||||||||||
Allra Fintech Corp. | ||||||||||||||||||||||||||||||||
Shinhan Global Mobility Fund No.1 | ( | ) | ||||||||||||||||||||||||||||||
SKB Next Unicorn K-Battery Fund No.1 | ( | ) | ||||||||||||||||||||||||||||||
Reboot Private Equity Fund | ( | ) | ||||||||||||||||||||||||||||||
(In millions of Korean won) | 2025* | |||||||||||||||||||||||||||||||
Beginning | Acquisition and others | Disposal and others | Dividends | Gains (losses) on equity- method accounting | Other compre- hensive income (loss) | Others | Ending | |||||||||||||||||||||||||
KB-SBI Global Strategic Capital Fund | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | ₩ | ||||||||||||||||||||||
KB-Cyrus Tourism Venture Fund | ( | ) | ||||||||||||||||||||||||||||||
IBKS Design Fund | ||||||||||||||||||||||||||||||||
NICE DATA INTELLIGENCE VENTURE FUND | ( | ) | ||||||||||||||||||||||||||||||
Pectus Hanhwa Fund 2 | ( | ) | ||||||||||||||||||||||||||||||
KB-IMM New Star Real Estate Private Fund I | ( | ) | ||||||||||||||||||||||||||||||
Korea Environment Technology Co.,Ltd. | ( | ) | ||||||||||||||||||||||||||||||
KB-LB Middle Market Enterprises Innovation Private Equity Fund | ( | ) | ||||||||||||||||||||||||||||||
YG AI Industrial Automation Solutions FUND | ( | ) | ||||||||||||||||||||||||||||||
Semicolon Susong REITs Co., Ltd. | ( | ) | ||||||||||||||||||||||||||||||
KB-Novus Genesis Private Equity Fund | ( | ) | ||||||||||||||||||||||||||||||
ATP TP VC Fund No.1 | ( | ) | ||||||||||||||||||||||||||||||
AIM-KB-DOUBLE | ( | ) | ||||||||||||||||||||||||||||||
KB-IMM New Star Real Estate Private Fund II | ( | ) | ||||||||||||||||||||||||||||||
K-1 23rd yeoksam Real Estate Investment Trust company Ltd. | ( | ) | ||||||||||||||||||||||||||||||
IMM Korea Beauty Co-Invest Private Equity Fund | ( | ) | ||||||||||||||||||||||||||||||
VP Inc. | ||||||||||||||||||||||||||||||||
DAILY Fountainhead Blind Private Equity Fund II | ( | ) | ( | ) | ||||||||||||||||||||||||||||
KB-ANDA Deep Tech Venture Fund | ||||||||||||||||||||||||||||||||
E&I Holdings | ( | ) | ||||||||||||||||||||||||||||||
Others | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| ₩ | | ₩ | | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ₩ | ( | ) | ₩ | |||||||||||||||||
* | Gains (losses) on disposal of investments in associates and joint ventures amount to ₩ (10,552) million and ₩ 12,041 million for the years ended December 31, 2024 and 2025, respectively. |
(In millions of Korean won) | Unrecognized losses (gains) for the period | Accumulated unrecognized losses | ||||||||||||||
2024 | 2025 | December 31, 2024 | December 31, 2025 | |||||||||||||
DSMETAL Co., Ltd. | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Incheon Bridge Co., Ltd. | ( | ) | ||||||||||||||
Jaeyang Industry Co., Ltd. | ||||||||||||||||
Terra Corporation | ||||||||||||||||
Jungdo Co., Ltd. | ||||||||||||||||
Korea NM Tech Co., Ltd. | ||||||||||||||||
Chongil Machine & Tools Co., Ltd. | ||||||||||||||||
Skydigital Inc. | ( | ) | ( | ) | ||||||||||||
Imt Technology Co., Ltd. | ||||||||||||||||
Jo Yang Industrial Co., Ltd. | ||||||||||||||||
MJT&I Corp. | ||||||||||||||||
Dae-A Leisure Co., Ltd. | ||||||||||||||||
Il-Kwang Electronic Materials Co., Ltd. | ||||||||||||||||
Dongjo Co., Ltd. | ( | ) | ( | ) | ||||||||||||
Iwon Alloy Co., Ltd. | ||||||||||||||||
Chunsung-meat co., ltd. | ||||||||||||||||
ALTSCS CO., LTD. | ( | ) | ( | ) | ||||||||||||
E-won Chemical Co.,Ltd. | ( | ) | ||||||||||||||
TKDS Co., Ltd | ||||||||||||||||
TAEYEONG PRECISION IND. Co., Ltd | ||||||||||||||||
MJ K Trading Co. | ||||||||||||||||
DNGV Co.,Ltd. | ( | ) | ||||||||||||||
Alpa Information&Communication Co.,Ltd. | ||||||||||||||||
JC TECHNO Co.,Ltd. | ||||||||||||||||
RAND Bio Science Co., Ltd. | ||||||||||||||||
Star-Lord General Investors Private Real Estate Investment Company No.10 | ||||||||||||||||
SD Speed Co.,Ltd. | ||||||||||||||||
Seokwang T&I Co., Ltd | ||||||||||||||||
Big Dipper Co., Ltd. | ( | ) | ( | ) | ||||||||||||
| ₩ | ( | ) | ₩ | ₩ | ₩ | |||||||||||
(In millions of Korean won) | December 31, 2024 | |||||||||||||||
Acquisition cost | Accumulated depreciation | Accumulated impairment losses | Carrying amount | |||||||||||||
Land | ₩ | ₩ | ₩ | ( | ) | ₩ | ||||||||||
Buildings | ( | ) | ( | ) | ||||||||||||
Leasehold improvements | ( | ) | ||||||||||||||
Equipment and vehicles | ( | ) | ||||||||||||||
Construction in-progress | ||||||||||||||||
Right-of-use | ( | ) | ( | ) | ||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | |||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||||||
Acquisition cost | Accumulated depreciation | Accumulated impairment losses | Carrying amount | |||||||||||||
Land | ₩ | ₩ | ₩ | ( | ) | ₩ | ||||||||||
Buildings | ( | ) | ( | ) | ||||||||||||
Leasehold improvements | ( | ) | ||||||||||||||
Equipment and vehicles | ( | ) | ||||||||||||||
Construction in-progress | ||||||||||||||||
Right-of-use | ( | ) | ( | ) | ||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | |||||||||
2024 | ||||||||||||||||||||||||||||
Beginning | Acquisition | Transfer 1 | Disposal | Depreciation 2 | Others | Ending | ||||||||||||||||||||||
Land | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | ₩ | |||||||||||||||||||
Buildings | ( | ) | ( | ) | ||||||||||||||||||||||||
Leasehold improvements | ( | ) | ( | ) | ||||||||||||||||||||||||
Equipment and vehicles | ( | ) | ( | ) | ||||||||||||||||||||||||
Construction in-progress | ( | ) | ( | ) | ||||||||||||||||||||||||
Right-of-use assets | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||
| ₩ | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ||||||||||||||||
2025 | ||||||||||||||||||||||||||||
Beginning | Acquisition | Transfer 1 | Disposal | Depreciation 2 | Others | Ending | ||||||||||||||||||||||
Land | ₩ | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ( | ) | ₩ | |||||||||||||||
Buildings | ( | ) | ( | ) | ||||||||||||||||||||||||
Leasehold improvements | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||
Equipment and vehicles | ( | ) | ( | ) | ( | |||||||||||||||||||||||
Construction in-progress | ( | ) | ( | ) | ||||||||||||||||||||||||
Right-of-use assets | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||
| ₩ | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ||||||||||||||
1 | Includes transfers with investment properties and assets held for sale. |
2 | Includes depreciation expenses amounting to ₩ |
(In millions of Korean won) | 2024 | |||||||||||||||||||
Beginning | Impairment | Reversal | Disposal and others | Ending | ||||||||||||||||
Accumulated impairment losses of property and equipment | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ₩ | ( | ) | |||||||||
(In millions of Korean won) | 2025 | |||||||||||||||||||
Beginning | Impairment | Reversal | Disposal and others | Ending | ||||||||||||||||
Accumulated impairment losses of property and equipment | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ₩ | ( | ) | |||||||||
(In millions of Korean won) | December 31, 2024 | |||||||||||||||
Acquisition cost | Accumulated depreciation | Accumulated impairment losses | Carrying amount | |||||||||||||
Land | ₩ | ₩ | ₩ | ( | ) | ₩ | ||||||||||
Buildings | ( | ) | ( | ) | ||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | |||||||||
(In millions of Korean won) |
December 31, 2025 |
|||||||||||||||
Acquisition cost |
Accumulated depreciation |
Accumulated impairment losses |
Carrying amount |
|||||||||||||
|
Land
|
₩ | ₩ | ₩ | ( |
) | ₩ | ||||||||||
|
Buildings
|
( |
) | ( |
) | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
(In millions of Korean won) |
December 31, 2025 |
|||||||
Fair value |
Valuation techniques |
Inputs
|
||||||
|
Land and buildings
|
₩ | Cost approach method | - Officially assessed value
- Replacement cost |
|||||
| Market comparison method |
|
|||||||
| Discounted cash flow method |
- Prospective rental market growth rate
- Period of vacancy
- Rental ratio
- Discount rate and others |
|||||||
2024 |
||||||||||||||||||||||||||||
Beginning |
Acquisition |
Transfer* |
Disposal |
Depreciation |
Others |
Ending |
||||||||||||||||||||||
|
Land
|
₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ₩ | ₩ | |||||||||||||||||||
|
Buildings
|
( |
) | ( |
) | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
2025 |
||||||||||||||||||||||||||||
Beginning |
Acquisition |
Transfer* |
Disposal |
Depreciation |
Others |
Ending |
||||||||||||||||||||||
|
Land
|
₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ₩ | ( |
) | ₩ | |||||||||||||||||
|
Buildings
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
| * |
Includes transfers with property and equipment and assets held for sale.
|
December 31, 2024 |
||||||||||||||||||||
Acquisition cost |
Accumulated amortization |
Accumulated impairment losses |
Others |
Carrying amount |
||||||||||||||||
|
Goodwill
|
₩ | ₩ | ₩ | ( |
) | ₩ | ₩ | |||||||||||||
|
Other intangible assets
|
( |
) | ( |
) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
December 31, 2025 |
||||||||||||||||||||
Acquisition cost |
Accumulated amortization |
Accumulated impairment losses |
Others |
Carrying amount |
||||||||||||||||
|
Goodwill
|
₩ | ₩ | ₩ | ( |
) | ₩ | ₩ | |||||||||||||
|
Other intangible assets
|
( |
) | ( |
) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
(In millions of Korean won) |
December 31, 2024 |
December 31, 2025 |
||||||||||||||
Acquisition cost |
Carrying amount 1 |
Acquisition cost |
Carrying amount 1 |
|||||||||||||
|
Housing & Commercial Bank
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
KB Securities Co., Ltd.
|
||||||||||||||||
|
KB Capital Co., Ltd.
|
||||||||||||||||
|
KB Savings Bank Co., Ltd.
|
||||||||||||||||
|
KB Securities Vietnam Joint Stock Company
|
||||||||||||||||
|
KB DAEHAN SPECIALIZED BANK PLC.
2 |
||||||||||||||||
|
KB PRASAC Bank PLC.
|
||||||||||||||||
|
PT Sunindo Kookmin Best Finance
|
||||||||||||||||
|
PT Bank KB Bukopin Tbk
|
||||||||||||||||
|
PT. KB Finansia Multi Finance
|
||||||||||||||||
|
PT. KB Valbury Sekurita
|
||||||||||||||||
|
Others
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
1 |
Includes the effect of exchange differences and others.
|
2 |
KB DAEHAN SPECIALIZED BANK PLC. and
I-Finance Leasing merged on December 19, 2024. |
(In millions of Korean won) | 2024 | |||||||||||||||
Beginning | Impairment | Others | Ending | |||||||||||||
Accumulated impairment losses of goodwill | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ||||
(In millions of Korean won) | 2025 | |||||||||||||||
Beginning | Impairment | Others | Ending | |||||||||||||
Accumulated impairment losses of goodwill | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ||||
(In millions of Korean won) | December 31, 2025 | |||||||||||||||||||
Carrying amount of goodwill | Recoverable amount exceeding carrying amount* | Discount rate (%) | Permanent growth rate (%) | |||||||||||||||||
Housing & Commercial Bank | Retail banking | ₩ | ₩ | |||||||||||||||||
| Corporate banking | ||||||||||||||||||||
KB Securities Co., Ltd. | ||||||||||||||||||||
KB Capital Co., Ltd. | ||||||||||||||||||||
KB Savings Bank Co., Ltd. and Yehansoul Savings Bank Co., Ltd. | ||||||||||||||||||||
KB Securities Vietnam Joint Stock Company | ||||||||||||||||||||
PT Bank KB Bukopin Tbk | ||||||||||||||||||||
KB PRASAC Bank Plc | ( | ) | ||||||||||||||||||
PT Sunindo Kookmin Best Finance | ( | ) | ||||||||||||||||||
PT. KB Finansia Multi Finance | ||||||||||||||||||||
PT. KB Valbury Sekurita | ||||||||||||||||||||
Others | ||||||||||||||||||||
| ₩ | ₩ | |||||||||||||||||||
| * | The recoverable amount exceeding carrying amount is the amount at the time of impairment testing. |
(In millions of Korean won) | December 31, 2024 | |||||||||||||||
Acquisition cost | Accumulated amortization | Accumulated impairment losses | Carrying amount | |||||||||||||
Industrial property rights | ₩ | ₩ | ( | ) | ₩ | ₩ | ||||||||||
Software | ( | ) | ( | ) | ||||||||||||
Other intangible assets | ( | ) | ( | ) | ||||||||||||
Right-of-use | ( | ) | ||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | |||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||||||
Acquisition cost | Accumulated amortization | Accumulated impairment losses | Carrying amount | |||||||||||||
Industrial property rights | ₩ | ₩ | ( | ) | ₩ | ₩ | ||||||||||
Software | ( | ) | ( | ) | ||||||||||||
Other intangible assets | ( | ) | ( | ) | ||||||||||||
Right-of-use | ( | ) | ||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | |||||||||
(In millions of Korean won) | ||||||||||||||||||||||||
2024 | ||||||||||||||||||||||||
Beginning | Acquisition & transfer | Disposal | Amortization 1 | Others | Ending | |||||||||||||||||||
Industrial property rights | ₩ | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ||||||||||||||
Software | ( | ) | ( | ) | ||||||||||||||||||||
Other intangible assets 2 | ( | ) | ( | ) | ( | ) | ||||||||||||||||||
Right-of-use | ( | ) | ||||||||||||||||||||||
| ₩ | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | |||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||
2025 | ||||||||||||||||||||||||
Beginning | Acquisition & transfer | Disposal | Amortization 1 | Others | Ending | |||||||||||||||||||
Industrial property rights | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ||||||||||||||
Software | ( | ) | ( | ) | ( | ) | ||||||||||||||||||
Other intangible assets 2 | ( | ) | ( | ) | ( | ) | ||||||||||||||||||
Right-of-use | ( | ) | ||||||||||||||||||||||
| ₩ | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | |||||||||||||
1 | Includes ₩ |
2 | Impairment losses for membership right with indefinite useful life among other intangible assets are recognized when its recoverable amount is lower than its carrying amount, and reversal of impairment losses are recognized when its recoverable amount is higher than its carrying amount. |
(In millions of Korean won) | 2024 | |||||||||||||||||||
Beginning | Impairment | Reversal | Disposal and others | Ending | ||||||||||||||||
Accumulated impairment losses of other intangible assets | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ₩ | ( | ) | |||||||||
(In millions of Korean won) | 2025 | |||||||||||||||||||
Beginning | Impairment | Reversal | Disposal and others | Ending | ||||||||||||||||
Accumulated impairment losses of other intangible assets | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ₩ | ( | ) | |||||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Right-of-use | ||||||||
Real estate | ₩ | ₩ | ||||||
Vehicles | ||||||||
Others | ||||||||
Right-of-use | ||||||||
| ₩ | ₩ | |||||||
Lease liabilities* | ₩ | ₩ | ||||||
| * | Included in property and equipment, intangible assets, and other liabilities. |
(In millions of Korean won) | 2024 | 2025 | ||||||
Depreciation and amortization of right-of-use | ||||||||
Real estate | ₩ | ₩ | ||||||
Vehicles | ||||||||
Others | ||||||||
Intangible assets | ||||||||
| ₩ | ₩ | |||||||
Interest expenses on the lease liabilities | ₩ | ₩ | ||||||
Expense relating to short-term lease | ||||||||
Expense relating to lease of low-value assets that are not short-term lease | ||||||||
Expense relating to variable lease payments not included in lease liabilities (included in administrative expenses) | ||||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||||||||||
Gross investment in the lease | Present value of minimum lease payments | Gross investment in the lease | Present value of minimum lease payments | |||||||||||||
Up to 1 year | ₩ | ₩ | ₩ | ₩ | ||||||||||||
1-5 years | ||||||||||||||||
Over 5 years | ||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Gross investment in the lease | ₩ | ₩ | ||||||
Net investment in the lease: | ||||||||
Present value of minimum lease payments | ||||||||
Present value of unguaranteed residual value | ||||||||
Unearned finance income | ₩ | ₩ | ||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Minimum lease payments to be received: | ||||||||
Up to 1 year | ₩ | ₩ | ||||||
1-5 years | ||||||||
Over 5 years | ||||||||
| ₩ | ₩ | |||||||
(In millions of Korean won) | December 31, 2024 | |||||||||||
Assets | Liabilities | Net amount | ||||||||||
Other provisions | ₩ | ₩ | ₩ | |||||||||
Allowances for credit losses | ||||||||||||
Impairment losses of property and equipment | ( | ) | ||||||||||
Share-based payments | ||||||||||||
Provisions for acceptances and guarantees | ( | ) | ||||||||||
Gains or losses on valuation of derivatives | ( | ) | ||||||||||
Present value discount | ( | ) | ||||||||||
Gains or losses on fair value hedge | ( | ) | ( | ) | ||||||||
Accrued interest | ( | ) | ( | ) | ||||||||
Deferred loan origination fees and costs | ( | ) | ( | ) | ||||||||
Advanced depreciation provision | ( | ) | ( | ) | ||||||||
Gains or losses on revaluation | ( | ) | ( | ) | ||||||||
Investments in subsidiaries and others | ( | ) | ( | ) | ||||||||
Gains or losses on valuation of security investment | ( | ) | ||||||||||
Defined benefit liabilities | ||||||||||||
Accrued expenses | ||||||||||||
Retirement insurance expense | ( | ) | ( | ) | ||||||||
Adjustments to the prepaid contributions | ( | ) | ( | ) | ||||||||
Derivative-linked securities | ( | ) | ( | ) | ||||||||
Others* | ( | ) | ( | ) | ||||||||
| ( | ) | ( | ) | |||||||||
Offsetting of deferred income tax assets and liabilities | ( | ) | — | |||||||||
| ₩ | ₩ | ( | ) | ₩ | ( | ) | ||||||
(In millions of Korean won) |
December 31, 2025 |
|||||||||||
Assets |
Liabilities |
Net amount |
||||||||||
|
Other provisions
|
₩ | ₩ | ₩ | |||||||||
|
Allowances for credit losses
|
( |
) | ||||||||||
|
Impairment losses of property and equipment
|
( |
) | ||||||||||
|
Interest on equity index-linked deposits
|
||||||||||||
|
Share-based payments
|
||||||||||||
|
Provisions for acceptances and guarantees
|
( |
) | ||||||||||
|
Gains or losses on valuation of derivatives
|
( |
) | ( |
) | ||||||||
|
Present value discount
|
( |
) | ||||||||||
|
Gains or losses on fair value hedge
|
( |
) | ( |
) | ||||||||
|
Accrued interest
|
( |
) | ( |
) | ( |
) | ||||||
|
Deferred loan origination fees and costs
|
( |
) | ( |
) | ||||||||
|
Advanced depreciation provision
|
( |
) | ( |
) | ||||||||
|
Gains or losses on revaluation
|
( |
) | ( |
) | ||||||||
|
Investments in subsidiaries and others
|
( |
) | ( |
) | ||||||||
|
Gains or losses on valuation of security investment
|
( |
) | ||||||||||
|
Defined benefit liabilities
|
||||||||||||
|
Accrued expenses
|
||||||||||||
|
Retirement insurance expense
|
( |
) | ( |
) | ||||||||
|
Adjustments to the prepaid contributions
|
( |
) | ( |
) | ||||||||
|
Derivative-linked securities
|
( |
) | ( |
) | ||||||||
|
Others*
|
( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|
|||||||
| ( |
) | ( |
) | |||||||||
|
|
|
|
|
|
|
|||||||
|
Offsetting of deferred income tax assets and liabilities
|
( |
) | — | |||||||||
|
|
|
|
|
|
|
|||||||
| ₩ | ₩ | ( |
) | ₩ | ( |
) | ||||||
|
|
|
|
|
|
|
|||||||
| * |
Includes Purchase Price Allocation (“PPA”) amount arising from the acquisition of KB Life Insurance Co., Ltd., KB Insurance Co., Ltd..
|
| • |
The Group is able to control the timing of the reversal of the temporary differences.
|
| • |
It is probable that these temporary differences will not reverse in the foreseeable future.
|
(In millions of Korean won) |
2024 |
|||||||||||||||
Beginning |
Decrease |
Increase |
Ending |
|||||||||||||
|
Deductible temporary differences
|
||||||||||||||||
|
Other provisions
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
Allowances for credit losses
|
||||||||||||||||
|
Impairment losses of property and equipment
|
||||||||||||||||
|
Deferred loan origination fees and costs
|
||||||||||||||||
|
Share-based payments
|
||||||||||||||||
|
Provisions for acceptances and guarantees
|
||||||||||||||||
|
Gains or losses on valuation of derivatives
|
||||||||||||||||
|
Present value discount
|
||||||||||||||||
|
Investments in subsidiaries and others
|
||||||||||||||||
|
Gains or losses on valuation of security investment
|
||||||||||||||||
|
Defined benefit liabilities
|
||||||||||||||||
|
Accrued expenses
|
||||||||||||||||
|
Derivative-linked securities
|
||||||||||||||||
|
Others
1 |
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Unrecognized deferred income tax assets
|
||||||||||||||||
|
Other provisions
|
||||||||||||||||
|
Investments in subsidiaries and others
|
||||||||||||||||
|
Others
|
||||||||||||||||
|
|
|
|
|
|||||||||||||
|
Tax rate (%)
|
||||||||||||||||
|
|
|
|
|
|||||||||||||
|
Total deferred income tax assets
|
₩ | ₩ | ||||||||||||||
|
|
|
|
|
|||||||||||||
|
Taxable temporary differences
|
||||||||||||||||
|
Gains or losses on fair value hedge
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ( |
) | ||||||
|
Accrued interest
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Impairment losses of property and equipment
|
( |
) | ( |
) | ( |
) | ||||||||||
|
Deferred loan origination fees and costs
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Advanced depreciation provision
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Gains or losses on valuation of derivatives
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Present value discount
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Goodwill arising from the merger
|
( |
) | ( |
) | ||||||||||||
|
Gains or losses on revaluation
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Investments in subsidiaries and others
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Gains or losses on valuation of security investment
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Defined benefit liabilities
|
( |
) | ( |
) | ||||||||||||
|
Retirement insurance expense
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Adjustments to the prepaid contributions
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Derivative-linked securities
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Others
1 |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ( |
) | ( |
) | ( |
) | ( |
) | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Unrecognized deferred income tax liabilities
|
||||||||||||||||
|
Goodwill arising from the merger
|
( |
) | ( |
) | ||||||||||||
|
Investments in subsidiaries and others
|
( |
) | ( |
) | ||||||||||||
|
Others
|
( |
) | ( |
) | ||||||||||||
| ( |
) | ( |
) | |||||||||||||
|
Tax rate (%)
|
||||||||||||||||
|
|
|
|
|
|||||||||||||
|
Total deferred income tax liabilities
|
₩ | ( |
) | ₩ | ( |
) | ||||||||||
|
|
|
|
|
|||||||||||||
1 |
Includes PPA amount arising from the acquisition of KB Life Insurance Co., Ltd., KB Insurance Co., Ltd..
|
(In millions of Korean won) | 2025 | |||||||||||||||
Beginning | Decrease | Increase | Ending | |||||||||||||
Deductible temporary differences | ||||||||||||||||
Other provisions | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Allowances for credit losses | ||||||||||||||||
Impairment losses of property and equipment | ||||||||||||||||
Deferred loan origination fees and costs | ||||||||||||||||
Interest on equity index-linked deposits | ||||||||||||||||
Share-based payments | ||||||||||||||||
Provisions for acceptances and guarantees | ||||||||||||||||
Gains or losses on valuation of derivatives | ||||||||||||||||
Present value discount | ||||||||||||||||
Investments in subsidiaries and others | ||||||||||||||||
Gains or losses on valuation of security investment | ||||||||||||||||
Defined benefit liabilities | ||||||||||||||||
Accrued expenses | ||||||||||||||||
Derivative-linked securities | ||||||||||||||||
Others 1 | ||||||||||||||||
Unrecognized deferred income tax assets | ||||||||||||||||
Other provisions | ||||||||||||||||
Investments in subsidiaries and others | ||||||||||||||||
Others | ||||||||||||||||
Tax rate (%) 2 | ||||||||||||||||
Total deferred income tax assets | ₩ | ₩ | ||||||||||||||
Taxable temporary differences | ||||||||||||||||
Gains or losses on fair value hedge | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ||||
Accrued interest | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Allowances for credit losses | ( | ) | ( | ) | ||||||||||||
Impairment losses of property and equipment | ( | ) | ( | ) | ( | ) | ||||||||||
Deferred loan origination fees and costs | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Advanced depreciation provision | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Gains or losses on valuation of derivatives | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Present value discount | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Goodwill arising from the merger | ( | ) | ( | ) | ||||||||||||
Gains or losses on revaluation | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Investments in subsidiaries and others | ( | ) | ( | ) | ( | ) | ||||||||||
Gains or losses on valuation of security investment | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Retirement insurance expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Adjustments to the prepaid contributions | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Derivative-linked securities | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Others 1 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| ( | ) | ( | ) | ( | ) | ( | ) | |||||||||
Unrecognized deferred income tax liabilities | ||||||||||||||||
Goodwill arising from the merger | ( | ) | ( | ) | ||||||||||||
Investments in subsidiaries and others | ( | ) | ( | ) | ||||||||||||
Others | ( | ) | ( | ) | ||||||||||||
| ( | ) | ( | ) | |||||||||||||
Tax rate (%) 2 | ||||||||||||||||
Total deferred income tax liabilities | ₩ | ( | ) | ₩ | ( | ) | ||||||||||
1 | Includes PPA amount arising from the acquisition of KB Life Insurance Co., Ltd., KB Insurance Co., Ltd.. |
2 | Deferred tax assets (liabilities) expected to be realized after 2026 have been measured at |
(In millions of Korean won) | December 31, 2024 | |||||||||||||||
Acquisition cost * | Accumulated impairment losses | Carrying amount | Fair value less costs to sell | |||||||||||||
Land held for sale | ₩ | ₩ | ( | ) | ₩ | ₩ | ||||||||||
Buildings held for sale | ( | ) | ||||||||||||||
Other assets held for sale | ( | ) | ||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ₩ | |||||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||||||
Acquisition cost * | Accumulated impairment losses | Carrying amount | Fair value less costs to sell | |||||||||||||
Land held for sale | ₩ | ₩ | ( | ) | ₩ | ₩ | ||||||||||
Buildings held for sale | ( | ) | ||||||||||||||
Other assets held for sale | ( | ) | ||||||||||||||
| ₩ | ₩ | ( | ) | ₩ | ₩ | |||||||||||
| * | Acquisition cost of buildings held for sale is net of accumulated depreciation amount immediately before the initial classification of the assets as held for sale. |
December 31, 2025 | ||||||||||||
Fair value | Valuation techniques 1 | Unobservable inputs 2 | Estimated range of unobservable inputs (%) | Effect of unobservable inputs to fair value | ||||||||
Land and buildings | ₩ | approach model and others | as the adjustment index rises | |||||||||
1 | The appraisal value is adjusted by the adjustment ratio in the event the public sale is unsuccessful. |
2 | Adjustment index is calculated using the time factor correction or local factors or individual factors and others. |
(In millions of Korean won) | 2024 | |||||||||||||||||||
Beginning | Provision | Reversal | Others | Ending | ||||||||||||||||
Accumulated impairment losses of assets held for sale | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ( | ) | ₩ | ( | ) | |||||||
(In millions of Korean won) | 2025 | |||||||||||||||||||
Beginning | Provision | Reversal | Others | Ending | ||||||||||||||||
Accumulated impairment losses of assets held for sale | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ₩ | ( | ) | |||||||||
(In millions of Korean won) | December 31, 2025 | |||
Other financial assets | ||||
Cash and deposits | ₩ | |||
Loans measured at amortized cost | ||||
Property and equipment | ||||
Intangible assets | ||||
Deferred tax assets | ||||
Other assets | ||||
| ₩ | ||||
(In millions of Korean won) | December 31, 2025 | |||
Other financial liabilities | ||||
Borrowings | ₩ | |||
Net defined benefit liabilities | ||||
Other liabilities | ||||
Current income tax liabilities | ||||
| ₩ | ||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Other financial assets | ||||||||
Other receivables | ₩ | ₩ | ||||||
Accrued income | ||||||||
Guarantee deposits | ||||||||
Domestic exchange settlement debits | ||||||||
Others | ||||||||
Less: Allowances for credit losses | ( | ) | ( | ) | ||||
Less: Present value discount | ( | ) | ( | ) | ||||
Other non-financial assets | ||||||||
Other receivables | ||||||||
Prepaid expenses | ||||||||
Guarantee deposits | ||||||||
Others | ||||||||
Less: Allowances for credit losses | ( | ) | ( | ) | ||||
| ₩ | ₩ | |||||||
(In millions of Korean won) | 2024 | |||||||||||
Other financial assets | Other non-financial assets | Total | ||||||||||
Beginning | ₩ | ₩ | ₩ | |||||||||
Write-offs | ( | ) | ( | ) | ( | ) | ||||||
Provision (reversal) | ||||||||||||
Others | ||||||||||||
Ending | ₩ | ₩ | ₩ | |||||||||
(In millions of Korean won) | 2025 | |||||||||||
Other financial assets | Other non-financial assets | Total | ||||||||||
Beginning | ₩ | ₩ | ₩ | |||||||||
Write-offs | ( | ) | ( | ) | ( | ) | ||||||
Provision (reversal) | ( | ) | ||||||||||
Others | ||||||||||||
Ending | ₩ | ₩ | ₩ | |||||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Financial liabilities at fair value through profit or loss | ||||||||
Borrowed securities sold | ₩ | ₩ | ||||||
Others | ||||||||
Financial liabilities designated at fair value through profit or loss | ||||||||
Derivative-linked securities | ||||||||
| ₩ | ₩ | |||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Amount contractually required to pay at maturity | ₩ | ₩ | ||||||
Carrying amount | | | ||||||
Difference | ₩ | ( | ) | ₩ | ( | ) | ||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Demand deposits | ||||||||
Demand deposits in Korean won | ₩ | ₩ | ||||||
Demand deposits in foreign currencies | ||||||||
Time deposits | ||||||||
Time deposits in Korean won | ||||||||
Fair value adjustments of fair value hedged time deposits in Korean won | ||||||||
Time deposits in foreign currencies | ||||||||
Fair value adjustments of fair value hedged time deposits in foreign currencies | ( | ) | ( | ) | ||||
Certificates of deposits | ||||||||
Investment contract liabilities | ||||||||
| ₩ | ₩ | |||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
General borrowings | ₩ | ₩ | ||||||
Bonds sold under repurchase agreements and others | ||||||||
Call money | ||||||||
| ₩ | ₩ | |||||||
(In millions of Korean won) | Lenders | Interest rate (%) as of December 31, 2025 | December 31, 2024 | December 31, 2025 | ||||||||||
Borrowings in Korean won | Borrowings from the Bank of Korea | The Bank of Korea | ₩ | ₩ | ||||||||||
Borrowings from the government | SEMAS and others | |||||||||||||
Borrowings from banks | The Korea Development Bank and others | |||||||||||||
Borrowings from non-banking financial institutions | Korea Securities Finance Corporation and others | |||||||||||||
Other borrowings | The Korea Development Bank and others | |||||||||||||
Borrowings in foreign currencies | Due to banks | Hana Bank and others | — | |||||||||||
Borrowings from banks | Citicorp International Ltd. and others | |||||||||||||
Borrowings from other financial institutions | The Export-Import Bank of Korea and others | |||||||||||||
Other borrowings | Standard Chartered Bank (Hong Kong) and others | |||||||||||||
| ₩ | ₩ | |||||||||||||
(In millions of Korean won) | Lenders | Interest rate (%) as of December 31, 2025 | December 31, 2024 | December 31, 2025 | ||||||||||
Bonds sold under repurchase agreements | Individuals, groups, and corporations | ₩ | ₩ | |||||||||||
Bills sold | Counter sale | |||||||||||||
| ₩ | ₩ | |||||||||||||
(In millions of Korean won) | Lenders | Interest rate (%) as of December 31, 2025 | December 31, 2024 | December 31, 2025 | ||||||||||
Call money in Korean won | JPMorgan Chase Bank and others | ₩ | ₩ | |||||||||||
Call money in foreign currencies | BANK OF THAILAND and others | |||||||||||||
| ₩ | ₩ | |||||||||||||
(In millions of Korean won) | Interest rate (%) as of December 31, 2025 | December 31, 2024 | December 31, 2025 | |||||||||
Debentures in Korean won | ||||||||||||
Structured debentures | ₩ | ₩ | ||||||||||
Subordinated fixed rate debentures | ||||||||||||
Fixed rate debentures | ||||||||||||
Floating rate debentures | ||||||||||||
Fair value adjustments of fair value hedged debentures in Korean won | ( | ) | ( | ) | ||||||||
Less: Discount on debentures in Korean won | ( | ) | ( | ) | ||||||||
Debentures in foreign currencies | ||||||||||||
Floating rate debentures | ||||||||||||
Fixed rate debentures | ||||||||||||
Fair value adjustments of fair value hedged debentures in foreign currencies | ( | ) | ( | ) | ||||||||
Less: Discount on debentures in foreign currencies | ( | ) | ( | ) | ||||||||
| ₩ | ₩ | |||||||||||
(In millions of Korean won) | 2024 | |||||||||||||||||||
Beginning | Issue | Repayment | Others | Ending | ||||||||||||||||
Debentures in Korean won | ||||||||||||||||||||
Structured debentures | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | |||||||||||||
Exchangeable bonds | ( | ) | ||||||||||||||||||
Subordinated fixed rate debentures | ( | ) | ||||||||||||||||||
Fixed rate debentures | ( | ) | ||||||||||||||||||
Floating rate debentures | ( | ) | ||||||||||||||||||
| ( | ) | |||||||||||||||||||
Debentures in foreign currencies | ||||||||||||||||||||
Floating rate debentures | ( | ) | ||||||||||||||||||
Fixed rate debentures | ( | ) | ||||||||||||||||||
| ( | ) | |||||||||||||||||||
| ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | ||||||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||||||
Beginning | Issue | Repayment | Others | Ending | ||||||||||||||||
Debentures in Korean won | ||||||||||||||||||||
Structured debentures | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | |||||||||||||
Subordinated fixed rate debentures | ||||||||||||||||||||
Fixed rate debentures | ( | ) | ||||||||||||||||||
Floating rate debentures | ( | ) | ||||||||||||||||||
| ( | ) | |||||||||||||||||||
Debentures in foreign currencies | ||||||||||||||||||||
Floating rate debentures | ( | ) | ( | ) | ||||||||||||||||
Fixed rate debentures | ( | ) | ||||||||||||||||||
| ( | ) | |||||||||||||||||||
| ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | ||||||||||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Provisions for credit losses of unused loan commitments | ₩ | ₩ | ||||||
Provisions for credit losses of acceptances and guarantees | ||||||||
Provisions for credit losses of financial guarantee contracts | ||||||||
Provisions for restoration costs | ||||||||
Others | ||||||||
| ₩ | ₩ | |||||||
(In millions of Korean won) | ||||||||||||||||||||||||
2024 | ||||||||||||||||||||||||
Provisions for credit losses of unused loan commitments | Provisions for credit losses of acceptances and guarantees | |||||||||||||||||||||||
12-month expected credit losses | Lifetime expected credit losses | 12-month expected credit losses | Lifetime expected credit losses | |||||||||||||||||||||
Non- impaired | Impaired | Non- impaired | Impaired | |||||||||||||||||||||
Beginning | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||
Transfer between stages: | ||||||||||||||||||||||||
Transfer to 12-month expected credit losses | ( | ) | ( | ) | ( | ) | ||||||||||||||||||
Transfer to lifetime expected credit losses | ( | ) | ( | ) | ( | ) | ||||||||||||||||||
Impairment | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||
Provision (reversal) for credit losses | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||
Others (exchange differences, etc.) | ( | ) | ||||||||||||||||||||||
Ending | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||
2025 | ||||||||||||||||||||||||
Provisions for credit losses of unused loan commitments | Provisions for credit losses of acceptances and guarantees | |||||||||||||||||||||||
12-month expected credit losses | Lifetime expected credit losses | 12-month expected credit losses | Lifetime expected credit losses | |||||||||||||||||||||
Non- impaired | Impaired | Non- impaired | Impaired | |||||||||||||||||||||
Beginning | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||
Transfer between stages: | ||||||||||||||||||||||||
Transfer to 12-month expected credit losses | ( | ) | ( | ) | ( | ) | ||||||||||||||||||
Transfer to lifetime expected credit losses | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||
Impairment | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||
Provision (reversal) for credit losses | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||
Others (exchange differences, etc.) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||
Ending | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||
(In millions of Korean won) | 2024 | 2025 | ||||||
Beginning | ₩ | ₩ | ||||||
Provision (reversal) | ( | ) | ||||||
Others | ( | ) | ( | ) | ||||
Ending | ₩ | | ₩ | | ||||
(In millions of Korean won) | 2024 | 2025 | ||||||
Beginning | ₩ | ₩ | ||||||
Provision | ||||||||
Reversal | ( | ) | ( | ) | ||||
Used | ( | ) | ( | ) | ||||
Unwinding of discount | ||||||||
Effect of changes in discount rate | ( | ) | ||||||
Ending | ₩ | ₩ | ||||||
2024 | ||||||||||||||||||||
Membership rewards program | Dormant accounts | Litigations | Others 1, 2, 3 | Total | ||||||||||||||||
Beginning | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
Increase | ||||||||||||||||||||
Decrease | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||
Others | ||||||||||||||||||||
Ending 1, 2, 3 | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||
2025 | ||||||||||||||||||||
Membership rewards program | Dormant accounts | Litigations | Others 1, 2, 3, 4 | Total | ||||||||||||||||
Beginning | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
Increase | ||||||||||||||||||||
Decrease | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||
Others | ( | ) | ( | ) | ( | ) | ||||||||||||||
Ending 1, 2, 3 , 4 | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
1 | Includes other provisions of ₩ |
2 | Includes other provisions of ₩ |
3 | Includes other provisions of ₩ |
4 | As of December 31, 2025, other provisions include ₩ |
| • |
| • |
2024 | ||||||||||||
(In millions of Korean won) | Present value of defined benefit obligation | Fair value of plan assets | Net defined benefit liabilities(assets) | |||||||||
Beginning | ₩ | ₩ | ( | ) | ₩ | ( | ) | |||||
Current service cost | ||||||||||||
Gains on settlement | ( | ) | ( | ) | ||||||||
Interest expense (income) | ( | ) | ( | ) | ||||||||
Remeasurements: | ||||||||||||
Actuarial gains and losses by changes in demographic assumptions | ( | ) | ( | ) | ||||||||
Actuarial gains and losses by changes in financial assumptions | ||||||||||||
Actuarial gains and losses by experience adjustments | ||||||||||||
Return on plan assets (excluding amounts included in interest income) | ( | ) | ( | ) | ||||||||
Contributions by the Group | ( | ) | ( | ) | ||||||||
Payments from plans (settlement) | ( | ) | ||||||||||
Payments from plans (benefit payments) | ( | ) | ||||||||||
Payments from the Group | ( | ) | ( | ) | ||||||||
Transfer in (out) | ( | ) | ||||||||||
Effect of exchange differences | ( | ) | ||||||||||
Others | ( | ) | ||||||||||
Ending* | ₩ | ₩ | ( | ) | ₩ | ( | ) | |||||
2025 | ||||||||||||
(In millions of Korean won) | Present value of defined benefit obligation | Fair value of plan assets | Net defined benefit liabilities(assets) | |||||||||
Beginning | ₩ | ₩ | ( | ) | ₩ | ( | ) | |||||
Current service cost | ||||||||||||
Past service cost | ||||||||||||
Gains on settlement | ( | ) | ( | ) | ||||||||
Interest expense (income) | ( | ) | ( | ) | ||||||||
Remeasurements: | ||||||||||||
Actuarial gains and losses by changes in demographic assumptions | ( | ) | ( | ) | ||||||||
Actuarial gains and losses by changes in financial assumptions | ( | ) | ( | ) | ||||||||
Actuarial gains and losses by experience adjustments | ||||||||||||
Return on plan assets (excluding amounts included in interest income) | ( | ) | ( | ) | ||||||||
Contributions by the Group | ( | ) | ( | ) | ||||||||
Payments from plans (settlement) | ( | ) | ||||||||||
Payments from plans (benefit payments) | ( | ) | ||||||||||
Payments from the Group | ( | ) | ( | ) | ||||||||
Transfer in (out) | ( | ) | ||||||||||
Effect of exchange differences | ( | ) | ( | ) | ||||||||
Others | ( | ) | ( | ) | ||||||||
Ending* | ₩ | ₩ | ( | ) | ₩ | ( | ) | |||||
| * | The net defined benefit assets of ₩ |
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Present value of defined benefit obligation | ₩ | ₩ | ||||||
Fair value of plan assets | ( | ) | ( | ) | ||||
Net defined benefit liabilities (assets) | ₩ | ( | ) | ₩ | ( | ) | ||
(In millions of Korean won) | 2023 | 2024 | 2025 | |||||||||
Current service cost | ₩ | ₩ | ₩ | |||||||||
Past service cost | ||||||||||||
Net interest expense (income) on net defined benefit liabilities | ( | ) | ( | ) | ( | ) | ||||||
Losses (gains) on settlement | ( | ) | ( | ) | ||||||||
Post-employment benefits * | ₩ | ₩ | ₩ | | ||||||||
| * | Includes post-employment benefits amounting to ₩ |
(In millions of Korean won) | 2023 | 2024 | 2025 | |||||||||
Remeasurements: | ||||||||||||
Return on plan assets (excluding amounts included in interest income) | ₩ | ₩ | ₩ | |||||||||
Actuarial gains and losses | ( | ) | ( | ) | ( | ) | ||||||
Income tax effect | ( | ) | ||||||||||
Effect of exchange differences | ( | ) | ||||||||||
Remeasurements after income tax expense | ₩ | ( | ) | ₩ | ( | ) | ₩ | |||||
(In millions of Korean won) | December 31, 2024 | |||||||||||
Assets quoted in an active market | Assets not quoted in an active market | Total | ||||||||||
Cash and due from financial institutions | ₩ | ₩ | ₩ | |||||||||
Debt securities | ||||||||||||
Investment fund | ||||||||||||
| ₩ | ₩ | ₩ | ||||||||||
(In millions of Korean won) | December 31, 2025 | |||||||||||
Assets quoted in an active market | Assets not quoted in an active market | Total | ||||||||||
Cash and due from financial institutions | ₩ | ₩ | ₩ | |||||||||
Debt securities | ||||||||||||
Investment fund | ||||||||||||
| ₩ | ₩ | ₩ | ||||||||||
December 31, 2024 | December 31, 2025 | |||||||
Discount rate (%) | ||||||||
Salary increase rate (%) | ||||||||
Turnover rate (%) | ||||||||
Changes in assumptions | Effect on defined benefit obligation | |||||||||||
Increase in assumptions | Decrease in assumptions | |||||||||||
Discount rate | %p | |||||||||||
Salary increase rate | %p | |||||||||||
Turnover rate | %p | |||||||||||
Up to 1 year | 1~2 years | 2~5 years | 5~10 years | Over 10 years | Total | |||||||||||||||||||
Pension benefits * | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||
| * |
(In millions of Korean won) |
December 31, 2024 |
December 31, 2025 |
||||||
|
Other financial liabilities
|
||||||||
|
Other payables
|
₩ | ₩ | ||||||
|
Prepaid card and debit card payables
|
||||||||
|
Accrued expenses
|
||||||||
|
Financial guarantee contracts liabilities
|
||||||||
|
Deposits for letter of guarantees and others
|
||||||||
|
Domestic exchange settlement credits
|
||||||||
|
Foreign exchange settlement credits
|
||||||||
|
Borrowings of other accounting businesses
|
||||||||
|
Due to trust accounts
|
||||||||
|
Liabilities incurred from agency relationships
|
||||||||
|
Account for agency business
|
||||||||
|
Dividend payables
|
||||||||
|
Lease liabilities
|
||||||||
|
Others
|
||||||||
|
|
|
|
|
|||||
|
|
|
|
|
|||||
|
Other
non-financial liabilities |
||||||||
|
Other payables
|
||||||||
|
Unearned revenue
|
||||||||
|
Accrued expenses
|
||||||||
|
Deferred revenue on credit card points
|
||||||||
|
Withholding taxes
|
||||||||
|
Others
|
||||||||
|
|
|
|
|
|||||
|
|
|
|
|
|||||
| ₩ | ₩ | |||||||
|
|
|
|
|
|||||
(In millions of Korean won and in number of shares) |
December 31, 2024 |
December 31, 2025 |
||||||
|
Type of share
|
Ordinary share |
Ordinary share |
||||||
|
Number of authorized shares
|
||||||||
|
Par value per share
(In Korean won) |
₩ | ₩ | ||||||
|
Number of issued shares
|
||||||||
|
Share capital*
|
₩ | ₩ | ||||||
| * |
Due to the retirement of shares deducted through retained earnings, it is different from the total par value of the shares issued.
|
(In number of shares) |
2024 |
2025 |
||||||
|
Beginning
|
||||||||
|
Increase
|
||||||||
|
Decrease
|
( |
) | ( |
) | ||||
|
|
|
|
|
|||||
|
Ending
|
||||||||
|
|
|
|
|
|||||
(In millions of Korean won) |
||||||||||||||||||||
|
Hybrid securities
|
Issuance date |
Maturity |
Interest rate (%) as of December 31, 2025 |
December 31, 2024 |
December 31, 2025 |
|||||||||||||||
|
Series
1-2 |
₩ | ₩ | ||||||||||||||||||
|
Series
2-1* |
||||||||||||||||||||
|
Series
2-2 |
||||||||||||||||||||
|
Series
3-1* |
||||||||||||||||||||
|
Series
3-2 |
||||||||||||||||||||
|
Series
4-1* |
||||||||||||||||||||
|
Series
4-2 |
||||||||||||||||||||
|
Series
5-1 |
||||||||||||||||||||
|
Series
5-2 |
||||||||||||||||||||
|
Series
5-3 |
||||||||||||||||||||
|
Series
6-1 |
||||||||||||||||||||
|
Series
6-2 |
||||||||||||||||||||
|
Series
7-1 |
||||||||||||||||||||
|
Series
7-2 |
||||||||||||||||||||
|
Series
8-1 |
||||||||||||||||||||
|
Series
8-2 |
||||||||||||||||||||
|
Series
9-1 |
||||||||||||||||||||
|
Series
9-2 |
||||||||||||||||||||
|
Series
10-1 |
||||||||||||||||||||
|
Series
10-2 |
||||||||||||||||||||
|
Series
10-3 |
||||||||||||||||||||
|
Series
11-1 |
||||||||||||||||||||
|
Series
11-2 |
||||||||||||||||||||
|
Series 12
|
||||||||||||||||||||
|
Series 13
|
||||||||||||||||||||
|
|
|
|
|
|||||||||||||||||
| ₩ | ₩ | |||||||||||||||||||
|
|
|
|
|
|||||||||||||||||
| * |
The Parent Company early redeemed in full its
2-1 Additional Tier 1 capital securities amounting to ₩ 3-1 Additional Tier 1 capital securities amounting to ₩ 4-1 Additional Tier 1 capital securities amounting to ₩ |
(In millions of Korean won) |
December 31, 2024 |
December 31, 2025 |
||||||
|
Paid-in capital in excess of par value |
₩ | ₩ | ||||||
|
Losses on sales of treasury shares
|
( |
) | ( |
) | ||||
|
Other capital surplus
|
||||||||
|
|
|
|
|
|||||
| ₩ | ₩ | |||||||
|
|
|
|
|
|||||
(In millions of Korean won) |
December 31, 2024 |
December 31, 2025 |
||||||
|
Remeasurements of net defined benefit liabilities
|
₩ | ( |
) | ₩ | ( |
) | ||
|
Currency translation differences
|
||||||||
|
Gains (losses) on financial instruments at fair value through other comprehensive income
|
( |
) | ( |
) | ||||
|
Share of other comprehensive loss of associates and joint ventures
|
( |
) | ( |
) | ||||
|
Gains (losses) on cash flow hedging instruments
|
( |
) | ||||||
|
Losses on hedging instruments of net investments in foreign operations
|
( |
) | ( |
) | ||||
|
Fair value changes of financial liabilities designated at fair value through profit or loss due to own credit risk
|
( |
) | ( |
) | ||||
|
Finance gains or losses on insurance contract assets (liabilities)
|
||||||||
|
|
|
|
|
|||||
| ₩ | ₩ | ( |
) | |||||
|
|
|
|
|
|||||
(In millions of Korean won) |
December 31, 2024 |
December 31, 2025 |
||||||
|
Legal reserves
1 |
₩ | ₩ | ||||||
|
Voluntary reserves
|
||||||||
|
Retained earnings
2 |
||||||||
|
|
|
|
|
|||||
| ₩ | ₩ | |||||||
|
|
|
|
|
|||||
1 |
With respect to the allocation of net profit earned in a fiscal term, the Parent Company must set aside in its legal reserve an amount equal to at least 10% of its profit after tax as reported in the financial statements, each time it pays dividends on its net profits earned until its legal reserve reaches the aggregate amount of its
paid-in capital in accordance with Article 53 of the Financial Holding Company Act. This reserve is not available for the payment of cash dividends, but may be transferred to share capital, or used to reduce accumulated deficit. |
2 |
The regulatory reserve for credit losses the Group appropriated in retained earnings is ₩
|
2024 |
||||||||||||||||||||
Beginning |
Acquisition |
Disposal |
Retirement |
Ending |
||||||||||||||||
|
Number of treasury shares*
|
( |
) | ( |
) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Carrying amount
|
₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | |||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
2025 |
||||||||||||||||||||
Beginning |
Acquisition |
Disposal |
Retirement |
Ending |
||||||||||||||||
|
Number of treasury shares
|
( |
) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Carrying amount
|
₩ | ₩ | ₩ | |
₩ | ( |
) | ₩ | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| * |
5 million treasury shares deposited at the Korea Securities Depository for the exchange of exchangeable bonds were disposed on February 14, 2024, due to the exercise of exchange right.
|
(In millions of Korean won) |
2023 |
2024 |
2025 |
|||||||||
|
Interest income
|
||||||||||||
|
Due from financial institutions measured at fair value through profit or loss
|
₩ | ₩ | ₩ | |||||||||
|
Securities measured at fair value through profit or loss
|
||||||||||||
|
Loans measured at fair value through profit or loss
|
||||||||||||
|
Securities measured at fair value through other comprehensive income
|
||||||||||||
|
Loans measured at fair value through other comprehensive income
|
||||||||||||
|
Due from financial institutions measured at amortized cost
|
||||||||||||
|
Securities measured at amortized cost
|
||||||||||||
|
Loans measured at amortized cost
|
||||||||||||
|
Insurance finance income
|
||||||||||||
|
Others
|
||||||||||||
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|||||||
|
Interest expense
|
||||||||||||
|
Deposits
|
||||||||||||
|
Borrowings
|
||||||||||||
|
Debentures
|
||||||||||||
|
Insurance finance expense
|
||||||||||||
|
Others
|
||||||||||||
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|||||||
|
Net interest income
|
₩ | ₩ | ₩ | |||||||||
|
|
|
|
|
|
|
|||||||
(In millions of Korean won) |
2023 |
2024 |
2025 |
|||||||||
|
Fee and commission income
|
||||||||||||
|
Banking activity fees
|
₩ | ₩ | ₩ | |||||||||
|
Lending activity fees
|
||||||||||||
|
Credit card and debit card related fees
|
||||||||||||
|
Agent activity fees
|
||||||||||||
|
Trust and other fiduciary fees
|
||||||||||||
|
Fund management related fees
|
||||||||||||
|
Acceptances and guarantees fees
|
||||||||||||
|
Foreign currency related fees
|
||||||||||||
|
Securities agency fees
|
||||||||||||
|
Other business account commission on consignment
|
||||||||||||
|
Commissions received on securities business
|
||||||||||||
|
Lease fees
|
||||||||||||
|
Others
|
||||||||||||
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|||||||
|
Fee and commission expense
|
||||||||||||
|
Trading activity related fees *
|
||||||||||||
|
Lending activity fees
|
||||||||||||
|
Credit card and debit card related fees
|
||||||||||||
|
Outsourcing related fees
|
||||||||||||
|
Foreign currency related fees
|
||||||||||||
|
Others
|
||||||||||||
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|||||||
|
Net fee and commission income
|
₩ | ₩ | ₩ | |||||||||
|
|
|
|
|
|
|
|||||||
| * |
Fees from financial instruments at fair value through profit or loss
|
(In millions of Korean won) | 2023 | 2024 | 2025 | |||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||
Financial assets at fair value through profit or loss: | ||||||||||||
Debt securities | ₩ | ₩ | ₩ | |||||||||
Equity securities | ||||||||||||
Derivatives held for trading: | ||||||||||||
Interest rate | ||||||||||||
Currency | ||||||||||||
Stock or stock index | ||||||||||||
Credit | ||||||||||||
Commodity | ||||||||||||
Others | ||||||||||||
Financial liabilities at fair value through profit or loss | ||||||||||||
Other financial instruments | ||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||
Financial assets at fair value through profit or loss: | ||||||||||||
Debt securities | ||||||||||||
Equity securities | ||||||||||||
Derivatives held for trading: | ||||||||||||
Interest rate | ||||||||||||
Currency | ||||||||||||
Stock or stock index | ||||||||||||
Credit | ||||||||||||
Commodity | ||||||||||||
Others | ||||||||||||
Financial liabilities at fair value through profit or loss | ||||||||||||
Other financial instruments | ||||||||||||
Net gains (losses) on financial instruments at fair value through profit or loss | ₩ | ₩ | ₩ | |||||||||
(In millions of Korean won) | 2023 | 2024 | 2025 | |||||||||
Gains on financial instruments designated at fair value through profit or loss | ||||||||||||
Financial liabilities designated at fair value through profit or loss | ₩ | ₩ | ₩ | |||||||||
Losses on financial instruments designated at fair value through profit or loss | ||||||||||||
Financial liabilities designated at fair value through profit or loss | ||||||||||||
Net gains (losses) on financial instruments designated at fair value through profit or loss | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | |||
(In millions of Korean won) | 2023 | 2024 | 2025 | |||||||||
Other operating income | ||||||||||||
Gains on securities at fair value through other comprehensive income: | ||||||||||||
Gains on redemption of securities at fair value through other comprehensive income | ₩ | ₩ | ₩ | |||||||||
Gains on disposal of securities at fair value through other comprehensive income | ||||||||||||
Gains on financial assets at amortized cost: | ||||||||||||
Gains on sale of loans measured at amortized cost | ||||||||||||
Gains on disposal of securities measured at amortized cost | ||||||||||||
Gains on hedge accounting | ||||||||||||
Gains on foreign exchange transactions | ||||||||||||
Dividend income | ||||||||||||
Others | ||||||||||||
Other operating expenses | ||||||||||||
Losses on securities at fair value through other comprehensive income: | ||||||||||||
Losses on redemption of securities at fair value through other comprehensive income | ||||||||||||
Losses on disposal of securities at fair value through other comprehensive income | ||||||||||||
Losses on financial assets at amortized cost: | ||||||||||||
Losses on sale of loans measured at amortized cost | ||||||||||||
Losses on disposal of securities measured at amortized cost | ||||||||||||
Losses on hedge accounting | ||||||||||||
Losses on foreign exchange transactions | ||||||||||||
Deposit insurance fee | ||||||||||||
Credit guarantee fund fee | ||||||||||||
Depreciation expenses of operating lease assets | ||||||||||||
Others | ||||||||||||
Net other operating expenses | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | |||
(In millions of Korean won) | 2023 | 2024 | 2025 | |||||||||
Expenses related to employee | ||||||||||||
Employee benefits—salaries | ₩ | ₩ | ₩ | |||||||||
Employee benefits—others | ||||||||||||
Post-employment benefits—defined benefit plans | ||||||||||||
Post-employment benefits—defined contribution plans | ||||||||||||
Termination benefits | ||||||||||||
Share-based payments | ||||||||||||
Depreciation and amortization | ||||||||||||
Other general and administrative expenses | ||||||||||||
Rental expense | ||||||||||||
Tax and dues | ||||||||||||
Communication | ||||||||||||
Electricity and utilities | ||||||||||||
Publication | ||||||||||||
Repairs and maintenance | ||||||||||||
Vehicle | ||||||||||||
Travel | ||||||||||||
Training | ||||||||||||
Service fees | ||||||||||||
Electronic data processing expenses | ||||||||||||
Advertising | ||||||||||||
Others | ||||||||||||
| ₩ | ₩ | ₩ | ||||||||||
(In number of shares) | Grant date | Number of granted shares 1 | Vesting conditions 2 | |||||
KB Financial Group Inc. | ||||||||
Series 38 | performance 3 35%, and non-market performance5 65% | |||||||
Series 39 | performance 3 0~30%, and non-market performance4 70~100% | |||||||
Series 40 | performance 3 30%, and non-market performance4 70% | |||||||
Series 41 | performance 3 30%, and non-market performance4 70% | |||||||
Series 43 | performance 3 0%, and non-market performance4 100% | |||||||
Series 44 | performance 3 0%, and non-market performance4 100% | |||||||
Deferred grant in 2015 | ||||||||
Deferred grant in 2020 | ||||||||
Deferred grant in 2022 | ||||||||
Deferred grant in 2023 | ||||||||
Deferred grant in 2024 | ||||||||
Kookmin Bank | ||||||||
Series 96 | performance 3 0~30%, and non-market performance4 70~100%Services fulfillment, market performance 3 30%, and non-market performance6 70% | |||||||
Series 97 | performance 3 0~30%, and non-market performance4 70~100% | |||||||
Series 98 | performance 3 0~30%, and non-market performance4 70~100% | |||||||
Series 99 | performance 3 0~30%, and non-market performance4 70~100% | |||||||
Series 101 | performance 3 0~30%, and non-market performance4 70~100% | |||||||
Series 102 | performance 3 0~30%, and non-market performance4 70~100%Services fulfillment, market performance 3 30%, and non-market performance6 70% | |||||||
Series 103 | performance 3 0~30%, and non-market performance4 70~100% | |||||||
Deferred grant in 2022 | ||||||||
Deferred grant in 2023 | ||||||||
Deferred grant in 2024 | ||||||||
(In number of shares) | Grant date | Number of granted shares 1 | Vesting conditions 2 | |||||
Other subsidiaries | ||||||||
Stock granted in 2012 | Services fulfillment, market performance 3 0~50%, and non-market performance4 50~100% | |||||||
Stock granted in 2013 | ||||||||
Stock granted in 2014 | ||||||||
Stock granted in 2015 | ||||||||
Stock granted in 2017 | ||||||||
Stock granted in 2018 | ||||||||
Stock granted in 2019 | ||||||||
Stock granted in 2020 | ||||||||
Stock granted in 2021 | ||||||||
Stock granted in 2022 | ||||||||
Stock granted in 2023 | ||||||||
Stock granted in 2024 | ||||||||
Stock granted in 2025 | ||||||||
1 | Granted shares represent the total number of shares initially granted to executives and employees who have residual shares as of December 31, 2025 (Deferred grants are residual shares vested as of December 31, 2025). |
2 | Executives and employees were given the right of choice about the timing of the deferred payment (after the date of retirement), payment ratio, and payment period. Accordingly, a certain percentage of the granted shares is deferred for up to five years after the date of retirement after the deferred grant has been confirmed. |
3 | Relative TSR (Total Shareholder Return): [(Fair value at the end of the contract—Fair value at the beginning of the contract) + (Total amount of dividend per share paid during the contract period)] / Fair value at the beginning of the contract |
4 | Performance results of company and employee |
5 | EPS (Earnings Per Share), Asset Quality, HCROI (Human Capital Return On Investment), Non-bank segment profit |
6 | EPS, Asset Quality |
(In number of shares) | Estimated number of vested shares* | Vesting conditions | ||
KB Financial Group Inc. | ||||
Stock granted in 2015 | ||||
Stock granted in 2016 | ||||
Stock granted in 2020 | ||||
Stock granted in 2022 | ||||
Stock granted in 2023 | ||||
Stock granted in 2024 | ||||
Stock granted in 2025 | ||||
Kookmin Bank | ||||
Stock granted in 2022 | ||||
Stock granted in 2023 | ||||
Stock granted in 2024 | ||||
Stock granted in 2025 | ||||
Other subsidiaries | ||||
Stock granted in 2015 | ||||
Stock granted in 2016 | ||||
Stock granted in 2017 | ||||
Stock granted in 2018 | ||||
Stock granted in 2019 | ||||
Stock granted in 2020 | ||||
Stock granted in 2021 | ||||
Stock granted in 2022 | ||||
Stock granted in 2023 | ||||
Stock granted in 2024 | ||||
Stock granted in 2025 | ||||
| * | Executives and employees were given the right of choice about the timing of the deferred payment (after the date of retirement), payment ratio, and payment period. Accordingly, a certain percentage of the granted shares is deferred for up to five years after the date of retirement after the deferred grant has been confirmed. |
(In Korean won) | Risk-free rate (%) | Fair value (market performance condition) | Fair value (non-market performance condition) | |||||||||
Linked to long-term performance | ||||||||||||
(KB Financial Group Inc.) | ||||||||||||
Series 38 | ||||||||||||
Series 39 | ||||||||||||
Series 40 | ||||||||||||
Series 41 | ||||||||||||
Series 43 | ||||||||||||
Series 44 | ||||||||||||
Deferred grant in 2015 | — | |||||||||||
Deferred grant in 2020 | — | |||||||||||
Deferred grant in 2022 | — | |||||||||||
Deferred grant in 2023 | — | |||||||||||
Deferred grant in 2024 | — | |||||||||||
(Kookmin Bank) | ||||||||||||
Series 96 | ||||||||||||
Series 97 | ||||||||||||
Series 98 | ||||||||||||
Series 99 | ||||||||||||
Series 101 | ||||||||||||
Series 102 | ||||||||||||
Series 103 | ||||||||||||
Grant deferred in 2022 | — | |||||||||||
Grant deferred in 2023 | — | |||||||||||
Grant deferred in 2024 | — | |||||||||||
(Other subsidiaries) | ||||||||||||
Stock granted in 2012 | — | |||||||||||
Stock granted in 2013 | — | |||||||||||
Stock granted in 2014 | — | |||||||||||
Stock granted in 2015 | — | |||||||||||
Stock granted in 2017 | — | |||||||||||
Stock granted in 2018 | — | |||||||||||
Stock granted in 2019 | — | |||||||||||
Stock granted in 2020 | — | |||||||||||
Stock granted in 2021 | — | |||||||||||
Stock granted in 2022 | — | |||||||||||
Stock granted in 2023 | ||||||||||||
Stock granted in 2024 | ||||||||||||
Stock granted in 2025 | ||||||||||||
(In Korean won) |
Risk-free rate (%) |
Fair value (market performance condition) |
Fair value (non-market performance condition) |
|||||||||
|
Linked to short-term performance
|
|
|||||||||||
|
(KB Financial Group Inc.)
|
|
|||||||||||
|
Stock granted in 2015
|
— | |||||||||||
|
Stock granted in 2016
|
— | |||||||||||
|
Stock granted in 2020
|
— | |||||||||||
|
Stock granted in 2022
|
— | |||||||||||
|
Stock granted in 2023
|
— | |||||||||||
|
Stock granted in 2024
|
— | |||||||||||
|
Stock granted in 2025
|
— | |||||||||||
|
(Kookmin Bank)
|
||||||||||||
|
Stock granted in 2022
|
— | |||||||||||
|
Stock granted in 2023
|
— | |||||||||||
|
Stock granted in 2024
|
— | |||||||||||
|
Stock granted in 2025
|
— | |||||||||||
|
(Other subsidiaries)
|
||||||||||||
|
Stock granted in 2015
|
— | |||||||||||
|
Stock granted in 2016
|
— | |||||||||||
|
Stock granted in 2017
|
— | |||||||||||
|
Stock granted in 2018
|
— | |||||||||||
|
Stock granted in 2019
|
— | |||||||||||
|
Stock granted in 2020
|
— | |||||||||||
|
Stock granted in 2021
|
— | |||||||||||
|
Stock granted in 2022
|
— | |||||||||||
|
Stock granted in 2023
|
— | |||||||||||
|
Stock granted in 2024
|
— | |||||||||||
|
Stock granted in 2025
|
— | |||||||||||
(In number of shares) |
||||||||||||||||
|
Grant date
|
Number of granted shares 1 |
Expected exercise period (years) 2 |
Remaining shares |
|||||||||||||
|
Stock granted in 2021 |
||||||||||||||||
|
Stock granted in 2022 |
||||||||||||||||
|
Stock granted in 2023 |
||||||||||||||||
|
Stock granted in 2024 |
||||||||||||||||
(In number of shares) |
||||||||||||
|
Grant date
|
Number of granted shares 1 |
Expected exercise period (years) 2 |
Remaining shares |
|||||||||
|
Stock granted in 2025 |
||||||||||||
|
|
|
|
|
|||||||||
|
|
|
|
|
|||||||||
1 |
one-year lock-up period. |
2 |
|
(In millions of Korean won) |
2023 |
2024 |
2025 |
|||||||||
|
Other
non-operating income |
||||||||||||
|
Gains on disposal of property and equipment
|
₩ | ₩ | ₩ | |||||||||
|
Rental income
|
||||||||||||
|
Others
|
||||||||||||
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|||||||
|
Other
non-operating expenses |
||||||||||||
|
Losses on disposal of property and equipment
|
||||||||||||
|
Donation
|
||||||||||||
|
Restoration costs
|
||||||||||||
|
Management cost for
written-off loans |
||||||||||||
|
Impairment losses on goodwill
|
||||||||||||
|
Others*
|
||||||||||||
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|||||||
|
Net other
non-operating income (expenses) |
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | |||
|
|
|
|
|
|
|
|||||||
| * |
Expenses of ₩million were recognized as other provisions in relation to ELS, LTV penalties, and other matters for the year ended December 31, 2025, and expenses of ₩million were recognized in connection with voluntary compensation for the performance of Hang Seng China Enterprises Index for the year ended December 31, 2024. Such amounts may change depending on future developments and the resolution of the related matters. |
(In millions of Korean won) | 2023 | 2024 | 2025 | |||||||||
Income tax payable | ||||||||||||
Current income tax expense | ₩ | ₩ | ₩ | |||||||||
Adjustments of income tax of prior years recognized in current tax | ( | ) | ( | ) | ( | ) | ||||||
Changes in deferred income tax assets and liabilities* | ( | ) | ||||||||||
Income tax recognized directly in equity and others | ||||||||||||
Remeasurements of net defined benefit liabilities | ( | ) | ||||||||||
Currency translation differences | ( | ) | ( | ) | ||||||||
Net gains or losses on financial assets at fair value through other comprehensive income | ( | ) | ( | ) | ||||||||
Share of other comprehensive income or loss of associates and joint ventures | ( | ) | ( | ) | ( | ) | ||||||
Gains or losses on cash flow hedging instruments | ( | ) | ( | ) | ||||||||
Gains or losses on hedging instruments of net investments in foreign operations | ( | ) | ||||||||||
Fair value changes of financial liabilities designated at fair value through profit or loss due to own credit risk | ||||||||||||
Finance gains or losses on insurance contract assets (liabilities) | ( | ) | ||||||||||
| ( | ) | |||||||||||
Others | ( | ) | ||||||||||
Income tax expense | ₩ | ₩ | ₩ | |||||||||
| * | Following the tax law amendment enacted at the end of 2025, the corporate tax rate was changed. Accordingly, deferred tax assets (liabilities) expected to be realized after 2026 have been measured using the |
(In millions of Korean won) | 2023 | 2024 | 2025 | |||||||||||||||||||||
Tax rate (%) | Amount | Tax rate (%) | Amount | Tax rate (%) | Amount | |||||||||||||||||||
Profit before income tax expense | ₩ | ₩ | ₩ | |||||||||||||||||||||
Income tax at the applicable tax rate 1 | ||||||||||||||||||||||||
Non-taxable income | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
Non-deductible expenses | ||||||||||||||||||||||||
Tax credit and tax exemption | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
Temporary difference for which no deferred tax is recognized | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||
Changes in recognition and measurement of deferred tax | ||||||||||||||||||||||||
Income tax refund for tax of prior years | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
Income tax expense of overseas branches | ||||||||||||||||||||||||
Tax rate change effect 2 | ||||||||||||||||||||||||
Others | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||
Average effective tax rate and income tax expense | ₩ | ₩ | ₩ | |||||||||||||||||||||
1 | Applicable income tax rate for ₩ |
2 | As a result of the tax law amendment enacted at the end of 2025, the corporate income tax rate has changed. Deferred tax assets (liabilities) expected to be realized after 2026 have been measured at |
(In millions of Korean won) |
2024 |
|||||||||||||||||||||||
Beginning |
Changes except for reclassification |
Reclassification to profit or loss |
Transfer within equity |
Tax effect |
Ending |
|||||||||||||||||||
|
Remeasurements of net defined benefit liabilities
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ₩ | ₩ | ( |
) | ||||||||||||
|
Currency translation differences
|
( |
) | ||||||||||||||||||||||
|
Gains (losses) on financial instruments at fair value through other comprehensive income
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
Share of other comprehensive income (loss) of associates and joint ventures
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
|
Gains (losses) on cash flow hedging instruments
|
( |
) | ( |
) | ||||||||||||||||||||
|
Gains (losses) on hedging instruments of net investments in foreign operations
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
Fair value changes of financial liabilities designated at fair value through profit or loss due to own credit risk
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
Finance gains or losses on insurance contract assets (liabilities)
|
( |
) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ₩ | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
(In millions of Korean won) |
2025 |
|||||||||||||||||||||||
Beginning |
Changes except for reclassification |
Reclassification to profit or loss |
Transfer within equity |
Tax effect |
Ending |
|||||||||||||||||||
|
Remeasurements of net defined benefit liabilities
|
₩ | ( |
) | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ||||||||||||
|
Currency translation differences
|
( |
) | ( |
) | ||||||||||||||||||||
|
Gains (losses) on financial instruments at fair value through other comprehensive income
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
|
Share of other comprehensive income (loss) of associates and joint ventures
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
Gains (losses) on cash flow hedging instruments
|
( |
) | ( |
) | ||||||||||||||||||||
|
Gains (losses) on hedging instruments of net investments in foreign operations
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
Fair value changes of financial liabilities designated at fair value through profit or loss due to own credit risk
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
Finance gains or losses on insurance contract assets (liabilities)
|
( |
) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| ₩ | ₩ | ( |
) | ₩ | ₩ | ( |
) | ₩ | ₩ | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
(In number of shares) | 2023 | 2024 | 2025 | |||||||||||||||||||||
Number of shares | Accumulated number of shares | Number of shares | Accumulated number of shares | Number of shares | Accumulated number of shares | |||||||||||||||||||
Number of issued ordinary shares | ||||||||||||||||||||||||
Number of treasury shares* | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
Average number of ordinary shares outstanding | ||||||||||||||||||||||||
Number of days | ||||||||||||||||||||||||
Weighted average number of ordinary shares outstanding | ||||||||||||||||||||||||
| * | Treasury shares retired during the year ended December 31, 2024 and 2025 were deducted from August 14, 2024 and May 15, 2025, respectively. |
(In Korean won and in number of shares) | 2023 | 2024 | 2025 | |||||||||
Profit attributable to shareholders of the Parent Company | ₩ | ₩ | ₩ | |||||||||
Deduction: Dividends on hybrid securities | ( | ) | ( | ) | ( | ) | ||||||
Profit attributable to ordinary equity holders of the Parent Company (A) | ||||||||||||
Weighted average number of ordinary shares outstanding (B) | ||||||||||||
Basic earnings per share (A/B) | ₩ | ₩ | ₩ | |||||||||
(In Korean won) | 2023 | 2024 | 2025 | |||||||||
Profit attributable to shareholders of the Parent Company | ₩ | ₩ | ₩ | |||||||||
Deduction: Dividends on hybrid securities | ( | ) | ( | ) | ( | ) | ||||||
Profit attributable to ordinary equity holders of the Parent Company* | ||||||||||||
Adjustments: Interest expense on exchangeable bonds | ||||||||||||
Adjusted profit for diluted earnings per share | ₩ | ₩ | ₩ | |||||||||
* | The amount is after deducting dividends on hybrid securities. |
(In number of shares) | 2023 | 2024 | 2025 | |||||||||
Weighted average number of ordinary shares outstanding | ||||||||||||
Adjustment: | ||||||||||||
Stock grants | ||||||||||||
Exchangeable bonds | ||||||||||||
Adjusted weighted average number of ordinary shares outstanding for diluted earnings per share | ||||||||||||
(In Korean won and in number of shares) | 2023 | 2024 | 2025 | |||||||||
Adjusted profit for diluted earnings per share | ₩ | ₩ | ₩ | |||||||||
Adjusted weighted average number of ordinary shares outstanding for diluted earnings per share | ||||||||||||
Diluted earnings per share | ₩ | ₩ | ₩ | |||||||||
December 31, 2024 | ||||||||||||||||||||||||||||||||||||
Life insurance | Non-life insurance | |||||||||||||||||||||||||||||||||||
Death | Health | Pension | Variables | Compound | Long-term | General | Automobile | Overseas | ||||||||||||||||||||||||||||
Insurance contract assets | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||||||
Insurance contract liabilities | ||||||||||||||||||||||||||||||||||||
Net insurance contract liabilities | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||||||
Reinsurance contract assets | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||||||
Reinsurance contract liabilities | ||||||||||||||||||||||||||||||||||||
Net reinsurance contract assets (liabilities) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||
December 31, 2025 | ||||||||||||||||||||||||||||||||||||
Life insurance | Non-life insurance | |||||||||||||||||||||||||||||||||||
Death | Health | Pension | Variables | Compound | Long-term | General | Automobile | Overseas | ||||||||||||||||||||||||||||
Insurance contract assets | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||||||
Insurance contract liabilities | ||||||||||||||||||||||||||||||||||||
Net insurance contract liabilities | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||||||
Reinsurance contract assets | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||||||
Reinsurance contract liabilities | ||||||||||||||||||||||||||||||||||||
Net reinsurance contract assets (liabilities) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||
(In millions of Korean won) | 2024 | |||||||||||||||
Liability for Remaining Coverage | Total | |||||||||||||||
Other than Loss Component | Loss Component | Liability for Incurred Claims | ||||||||||||||
Beginning | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Insurance revenue | ( | ) | — | — | ( | ) | ||||||||||
Insurance service expenses | ||||||||||||||||
Insurance claims and expenses | ( | ) | ||||||||||||||
Amortization of insurance acquisition cash flows | ||||||||||||||||
Changes in fulfillment cash flows relating to incurred claims | ( | ) | ( | ) | ||||||||||||
Losses on onerous contracts and reversals | ||||||||||||||||
Other insurance service expenses | ||||||||||||||||
Insurance service result | ( | ) | ( | ) | ||||||||||||
Insurance finance income and expenses | ||||||||||||||||
Investment components | ( | ) | ||||||||||||||
Cashflow | ||||||||||||||||
Premiums received | ||||||||||||||||
Insurance acquisition cash flows | ( | ) | ( | ) | ||||||||||||
Incurred claims and expenses | ( | ) | ( | ) | ||||||||||||
Other cashflow | ( | ) | ( | ) | ||||||||||||
Total cashflow | ( | ) | ||||||||||||||
Other | ||||||||||||||||
Ending | ₩ | ₩ | ₩ | ₩ | ||||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||
Liability for Remaining Coverage | Total | |||||||||||||||
Other than Loss Component | Loss Component | Liability for Incurred Claims | ||||||||||||||
Beginning | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Insurance revenue | ( | ) | — | — | ( | ) | ||||||||||
Insurance service expenses | ||||||||||||||||
Insurance claims and expenses | ( | ) | ||||||||||||||
Amortization of insurance acquisition cash flows | ||||||||||||||||
Changes in fulfillment cash flows relating to incurred claims | ( | ) | ( | ) | ||||||||||||
Losses on onerous contracts and reversals | ||||||||||||||||
Other insurance service expenses | ( | ) | ( | ) | ||||||||||||
Insurance service result | ( | ) | ( | ) | ||||||||||||
Insurance finance income and expenses | ||||||||||||||||
Investment components | ( | ) | ||||||||||||||
Cashflow | ||||||||||||||||
Premiums received | ||||||||||||||||
Insurance acquisition cash flows | ( | ) | ( | ) | ||||||||||||
Incurred claims and expenses | ( | ) | ( | ) | ||||||||||||
Other cashflow | ( | ) | ( | ) | ||||||||||||
Total cashflow | ( | ) | ||||||||||||||
Other | ||||||||||||||||
Ending | ₩ | ₩ | ₩ | ₩ | ||||||||||||
(In millions of Korean won) | 2024 | |||||||||||||||||||
Liability for Remaining Coverage | Liability for Incurred Claims | |||||||||||||||||||
Other than Loss Component | Loss Component | Present value of estimated future cashflow | Risk adjustment for non-financial risks | Total | ||||||||||||||||
Beginning | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
Insurance revenue | ( | ) | ( | ) | ||||||||||||||||
Insurance service expenses | ||||||||||||||||||||
Insurance claims and expenses | ||||||||||||||||||||
Amortization of insurance acquisition cash flows | ||||||||||||||||||||
Changes in fulfillment cash flows relating to incurred claims | ( | ) | ( | ) | ( | ) | ||||||||||||||
Losses on onerous contracts and reversals | ||||||||||||||||||||
Other insurance service expenses | ||||||||||||||||||||
Insurance service result | ( | ) | ( | ) | ( | ) | ||||||||||||||
Insurance finance income and expenses | ||||||||||||||||||||
Investment components | ( | ) | ||||||||||||||||||
Cashflow | ||||||||||||||||||||
Premiums received | ||||||||||||||||||||
Insurance acquisition cash flows | ( | ) | ( | ) | ||||||||||||||||
Incurred claims and expenses | ( | ) | ( | ) | ||||||||||||||||
Other cashflow | ||||||||||||||||||||
Total cashflow | ( | ) | ||||||||||||||||||
Other | ||||||||||||||||||||
Ending | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||||||
Liability for Remaining Coverage | Liability for Incurred Claims | |||||||||||||||||||
Other than Loss Component | Loss Component | Present value of estimated future cashflow | Risk adjustment for non-financial risks | Total | ||||||||||||||||
Beginning | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
Insurance revenue | ( | ) | ( | ) | ||||||||||||||||
Insurance service expenses | ||||||||||||||||||||
Insurance claims and expenses | ||||||||||||||||||||
Amortization of insurance acquisition cash flows | ||||||||||||||||||||
Changes in fulfillment cash flows relating to incurred claims | ( | ) | ||||||||||||||||||
Losses on onerous contracts and reversals | ||||||||||||||||||||
Other insurance service expenses | ||||||||||||||||||||
Insurance service result | ( | ) | ( | ) | ( | ) | ||||||||||||||
Insurance finance income and expenses | ( | ) | ||||||||||||||||||
Investment components | ||||||||||||||||||||
Cashflow | ||||||||||||||||||||
Premiums received | ||||||||||||||||||||
Insurance acquisition cash flows | ( | ) | ( | ) | ||||||||||||||||
Incurred claims and expenses | ( | ) | ( | ) | ||||||||||||||||
Other cashflow | ||||||||||||||||||||
Total cashflow | ( | ) | ||||||||||||||||||
Other | ( | ) | ( | ) | ||||||||||||||||
Ending | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
(In millions of Korean won) | 2024 | |||||||||||||||
Liability for Remaining Coverage | Total | |||||||||||||||
Other than Loss-recovery Component | Loss-recovery Component | Liability for Incurred Claims | ||||||||||||||
Beginning | ₩ | ( | ) | ₩ | ₩ | ₩ | ||||||||||
Allocation of Reinsurance Premiums | ( | ) | ( | ) | ||||||||||||
Reinsurance Recoverables | ||||||||||||||||
Reinsurance claims and expenses | ( | ) | ||||||||||||||
Changes in fulfillment cash flows relating to incurred claims | ( | ) | ( | ) | ||||||||||||
Recovery from loss recovery component and reversals | ||||||||||||||||
Reinsurance service result | ( | ) | ( | ) | ||||||||||||
Reinsurance finance income and expenses | ||||||||||||||||
Effect of changes in exchange rate | ( | ) | ( | ) | ||||||||||||
Effect of changes in credit default risk of reinsurer | ||||||||||||||||
Total reinsurance finance income and expenses | ||||||||||||||||
Investment components | ( | ) | ||||||||||||||
Cashflow | ||||||||||||||||
Reinsurance Premiums Paid | ||||||||||||||||
Amounts recovered from reinsurer | ( | ) | ( | ) | ||||||||||||
Total cashflow | ( | ) | ||||||||||||||
Other | ||||||||||||||||
Ending | ₩ | ( | ) | ₩ | ₩ | ₩ | ||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||
Liability for Remaining Coverage | Total | |||||||||||||||
Other than Loss-recovery Component | Loss-recovery Component | Liability for Incurred Claims | ||||||||||||||
Beginning | ₩ | ( | ) | ₩ | ₩ | ₩ | ||||||||||
Allocation of Reinsurance Premiums | ( | ) | ( | ) | ||||||||||||
Reinsurance Recoverables | ||||||||||||||||
Reinsurance claims and expenses | ( | ) | ||||||||||||||
Changes in fulfillment cash flows relating to incurred claims | ||||||||||||||||
Recovery from loss recovery component and reversals | ( | ) | ( | ) | ||||||||||||
Reinsurance service result | ( | ) | ( | ) | ( | ) | ||||||||||
Reinsurance finance income and expenses | ||||||||||||||||
Effect of changes in exchange rate | ( | ) | ||||||||||||||
Effect of changes in credit default risk of reinsurer | ( | ) | ||||||||||||||
Total reinsurance finance income and expenses | ||||||||||||||||
Investment components | ( | ) | ||||||||||||||
Cashflow | ||||||||||||||||
Reinsurance Premiums Paid | ||||||||||||||||
Amounts recovered from reinsurer | ( | ) | ( | ) | ||||||||||||
Total cashflow | ( | ) | ( | ) | ||||||||||||
Other | ||||||||||||||||
Ending | ₩ | ( | ) | ₩ | ₩ | ₩ | ||||||||||
(In millions of Korean won) | 2024 | |||||||||||||||||||
Liability for Remaining Coverage | Liability for Incurred Claims | |||||||||||||||||||
Other than Loss-recovery Component | Loss-recovery Component | Present value of estimated future cashflow | Risk adjustment for non-financial risks | Total | ||||||||||||||||
Beginning | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
Reinsurance service expenses | ( | ) | ( | ) | ||||||||||||||||
Reinsurance service income | ||||||||||||||||||||
Reinsurance claims and expenses | ||||||||||||||||||||
Changes in fulfillment cash flows relating to incurred claims | ( | ) | ( | ) | ( | ) | ||||||||||||||
Recovery from loss recovery component and reversals | ||||||||||||||||||||
Reinsurance service result | ( | ) | ( | ) | ( | ) | ||||||||||||||
Reinsurance finance income and expenses | ( | ) | ( | ) | ||||||||||||||||
Effect of changes in exchange rate | ||||||||||||||||||||
Effect of changes in credit default risk of reinsurer | ||||||||||||||||||||
Total reinsurance finance income and expenses | ( | ) | ( | ) | ||||||||||||||||
Investment components | ( | ) | ||||||||||||||||||
Cashflow | ||||||||||||||||||||
Reinsurance Premiums Paid | ||||||||||||||||||||
Amounts recovered from reinsurer | ( | ) | ( | ) | ||||||||||||||||
Total cashflow | ( | ) | ||||||||||||||||||
Other | ||||||||||||||||||||
Ending | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||||||
Liability for Remaining Coverage | Liability for Incurred Claims | |||||||||||||||||||
Other than Loss-recovery Component | Loss-recovery Component | Present value of estimated future cashflow | Risk adjustment for non-financial risks | Total | ||||||||||||||||
Beginning | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
Reinsurance service expenses | ( | ) | ( | ) | ||||||||||||||||
Reinsurance service income | ||||||||||||||||||||
Reinsurance claims and expenses | ||||||||||||||||||||
Changes in fulfillment cash flows relating to incurred claims | ( | ) | ||||||||||||||||||
Recovery from loss recovery component and reversals | ||||||||||||||||||||
Reinsurance service result | ( | ) | ( | ) | ( | ) | ||||||||||||||
Reinsurance finance income and expenses | ||||||||||||||||||||
Effect of changes in exchange rate | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
Effect of changes in credit default risk of reinsurer | ( | ) | ||||||||||||||||||
Total reinsurance finance income and expenses | ||||||||||||||||||||
Investment components | ( | ) | ||||||||||||||||||
Cashflow | ||||||||||||||||||||
Reinsurance Premiums Paid | ||||||||||||||||||||
Amounts recovered from reinsurer | ( | ) | ( | ) | ||||||||||||||||
Total cashflow | ( | ) | ||||||||||||||||||
Other | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||
Ending | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
(In millions of Korean won) | 2024 | |||||||||||||||
Present value of estimated future cashflow | Risk adjustment for non-financial risks | Contractual service margin | Total | |||||||||||||
Beginning | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Future service related changes: | ||||||||||||||||
Changes in estimations adjusting contractual service margin | ( | ) | ||||||||||||||
Losses on onerous contracts and reversals | ||||||||||||||||
Effect of new contracts | ( | ) | ||||||||||||||
Current period service related changes: | ||||||||||||||||
Contractual service margin recognized in profit or loss for the services provided | ( | ) | ( | ) | ||||||||||||
Changes in risk adjustment due to release of risk | ( | ) | ( | ) | ||||||||||||
Experience adjustment | ( | ) | ( | ) | ||||||||||||
Past period service related changes: | ||||||||||||||||
Changes in fulfillment cash flows relating to incurred claims | ( | ) | ( | ) | ( | ) | ||||||||||
Insurance service result | ( | ) | ( | ) | ( | ) | ||||||||||
Insurance finance income and expenses | ||||||||||||||||
Cashflow for the period: | ||||||||||||||||
Premiums received | ||||||||||||||||
Insurance acquisition cash flows | ( | ) | ( | ) | ||||||||||||
Incurred claims and expenses | ( | ) | ( | ) | ||||||||||||
Other cashflow | ( | ) | ( | ) | ||||||||||||
Total cashflow | ||||||||||||||||
Other | ||||||||||||||||
Ending | ₩ | ₩ | ₩ | ₩ | ||||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||
Present value of estimated future cashflow | Risk adjustment for non-financial risks | Contractual service margin | Total | |||||||||||||
Beginning | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Future service related changes: | ||||||||||||||||
Changes in estimations adjusting contractual service margin | ( | ) | ( | ) | ||||||||||||
Losses on onerous contracts and reversals | ||||||||||||||||
Effect of new contracts | ( | ) | ||||||||||||||
Current period service related changes: | ||||||||||||||||
Contractual service margin recognized in profit or loss for the services provided | ( | ) | ( | ) | ||||||||||||
Changes in risk adjustment due to release of risk | ( | ) | ( | ) | ||||||||||||
Experience adjustment | ||||||||||||||||
Past period service related changes: | ||||||||||||||||
Changes in fulfillment cash flows relating to incurred claims | ( | ) | ( | ) | ( | ) | ||||||||||
Insurance service result | ( | ) | ( | ) | ||||||||||||
Insurance finance income and expenses | ||||||||||||||||
Cashflow for the period: | ||||||||||||||||
Premiums received | ||||||||||||||||
Insurance acquisition cash flows | ( | ) | ( | ) | ||||||||||||
Incurred claims and expenses | ( | ) | ( | ) | ||||||||||||
Other cashflow | ( | ) | ( | ) | ||||||||||||
Total cashflow | ||||||||||||||||
Other | ||||||||||||||||
Ending | ₩ | ₩ | ₩ | ₩ | ||||||||||||
(In millions of Korean won) | 2024 | |||||||||||||||
Present value of estimated future cashflow | Risk adjustment for non-financial risks | Contractual service margin | Total | |||||||||||||
Beginning | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Future service related changes | ||||||||||||||||
Changes in estimations adjusting contractual service margin | ( | ) | ( | ) | ||||||||||||
Losses on onerous contracts and reversals | ||||||||||||||||
Effect of new contracts | ( | ) | ||||||||||||||
Current period service related changes | ||||||||||||||||
Contractual service margin recognized in profit or loss for the services provided | ||||||||||||||||
Changes in risk adjustment due to release of risk | ( | ) | ( | ) | ||||||||||||
Experience adjustment | ( | ) | ( | ) | ||||||||||||
Past period service related changes | ||||||||||||||||
Changes in fulfillment cash flows relating to incurred claims | ( | ) | ( | ) | ( | ) | ||||||||||
Reinsurance service result | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
Reinsurance finance income and expenses | ||||||||||||||||
Effect of changes in exchange rate | ( | ) | ( | ) | ( | ) | ||||||||||
Effect of changes in credit default risk of reinsurer | ||||||||||||||||
Total reinsurance finance income and expenses | ||||||||||||||||
Cashflow for the period | ||||||||||||||||
Reinsurance Premiums Paid | ||||||||||||||||
Amounts recovered from reinsurer | ( | ) | ( | ) | ||||||||||||
Other cashflow | ||||||||||||||||
Total cashflow | ||||||||||||||||
Other | ||||||||||||||||
Ending | ₩ | ₩ | ₩ | ₩ | ||||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||
Present value of estimated future cashflow | Risk adjustment for non-financial risks | Contractual service margin | Total | |||||||||||||
Beginning | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Future service related changes | ||||||||||||||||
Changes in estimations adjusting contractual service margin | ( | ) | ( | ) | ||||||||||||
Losses on onerous contracts and reversals | ( | ) | ( | ) | ( | ) | ||||||||||
Effect of new contracts | ( | ) | ||||||||||||||
Current period service related changes | ||||||||||||||||
Contractual service margin recognized in profit or loss for the services provided | ( | ) | ( | ) | ||||||||||||
Changes in risk adjustment due to release of risk | ( | ) | ( | ) | ||||||||||||
Experience adjustment | ( | ) | ( | ) | ||||||||||||
Past period service related changes | ||||||||||||||||
Changes in fulfillment cash flows relating to incurred claims | ( | ) | ||||||||||||||
Reinsurance service result | ( | ) | ( | ) | ( | ) | ||||||||||
Reinsurance finance income and expenses | ( | ) | ||||||||||||||
Effect of changes in exchange rate | ( | ) | ( | ) | ||||||||||||
Effect of changes in credit default risk of reinsurer | ||||||||||||||||
Total reinsurance finance income and expenses | ( | ) | ||||||||||||||
Cashflow for the period | ||||||||||||||||
Reinsurance Premiums Paid | ||||||||||||||||
Amounts recovered from reinsurer | ( | ) | ( | ) | ||||||||||||
Other cashflow | ||||||||||||||||
Total cashflow | ( | ) | ( | ) | ||||||||||||
Other | ||||||||||||||||
Ending | ₩ | ₩ | ₩ | ₩ | ||||||||||||
(In millions of Korean won) |
2023 |
|||||||||||||||||||||||||||||||||||||||
Life insurance |
Non-life insurance |
Total |
||||||||||||||||||||||||||||||||||||||
Death |
Health |
Pension |
Variables |
Compound |
Long-term |
General |
Automobile |
Overseas |
||||||||||||||||||||||||||||||||
|
Insurance revenue:
|
||||||||||||||||||||||||||||||||||||||||
|
Insurance contracts not applying the premium allocation approach:
|
||||||||||||||||||||||||||||||||||||||||
|
Expected insurance claims and expenses
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||||||||
|
Changes in risk adjustment due to release of risk
|
||||||||||||||||||||||||||||||||||||||||
|
Contractual service margin recognized in profit or loss for the services provided
|
||||||||||||||||||||||||||||||||||||||||
|
Experience adjustments on premium related to current and past services
|
||||||||||||||||||||||||||||||||||||||||
|
Recovery of insurance acquisition cash flows
|
||||||||||||||||||||||||||||||||||||||||
|
Other insurance revenues
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Insurance revenue for insurance contracts not applying the premium allocation approach
|
||||||||||||||||||||||||||||||||||||||||
|
Insurance revenue for insurance contracts applying the premium allocation approach
|
||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Total insurance revenue
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
(In millions of Korean won) |
2023 |
|||||||||||||||||||||||||||||||||||||||
Life insurance |
Non-life insurance |
Total |
||||||||||||||||||||||||||||||||||||||
Death |
Health |
Pension |
Variables |
Compound |
Long-term |
General |
Automobile |
Overseas |
||||||||||||||||||||||||||||||||
|
Insurance service expenses:
|
||||||||||||||||||||||||||||||||||||||||
|
Incurred claims and expenses
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ||||||||||||
|
Amortization of insurance acquisition cash flows
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
|
Changes in fulfillment cash flows relating to incurred claims
|
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
|
Losses on onerous contracts and reversals
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Other insurance service expenses
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Insurance service expenses for insurance contracts not applying the premium allocation approach
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Insurance service expenses for insurance contracts applying the premium allocation approach
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Total insurance service expenses
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Reinsurance income:
|
||||||||||||||||||||||||||||||||||||||||
|
Recovery of incurred reinsurance claims and expenses
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||||||||
|
Changes in fulfillment cash flows relating to incurred claims
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
|
Recognition and reversal of loss-recovery component
|
||||||||||||||||||||||||||||||||||||||||
|
Other reinsurance income
|
||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Reinsurance income for reinsurance contracts not applying the premium allocation approach
|
||||||||||||||||||||||||||||||||||||||||
|
Reinsurance income for reinsurance contracts applying the premium allocation approach
|
( |
) | ||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Total reinsurance income
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ₩ | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
(In millions of Korean won) |
2023 |
|||||||||||||||||||||||||||||||||||||||
Life insurance |
Non-life insurance |
Total |
||||||||||||||||||||||||||||||||||||||
Death |
Health |
Pension |
Variables |
Compound |
Long-term |
General |
Automobile |
Overseas |
||||||||||||||||||||||||||||||||
|
Reinsurance expense:
|
||||||||||||||||||||||||||||||||||||||||
|
Reinsurance contracts not applying the premium allocation approach:
|
||||||||||||||||||||||||||||||||||||||||
|
Expected recovery of incurred claims and expenses
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ₩ | ₩ | ( |
) | ||||||||||||||||||||
|
Changes in risk adjustment due to release of risk
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
|
Contractual service margin recognized in profit or loss for the services received
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||
|
Experience adjustments on reinsurance premium related to current and past services
|
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
|
Other reinsurance expenses
|
||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
| ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||
|
Reinsurance expenses for reinsurance contracts applying the premium allocation approach
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Total reinsurance expense
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Total insurance service result
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
(In millions of Korean won) |
2024 |
|||||||||||||||||||||||||||||||||||||||
Life insurance |
Non-life insurance |
Total |
||||||||||||||||||||||||||||||||||||||
Death |
Health |
Pension |
Variables |
Compound |
Long-term |
General |
Automobile |
Overseas |
||||||||||||||||||||||||||||||||
|
Insurance revenue:
|
||||||||||||||||||||||||||||||||||||||||
|
Insurance contracts not applying the premium allocation approach:
|
||||||||||||||||||||||||||||||||||||||||
|
Expected insurance claims and expenses
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||||||||
|
Changes in risk adjustment due to release of risk
|
||||||||||||||||||||||||||||||||||||||||
|
Contractual service margin recognized in profit or loss for the services provided
|
||||||||||||||||||||||||||||||||||||||||
|
Experience adjustments on premium related to current and past services
|
||||||||||||||||||||||||||||||||||||||||
|
Recovery of insurance acquisition cash flows
|
||||||||||||||||||||||||||||||||||||||||
|
Other insurance revenues
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Insurance revenue for insurance contracts not applying the premium allocation approach
|
||||||||||||||||||||||||||||||||||||||||
|
Insurance revenue for insurance contracts applying the premium allocation approach
|
||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Total insurance revenue
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
(In millions of Korean won) |
2024 |
|||||||||||||||||||||||||||||||||||||||
Life insurance |
Non-life insurance |
Total |
||||||||||||||||||||||||||||||||||||||
Death |
Health |
Pension |
Variables |
Compound |
Long-term |
General |
Automobile |
Overseas |
||||||||||||||||||||||||||||||||
|
Insurance service expenses:
|
||||||||||||||||||||||||||||||||||||||||
|
Incurred claims and expenses
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ||||||||||||
|
Amortization of insurance acquisition cash flows
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
|
Changes in fulfillment cash flows relating to incurred claims
|
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
|
Losses on onerous contracts and reversals
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Other insurance service expenses
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Insurance service expenses for insurance contracts not applying the premium allocation approach
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Insurance service expenses for insurance contracts applying the premium allocation approach
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Total insurance service expenses
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Reinsurance income:
|
||||||||||||||||||||||||||||||||||||||||
|
Recovery of incurred reinsurance claims and expenses
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||||||||
|
Changes in fulfillment cash flows relating to incurred claims
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||
|
Recognition and reversal of loss-recovery component
|
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
|
Other reinsurance income
|
||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Reinsurance income for reinsurance contracts not applying the premium allocation approach
|
||||||||||||||||||||||||||||||||||||||||
|
Reinsurance income for reinsurance contracts applying the premium allocation approach
|
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Total reinsurance income
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ₩ | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
(In millions of Korean won) |
2024 |
|||||||||||||||||||||||||||||||||||||||
Life insurance |
Non-life insurance |
Total |
||||||||||||||||||||||||||||||||||||||
Death |
Health |
Pension |
Variables |
Compound |
Long-term |
General |
Automobile |
Overseas |
||||||||||||||||||||||||||||||||
|
Reinsurance expense:
|
||||||||||||||||||||||||||||||||||||||||
|
Reinsurance contracts not applying the premium allocation approach:
|
||||||||||||||||||||||||||||||||||||||||
|
Expected recovery of incurred claims and expenses
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ₩ | ₩ | ( |
) | ||||||||||||||||||||
|
Changes in risk adjustment due to release of risk
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
|
Contractual service margin recognized in profit or loss for the services received
|
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
|
Experience adjustments on reinsurance premium related to current and past services
|
||||||||||||||||||||||||||||||||||||||||
|
Other reinsurance expenses
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
| ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||
|
Reinsurance expenses for reinsurance contracts applying the premium allocation approach
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Total reinsurance expense
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Total insurance service result
|
₩ | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
(In millions of Korean won) |
2025 |
|||||||||||||||||||||||||||||||||||||||
Life insurance |
Non-life insurance |
Total |
||||||||||||||||||||||||||||||||||||||
Death |
Health |
Pension |
Variables |
Compound |
Long-term |
General |
Automobile |
Overseas |
||||||||||||||||||||||||||||||||
|
Insurance revenue:
|
||||||||||||||||||||||||||||||||||||||||
|
Insurance contracts not applying the premium allocation approach:
|
||||||||||||||||||||||||||||||||||||||||
|
Expected insurance claims and expenses
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||||||||
|
Changes in risk adjustment due to release of risk
|
||||||||||||||||||||||||||||||||||||||||
|
Contractual service margin recognized in profit or loss for the services provided
|
||||||||||||||||||||||||||||||||||||||||
|
Experience adjustments on premium related to current and past services
|
||||||||||||||||||||||||||||||||||||||||
|
Recovery of insurance acquisition cash flows
|
||||||||||||||||||||||||||||||||||||||||
|
Other insurance revenues
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Insurance revenue for insurance contracts not applying the premium allocation approach
|
||||||||||||||||||||||||||||||||||||||||
|
Insurance revenue for insurance contracts applying the premium allocation approach
|
||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Total insurance revenue
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||||||||||||||||||||||||||
Life insurance | Non-life insurance | Total | ||||||||||||||||||||||||||||||||||||||
Death | Health | Pension | Variables | Compound | Long-term | General | Automobile | Overseas | ||||||||||||||||||||||||||||||||
Insurance service expenses: | ||||||||||||||||||||||||||||||||||||||||
Incurred claims and expenses | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ||||||||||||
Amortization of insurance acquisition cash flows | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||
Changes in fulfillment cash flows relating to incurred claims | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Losses on onerous contracts and reversals | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||
Other insurance service expenses | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
Insurance service expenses for insurance contracts not applying the premium allocation approach | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||
Insurance service expenses for insurance contracts applying the premium allocation approach | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
Total insurance service expenses | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ||||||||||||
Reinsurance income: | ||||||||||||||||||||||||||||||||||||||||
Recovery of incurred reinsurance claims and expenses | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||||||||
Changes in fulfillment cash flows relating to incurred claims | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
Recognition and reversal of loss-recovery component | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
Other reinsurance income | ||||||||||||||||||||||||||||||||||||||||
Reinsurance income for reinsurance contracts not applying the premium allocation approach | ||||||||||||||||||||||||||||||||||||||||
Reinsurance income for reinsurance contracts applying the premium allocation approach | ||||||||||||||||||||||||||||||||||||||||
Total reinsurance income | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||||||||||||||||||||||||||
Life insurance | Non-life insurance | Total | ||||||||||||||||||||||||||||||||||||||
Death | Health | Pension | Variables | Compound | Long-term | General | Automobile | Overseas | ||||||||||||||||||||||||||||||||
Reinsurance expense: | ||||||||||||||||||||||||||||||||||||||||
Reinsurance contracts not applying the premium allocation approach: | ||||||||||||||||||||||||||||||||||||||||
Expected recovery of incurred claims and expenses | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ₩ | ₩ | ( | ) | ||||||||||||||||||||
Changes in risk adjustment due to release of risk | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Contractual service margin recognized in profit or loss for the services received | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Experience adjustments on reinsurance premium related to current and past services | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||
Other reinsurance expenses | ||||||||||||||||||||||||||||||||||||||||
| ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||||||
Reinsurance expenses for reinsurance contracts applying the premium allocation approach | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||
Total reinsurance expense | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||
Total insurance service result | ₩ | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ||||||||||||||||||||||||
(In millions of Korean won) |
2024 |
|||||||||||
Issued contract |
||||||||||||
Other than onerous contract |
Onerous contract |
Total |
||||||||||
|
Estimated Present Value of Future Cash Outflows
|
₩ | ₩ | ₩ | |||||||||
|
Insurance Acquisition Cash Flow
|
||||||||||||
|
Insurance Claims and Service Expenses
|
||||||||||||
|
Estimated Present Value of Future Cash Inflows
|
( |
) | ( |
) | ( |
) | ||||||
|
Risk Adjustment for
Non-Financial Risks |
||||||||||||
|
Contractual service margin
|
||||||||||||
|
|
|
|
|
|
|
|||||||
|
Effect on financial statements of initial recognition of contracts
|
₩ | ₩ | ₩ | |||||||||
|
|
|
|
|
|
|
|||||||
(In millions of Korean won) |
2025 |
|||||||||||
Issued contract |
||||||||||||
Other than onerous contract |
Onerous contract |
Total |
||||||||||
|
Estimated Present Value of Future Cash Outflows
|
₩ | ₩ | ₩ | |||||||||
|
Insurance Acquisition Cash Flow
|
||||||||||||
|
Insurance Claims and Service Expenses
|
||||||||||||
|
Estimated Present Value of Future Cash Inflows
|
( |
) | ( |
) | ( |
) | ||||||
|
Risk Adjustment for
Non-Financial Risks |
||||||||||||
|
Contractual service margin
|
||||||||||||
|
|
|
|
|
|
|
|||||||
|
Effect on financial statements of initial recognition of contracts
|
₩ | ₩ | ₩ | |||||||||
|
|
|
|
|
|
|
|||||||
(In millions of Korean won) |
2024 |
|||||||||||
Purchased contract |
||||||||||||
Net cost contract |
Net gain contract |
Total |
||||||||||
|
Estimated Present Value of Future Cash Inflows
|
₩ | ₩ | ₩ | |||||||||
|
Estimated Present Value of Future Cash Outflows
|
( |
) | ( |
) | ( |
) | ||||||
|
Risk Adjustment for
Non-Financial Risks |
||||||||||||
|
Contractual service margin
|
( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|
|||||||
|
Effect on financial statements of initial recognition of contracts
|
₩ | ₩ | ₩ | |||||||||
|
|
|
|
|
|
|
|||||||
(In millions of Korean won) |
2025 |
|||||||||||
Purchased contract |
||||||||||||
Net cost contract |
Net gain contract |
Total |
||||||||||
|
Estimated Present Value of Future Cash Inflows
|
₩ | ₩ | ₩ | |||||||||
|
Estimated Present Value of Future Cash Outflows
|
( |
) | ( |
) | ( |
) | ||||||
|
Risk Adjustment for
Non-Financial Risks |
||||||||||||
|
Contractual service margin
|
( |
) | ||||||||||
|
|
|
|
|
|
|
|||||||
|
Effect on financial statements of initial recognition of contracts
|
₩ | ₩ | ₩ | |||||||||
|
|
|
|
|
|
|
|||||||
(In millions of Korean won) |
||||||||||||||||||||||||||||||||||||||
December 31, 2024 |
||||||||||||||||||||||||||||||||||||||
Less than a year |
1 ~ 2 years |
2 ~ 3 years |
3 ~ 4 years |
4 ~ 5 years |
5 ~ 10 years |
10 ~ 20 years |
20 ~ 30 years |
Over 30 years |
||||||||||||||||||||||||||||||
|
Insurance contract issued
|
|
|||||||||||||||||||||||||||||||||||||
|
Life insurance
|
Death | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||||||
| Health | ||||||||||||||||||||||||||||||||||||||
| Pension | ||||||||||||||||||||||||||||||||||||||
| Variables | ||||||||||||||||||||||||||||||||||||||
|
Non-life insurance |
||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Total insurance contract issued
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Reinsurance contract held
|
||||||||||||||||||||||||||||||||||||||
|
Life insurance
|
Death | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||||||
| Health | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||
| Compound | ||||||||||||||||||||||||||||||||||||||
|
Non-life insurance |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Total reinsurance contract held
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ₩ | ₩ | ₩ | ( |
) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
(In millions of Korean won) |
||||||||||||||||||||||||||||||||||||||
December 31, 2025 |
||||||||||||||||||||||||||||||||||||||
Less than a year |
1 ~ 2 years |
2 ~ 3 years |
3 ~ 4 years |
4 ~ 5 years |
5 ~ 10 years |
10 ~ 20 years |
20 ~ 30 years |
Over 30 years |
||||||||||||||||||||||||||||||
|
Insurance contract issued
|
|
|||||||||||||||||||||||||||||||||||||
|
Life insurance
|
Death | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||||||
| Health | ||||||||||||||||||||||||||||||||||||||
| Pension | ||||||||||||||||||||||||||||||||||||||
| Variables | ||||||||||||||||||||||||||||||||||||||
|
Non-life insurance |
||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Total insurance contract issued
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Reinsurance contract held
|
||||||||||||||||||||||||||||||||||||||
|
Life insurance
|
Death | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||||||
| Health | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||
| Compound | ||||||||||||||||||||||||||||||||||||||
|
Non-life insurance |
||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Total reinsurance contract held
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
(In millions of Korean won) |
2024 |
2025 |
||||||
|
Underlying items held by the Group
|
||||||||
|
Cash and cash equivalents
|
₩ | ₩ | ||||||
|
Equity securities
|
||||||||
|
Debt securities
|
||||||||
|
Beneficiary certificates
|
||||||||
|
Other securities
|
||||||||
|
Loans
|
||||||||
|
Others
|
||||||||
|
|
|
|
|
|||||
|
Total
|
₩ | ₩ | ||||||
|
|
|
|
|
|||||
(In millions of Korean won) |
2023 |
|||||||||||||||||||||||||||||||
Life insurance |
Non-life insurance |
Total |
||||||||||||||||||||||||||||||
Retirement |
Variables |
Others |
Long-term |
General and Automobile |
Overseas |
Others |
||||||||||||||||||||||||||
|
Investment income (expenses)
|
||||||||||||||||||||||||||||||||
|
Investment income (expenses) recognized in profit or loss:
|
||||||||||||||||||||||||||||||||
|
Net Interest Income (expense)
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ||||||||||||||||||||||
|
Dividend income
|
||||||||||||||||||||||||||||||||
|
Gains (losses) on valuation and disposal of securities
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
|
Gains (losses) on valuation and disposal of loans and receivables
|
( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Gains (losses) on derivatives
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||
|
Gains (losses) on investments in subsidiaries
|
( |
) | ||||||||||||||||||||||||||||||
|
Foreign exchange gains (losses)
|
( |
) | ||||||||||||||||||||||||||||||
|
Other investment income (expenses)
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||
|
Investment income (expenses) recognized in other comprehensive income
|
||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Total investment income (expenses)
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
(In millions of Korean won) |
2023 |
|||||||||||||||||||||||||||||||
Life insurance |
Non-life insurance |
Total |
||||||||||||||||||||||||||||||
Retirement |
Variables |
Others |
Long-term |
General and Automobile |
Overseas |
Others |
||||||||||||||||||||||||||
|
Insurance finance income (expenses)
|
||||||||||||||||||||||||||||||||
|
Insurance finance income (expenses) recognized in profit or loss:
|
||||||||||||||||||||||||||||||||
|
Net Interest Income (expense)
|
₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ₩ | ( |
) | ||||||||||||||
|
Effect of changes in discount rates and financial assumptions
|
||||||||||||||||||||||||||||||||
|
Effect of exchange rate fluctuations
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
|
Changes in the fair value of the underlying assets of insurance contract with direct participation features
|
( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Other insurance finance income (expenses)
|
( |
) | ( |
) | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||
|
Insurance finance income (expenses) recognized in other comprehensive income
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Total insurance finance income (expenses)
|
₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ( |
) | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Reinsurance finance income (expenses)
|
||||||||||||||||||||||||||||||||
|
Reinsurance finance income (expenses) recognized in profit or loss:
|
||||||||||||||||||||||||||||||||
|
Net Interest Income (expense)
|
₩ | ₩ | ₩ | ( |
) | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||
|
Effect of changes in discount rates and financial assumptions
|
||||||||||||||||||||||||||||||||
|
Effect of exchange rate fluctuations
|
( |
) | ||||||||||||||||||||||||||||||
|
Other reinsurance finance income (expenses)
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||
|
Reinsurance finance income (expenses) recognized in other comprehensive income
|
( |
) | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Total reinsurance finance income (expenses)
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Net investment income (expenses)
|
₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
(In millions of Korean won) |
2024 |
|||||||||||||||||||||||||||||||
Life insurance |
Non-life insurance |
Total |
||||||||||||||||||||||||||||||
Retirement |
Variables |
Others |
Long-term |
General and Automobile |
Overseas |
Others |
||||||||||||||||||||||||||
|
Investment income (expenses)
|
||||||||||||||||||||||||||||||||
|
Investment income (expenses) recognized in profit or loss:
|
||||||||||||||||||||||||||||||||
|
Net Interest Income (expense)
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ||||||||||||||||||||||
|
Dividend income
|
||||||||||||||||||||||||||||||||
|
Gains (losses) on valuation and disposal of securities
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
|
Gains (losses) on valuation and disposal of loans and receivables
|
( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Gains (losses) on derivatives
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||
|
Gains (losses) on investments in subsidiaries
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
|
Foreign exchange gains (losses)
|
||||||||||||||||||||||||||||||||
|
Other investment income (expenses)
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| ( |
) | ( |
) | |||||||||||||||||||||||||||||
|
Investment income (expenses) recognized in other comprehensive income
|
||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Total investment income (expenses)
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
(In millions of Korean won) |
2024 |
|||||||||||||||||||||||||||||||
Life insurance |
Non-life insurance |
Total |
||||||||||||||||||||||||||||||
Retirement |
Variables |
Others |
Long-term |
General and Automobile |
Overseas |
Others |
||||||||||||||||||||||||||
|
Insurance finance income (expenses)
|
||||||||||||||||||||||||||||||||
|
Insurance finance income (expenses) recognized in profit or loss:
|
||||||||||||||||||||||||||||||||
|
Net Interest Income (expense)
|
₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ₩ | ( |
) | ||||||||||||||
|
Effect of changes in discount rates and financial assumptions
|
( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Effect of exchange rate fluctuations
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
|
Changes in the fair value of the underlying assets of insurance contract with direct participation features
|
( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Other insurance finance income (expenses)
|
( |
) | ( |
) | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||
|
Insurance finance income (expenses) recognized in other comprehensive income
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Total insurance finance income (expenses)
|
₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ( |
) | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Reinsurance finance income (expenses)
|
||||||||||||||||||||||||||||||||
|
Reinsurance finance income (expenses) recognized in profit or loss:
|
||||||||||||||||||||||||||||||||
|
Net Interest Income (expense)
|
₩ | ₩ | ₩ | ( |
) | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||
|
Effect of changes in discount rates and financial assumptions
|
( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Effect of exchange rate fluctuations
|
( |
) | ||||||||||||||||||||||||||||||
|
Other reinsurance finance income (expenses)
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| ( |
) | ( |
) | |||||||||||||||||||||||||||||
|
Reinsurance finance income (expenses) recognized in other comprehensive income
|
( |
) | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Total reinsurance finance income (expenses)
|
( |
) | ( |
) | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Net investment income (expenses)
|
₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ₩ | ₩ | ( |
) | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
(In millions of Korean won) |
2025 |
|||||||||||||||||||||||||||||||
Life insurance |
Non-life insurance |
Total |
||||||||||||||||||||||||||||||
Retirement |
Variables |
Others |
Long-term |
General and Automobile |
Overseas |
Others |
||||||||||||||||||||||||||
|
Investment income (expenses)
|
||||||||||||||||||||||||||||||||
|
Investment income (expenses) recognized in profit or loss:
|
||||||||||||||||||||||||||||||||
|
Net Interest Income (expense)
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ||||||||||||||||||||||
|
Dividend income
|
||||||||||||||||||||||||||||||||
|
Gains (losses) on valuation and disposal of securities
|
( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Gains (losses) on valuation and disposal of loans and receivables
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
|
Gains (losses) on derivatives
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||
|
Gains (losses) on investments in subsidiaries
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
|
Foreign exchange gains (losses)
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||
|
Other investment income (expenses)
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| ( |
) | ( |
) | |||||||||||||||||||||||||||||
|
Investment income (expenses) recognized in other comprehensive income
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Total investment income (expenses)
|
₩ | ( |
) | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ₩ | ( |
) | ₩ | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
(In millions of Korean won) |
2025 |
|||||||||||||||||||||||||||||||
Life insurance |
Non-life insurance |
Total |
||||||||||||||||||||||||||||||
Retirement |
Variables |
Others |
Long-term |
General and Automobile |
Overseas |
Others |
||||||||||||||||||||||||||
|
Insurance finance income (expenses)
|
||||||||||||||||||||||||||||||||
|
Insurance finance income (expenses) recognized in profit or loss:
|
||||||||||||||||||||||||||||||||
|
Net Interest Income (expense)
|
₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ₩ | ( |
) | ||||||||||||||
|
Effect of changes in discount rates and financial assumptions
|
||||||||||||||||||||||||||||||||
|
Effect of exchange rate fluctuations
|
||||||||||||||||||||||||||||||||
|
Changes in the fair value of the underlying assets of insurance contract with direct participation features
|
( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Other insurance finance income (expenses)
|
( |
) | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||
|
Insurance finance income (expenses) recognized in other comprehensive income
|
( |
) | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Total insurance finance income (expenses)
|
₩ | ₩ | ( |
) | ₩ | ₩ | ₩ | ( |
) | ₩ | ₩ | ₩ | ( |
) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Reinsurance finance income (expenses)
|
||||||||||||||||||||||||||||||||
|
Reinsurance finance income (expenses) recognized in profit or loss:
|
||||||||||||||||||||||||||||||||
|
Net Interest Income (expense)
|
₩ | ₩ | ₩ | ( |
) | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||
|
Effect of changes in discount rates and financial assumptions
|
( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Effect of exchange rate fluctuations
|
( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Other reinsurance finance income (expenses)
|
( |
) | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| ( |
) | |||||||||||||||||||||||||||||||
|
Reinsurance finance income (expenses) recognized in other comprehensive income
|
( |
) | ( |
) | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Total reinsurance finance income (expenses)
|
||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
|
Net investment income (expenses)
|
₩ | ( |
) | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
(In millions of Korean won) |
2024 |
|||||||||||
Contracts applying the fair value approach |
All other contracts |
Total |
||||||||||
|
Insurance income
|
₩ | ₩ | ₩ | |||||||||
|
|
|
|
|
|
|
|||||||
|
Beginning contractual service margin
|
||||||||||||
|
Current period service related changes
|
||||||||||||
|
Profit or loss recognized related to service provided
|
( |
) | ( |
) | ( |
) | ||||||
|
Future service related changes
|
||||||||||||
|
Changes in estimations adjusting contractual service margin
|
( |
) | ( |
) | ||||||||
|
Effect of new contracts
|
||||||||||||
|
|
|
|
|
|
|
|||||||
|
Insurance service result
|
( |
) | ( |
) | ||||||||
|
Insurance finance income and expenses
|
||||||||||||
|
|
|
|
|
|
|
|||||||
|
Ending contractual service margin
|
₩ | ₩ | ₩ | |||||||||
|
|
|
|
|
|
|
|||||||
(In millions of Korean won) | 2025 | |||||||||||
Contracts applying the fair value approach | All other contracts | Total | ||||||||||
Insurance income | ₩ | ₩ | ₩ | |||||||||
Beginning contractual service margin | ||||||||||||
Current period service related changes | ||||||||||||
Profit or loss recognized related to service provided | ( | ) | ( | ) | ( | ) | ||||||
Future service related changes | ||||||||||||
Changes in estimations adjusting contractual service margin | ( | ) | ( | ) | ||||||||
Effect of new contracts | ||||||||||||
Insurance service result | ( | ) | ||||||||||
Insurance finance income and expenses | ||||||||||||
Ending contractual service margin | ₩ | ₩ | ₩ | |||||||||
(In millions of Korean won) | 2024 | |||||||||||
Contracts applying the fair value approach | All other contracts | Total | ||||||||||
Allocation of Reinsurance Premiums | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | |||
Beginning contractual service margin | ( | ) | ||||||||||
Current period service related changes | ||||||||||||
Profit or loss recognized related to service received | ( | ) | ||||||||||
Future service related changes | ||||||||||||
Changes in estimations adjusting contractual service margin | ( | ) | ||||||||||
Effect of new contracts | ( | ) | ( | ) | ||||||||
Reinsurance service result | ( | ) | ( | ) | ||||||||
Reinsurance finance income and expenses | ( | ) | ||||||||||
Ending contractual service margin | ₩ | ₩ | ( | ) | ₩ | |||||||
(In millions of Korean won) | 2025 | |||||||||||
Contracts applying the fair value approach | All other contracts | Total | ||||||||||
Allocation of Reinsurance Premiums | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | |||
Beginning contractual service margin | ( | ) | ||||||||||
Current period service related changes | ||||||||||||
Profit or loss recognized related to service received | ( | ) | ( | ) | ||||||||
Future service related changes | ||||||||||||
Changes in estimations adjusting contractual service margin | ||||||||||||
Effect of new contracts | ||||||||||||
Reinsurance service result | ||||||||||||
Reinsurance finance income and expenses | ( | ) | ||||||||||
Ending contractual service margin | ₩ | ₩ | ( | ) | ₩ | |||||||
(In millions of Korean won) | 2024 | 2025 | ||||||
Beginning | ₩ | ( | ) | ₩ | ( | ) | ||
Changes due to fair value measurement | ( | ) | ||||||
Changes due to reclassification to profit or loss | ||||||||
Income tax effect | ( | ) | ||||||
Ending | ₩ | ( | ) | ₩ | ( | ) | ||
| Mortality Risk | Risk of unexpected losses due to premature death compared to the insured’s expectations. | |
| Longevity Risk | Risk of unexpected losses due to delayed death compared to the insured’s expectations. | |
| Disability/Illness Risk | Risk of unexpected losses related to the insured’s disability and illness. | |
| Long-term Property/Other Risks | Risk of unexpected losses related to property, expenses, indemnities, and other collateral in long-term insurance. | |
| Termination Risk | Risk of losses due to unexpected exercise of legal rights or contractual options by policyholders. | |
| Expense Risk | Risk of losses due to fluctuations in future costs and expenditure variations caused by inflation in relation to insurance contract costs. | |
| Catastrophic Risk | Risk of extreme, exceptional losses (e.g., epidemics, major accidents) not considered in mortality risk, etc. | |
| Price Risk | Risk of losses exceeding the expected mortality rate and expense ratio calculated when determining insurance premiums. | |
| Reserve Risk | Risk of being unable to cover future insurance payments reserved for incurred but not reported insurance accidents. | |
| Catastrophic Risk | Risk of losses due to extreme, exceptional risks not considered in insurance price risk and reserve risk. | |
(In millions of Korean won) |
December 31, 2024 |
|||||||||||||||
Domestic |
United States |
China |
Others |
|||||||||||||
|
General insurance
|
||||||||||||||||
|
Fire
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
Maritime
|
||||||||||||||||
|
Others
|
||||||||||||||||
|
Long-term insurance
|
||||||||||||||||
|
Injury, illness, and property
|
||||||||||||||||
|
Pension
|
||||||||||||||||
|
Others
|
( |
) | ||||||||||||||
|
Automobile insurance
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Total
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
(In millions of Korean won) |
December 31, 2025 |
|||||||||||||||
Domestic |
United States |
China |
Others |
|||||||||||||
|
General insurance
|
||||||||||||||||
|
Fire
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
Maritime
|
||||||||||||||||
|
Others
|
||||||||||||||||
|
Long-term insurance
|
||||||||||||||||
|
Injury, illness, and property
|
||||||||||||||||
|
Pension
|
||||||||||||||||
|
Others
|
( |
) | ||||||||||||||
|
Automobile insurance
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Total
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
(In millions of Korean won) |
December 31, 2024 |
|||||||||||||||
Domestic |
United States |
China |
Others |
|||||||||||||
|
General insurance
|
||||||||||||||||
|
Fire
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
Maritime
|
||||||||||||||||
|
Others
|
||||||||||||||||
|
Long-term insurance
|
||||||||||||||||
|
Injury, illness, and property
|
||||||||||||||||
|
Pension
|
||||||||||||||||
|
Others
|
( |
) | ||||||||||||||
|
Automobile insurance
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Total
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
(In millions of Korean won) |
December 31, 2025 |
|||||||||||||||
Domestic |
United States |
China |
Others |
|||||||||||||
|
General insurance
|
||||||||||||||||
|
Fire
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
Maritime
|
||||||||||||||||
|
Others
|
||||||||||||||||
|
Long-term insurance
|
||||||||||||||||
|
Injury, illness, and property
|
||||||||||||||||
|
Pension
|
||||||||||||||||
|
Others
|
( |
) | ||||||||||||||
|
Automobile insurance
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Total
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
(In millions of Korean won) |
Accident year |
|||||||||||||||||||||||||||
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Total |
||||||||||||||||||||||
|
Estimated final loss undiscounted
|
||||||||||||||||||||||||||||
|
Development year
|
||||||||||||||||||||||||||||
|
1 year
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
2 years
|
||||||||||||||||||||||||||||
|
3 years
|
||||||||||||||||||||||||||||
|
4 years
|
||||||||||||||||||||||||||||
|
5 years
|
||||||||||||||||||||||||||||
|
6 years
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Estimated final loss
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Gross cumulative claim payments
|
||||||||||||||||||||||||||||
|
Total gross cumulative claim payments
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | |||||||||
|
Difference between estimated final loss and claim payments
|
||||||||||||||||||||||||||||
|
Estimated claim handling costs and expected indemnity
|
||||||||||||||||||||||||||||
|
Incurred claims over 6 years ago
|
||||||||||||||||||||||||||||
|
Incurred claims settled but not yet paid
|
( |
) | ||||||||||||||||||||||||||
|
Discount rate effect
|
( |
) | ||||||||||||||||||||||||||
|
Risk adjustment
|
||||||||||||||||||||||||||||
|
Others
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Liability for incurred claims book value
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
(In millions of Korean won) |
Accident year |
|||||||||||||||||||||||||||
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Total |
||||||||||||||||||||||
|
Estimated final loss undiscounted
|
||||||||||||||||||||||||||||
|
Development year
|
||||||||||||||||||||||||||||
|
1 year
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
2 years
|
||||||||||||||||||||||||||||
|
3 years
|
||||||||||||||||||||||||||||
|
4 years
|
||||||||||||||||||||||||||||
|
5 years
|
||||||||||||||||||||||||||||
|
6 years
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Estimated final loss
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Gross cumulative claim payments
|
||||||||||||||||||||||||||||
|
Total gross cumulative claim payments
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | |||||||||
|
Difference between estimated final loss and claim payments
|
||||||||||||||||||||||||||||
|
Estimated claim handling costs and expected indemnity
|
||||||||||||||||||||||||||||
|
Incurred claims over 6 years ago
|
||||||||||||||||||||||||||||
|
Incurred claims settled but not yet paid
|
||||||||||||||||||||||||||||
|
Discount rate effect
|
( |
) | ||||||||||||||||||||||||||
|
Risk adjustment
|
||||||||||||||||||||||||||||
|
Others
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Liability for incurred claims book value
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
(In millions of Korean won) |
Accident year |
|||||||||||||||||||||||||||
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Total |
||||||||||||||||||||||
|
Estimated final loss undiscounted
|
||||||||||||||||||||||||||||
|
Development year
|
||||||||||||||||||||||||||||
|
1 year
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
2 years
|
||||||||||||||||||||||||||||
|
3 years
|
||||||||||||||||||||||||||||
|
4 years
|
||||||||||||||||||||||||||||
|
5 years
|
||||||||||||||||||||||||||||
|
6 years
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Estimated final loss
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Gross cumulative claim payments
|
||||||||||||||||||||||||||||
|
Total gross cumulative claim payments
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | |||||||||
|
Difference between estimated final loss and claim payments
|
||||||||||||||||||||||||||||
|
Estimated claim handling costs and expected indemnity
|
||||||||||||||||||||||||||||
|
Incurred claims over 6 years ago
|
||||||||||||||||||||||||||||
|
Incurred claims settled but not yet paid
|
||||||||||||||||||||||||||||
|
Discount rate effect
|
( |
) | ||||||||||||||||||||||||||
|
Risk adjustment
|
||||||||||||||||||||||||||||
|
Others
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Liability for incurred claims book value
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
(In millions of Korean won) |
Accident year |
|||||||||||||||||||||||||||
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Total |
||||||||||||||||||||||
|
Estimated final loss undiscounted
|
||||||||||||||||||||||||||||
|
Development year
|
||||||||||||||||||||||||||||
|
1 year
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
2 years
|
||||||||||||||||||||||||||||
|
3 years
|
||||||||||||||||||||||||||||
|
4 years
|
||||||||||||||||||||||||||||
|
5 years
|
||||||||||||||||||||||||||||
|
6 years
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Estimated final loss
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Gross cumulative claim payments
|
||||||||||||||||||||||||||||
|
Total gross cumulative claim payments
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | |||||||||
|
Difference between estimated final loss and claim payments
|
||||||||||||||||||||||||||||
|
Estimated claim handling costs and expected indemnity
|
||||||||||||||||||||||||||||
|
Incurred claims over 6 years ago
|
||||||||||||||||||||||||||||
|
Incurred claims settled but not yet paid
|
( |
) | ||||||||||||||||||||||||||
|
Discount rate effect
|
( |
) | ||||||||||||||||||||||||||
|
Risk adjustment
|
||||||||||||||||||||||||||||
|
Others
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Liability for incurred claims book value
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
(In millions of Korean won) |
Accident year |
|||||||||||||||||||||||||||
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Total |
||||||||||||||||||||||
|
Estimated final loss undiscounted
|
||||||||||||||||||||||||||||
|
Development year
|
||||||||||||||||||||||||||||
|
1 year
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
2 years
|
||||||||||||||||||||||||||||
|
3 years
|
||||||||||||||||||||||||||||
|
4 years
|
||||||||||||||||||||||||||||
|
5 years
|
||||||||||||||||||||||||||||
|
6 years
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Estimated final loss
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Gross cumulative claim payments
|
||||||||||||||||||||||||||||
|
Total gross cumulative claim payments
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | |||||||||
|
Difference between estimated final loss and claim payments
|
||||||||||||||||||||||||||||
|
Estimated claim handling costs and expected indemnity
|
||||||||||||||||||||||||||||
|
Incurred claims over 6 years ago
|
||||||||||||||||||||||||||||
|
Incurred claims settled but not yet paid
|
||||||||||||||||||||||||||||
|
Discount rate effect
|
( |
) | ||||||||||||||||||||||||||
|
Risk adjustment
|
||||||||||||||||||||||||||||
|
Others
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Liability for incurred claims book value
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
(In millions of Korean won) |
Accident year |
|||||||||||||||||||||||||||
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Total |
||||||||||||||||||||||
|
Estimated final loss undiscounted
|
||||||||||||||||||||||||||||
|
Development year
|
||||||||||||||||||||||||||||
|
1 year
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
2 years
|
||||||||||||||||||||||||||||
|
3 years
|
||||||||||||||||||||||||||||
|
4 years
|
||||||||||||||||||||||||||||
|
5 years
|
||||||||||||||||||||||||||||
|
6 years
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Estimated final loss
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Gross cumulative claim payments
|
||||||||||||||||||||||||||||
|
Total gross cumulative claim payments
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | |||||||||
|
Difference between estimated final loss and claim payments
|
||||||||||||||||||||||||||||
|
Estimated claim handling costs and expected indemnity
|
||||||||||||||||||||||||||||
|
Incurred claims over 6 years ago
|
||||||||||||||||||||||||||||
|
Incurred claims settled but not yet paid
|
||||||||||||||||||||||||||||
|
Discount rate effect
|
( |
) | ||||||||||||||||||||||||||
|
Risk adjustment
|
||||||||||||||||||||||||||||
|
Others
|
( |
) | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Liability for incurred claims book value
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
(In millions of Korean won) |
Accident year |
|||||||||||||||||||||||||||
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
Total |
||||||||||||||||||||||
|
Estimated final loss undiscounted
|
||||||||||||||||||||||||||||
|
Development year
|
||||||||||||||||||||||||||||
|
1 year
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
2 years
|
||||||||||||||||||||||||||||
|
3 years
|
||||||||||||||||||||||||||||
|
4 years
|
||||||||||||||||||||||||||||
|
5 years
|
||||||||||||||||||||||||||||
|
6 years
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Estimated final loss
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Gross cumulative claim payments
|
||||||||||||||||||||||||||||
|
Total gross cumulative claim payments
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | |||||||||
|
Difference between estimated final loss and claim payments
|
||||||||||||||||||||||||||||
|
Estimated claim handling costs and expected indemnity
|
||||||||||||||||||||||||||||
|
Incurred claims over 6 years ago
|
||||||||||||||||||||||||||||
|
Incurred claims settled but not yet paid
|
( |
) | ||||||||||||||||||||||||||
|
Discount rate effect
|
( |
) | ||||||||||||||||||||||||||
|
Risk adjustment
|
||||||||||||||||||||||||||||
|
Others
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Liability for incurred claims book value
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
(In millions of Korean won) |
Accident year |
|||||||||||||||||||||||||||
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
Total |
||||||||||||||||||||||
|
Estimated final loss undiscounted
|
||||||||||||||||||||||||||||
|
Development year
|
||||||||||||||||||||||||||||
|
1 year
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
2 years
|
||||||||||||||||||||||||||||
|
3 years
|
||||||||||||||||||||||||||||
|
4 years
|
||||||||||||||||||||||||||||
|
5 years
|
||||||||||||||||||||||||||||
|
6 years
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Estimated final loss
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Gross cumulative claim payments
|
||||||||||||||||||||||||||||
|
Total gross cumulative claim payments
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | |||||||||
|
Difference between estimated final loss and claim payments
|
||||||||||||||||||||||||||||
|
Estimated claim handling costs and expected indemnity
|
||||||||||||||||||||||||||||
|
Incurred claims over 6 years ago
|
||||||||||||||||||||||||||||
|
Incurred claims settled but not yet paid
|
||||||||||||||||||||||||||||
|
Discount rate effect
|
( |
) | ||||||||||||||||||||||||||
|
Risk adjustment
|
||||||||||||||||||||||||||||
|
Others
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Liability for incurred claims book value
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
(In millions of Korean won) |
Accident year |
|||||||||||||||||||||||||||
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
Total |
||||||||||||||||||||||
|
Estimated final loss undiscounted
|
||||||||||||||||||||||||||||
|
Development year
|
||||||||||||||||||||||||||||
|
1 year
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
2 years
|
||||||||||||||||||||||||||||
|
3 years
|
||||||||||||||||||||||||||||
|
4 years
|
||||||||||||||||||||||||||||
|
5 years
|
||||||||||||||||||||||||||||
|
6 years
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Estimated final loss
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Gross cumulative claim payments
|
||||||||||||||||||||||||||||
|
Total gross cumulative claim payments
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | |||||||||
|
Difference between estimated final loss and claim payments
|
||||||||||||||||||||||||||||
|
Estimated claim handling costs and expected indemnity
|
||||||||||||||||||||||||||||
|
Incurred claims over 6 years ago
|
||||||||||||||||||||||||||||
|
Incurred claims settled but not yet paid
|
||||||||||||||||||||||||||||
|
Discount rate effect
|
( |
) | ||||||||||||||||||||||||||
|
Risk adjustment
|
||||||||||||||||||||||||||||
|
Others
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Liability for incurred claims book value
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
(In millions of Korean won) |
Accident year |
|||||||||||||||||||||||||||
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
Total |
||||||||||||||||||||||
|
Estimated final loss undiscounted
|
||||||||||||||||||||||||||||
|
Development year
|
||||||||||||||||||||||||||||
|
1 year
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
2 years
|
||||||||||||||||||||||||||||
|
3 years
|
||||||||||||||||||||||||||||
|
4 years
|
||||||||||||||||||||||||||||
|
5 years
|
||||||||||||||||||||||||||||
|
6 years
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Estimated final loss
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Gross cumulative claim payments
|
||||||||||||||||||||||||||||
|
Total gross cumulative claim payments
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | |||||||||
|
Difference between estimated final loss and claim payments
|
||||||||||||||||||||||||||||
|
Estimated claim handling costs and expected indemnity
|
||||||||||||||||||||||||||||
|
Incurred claims over 6 years ago
|
||||||||||||||||||||||||||||
|
Incurred claims settled but not yet paid
|
( |
) | ||||||||||||||||||||||||||
|
Discount rate effect
|
( |
) | ||||||||||||||||||||||||||
|
Risk adjustment
|
||||||||||||||||||||||||||||
|
Others
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Liability for incurred claims book value
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
(In millions of Korean won) |
Accident year |
|||||||||||||||||||||||||||
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
Total |
||||||||||||||||||||||
|
Estimated final loss undiscounted
|
||||||||||||||||||||||||||||
|
Development year
|
||||||||||||||||||||||||||||
|
1 year
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
2 years
|
||||||||||||||||||||||||||||
|
3 years
|
||||||||||||||||||||||||||||
|
4 years
|
||||||||||||||||||||||||||||
|
5 years
|
||||||||||||||||||||||||||||
|
6 years
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Estimated final loss
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Gross cumulative claim payments
|
||||||||||||||||||||||||||||
|
Total gross cumulative claim payments
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | |||||||||
|
Difference between estimated final loss and claim payments
|
||||||||||||||||||||||||||||
|
Estimated claim handling costs and expected indemnity
|
||||||||||||||||||||||||||||
|
Incurred claims over 6 years ago
|
||||||||||||||||||||||||||||
|
Incurred claims settled but not yet paid
|
||||||||||||||||||||||||||||
|
Discount rate effect
|
( |
) | ||||||||||||||||||||||||||
|
Risk adjustment
|
||||||||||||||||||||||||||||
|
Others
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Liability for incurred claims book value
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
(In millions of Korean won) |
Accident year |
|||||||||||||||||||||||||||
2020 |
2021 |
2022 |
2023 |
2024 |
2025 |
Total |
||||||||||||||||||||||
|
Estimated final loss undiscounted
|
||||||||||||||||||||||||||||
|
Development year
|
||||||||||||||||||||||||||||
|
1 year
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
2 years
|
||||||||||||||||||||||||||||
|
3 years
|
||||||||||||||||||||||||||||
|
4 years
|
||||||||||||||||||||||||||||
|
5 years
|
||||||||||||||||||||||||||||
|
6 years
|
||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Estimated final loss
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Gross cumulative claim payments
|
||||||||||||||||||||||||||||
|
Total gross cumulative claim payments
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | |||||||||
|
Difference between estimated final loss and claim payments
|
||||||||||||||||||||||||||||
|
Estimated claim handling costs and expected indemnity
|
||||||||||||||||||||||||||||
|
Incurred claims over 6 years ago
|
||||||||||||||||||||||||||||
|
Incurred claims settled but not yet paid
|
||||||||||||||||||||||||||||
|
Discount rate effect
|
( |
) | ||||||||||||||||||||||||||
|
Risk adjustment
|
||||||||||||||||||||||||||||
|
Others
|
( |
) | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
|
Liability for incurred claims book value
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||
(In millions of Korean won) |
December 31, 2024 |
|||||||||||||||||||||||||||||||||||||||||||||||||
Baseline amount |
Variance amount |
Impact on profit or equity (before tax) |
||||||||||||||||||||||||||||||||||||||||||||||||
Shock level |
Fulfillment Cashflow |
CSM |
Fulfillment Cashflow |
CSM |
Profit or loss |
OCI |
||||||||||||||||||||||||||||||||||||||||||||
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
|||||||||||||||||||||||||||||||||||||||
|
Mortality rate
|
increase |
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | |||||||||||||||||||||||||||||
|
Disability/illness (fixed compensation)
|
increase |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||
|
Disability/illness (actual expense compensation)
|
increase |
|||||||||||||||||||||||||||||||||||||||||||||||||
|
Long-term property/other risks
|
increase |
( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||||||
|
Lapse rate (increase)
|
increase |
( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||
|
Lapse rate (decrease)
|
decrease |
( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||
|
Expense ratio (level)
|
increase |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||
|
Expense ratio (inflation)
|
increase |
|||||||||||||||||||||||||||||||||||||||||||||||||
(In millions of Korean won) |
December 31, 2025 |
|||||||||||||||||||||||||||||||||||||||||||||||||
Baseline amount |
Variance amount |
Impact on profit or equity (before tax) |
||||||||||||||||||||||||||||||||||||||||||||||||
Shock level |
Fulfillment Cashflow |
CSM |
Fulfillment Cashflow |
CSM |
Profit or loss |
OCI |
||||||||||||||||||||||||||||||||||||||||||||
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
|||||||||||||||||||||||||||||||||||||||
|
Mortality rate
|
increase |
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | |||||||||||||||||||||||||||||
|
Disability/illness (fixed compensation)
|
increase |
( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||
|
Disability/illness (actual expense compensation)
|
increase |
|||||||||||||||||||||||||||||||||||||||||||||||||
|
Long-term property/other risks
|
increase |
( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||||||
|
Lapse rate (increase)
|
increase |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||
|
Lapse rate (decrease)
|
decrease |
( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||||
|
Expense ratio (level)
|
increase |
( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||
|
Expense ratio (inflation)
|
increase |
|||||||||||||||||||||||||||||||||||||||||||||||||
(In millions of Korean won) |
December 31, 2024 |
|||||||||||||||||||||||||||||||||||||||||||||||||
Baseline amount |
Variance amount |
Impact on profit or equity (before tax) |
||||||||||||||||||||||||||||||||||||||||||||||||
Shock level |
Fulfillment Cashflow |
CSM |
Fulfillment Cashflow |
CSM |
Profit or loss |
OCI |
||||||||||||||||||||||||||||||||||||||||||||
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
|||||||||||||||||||||||||||||||||||||||
|
Mortality rate
|
increase |
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | |||||||||||||||||||||||||||||
|
Disability/illness (fixed compensation)
|
increase |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||
|
Disability/illness (actual expense compensation)
|
increase |
|||||||||||||||||||||||||||||||||||||||||||||||||
|
Long-term property/other risks
|
increase |
( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||||
|
Lapse rate (increase)
|
increase |
( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||
|
Lapse rate (decrease)
|
decrease |
( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||
|
Expense ratio (level)
|
increase |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||
|
Expense ratio (inflation)
|
increase |
|||||||||||||||||||||||||||||||||||||||||||||||||
(In millions of Korean won) |
December 31, 2025 |
|||||||||||||||||||||||||||||||||||||||||||||||||
Baseline amount |
Variance amount |
Impact on profit or equity (before tax) |
||||||||||||||||||||||||||||||||||||||||||||||||
Shock level |
Fulfillment Cashflow |
CSM |
Fulfillment Cashflow |
CSM |
Profit or loss |
OCI |
||||||||||||||||||||||||||||||||||||||||||||
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
Insurance contracts with participation features |
Insurance contracts without participation features |
|||||||||||||||||||||||||||||||||||||||
|
Mortality rate
|
increase |
₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | |||||||||||||||||||||||||||||||||
|
Disability/illness (fixed compensation)
|
increase |
( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||
|
Disability/illness (actual expense compensation)
|
increase |
|||||||||||||||||||||||||||||||||||||||||||||||||
|
Long-term property/other risks
|
increase |
₩ | ₩ | ₩ | ₩ | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||
|
Lapse rate (increase)
|
increase |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||
|
Lapse rate (decrease)
|
decrease |
( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||||
|
Expense ratio (level)
|
increase |
|||||||||||||||||||||||||||||||||||||||||||||||||
|
Expense ratio (inflation)
|
increase |
( |
) | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||||||
(In millions of Korean won) |
||||||||||||||||||||||||||||||||
December 31, 2024 |
||||||||||||||||||||||||||||||||
1 year |
1 year ~ 2 years |
2 years ~ 3 years |
3 years ~ 4 years |
4 years ~ 5 years |
5 years ~ 10 years |
Over 10 years |
Total |
|||||||||||||||||||||||||
|
Net insurance contract liabilities with participation features
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||
|
Net insurance contract liabilities without participation features
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
(In millions of Korean won) |
||||||||||||||||||||||||||||||||
December 31, 2025 |
||||||||||||||||||||||||||||||||
1 year |
1 year ~ 2 years |
2 years ~ 3 years |
3 years ~ 4 years |
4 years ~ 5 years |
5 years ~ 10 years |
Over 10 years |
Total |
|||||||||||||||||||||||||
|
Net insurance contract liabilities with participation features
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||
|
Net insurance contract liabilities without participation features
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||
|
Reinsurance company
|
Ratio |
Credit rating |
||||||
|
KOREANRE
|
% | AA+ | ||||||
|
MUNICHRE
|
% | AAA | ||||||
|
SWISSREINSURANCE
|
% | AAA | ||||||
(In millions of Korean won) |
||||||||||
|
December 31, 2024
|
December 31, 2025
|
|||||||||
|
Reference
|
Amount |
Reference
|
Amount |
|||||||
|
Reinsurance contract assets
|
₩ |
Reinsurance contract assets
|
₩ | |||||||
|
Reinsurance contract liabilities
|
Reinsurance contract liabilities
|
|||||||||
(In millions of Korean won) |
December 31, 2024 |
December 31, 2025 |
||||||
|
Net insurance contract liabilities
|
₩ | ₩ | ||||||
|
Net insurance contract liabilities with participation features
|
||||||||
|
Net insurance contract liabilities without participation features
|
||||||||
|
Net reinsurance contract assets
|
||||||||
|
|
|
|
|
|||||
|
Net liability effect
|
₩ | ₩ | ||||||
(In millions of Korean won) |
December 31, 2024 |
|||||||
Equity |
||||||||
1% increase |
1% decrease |
|||||||
|
Net insurance contract liabilities
|
₩ | ₩ | ( |
) | ||||
|
Net insurance contract liabilities with participation features
|
( |
) | ||||||
|
Net insurance contract liabilities without participation features
|
( |
) | ||||||
|
Net reinsurance contract assets
|
( |
) | ||||||
|
Net equity effect
|
₩ | ₩ | ( |
) | ||||
(In millions of Korean won) |
December 31, 2025 |
|||||||
Equity |
||||||||
1% increase |
1% decrease |
|||||||
|
Net insurance contract liabilities
|
₩ | ₩ | ( |
) | ||||
|
Net insurance contract liabilities with participation features
|
( |
) | ( |
) | ||||
|
Net insurance contract liabilities without participation features
|
( |
) | ||||||
|
Net reinsurance contract assets
|
( |
) | ||||||
|
Net equity effect
|
₩ | ₩ | ( |
) | ||||
| Mortality Risk | Risk of unexpected losses due to premature death compared to the insured’s expectations. | |
| Longevity Risk | Risk of unexpected losses due to delayed death compared to the insured’s expectations. | |
| Disability/Illness Risk | Risk of unexpected losses related to the insured’s disability and illness. | |
| Termination Risk | Risk of losses due to unexpected exercise of legal rights or contractual options by policyholders. | |
| Expense Risk | Risk of losses due to fluctuations in future costs and expenditure variations caused by inflation in relation to insurance contract costs. | |
| Catastrophic Risk | Risk of extreme, exceptional losses (e.g., epidemics, major accidents) not considered in mortality risk, etc. | |
(In millions of Korean won) |
Exposure |
|||||||
December 31, 2024 |
December 31, 2025 |
|||||||
|
Insurance contract liabilities
|
₩ | ₩ | ||||||
|
Death
|
||||||||
|
Health
|
||||||||
|
Pension
|
||||||||
|
Asset-linked
|
||||||||
|
Variable death
|
||||||||
|
Variable pension
|
||||||||
|
Reinsurance contract assets*
|
( |
) | ( |
) | ||||
|
Death
|
( |
) | ( |
) | ||||
|
Health
|
( |
) | ( |
) | ||||
|
Compound
|
( |
) | ( |
) | ||||
| * |
Reinsurance contract assets is the net amount after deducting reinsurance contract liabilities
|
(In millions of Korean won) |
Exposure |
|||||||
December 31, 2024 |
December 31, 2025 |
|||||||
|
Insurance contracts
|
₩ | ₩ | ||||||
|
Fixed-rate
|
||||||||
|
Interest rate-linked
|
||||||||
|
Variable
|
||||||||
|
Reinsurance contract assets*
|
( |
) | ( |
) | ||||
| * |
Reinsurance contract assets is the net amount after deducting reinsurance contract liabilities
|
(In millions of Korean won) |
Exposure |
|||||||
December 31, 2024 |
December 31, 2025 |
|||||||
|
Variable
|
₩ | ₩ | ||||||
(In millions of Korean won) |
Exposure |
|||||||
December 31, 2024 |
December 31, 2025 |
|||||||
|
Foreign currency liability
|
₩ | ₩ | ||||||
(In millions of Korean won) |
December 31, 2024 |
|||||||||||||||||||||||
AAA~AA+ |
AA~A+ |
A~BBB+ |
Under BBB |
Unrated |
Total |
|||||||||||||||||||
|
Reinsurance contract assets
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||
|
Reinsurance contract liabilities
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
(In millions of Korean won) |
December 31, 2025 |
|||||||||||||||||||||||
AAA~AA+ |
AA~A+ |
A~BBB+ |
Under BBB |
Unrated |
Total |
|||||||||||||||||||
|
Reinsurance contract assets
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||
|
Reinsurance contract liabilities
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||
(In millions of Korean won) |
December 31, 2024 |
|||||||||||||||
1 |
Above AA- |
A+ ~ A- |
Below BBB+ |
Others |
||||||||||||
|
Reinsurance premiums
3 |
₩ | ₩ | |
₩ | ₩ | |
||||||||||
|
Ratio
2 |
||||||||||||||||
(In millions of Korean won) |
December 31, 2025 |
|||||||||||||||
1 |
Above AA- |
A+ ~ A- |
Below BBB+ |
Others |
||||||||||||
|
Reinsurance premiums
3 |
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
Ratio
2 |
||||||||||||||||
1 |
Credit ratings from foreign credit rating agencies are converted to domestic credit ratings based on the criteria outlined in Annex 22 of the Korean DETAILED REGULATIONS ON SUPERVISION OF INSURANCE BUSINESS.
|
2 |
The proportion of ceded insurance premiums represents the percentage relative to total insurance premiums
|
3 |
Based on the gross amount before deduction of reinsurance commissions.
|
(In millions of Korean won) |
December 31, 2024 |
|||||||||||||||||||
Credit ratings |
||||||||||||||||||||
Above AA- |
A+ ~ A- |
BBB+ Below |
Others |
Total |
||||||||||||||||
|
Reinsurance premiums *
|
₩ | ₩ | |
₩ | ₩ | |
₩ | |||||||||||||
|
Ratio
|
||||||||||||||||||||
(In millions of Korean won) |
December 31, 2025 |
|||||||||||||||||||
Credit ratings |
||||||||||||||||||||
Above AA- |
A+ ~ A- |
BBB+ Below |
Others |
Total |
||||||||||||||||
|
Reinsurance premiums *
|
₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
|
Ratio
|
||||||||||||||||||||
| * |
Based on the gross amount before deduction of reinsurance commissions.
|
(In millions of Korean won) | ||||||||||||||||||||||||||||||||
December 31, 2024 | ||||||||||||||||||||||||||||||||
1 year | 1 year ~ 2 years | 2 years ~ 3 years | 3 years ~ 4 years | 4 years ~ 5 years | 5 years ~ 10 years | 10 years ~ 20 years | Over 20 years | |||||||||||||||||||||||||
Insurance contract | ₩ | ( | ) | ₩ | ( | ) | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||
Asset portfolio | ||||||||||||||||||||||||||||||||
Liability portfolio | ( | ) | ( | ) | ||||||||||||||||||||||||||||
Reinsurance contract | ||||||||||||||||||||||||||||||||
Asset portfolio | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||
Liability portfolio | ||||||||||||||||||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||||||||||
December 31, 2025 | ||||||||||||||||||||||||||||||||
1 year | 1 year ~ 2 years | 2 years ~ 3 years | 3 years ~ 4 years | 4 years ~ 5 years | 5 years ~ 10 years | 10 years ~ 20 years | Over 20 years | |||||||||||||||||||||||||
Insurance contract | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||||||||
Asset portfolio | ||||||||||||||||||||||||||||||||
Liability portfolio | ||||||||||||||||||||||||||||||||
Reinsurance contract | ||||||||||||||||||||||||||||||||
Asset portfolio | ( | ) | ||||||||||||||||||||||||||||||
Liability portfolio | ||||||||||||||||||||||||||||||||
December 31, 2024 | December 31, 2025 | |||||||||||||||
Amount payable upon demand | Book value | Amount payable upon demand | Book value | |||||||||||||
Insurance contracts | ₩ | ₩ | ₩ | ₩ | ||||||||||||
Death | ||||||||||||||||
Health | ||||||||||||||||
Pension | ||||||||||||||||
Asset-linked | ||||||||||||||||
Variable death | ||||||||||||||||
Variable pension | ||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||||||
December 31, 2024 | ||||||||||||||||||||||||||||
Sensitivit 1 | Baseline amount | Change amount | Impact on profit and equity (before tax) | |||||||||||||||||||||||||
Fulfillment | Insurance | Fulfillment | Insurance | Profit or loss 2 | OCI | |||||||||||||||||||||||
Cash flows | CSM | Cash flow 3 | CSM | |||||||||||||||||||||||||
Loss rate | Mortality rate | Increase by | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ||||||||||||||||
Disability/illness (fixed benefit) | Increase by | ( | ) | ( | ) | |||||||||||||||||||||||
| Disability/illness (indemnity benefit) | Increase by | ( | ) | ( | ) | |||||||||||||||||||||||
| Long-term property/other risks | Increase by | |||||||||||||||||||||||||||
Lapse rate | Lapse rate (increase) | Increase by | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||
| Lapse rate (decrease) | Decrease by | ( | ) | |||||||||||||||||||||||||
Expense ratio | Expense ratio (level) | Increase by | ( | ) | ( | ) | ||||||||||||||||||||||
| Expense ratio (inflation) | ||||||||||||||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||||||
December 31, 2024 | ||||||||||||||||||||||||||||
Sensitivity 1 | Baseline amount | Change amount | Impact on profit and equity (before tax) | |||||||||||||||||||||||||
Fulfillment | Insurance | Fulfillment | Insurance | Profit or loss 2 | OCI | |||||||||||||||||||||||
Cash flows | CSM | Cash flow 3 | CSM | |||||||||||||||||||||||||
Loss rate | Mortality rate | Increase by | ₩ | ₩ | ( | ) | ₩ | ( | ) | ₩ | ( | ) | ||||||||||||||||
Disability/illness (fixed benefit) | Increase by | ( | ) | ( | ) | |||||||||||||||||||||||
| Disability/illness (indemnity benefit) | Increase by | ( | ) | ( | ) | |||||||||||||||||||||||
| Long-term property/other risks | Increase by | |||||||||||||||||||||||||||
Lapse rate | Lapse rate (increase) | Increase by | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||
| Lapse rate (decrease) | Decrease by | ( | ) | |||||||||||||||||||||||||
Expense ratio | Expense ratio (level) | Increase by | ( | ) | ( | ) | ||||||||||||||||||||||
| Expense ratio (inflation) | ||||||||||||||||||||||||||||
1 | The sensitivity analysis is on liability for remaining coverage of insurance, and the shock levels of actuarial assumptions are based on supervisory criteria for calculating the risk adjustment (confidence level of 75%). |
2 |
The impact on profit or loss represents the increase in the best estimate liability that exceeds the carrying amount of the contractual service margin due to changes in assumptions.
|
3 |
No shocks were applied to the risk adjustment within the fulfillment cash flows.
|
(In millions of Korean won) |
||||||||||||||||||||||||||||
|
December 31, 2025
|
||||||||||||||||||||||||||||
|
Sensitivity
1 |
Baseline amount |
Change amount |
Impact on profit and equity (before tax) |
|||||||||||||||||||||||||
Fulfillment |
Insurance |
Fulfillment |
Insurance |
Profit or loss 2 |
OCI |
|||||||||||||||||||||||
Cash flows |
CSM |
Cash flow 3 |
CSM |
|||||||||||||||||||||||||
|
Loss rate
|
Mortality rate | Increase by |
₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ||||||||||||||||
| Disability/illness (fixed benefit) | Increase by |
( |
) | ( |
) | |||||||||||||||||||||||
| Disability/illness (indemnity benefit) | Increase by |
|||||||||||||||||||||||||||
| Long-term property/other risks | Increase by |
|||||||||||||||||||||||||||
|
Lapse rate
|
Lapse rate (increase) | Increase by |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||
| Lapse rate (decrease) | Decrease by |
( |
) | |||||||||||||||||||||||||
|
Expense ratio
|
Expense ratio (level) | Increase by |
( |
) | ( |
) | ||||||||||||||||||||||
| Expense ratio (inflation) | ||||||||||||||||||||||||||||
(In millions of Korean won) |
||||||||||||||||||||||||||||
|
December 31, 2025
|
||||||||||||||||||||||||||||
|
Sensitivity
1 |
Baseline amount |
Change amount |
Impact on profit and equity (before tax) |
|||||||||||||||||||||||||
Fulfillment |
Insurance |
Fulfillment |
Insurance |
Profit or loss 2 |
OCI |
|||||||||||||||||||||||
Cash flows |
CSM |
Cash flow 3 |
CSM |
|||||||||||||||||||||||||
|
Loss rate
|
Mortality rate | Increase by |
₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ||||||||||||||||
| Disability/illness (fixed benefit) | Increase by |
( |
) | ( |
) | |||||||||||||||||||||||
| Disability/illness (indemnity benefit) | Increase by |
|||||||||||||||||||||||||||
| Long-term property/other risks | Increase by |
|||||||||||||||||||||||||||
|
Lapse rate
|
Lapse rate (increase) | Increase by |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||
| Lapse rate (decrease) | Decrease by |
( |
) | |||||||||||||||||||||||||
|
Expense ratio
|
Expense ratio (level) | Increase by |
( |
) | ( |
) | ||||||||||||||||||||||
| Expense ratio (inflation) | ||||||||||||||||||||||||||||
1 |
The sensitivity analysis is on liability for remaining coverage of insurance, and the shock levels of actuarial assumptions are based on supervisory criteria for calculating the risk adjustment (confidence level of 75%).
|
2 |
The impact on profit or loss represents the increase in the best estimate liability that exceeds the carrying amount of the contractual service margin due to changes in assumptions.
|
3 |
No shocks were applied to the risk adjustment within the fulfillment cash flows.
|
(In millions of Korean won) |
||||||||||
December 31, 2024 |
||||||||||
Profit or loss (before tax) |
OCI (before tax) |
|||||||||
|
100bp increase
|
Insurance contracts * | ₩ | ₩ | |||||||
| Reinsurance contracts * | ( |
) | ||||||||
|
100bp decrease
|
Insurance contracts * | ( |
) | ( |
) | |||||
| Reinsurance contracts * | ( |
|||||||||
(In millions of Korean won) |
||||||||||
December 31, 2025 |
||||||||||
Profit or loss (before tax) |
OCI (before tax) |
|||||||||
|
100bp increase
|
Insurance contracts * | ₩ | ₩ | |||||||
| Reinsurance contracts * | ||||||||||
|
100bp decrease
|
Insurance contracts * | ( |
) | ( |
) | |||||
| Reinsurance contracts * | ( |
|||||||||
1 |
For insurance contracts (original insurance and accepted reinsurance) and reinsurance contracts, the impacts are on liability for remaining coverage.
|
2 |
No shocks were applied to the risk adjustment within the fulfillment cash flows.
|
(In millions of Korean won) |
||||||||||
December 31, 2024 |
||||||||||
Profit or loss (before tax) |
OCI (before tax) |
|||||||||
|
100won increase
|
Insurance contracts * | ₩ | ( |
) | ₩ | |||||
| Reinsurance contracts * | ( |
) | ||||||||
|
100won decrease
|
Insurance contracts * | ( |
) | |||||||
| Reinsurance contracts * | ( |
|||||||||
(In millions of Korean won) |
||||||||||
December 31, 2025 |
||||||||||
Profit or loss (before tax) |
OCI (before tax) |
|||||||||
|
100won increase
|
Insurance contracts * | ₩ | ( |
) | ₩ | |||||
| Reinsurance contracts * | ( |
) | ||||||||
|
100won decrease
|
Insurance contracts * | ( |
) | |||||||
| Reinsurance contracts * | ( |
|||||||||
1 |
For insurance contracts (original insurance and accepted reinsurance) and reinsurance contracts, the impacts are on liability for remaining coverage. |
2 |
No shocks were applied to the risk adjustment within the fulfillment cash flows. |
(In millions of Korean won) |
||||||||||
December 31, 2024 |
||||||||||
Profit or loss (before tax) |
OCI (before tax) |
|||||||||
|
10% increase
|
Insurance contracts * | ₩ | ( |
) | ₩ | |||||
| Reinsurance contracts * | ||||||||||
|
10% decrease
|
Insurance contracts * | |||||||||
| Reinsurance contracts * | ( |
|||||||||
(In millions of Korean won) |
||||||||||
December 31, 2025 |
||||||||||
|
|
Profit or loss (before tax) |
OCI (before tax) |
||||||||
|
10% increase
|
Insurance contracts * | ₩ | ( |
) | ₩ | |||||
| Reinsurance contracts * | ||||||||||
|
10% decrease
|
Insurance contracts * | |||||||||
| Reinsurance contracts * | ||||||||||
1 |
For insurance contracts (original insurance and accepted reinsurance) and reinsurance contracts, the impacts are on liability for remaining coverage.
|
2 |
No shocks were applied to the risk adjustment within the fulfillment cash flows.
|
(In millions of Korean won) |
December 31, 2024 |
|||||||||||||||||||||||
Accident year |
||||||||||||||||||||||||
2020 |
2021 |
2022 |
2023 |
2024 |
Total |
|||||||||||||||||||
Development year |
||||||||||||||||||||||||
|
Estimated final loss undiscounted
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||
|
Claims paid
|
||||||||||||||||||||||||
|
Current year
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
|
After 1 year
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
|
After 2 years
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
After 3 years
|
( |
) | ( |
) | ||||||||||||||||||||
|
After 4 years
|
( |
) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Total gross cumulative claim payments
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ||||||||
|
Difference between estimated final loss and claim payments.
|
||||||||||||||||||||||||
|
Discount rate effect
|
( |
) | ||||||||||||||||||||||
|
Future claims expense
|
||||||||||||||||||||||||
|
Incurred claims settled but not yet paid
|
||||||||||||||||||||||||
|
Risk adjustment
|
||||||||||||||||||||||||
|
Reinsurance effects*
|
( |
) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Total Liability for incurred claims
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
(In millions of Korean won) |
December 31, 2025 |
|||||||||||||||||||||||
Accident year |
||||||||||||||||||||||||
Development year |
2021 |
2022 |
2023 |
2024 |
2025 |
Total |
||||||||||||||||||
|
Estimated final loss undiscounted
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||
|
Claims paid
|
||||||||||||||||||||||||
|
Current year
|
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||
|
After 1 year
|
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||
|
After 2 years
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
After 3 years
|
( |
) | ( |
) | ||||||||||||||||||||
|
After 4 years
|
( |
) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Total gross cumulative claim payments
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ||||||||
|
Difference between estimated final loss and claim payments.
|
||||||||||||||||||||||||
|
Discount rate effect
|
( |
) | ||||||||||||||||||||||
|
Future claims expense
|
||||||||||||||||||||||||
|
Incurred claims settled but not yet paid
|
||||||||||||||||||||||||
|
Risk adjustment
|
||||||||||||||||||||||||
|
Reinsurance effects*
|
( |
) | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
|
Total Liability for incurred claims
|
₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
| * |
The reinsurance effect is presented as a total amount.
|
(In millions of Korean won) |
December 31, 2024 |
December 31, 2025 |
||||||
|
Cash
|
₩ | ₩ | ||||||
|
Checks issued by other banks
|
||||||||
|
Due from the Bank of Korea
|
||||||||
|
Due from other financial institutions
|
||||||||
|
Disposal group held for sale
1 |
||||||||
|
|
|
|
|
|||||
|
|
|
|
|
|||||
|
Due from financial institutions measured at fair value through profit or loss
|
||||||||
|
|
|
|
|
|||||
|
|
|
|
|
|||||
|
Deduction:
|
||||||||
|
Restricted due from financial institutions
2 |
( |
) | ( |
) | ||||
|
Due from financial institutions with original maturities over three months
|
( |
) | ( |
) | ||||
|
|
|
|
|
|||||
| ( |
) | ( |
) | |||||
|
|
|
|
|
|||||
| ₩ | ₩ | |||||||
|
|
|
|
|
|||||
1 |
The cash and deposits classified as a disposal group held for sale as of December 31, 2025 are included, as described in Note 18
|
2 |
Items meeting the definition of cash are excluded.
|
(In millions of Korean won) |
Financial institutions
|
December 31, 2024 |
December 31, 2025 |
|||||||||
|
Due from financial institutions in Korean won
|
Due from the Bank of Korea
|
The Bank of Korea | ₩ | ₩ | ||||||||
|
Due from others
|
Korea Development Bank and others
|
|||||||||||
|
Due from financial institutions in foreign currencies
|
Due from banks in foreign currencies
|
Bank Indonesia and others
|
||||||||||
|
|
|
|
|
|||||||||
| ₩ | ₩ | |||||||||||
|
|
|
|
|
|||||||||
(In millions of Korean won) |
2023 |
2024 |
2025 |
|||||||||
|
Write-offs of loans
|
₩ | ₩ | ₩ | |||||||||
|
Changes in accumulated other comprehensive income from valuation of financial instruments at fair value through other comprehensive income
|
( |
) | ||||||||||
|
Changes in accumulated other comprehensive income from valuation of investments in associates
|
||||||||||||
(In millions of Korean won) |
Activities |
2023 |
2024 |
2025 |
||||||||||||
|
Income tax paid
|
Operating | ₩ | ₩ | ₩ | ||||||||||||
|
Interest received
|
Operating | |||||||||||||||
|
Interest paid
|
Operating | |||||||||||||||
|
Dividends received
|
Operating | |||||||||||||||
|
Dividends paid
|
Financing | |||||||||||||||
(In millions of Korean won) |
||||||||||||||||||||||||||||||||
2024 |
||||||||||||||||||||||||||||||||
Non-cash changes |
||||||||||||||||||||||||||||||||
Beginning |
Net cash flows |
Acquisition (disposal) |
Exchange differences |
Changes in fair value |
Subsidiaries |
Others |
Ending |
|||||||||||||||||||||||||
|
Derivatives held for hedging*
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ₩ | ( |
) | ||||||||||||||
|
Borrowings and debentures
|
( |
) | ||||||||||||||||||||||||||||||
|
Due to trust accounts
|
||||||||||||||||||||||||||||||||
|
Others
|
( |
) | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
(In millions of Korean won) |
||||||||||||||||||||||||||||||||
2025 |
||||||||||||||||||||||||||||||||
Non-cash changes |
||||||||||||||||||||||||||||||||
Beginning |
Net cash flows |
Acquisition (disposal) |
Exchange differences |
Changes in fair value |
Subsidiaries |
Others |
Ending |
|||||||||||||||||||||||||
|
Derivatives held for hedging*
|
₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | ₩ | ||||||||||||||||
|
Borrowings and debentures
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
|
Due to trust accounts
|
||||||||||||||||||||||||||||||||
|
Others
|
( |
) | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| ₩ | ₩ | ₩ | ₩ | ( |
) | ₩ | ( |
) | ₩ | ( |
) | ₩ | ₩ | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| * |
Derivatives held for hedging purposes are the net amount after offsetting liabilities and assets.
|
(In millions of Korean won) |
December 31, 2024 |
December 31, 2025 |
||||||
|
Confirmed acceptances and guarantees
|
||||||||
|
Confirmed acceptances and guarantees in Korean won:
|
||||||||
|
Acceptances and guarantees for KB purchasing loan
|
₩ | ₩ | ||||||
|
Others
|
||||||||
|
|
|
|
|
|||||
|
|
|
|
|
|||||
|
Confirmed acceptances and guarantees in foreign currencies:
|
||||||||
|
Acceptances of letter of credit
|
||||||||
|
Letter of guarantees
|
||||||||
|
Bid bond
|
||||||||
|
Performance bond
|
||||||||
|
Refund guarantees
|
||||||||
|
Others
|
||||||||
|
|
|
|
|
|||||
|
|
|
|
|
|||||
|
Financial guarantee contracts:
|
||||||||
|
Acceptances and guarantees for mortgage
|
||||||||
|
Overseas debt guarantees
|
||||||||
|
International financing guarantees in foreign currencies
|
||||||||
|
Other financial guarantees
|
||||||||
|
|
|
|
|
|||||
|
|
|
|
|
|||||
|
|
|
|
|
|||||
|
Unconfirmed acceptances and guarantees
|
||||||||
|
Guarantees of letter of credit
|
||||||||
|
Refund guarantees
|
||||||||
|
|
|
|
|
|||||
|
|
|
|
|
|||||
| ₩ | ₩ | |||||||
|
|
|
|
|
|||||
(In millions of Korean won) |
December 31, 2024 |
|||||||||||||||
12-month expected credit losses |
Lifetime expected credit losses |
Total |
||||||||||||||
Non-impaired |
Impaired |
|||||||||||||||
|
Confirmed acceptances and guarantees
|
|
|||||||||||||||
|
Grade 1
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
Grade 2
|
||||||||||||||||
|
Grade 3
|
||||||||||||||||
|
Grade 4
|
||||||||||||||||
|
Grade 5
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Unconfirmed acceptances and guarantees
|
|
|||||||||||||||
|
Grade 1
|
||||||||||||||||
|
Grade 2
|
||||||||||||||||
|
Grade 3
|
||||||||||||||||
|
Grade 4
|
||||||||||||||||
|
Grade 5
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
(In millions of Korean won) |
December 31, 2025 |
|||||||||||||||
12-month expected credit losses |
Lifetime expected credit losses |
Total |
||||||||||||||
Non-impaired |
Impaired |
|||||||||||||||
|
Confirmed acceptances and guarantees
|
|
|||||||||||||||
|
Grade 1
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
Grade 2
|
||||||||||||||||
|
Grade 3
|
||||||||||||||||
|
Grade 4
|
||||||||||||||||
|
Grade 5
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
Unconfirmed acceptances and guarantees
|
|
|||||||||||||||
|
Grade 1
|
||||||||||||||||
|
Grade 2
|
||||||||||||||||
|
Grade 3
|
||||||||||||||||
|
Grade 4
|
||||||||||||||||
|
Grade 5
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
(In millions of Korean won) |
December 31, 2024 |
|||||||||||||||
Confirmed guarantees |
Unconfirmed guarantees |
Total |
Proportion (%) |
|||||||||||||
|
Large companies
|
₩ | ₩ | ₩ | |||||||||||||
|
Small and
medium-sized companies |
||||||||||||||||
|
Public sector and others
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | ₩ | ₩ | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
(In millions of Korean won) |
December 31, 2025 |
|||||||||||||||
Confirmed guarantees |
Unconfirmed guarantees |
Total |
Proportion (%) |
|||||||||||||
|
Large companies
|
₩ | ₩ | ₩ | |||||||||||||
|
Small and
medium-sized companies |
||||||||||||||||
|
Public sector and others
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | ₩ | ₩ | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
(In millions of Korean won) |
December 31, 2024 |
|||||||||||||||
Confirmed guarantees |
Unconfirmed guarantees |
Total |
Proportion (%) |
|||||||||||||
|
Financial institutions
|
₩ | ₩ | ₩ | |||||||||||||
|
Manufacturing
|
||||||||||||||||
|
Service
|
||||||||||||||||
|
Wholesale and retail
|
||||||||||||||||
|
Construction
|
||||||||||||||||
|
Public sector
|
||||||||||||||||
|
Others
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | ₩ | ₩ | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
(In millions of Korean won) |
December 31, 2025 |
|||||||||||||||
Confirmed guarantees |
Unconfirmed guarantees |
Total |
Proportion (%) |
|||||||||||||
|
Financial institutions
|
₩ | ₩ | ₩ | |||||||||||||
|
Manufacturing
|
||||||||||||||||
|
Service
|
||||||||||||||||
|
Wholesale and retail
|
||||||||||||||||
|
Construction
|
||||||||||||||||
|
Public sector
|
||||||||||||||||
|
Others
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | ₩ | ₩ | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
(In millions of Korean won) |
December 31, 2024 |
December 31, 2025 |
||||||
|
Commitments
|
||||||||
|
Corporate loan commitments
|
₩ | ₩ | ||||||
|
Retail loan commitments
|
||||||||
|
Credit line of credit cards
|
||||||||
|
Purchase of other securities
|
||||||||
|
|
|
|
|
|||||
|
|
|
|
|
|||||
|
Financial guarantee contracts
|
||||||||
|
Credit line
|
||||||||
|
Purchase of securities
|
||||||||
|
|
|
|
|
|||||
|
|
|
|
|
|||||
| ₩ | ₩ | |||||||
|
|
|
|
|
|||||
|
Company
|
Lawsuits
|
No. of cases |
Amount |
Description of the lawsuits
|
Status of the lawsuits
|
|||||||||
| Kookmin Bank | Request for a return of redemption amount | ₩ | Kookmin Bank invested the assets entrusted by OO Invest Trust Management in the Fairfield Sentry Limited and Fairfield Sentry Limited reinvested the assets in Bernard L. Madoff Investment Securities LLC managed by Bernard Madoff. (Bernard L. Madoff Investment Securities LLC is in the liquidation process due to Ponzi scheme fraud-related losses.)
Bankruptcy trustee of Bernard L. Madoff Investment Securities LLC filed a lawsuit against Kookmin Bank seeking to return the amount of redemptions received by Kookmin Bank through Fairfield Sentry Limited. |
Application for dismissal by the defendant has been denied, and further proceedings are scheduled. [Related litigation is pending at the New York Southern District Federal Bankruptcy Court
(10-3777)] The financial impact on Kookmin Bank is not significant because the likelihood of winning the lawsuit is high |
||||||||||
|
Company
|
Lawsuits
|
No. of cases |
Amount |
Description of the lawsuits
|
Status of the lawsuits
|
|||||||||
| Return of unjust enrichment | As MTS Bank, which was trading with Kookmin Bank through a foreign exchange account, was listed on the SDN (Specifically Designated Nationals) list of the Office of Foreign Assets Control (OFAC) under the U.S. Treasury Department, Kookmin Bank froze the foreign currency account in the name of MTS Bank.
Accordingly, MTS Bank filed a lawsuit seeking the return of the account balance to the Moscow City Commercial Court in Russia |
Responding in accordance with the schedule of the local court proceedings (following the first-instance judgment rendered against the Bank on December 2, 2025, the Bank is currently responding to the appellate proceedings).
Due to compliance with U.S. OFAC regulations, it is difficult to predict the likelihood of success in the litigation being conducted before the Russian courts. However, the amount in dispute can be covered by the balance in the plaintiff’s account, and a financial impact equivalent to delayed interest is expected for the Bank. |
||||||||||||
| KB Securities Co., Ltd. | Request for the return of unjust enrichment and transaction amount (Australian fund) | No.1 case: The third trial is in progress (The first trial: On February 7, 2023, a ruling was made to pay the principal investment of ₩ 29,800 million and the delayed interest on it. The second trial: On January 29, 2024, the conclusion was different; a ruling was made to pay the principal investment of ₩ 12,000 million and the delayed interest on it.)
No. 2 case: The second trial is in progress (The first trial: On February 14, 2024, a ruling was made to pay the principal investment of ₩ 12,200 million and the delayed interest on it.)
No. 3 case: The third trial is in progress (The first trial: On October 26, 2023, a ruling was made to pay the remaining principal and interest of ₩ 8,460 million and the delayed interest on the principal of ₩ 8,290 million. The second trial: On January 16, 2025, a ruling was made ordering the return of ₩ 4,400 million, which represents a portion of the ₩ 8,070 million paid following the first-instance judgment.) |
||||||||||||
|
Investor
|
Investee
|
Ownership (%) |
Location
|
Date of
financial statements |
Industry
|
|||||||
|
|
|
|
|
|||||||||
|
|
|
|
||||||||||
|
|
|
|
||||||||||
|
|
|
|
||||||||||
|
|
|
|
||||||||||
|
|
|
|
||||||||||
|
|
|
|
||||||||||
|
|
|
|
||||||||||
|
|
|
|
||||||||||
|
|
|
|
||||||||||
|
|
|
|
||||||||||
|
|
|
|
|
|||||||||
|
|
|
|
||||||||||
|
|
|
|
||||||||||
PT Bank KB Bukopin Syariah 5 |
|
|
||||||||||
PT KB Bukopin Finance 6 8 |
|
|
||||||||||
|
|
|
|
||||||||||
|
|
|
|
||||||||||
Investor | Investee | Ownership (%) | Location | Date of financial statements | Industry | |||||||
| PT Bank KB Indonesia,Tbk. 7 | ||||||||||||
| KB FINA COMPANY LIMITED 4 | ||||||||||||
| Non-life insurance | ||||||||||||
| Non-life insurance | ||||||||||||
| KB Claims Survey & Adjusting | ||||||||||||
| KB Daehan Specialized Bank Plc. 2 | ||||||||||||
| KBFintech Inc. 3 | ||||||||||||
| PT KB Valbury Asset Management 1 | ||||||||||||
1 | During the first quarter of 2024, PT Valbury Capital Management was changed from a sub-subsidiary of KB Securities Co., Ltd. to a subsidiary of KB Asset Management Co., Ltd., and its name was changed to PT KB Valbury Asset Management during the second quarter of 2024. |
2 | KB DAEHAN SPECIALIZED BANK PLC. (merging entity) merged with i-Finance Leasing PLC. (merged entity) on December 19, 2024. |
3 | On October 14, 2024, Teamwink Co., Ltd. changed its name to KB Fintech Co., Ltd. |
4 | During the first quarter of 2025, KB FINA Joint Stock Company changed its name to KB FINA COMPANY LIMITED. |
5 | During the third quarter of 2025, PT Bank Syariah Bukopin changed its name to PT Bank KB Bukopin Syariah. |
6 | During the third quarter of 2025, PT Bukopin Finance changed its name to PT KB Bukopin Finance. |
7 | During the third quarter of 2025, PT Bank KB Bukopin,Tbk. changed its name to PT Bank KB Indonesia,Tbk. |
8 | The disposal group was classified as held for sale, as of December 31, 2025. |
Consolidated structured entities | Reasons for consolidation | |||
Trusts | Kookmin Bank (development trust) and 10 others | The Group controls the trust because it has power to determine management performance of the trust and is significantly exposed to variable returns that absorb losses through the guarantees of payment of principal, or payment of principal and fixed rate of return. | ||
Asset-backed securitization | Taejon Samho The First Co., Ltd. and 82 others | The Group controls these investees because it has power over relevant activities in the event of default, is significantly exposed to variable returns by providing lines of credit, ABCP purchase commitments or acquisition of subordinated debt and has ability to affect those returns through its power. | ||
Investment funds and others | KB Global Platform Fund No.2 and 237 others | Funds are consolidated if the Group, as a collective investor or operating manager (member), etc., can manage fund assets on behalf of other investors, or dismiss the collective investor and operating manager, and is substantially exposed to significant variable returns or has such rights. | ||
(In millions of Korean won) | ||||||||||||||||||||||||
December 31, 2024 | 2024 | |||||||||||||||||||||||
Assets | Liabilities | Equity | Operating revenue | Profit (loss) attributable to shareholders of the Parent Company | Total comprehensive income (loss) attributable to shareholders of the Parent Company | |||||||||||||||||||
Kookmin Bank 1 | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||
KB Securities Co., Ltd. 1,2 | ||||||||||||||||||||||||
KB Insurance Co., Ltd. 1,2 | ( | ) | ||||||||||||||||||||||
KB Kookmin Card Co., Ltd. 1 | ||||||||||||||||||||||||
KB Life Insurance Co., Ltd. 1,2 | ( | ) | ||||||||||||||||||||||
KB Asset Management Co., Ltd. 1 | ||||||||||||||||||||||||
KB Capital Co., Ltd. 1,2 | ||||||||||||||||||||||||
KB Real Estate Trust Co., Ltd. 1 | ( | ) | ( | ) | ||||||||||||||||||||
KB Savings Bank Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||||||
KB Investment Co., Ltd. 1 | ||||||||||||||||||||||||
KB Data System Co., Ltd. 1 | ||||||||||||||||||||||||
(In millions of Korean won) | ||||||||||||||||||||||||
December 31, 2025 | 2025 | |||||||||||||||||||||||
Assets | Liabilities | Equity | Operating revenue | Profit (loss) attributable to shareholders of the Parent Company | Total comprehensive income (loss) attributable to shareholders of the Parent Company | |||||||||||||||||||
Kookmin Bank 1 | ₩ | ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||||
KB Securities Co., Ltd. 1,2 | ||||||||||||||||||||||||
KB Insurance Co., Ltd. 1,2 | ||||||||||||||||||||||||
KB Kookmin Card Co., Ltd. 1 | ||||||||||||||||||||||||
KB Life Insurance Co., Ltd. 1,2 | ( | ) | ||||||||||||||||||||||
KB Asset Management Co., Ltd. 1 | ||||||||||||||||||||||||
KB Capital Co., Ltd. 1,2 | ||||||||||||||||||||||||
KB Real Estate Trust Co., Ltd. 1 | ( | ) | ( | ) | ||||||||||||||||||||
KB Savings Bank Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||||||
KB Investment Co., Ltd. 1 | ||||||||||||||||||||||||
KB Data System Co., Ltd. 1 | ||||||||||||||||||||||||
1 | Financial information is based on its consolidated financial statements. |
2 | Includes fair value adjustments arising from the acquisition. |
Company | Reasons for obtaining control | |||
IM Asset General Private Securities Investment Trust No.55(Bond) and 21 others | ||||
KB Great On 1st.L.L.C. and 44 others | ||||
KB HL Infra Private Special Asset Fund 1(FOFs) and 45 others |
Company | Reasons for losing control | |||
Able Eunhwasam 2nd Co., Ltd. and 36 others | ||||
KB High-tech Company Investment Fund and 20 others | ||||
Black Sappahire Holdings Co., Ltd. and 1 other | ||||
KB RISE Global AI Value Chain ETF Moa Dream Securities Fund (FoFs) and 23 others |
|
Nature
|
Purpose
|
Activity
|
Method of financing
|
|||
|
Structured financing
|
Granting PF loans to SOC and real estate
Granting loans to ships/aircrafts SPC |
Construction of SOC and real estate
Building ships, construction and purchase of aircrafts |
|
|||
|
Investment funds
|
Investment in beneficiary certificates
Investment in PEF and partnerships |
Management of fund assets
Payment of fund fees and allocation of fund profits |
Sales of beneficiary certificate instruments
Investment from general partners and limited partners |
|||
|
Trusts
|
Management of financial trusts;
— Development trust
— General unspecified money trust
— Trust whose principal is not guaranteed
— Other trusts |
Management of trusted financial assets
Payment of trust fees and allocation of trust profits. |
|
|||
|
Asset-backed securitization
|
Early cash generation through transfer of securitized assets
Fees earned through services to SPC, such as providing lines of credit and ABCP purchase commitments |
Fulfillment of asset-backed securitization plan
Purchase and collection of securitized assets
Issuance and repayment of ABS and ABCP |
|
|||
(In millions of Korean won) |
December 31, 2024 |
|||||||||||||||||||
Structured financing |
Investment funds |
Trusts |
Asset-backed securitization and others |
Total |
||||||||||||||||
|
Total assets of unconsolidated structured entities
|
₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
|
Carrying amount in the financial statements
|
||||||||||||||||||||
|
Assets:
|
||||||||||||||||||||
|
Financial assets at fair value through profit or loss
|
₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
|
Derivative financial assets
|
||||||||||||||||||||
|
Loans measured at amortized cost
|
||||||||||||||||||||
|
Financial investments
|
— | — | ||||||||||||||||||
|
Investments in associates
|
— | — | — | |||||||||||||||||
|
Other assets
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Liabilities:
|
||||||||||||||||||||
|
Deposits
|
₩ | ₩ | ₩ | — | ₩ | ₩ | ||||||||||||||
|
Derivative financial liabilities
|
— | |||||||||||||||||||
|
Other liabilities
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Maximum exposure *
|
||||||||||||||||||||
|
Assets held
|
₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
|
Purchase and investment commitments
|
||||||||||||||||||||
|
Unused credit
|
||||||||||||||||||||
|
Acceptances and guarantees and loan commitments
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Methods of determining the maximum exposure
|
|
commitments / investment agreements / purchase commitments and acceptances and guarantees |
|
|
loans and Investment agreements |
|
paying dividends by results: Total amount of trust exposure |
|
|
credit lines/ purchase commitments/ loan commitments and acceptances and guarantees |
|
|||||||||
| * |
Maximum exposure includes the asset amounts, after deducting loss (provisions for credit losses, impairment losses, and others), recognized in the consolidated financial statements of the Group.
|
(In millions of Korean won) |
December 31, 2025 |
|||||||||||||||||||
Structured financing |
Investment funds |
Trusts |
Asset-backed securitization and others |
Total |
||||||||||||||||
|
Total assets of unconsolidated structured entities
|
₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
|
Carrying amount in the financial statements
|
||||||||||||||||||||
|
Assets:
|
||||||||||||||||||||
|
Financial assets at fair value through profit or loss
|
₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
|
Derivative financial assets
|
— | — | ||||||||||||||||||
|
Loans measured at amortized cost
|
||||||||||||||||||||
|
Financial investments
|
— | — | — | |||||||||||||||||
|
Investments in associates
|
— | — | — | |||||||||||||||||
|
Other assets
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Liabilities:
|
||||||||||||||||||||
|
Deposits
|
₩ | ₩ | ₩ | — | ₩ | ₩ | ||||||||||||||
|
Derivative financial liabilities
|
— | — | ||||||||||||||||||
|
Other liabilities
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Maximum exposure *
|
||||||||||||||||||||
|
Assets held
|
₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
|
Purchase and investment commitments
|
||||||||||||||||||||
|
Unused credit
|
||||||||||||||||||||
|
Acceptances and guarantees and loan commitments
|
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| ₩ | ₩ | ₩ | ₩ | ₩ | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Methods of determining the maximum exposure
|
|
commitments / investment agreements / purchase commitments and acceptances and guarantees |
|
|
loans and Investment agreements |
|
paying dividends by results: Total amount of trust exposure |
|
|
credit lines/ purchase commitments/ loan commitments and acceptances and guarantees |
|
|||||||||
| * |
|
(In millions of Korean won) |
||||||||||||||
2023 |
2024 |
2025 |
||||||||||||
|
Associates and joint ventures
|
||||||||||||||
|
Balhae Infrastructure Company
|
Fee and commission income | ₩ | ₩ | ₩ | ||||||||||
| Interest income | ||||||||||||||
| Provision for credit losses | ||||||||||||||
|
Korea Credit Bureau Co., Ltd.
|
Interest expense | |||||||||||||
| Fee and commission income | ||||||||||||||
| Fee and commission expense | ||||||||||||||
| Insurance income | ||||||||||||||
| Reversal of credit losses | ||||||||||||||
| Provision for credit losses | ||||||||||||||
| Other operating expenses | ||||||||||||||
|
Incheon Bridge Co., Ltd.
|
Interest income | |||||||||||||
| Interest expense | ||||||||||||||
| Fee and commission income | ||||||||||||||
| Fee and commission expense | ||||||||||||||
| Insurance income | ||||||||||||||
|
Gains on financial instruments at fair value through profit or loss
|
||||||||||||||
|
Losses on financial instruments at fair value through profit or loss
|
||||||||||||||
| Reversal of credit losses | ||||||||||||||
| Provision for credit losses | ||||||||||||||
|
Aju Good Technology Venture Fund
|
Interest expense | |||||||||||||
|
Taeyoungjungkong Co.,Ltd.
|
Interest income | |||||||||||||
|
Star-Lord General Investors Private Real Estate Investment Company No.10
|
Insurance income | |||||||||||||
| Interest income | ||||||||||||||
| Interest expense | ||||||||||||||
| Fee and commission income | ||||||||||||||
| Provision for credit losses | ||||||||||||||
|
General and administrative expenses
|
||||||||||||||
|
Other income
|
||||||||||||||
| Other expense | ||||||||||||||
|
KG Capital Co., Ltd. *
|
Interest income
|
|||||||||||||
|
Fee and commission income
|
||||||||||||||
|
Fee and commission expense
|
||||||||||||||
|
Insurance income
|
||||||||||||||
|
Other operating expenses
|
||||||||||||||
|
Reversal of credit losses
|
||||||||||||||
(In millions of Korean won) | ||||||||||||||
2023 | 2024 | 2025 | ||||||||||||
Food Factory Co., Ltd. | Interest income | |||||||||||||
Interest expense | ||||||||||||||
Insurance income | ||||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
Reversal of credit losses | ||||||||||||||
Provision for credit losses | ||||||||||||||
Dongjo Co., Ltd. | Interest income | |||||||||||||
POSCO-KB Shipbuilding Fund | Fee and commission income | ( | ) | ( | ) | |||||||||
Paycoms Co., Ltd. * | Interest income | |||||||||||||
Big Dipper Co., Ltd. | Fee and commission income | |||||||||||||
Fee and commission expense | ||||||||||||||
Reversal of credit losses | ||||||||||||||
Provision for credit losses | ||||||||||||||
KB-KDBC Pre-IPO New Technology Business Investment Fund | Interest expense | |||||||||||||
KB-TS Technology Venture Private Equity Fund | Fee and commission income | |||||||||||||
KB-SJ Tourism Venture Fund | Fee and commission income | |||||||||||||
Banksalad Co., Ltd. * | Gains on financial instruments at fair value through profit or loss | |||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
Fee and commission income | ||||||||||||||
Fee and commission expense | ||||||||||||||
Iwon Alloy Co., Ltd. | Insurance income | |||||||||||||
Bioprotect Ltd. | Gains on financial instruments at fair value through profit or loss | |||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
RMGP Bio-Pharma Investment Fund, L.P. | Fee and commission income | |||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
RMGP Bio-Pharma Investment, L.P. | Gains on financial instruments at fair value through profit or loss | |||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
KB-MDI Centauri Fund L.P. | Fee and commission income | |||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
(In millions of Korean won) | ||||||||||||||
2023 | 2024 | 2025 | ||||||||||||
Hibiscus Fund L.P. | Fee and commission income | |||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
RMG-KB BP Management Ltd. | Gains on financial instruments at fair value through profit or loss | |||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
RMG-KB BioAccess Fund L.P. | Fee and commission income | |||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
S&E Bio Co., Ltd. | Interest income | |||||||||||||
Interest expense | ||||||||||||||
Provision for credit losses | ||||||||||||||
Reversal of credit losses | ||||||||||||||
Contents First Inc. | Interest income | |||||||||||||
Interest expense | ||||||||||||||
Fee and commission income | ||||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
Provision for credit losses | ||||||||||||||
Reversal of credit losses | ||||||||||||||
December & Company Inc. * | Insurance income | |||||||||||||
Pin Therapeutics Inc. | Interest expense | |||||||||||||
Provision for credit losses | ||||||||||||||
Reversal of credit losses | ||||||||||||||
Wyatt Co., Ltd. * | Interest income | |||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Insurance income | ||||||||||||||
KB-Brain KOSDAQ Scale-up New Technology Business Investment Fund * | Interest expense | |||||||||||||
Fee and commission income | ||||||||||||||
Spark Biopharma Inc. | Interest expense | |||||||||||||
Provision for credit losses | ||||||||||||||
Reversal of credit losses | ||||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
(In millions of Korean won) | ||||||||||||||
2023 | 2024 | 2025 | ||||||||||||
Skydigital Inc. | Fee and commission income | |||||||||||||
Il-Kwang Electronic Materials Co., Ltd. | Other non-operating expenses | |||||||||||||
SO-MYUNG Recycling Co., Ltd. | Insurance income | |||||||||||||
KB No.21 Special Purpose Acquisition Company * | Gains on financial instruments at fair value through profit or loss | |||||||||||||
Interest expense | ( | ) | ||||||||||||
KB No.22 Special Purpose Acquisition Company * | Gains on financial instruments at fair value through profit or loss | |||||||||||||
Interest expense | ||||||||||||||
KB No.23 Special Purpose Acquisition Company * | Losses on financial instruments at fair value through profit or loss | |||||||||||||
Interest expense | ||||||||||||||
KB No.24 Special Purpose Acquisition Company * | Interest expense | |||||||||||||
KB No.25 Special Purpose Acquisition Company | Interest expense | |||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
KB No.26 Special Purpose Acquisition Company * | Interest expense | ( | ) | |||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
KB No.27 Special Purpose Acquisition Company | Interest expense | |||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
KB No.28 Special Purpose Acquisition Company * | Interest expense | |||||||||||||
Fee and commission income | ||||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
KB No.29 Special Purpose Acquisition Company | Fee and commission income | |||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Interest expense | ||||||||||||||
KB No.30 Special Purpose Acquisition Company | Interest expense | |||||||||||||
| Fee and commission income | ||||||||||||||
| Gains on financial instruments at fair value through profit or loss | ||||||||||||||
KB No.31 Special Purpose Acquisition Company | Gains on financial instruments at fair value through profit or loss | |||||||||||||
| Interest expense | ||||||||||||||
KB No.32 Special Purpose Acquisition Company | Interest expense | |||||||||||||
(In millions of Korean won) | ||||||||||||||
2023 | 2024 | 2025 | ||||||||||||
KB No.33 Special Purpose Acquisition Company | Gains on financial instruments at fair value through profit or loss | |||||||||||||
| Interest expense | ||||||||||||||
KB SPROTT Renewable Private Equity Fund No.1 | Fee and commission income | |||||||||||||
KB-Stonebridge Secondary Private Equity Fund | Fee and commission income | |||||||||||||
| Other operating income | ||||||||||||||
COSES GT Co., Ltd. * | Gains on financial instruments at fair value through profit or loss | |||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
| Interest income | ||||||||||||||
| Reversal of credit losses | ||||||||||||||
TeamSparta Inc. * | Fee and commission income | |||||||||||||
| Provision for credit losses | ||||||||||||||
| Reversal of credit losses | ||||||||||||||
| Interest expense | ||||||||||||||
Newavel Co., Ltd. | Fee and commission income | |||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
SuperNGine Co., Ltd. | Interest income | |||||||||||||
Fee and commission income | ||||||||||||||
| Provision for credit losses | ||||||||||||||
| Reversal of credit losses | ||||||||||||||
Desilo Inc. | Interest income | |||||||||||||
| Provision for credit losses | ||||||||||||||
| Reversal of credit losses | ||||||||||||||
Turing Co., Ltd. | Interest expense | |||||||||||||
| Interest income | ||||||||||||||
| Provision for credit losses | ||||||||||||||
| Reversal of credit losses | ||||||||||||||
IGGYMOB Co., Ltd. | Losses on financial instruments at fair value through profit or loss | |||||||||||||
ZIPDOC Inc. * | Losses on financial instruments at fair value through profit or loss | |||||||||||||
Grinergy Co., Ltd. | Provision for credit losses | |||||||||||||
| Reversal of credit losses | ||||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
| Interest expense | ||||||||||||||
(In millions of Korean won) | ||||||||||||||
2023 | 2024 | 2025 | ||||||||||||
Chabot Mobility Co., Ltd. * | Fee and commission income | |||||||||||||
Interest expense | ||||||||||||||
Fee and commission expense | ||||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Wemade Connect Co., Ltd. | Insurance income | |||||||||||||
Interest expense | ||||||||||||||
Fee and commission income | ||||||||||||||
Reversal of credit losses | ||||||||||||||
Provision for credit losses | ||||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
TMAP Mobility Co., Ltd. | Interest expense | |||||||||||||
Fee and commission income | ||||||||||||||
Fee and commission expense | ||||||||||||||
Provision for credit losses | ||||||||||||||
Chabot Mobility Co., Ltd. * | Reversal of credit losses | |||||||||||||
TMAP Mobility Co., Ltd. | Insurance income | |||||||||||||
Nextrade Co., Ltd. | Fee and commission income | |||||||||||||
Interest expense | ||||||||||||||
WJ Private Equity Fund No.1 | Fee and commission income | |||||||||||||
UPRISE, Inc. | Gains on financial instruments at fair value through profit or loss | |||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
Channel Corporation | Interest expense | |||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
CWhy Inc. | Insurance income | |||||||||||||
CellinCells Co., Ltd. * | Provision for credit losses | |||||||||||||
KB Social Impact Investment Fund | Fee and commission income | |||||||||||||
KB-UTC Inno-Tech Venture Fund | Fee and commission income | |||||||||||||
Other operating income | ||||||||||||||
KB-SP Private Equity Fund IV * | Fee and commission income | |||||||||||||
KB-NAU Special Situation Corporate Restructuring Private Equity Fund | Fee and commission income | |||||||||||||
2020 KB Fintech Renaissance Fund | Fee and commission income | |||||||||||||
KB Material and Parts No.1 PEF * | Fee and commission income | |||||||||||||
Other operating income | ||||||||||||||
(In millions of Korean won) | ||||||||||||||
2023 | 2024 | 2025 | ||||||||||||
FineKB Private Equity Fund No.1 | Fee and commission income | |||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Interest expense | ||||||||||||||
Paramark KB Fund No.1 | Fee and commission income | |||||||||||||
KB-Badgers Future Mobility ESG Fund No.1 | Fee and commission income | |||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
KB-KTB Technology Venture Fund | Fee and commission income | |||||||||||||
Bluepointpartners Inc. | Gains on financial instruments at fair value through profit or loss | |||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
KB-Solidus Global Healthcare Fund | Fee and commission income | |||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
ASSEMBLE CORPORATION | Interest income | |||||||||||||
Fee and commission income | ||||||||||||||
Insurance income | ||||||||||||||
Provision for credit losses | ||||||||||||||
Reversal of credit losses | ||||||||||||||
KB Cape No.1 Private Equity Fund * | Fee and commission income | |||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
KB-GeneN Medical Venture Fund No.1 | Fee and commission income | |||||||||||||
KB-BridgePole Venture Investment Fund * | Fee and commission income | |||||||||||||
Other operating income | ||||||||||||||
KB-BridgePole Venture Investment Fund No.2 | Fee and commission income | |||||||||||||
KB-Kyobo New Mobility Power Fund * | Fee and commission income | |||||||||||||
KB Co-Investment Private Equity Fund No.1 | Fee and commission income | |||||||||||||
KB-NP Green ESG New Technology Venture Capital Fund | Fee and commission income | |||||||||||||
KB-FT Green Growth 1st Technology Investment Association | Fee and commission income | |||||||||||||
Interest expense | ||||||||||||||
Spoonlabs Co., Ltd. * | Losses on financial instruments at fair value through profit or loss | |||||||||||||
(In millions of Korean won) | ||||||||||||||
2023 | 2024 | 2025 | ||||||||||||
Gushcloud Talent Agency | Gains on financial instruments at fair value through profit or loss | |||||||||||||
KB-SUSUNG 1st Investment Fund | Fee and commission income | |||||||||||||
KB-SUSUNG 2nd Investment Fund | Fee and commission income | |||||||||||||
Youngwon Corporation * | Insurance income | |||||||||||||
Seokwang T&I Co., Ltd. | Insurance income | |||||||||||||
3D Interactive Co., Ltd. | Fee and commission income | |||||||||||||
Interest expense | ||||||||||||||
Provision for credit losses | ||||||||||||||
Reversal of credit losses | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
Bigwave Robotics Corp. | Fee and commission income | |||||||||||||
Interest income | ( | ) | ||||||||||||
Interest expense | ( | ) | ||||||||||||
Provision for credit losses | ||||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
U-KB Credit No.1 Private Equity | Fee and commission income | |||||||||||||
KY Global Cell & Gene Private Equity Fund 2nd * | Interest expense | ( | ) | |||||||||||
KB-SOLIDUS Healthcare Investment Fund | Fee and commission income | |||||||||||||
AKK Robotech Valueup New Technology Investment Fund * | Fee and commission income | |||||||||||||
New Daegu Busan Expressway Co., Ltd. | Interest income | |||||||||||||
Reversal of credit losses | ||||||||||||||
Interest expense | ||||||||||||||
Insurance income | ||||||||||||||
AIM FUTURE, Inc. | Interest income | |||||||||||||
Interest expense | ||||||||||||||
Insurance income | ||||||||||||||
Provision for credit losses | ||||||||||||||
ADP Holdings Co., Ltd. | Interest expense | |||||||||||||
ADPGREEN | Interest expense | |||||||||||||
Provision for credit losses | ||||||||||||||
Reversal of credit losses | ||||||||||||||
Insurance income | ||||||||||||||
KB-CJ Venture Fund 1st | Fee and commission income | |||||||||||||
OKXE Inc. | Gains on financial instruments at fair value through profit or loss | |||||||||||||
Ascent Global Fund III | Gains on financial instruments at fair value through profit or loss | |||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
(In millions of Korean won) | ||||||||||||||
2023 | 2024 | 2025 | ||||||||||||
Elev8-Capital Fund I | Gains on financial instruments at fair value through profit or loss | |||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
H Energy Co., Ltd * | Gains on financial instruments at fair value through profit or loss | |||||||||||||
XL8 INC. | Gains on financial instruments at fair value through profit or loss | |||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
SDT Inc. | Interest expense | |||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
DYNE MEDICAL GROUP Inc. | Interest income | |||||||||||||
Interest expense | ||||||||||||||
Fee and commission income | ||||||||||||||
Insurance income | ||||||||||||||
Provision for credit losses | ||||||||||||||
Reversal of credit losses | ||||||||||||||
Bitgoeul Cheomdan Green 1st Co., Ltd. | Interest expense | |||||||||||||
Logpresso Inc. | Fee and commission income | |||||||||||||
Interest expense | ||||||||||||||
Onheal Co., Ltd. | Interest expense | ( | ) | |||||||||||
Fee and commission income | ||||||||||||||
TriOar Inc. | Interest expense | |||||||||||||
Blinkers Inc. * | Losses on financial instruments at fair value through profit or loss | |||||||||||||
KB-VEP Contact Fund | Fee and commission income | |||||||||||||
SD Speed Co., Ltd. | Insurance income | |||||||||||||
Xpanner Inc. | Insurance income | |||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
KB-Cyrus Tourism Venture Fund | Fee and commission income | |||||||||||||
Qoala * | Gains on financial instruments at fair value through profit or loss | |||||||||||||
FineKB Private Equity Fund No.2 GCSM Holdings Limited | Fee and commission income | |||||||||||||
Gains on financial instruments at fair value through profit or loss | ||||||||||||||
Losses on financial instruments at fair value through profit or loss | ||||||||||||||
MitoImmune Therapeutics | Losses on financial instruments at fair value through profit or loss | |||||||||||||
(In millions of Korean won) |
||||||||||||||
2023 |
2024 |
2025 |
||||||||||||
|
Honest Fund, Inc.
|
Losses on financial instruments at fair value through profit or loss
|
|||||||||||||
|
KB Rejuvenation Fund
|
Fee and commission income
|
|||||||||||||
|
Allra Fintech Corp.
|
Provision for credit losses
|
|||||||||||||
|
Interest expense
|
||||||||||||||
|
Yeoulhyulgangho
|
Interest expense
|
|||||||||||||
|
KB-IMM New Star Real Estate Private Fund I
|
Fee and commission income
|
|||||||||||||
|
KB-LB Middle Market Enterprises Innovation Private Equity Fund
|
Fee and commission income
|
|||||||||||||
|
Semicolon Susong REITs Co., Ltd.
|
Interest income
|
|||||||||||||
|
Fee and commission income
|
||||||||||||||
|
Provision for credit losses
|
||||||||||||||
|
Insurance income
|
||||||||||||||
|
KB-Novus Genesis Private Equity Fund
|
Fee and commission income
|
|||||||||||||
|
AIM-KB-DOUBLE Connected Future Investment Fund
|
Fee and commission income
|
|||||||||||||
|
E&I Holdings *
|
Fee and commission income
|
|||||||||||||
|
WhaTap Laps Inc.
|
Interest income
|
|||||||||||||
|
Interest expense
|
||||||||||||||
|
Gains on financial instruments at fair value through profit or loss
|
||||||||||||||
|
Losses on financial instruments at fair value through profit or loss
|
||||||||||||||
|
Provision for credit losses
|
||||||||||||||
|
Streami Inc.
|
Gains on financial instruments at fair value through profit or loss
|
|||||||||||||
|
ANTIGRAVITY
|
Losses on financial instruments at fair value through profit or loss
|
|||||||||||||
|
Interest income
|
||||||||||||||
|
Provision for credit losses
|
||||||||||||||
|
KB a2z 2025 Fund
|
Fee and commission income
|
|||||||||||||
|
IMBiologics Corp.
|
Gains on financial instruments at fair value through profit or loss
|
|||||||||||||
|
Provision for credit losses
|
||||||||||||||
|
Aculys Pharma, Inc.
|
Gains on financial instruments at fair value through profit or loss
|
|||||||||||||
|
Koru Pharma Co., Ltd.
|
Interest expense
|
|||||||||||||
|
Insurance income
|
||||||||||||||
|
Aldaver
|
Interest expense
|
|||||||||||||
|
K-1 23rd yeoksam Real Estate Investment Trust company Ltd.
|
Insurance income
|
|||||||||||||
|
Novorex Inc.
|
Interest expense
|
|||||||||||||
|
Provision for credit losses
|
||||||||||||||
|
Xenohelix Co., Ltd.
|
Interest income
|
|||||||||||||
|
Provision for credit losses
|
||||||||||||||
(In millions of Korean won) |
||||||||||||||
2023 |
2024 |
2025 |
||||||||||||
|
Al Spera Inc.
|
Interest expense
|
|||||||||||||
|
enParticle Co., Ltd
|
Interest expense
|
|||||||||||||
|
Emocog Inc.
|
Interest expense
|
|||||||||||||
|
Lemontree Inc.
|
Fee and commission income
|
|||||||||||||
|
Interest expense
|
||||||||||||||
|
Fee and commission expense
|
||||||||||||||
|
Provision for credit losses
|
||||||||||||||
|
ByL
|
Interest expense
|
|||||||||||||
|
eRoun & company Co., Ltd
|
Interest expense
|
|||||||||||||
|
Others
|
||||||||||||||
|
Retirement pension
|
Fee and commission income
|
|||||||||||||
|
Interest expense
|
||||||||||||||
| * |
|
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||||
Associates and joint ventures | ||||||||||
Balhae Infrastructure Company | Other assets | ₩ | ₩ | |||||||
Loans measured at amortized cost (gross amount) | ||||||||||
Allowances for credit losses | ||||||||||
Provisions | ||||||||||
Other liabilities | ||||||||||
Korea Credit Bureau Co., Ltd. | Loans measured at amortized cost (gross amount) | |||||||||
Deposits | ||||||||||
Insurance liabilities | ||||||||||
Other liabilities | ||||||||||
Incheon Bridge Co., Ltd. | Financial assets at fair value through profit or loss | |||||||||
Loans measured at amortized cost (gross amount) | ||||||||||
Allowances for credit losses | ||||||||||
Other assets | ||||||||||
Deposits | ||||||||||
Provisions | ||||||||||
Insurance liabilities | ||||||||||
Other liabilities | ||||||||||
Jungdo Co., Ltd. | Deposits | |||||||||
Aju Good Technology Venture Fund | Deposits | |||||||||
Star-Lord General Investors Private Real Estate Investment Company No.10 | Loans measured at amortized cost (gross amount) | |||||||||
Allowances for credit losses | ||||||||||
Property and equipment | ||||||||||
Other assets | ||||||||||
Insurance liabilities | ||||||||||
Other liabilities | ||||||||||
WJ Private Equity Fund No.1 | Other assets | |||||||||
Deposits | ||||||||||
RAND Bio Science Co., Ltd. * | Deposits | |||||||||
Food Factory Co., Ltd. | Loans measured at amortized cost (gross amount) | |||||||||
Allowances for credit losses | ||||||||||
Other assets | ||||||||||
Deposits | ||||||||||
Insurance liabilities | ||||||||||
Other liabilities | ||||||||||
Big Dipper Co., Ltd. | Loans measured at amortized cost (gross amount) | |||||||||
Allowances for credit losses | ||||||||||
Deposits | ||||||||||
Other assets | ||||||||||
Other liabilities | ||||||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||||
KB-KDBC Pre-IPO New Technology Business Investment Fund | Deposits | |||||||||
Iwon Alloy Co., Ltd. | Deposits | |||||||||
RMGP Bio-Pharma Investment Fund, L.P. | Financial assets at fair value through profit or loss | |||||||||
Other assets | ||||||||||
Other liabilities | ||||||||||
RMGP Bio-Pharma Investment, L.P. | Financial assets at fair value through profit or loss | |||||||||
Wyatt Co., Ltd. * | Financial assets at fair value through profit or loss | |||||||||
Deposits | ||||||||||
Insurance liabilities | ||||||||||
Skydigital Inc. | Deposits | |||||||||
Banksalad Co., Ltd. * | Financial assets at fair value through profit or loss | |||||||||
Spark Biopharma Inc. | Financial assets at fair value through profit or loss | |||||||||
Loans measured at amortized cost (gross amount) | ||||||||||
Deposits | ||||||||||
Other liabilities | ||||||||||
Allowances for credit losses | ||||||||||
Provisions | ||||||||||
UPRISE, Inc. | Financial assets at fair value through profit or loss | |||||||||
Stratio, Inc. | Financial assets at fair value through profit or loss | |||||||||
Honest Fund, Inc. | Financial assets at fair value through profit or loss | |||||||||
CellinCells Co., Ltd. * | Financial assets at fair value through profit or loss | |||||||||
Loans measured at amortized cost (gross amount) | ||||||||||
Allowances for credit losses | ||||||||||
Deposits | ||||||||||
Provisions | ||||||||||
Channel Corporation | Financial assets at fair value through profit or loss | |||||||||
Deposits | ||||||||||
KB No.21 Special Purpose Acquisition Company * | Financial assets at fair value through profit or loss | |||||||||
Deposits | ||||||||||
Other liabilities | ||||||||||
(In millions of Korean won) |
December 31, 2024 |
December 31, 2025 |
||||||||
|
KB No.25 Special Purpose Acquisition Company
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Deposits
|
||||||||||
|
Other liabilities
|
||||||||||
|
KB No.26 Special Purpose Acquisition Company *
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Deposits
|
||||||||||
|
Other liabilities
|
||||||||||
|
KB No.27 Special Purpose Acquisition Company
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Deposits
|
||||||||||
|
Other liabilities
|
||||||||||
|
KB No.28 Special Purpose Acquisition Company *
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Deposits
|
||||||||||
|
Other liabilities
|
||||||||||
|
KB No.29 Special Purpose Acquisition Company
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Deposits
|
||||||||||
|
Other liabilities
|
||||||||||
|
KB No.30 Special Purpose Acquisition Company
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Deposits
|
||||||||||
|
Other liabilities
|
||||||||||
|
KB No.31 Special Purpose Acquisition Company
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Deposits
|
||||||||||
|
Other liabilities
|
||||||||||
|
KB No.32 Special Purpose Acquisition Company
|
Deposits
|
|||||||||
|
Other liabilities
|
||||||||||
|
KB No.33 Special Purpose Acquisition Company
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Deposits
|
||||||||||
|
Other liabilities
|
||||||||||
|
MitoImmune Therapeutics
|
Financial assets at fair value through profit or loss
|
|||||||||
|
KB-Solidus Global Healthcare Fund
|
Other assets
|
|||||||||
|
Bioprotect Ltd.
|
Financial assets at fair value through profit or loss
|
|||||||||
(In millions of Korean won) |
December 31, 2024 |
December 31, 2025 |
||||||||
|
ASSEMBLE CORPORATION
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Loans measured at amortized cost (gross amount)
|
||||||||||
|
Allowances for credit losses
|
||||||||||
|
Other assets
|
||||||||||
|
Deposits
|
||||||||||
|
Other liabilities
|
||||||||||
|
Provisions
|
||||||||||
|
Insurance liabilities
|
||||||||||
|
SO-MYUNG Recycling Co., Ltd.
|
Insurance liabilities
|
|||||||||
|
Go2joy Co., Ltd.
|
Financial assets at fair value through profit or loss
|
|||||||||
|
S&E Bio Co., Ltd.
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Loans measured at amortized cost (gross amount)
|
||||||||||
|
Other assets
|
||||||||||
|
Deposits
|
||||||||||
|
Other liabilities
|
||||||||||
|
Allowances for credit losses
|
||||||||||
|
Provisions
|
||||||||||
|
Bluepointpartners Inc.
|
Financial assets at fair value through profit or loss
|
|||||||||
|
4N Inc.
|
Deposits
|
|||||||||
|
Xenohelix Co., Ltd.
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Loans measured at amortized cost (gross amount)
|
||||||||||
|
Other assets
|
||||||||||
|
Allowances for credit losses
|
||||||||||
|
Deposits
|
||||||||||
|
Contents First Inc.
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Loans measured at amortized cost (gross amount)
|
||||||||||
|
Allowances for credit losses
|
||||||||||
|
Other assets
|
||||||||||
|
Deposits
|
||||||||||
|
Provisions
|
||||||||||
|
Other liabilities
|
||||||||||
|
KB-MDI Centauri Fund L.P.
|
Financial assets at fair value through profit or loss
|
|||||||||
|
2020 KB Fintech Renaissance Fund
|
Other assets
|
|||||||||
|
OKXE Inc.
|
Financial assets at fair value through profit or loss
|
|||||||||
(In millions of Korean won) |
December 31, 2024 |
December 31, 2025 |
||||||||
|
Newavel Co., Ltd.
|
Loans measured at amortized cost (gross amount)
|
|||||||||
|
Deposits
|
||||||||||
|
Pin Therapeutics Inc.
|
Loans measured at amortized cost (gross amount)
|
|||||||||
|
Financial assets at fair value through profit or loss
|
||||||||||
|
Deposits
|
||||||||||
|
Other liabilities
|
||||||||||
|
Allowances for credit losses
|
||||||||||
|
Provisions
|
||||||||||
|
IMBiologics Corp.
|
Loans measured at amortized cost (gross amount)
|
|||||||||
|
Financial assets at fair value through profit or loss
|
||||||||||
|
SuperNGine Co., Ltd.
|
Loans measured at amortized cost (gross amount)
|
|||||||||
|
Deposits
|
||||||||||
|
Allowances for credit losses
|
||||||||||
|
Other assets
|
||||||||||
|
Financial assets at fair value through profit or loss
|
||||||||||
|
Desilo Inc.
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Loans measured at amortized cost (gross amount)
|
||||||||||
|
Allowances for credit losses
|
||||||||||
|
Deposits
|
||||||||||
|
Turing Co., Ltd.
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Loans measured at amortized cost (gross amount)
|
||||||||||
|
Allowances for credit losses
|
||||||||||
|
Other assets
|
||||||||||
|
Deposits
|
||||||||||
|
Kukka Co., Ltd. *
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Insurance liabilities
|
||||||||||
|
ZIPDOC Inc. *
|
Deposits
|
|||||||||
|
TeamSparta Inc. *
|
Loans measured at amortized cost (gross amount)
|
|||||||||
|
Financial assets at fair value through profit or loss
|
||||||||||
|
Provisions
|
||||||||||
|
Deposits
|
||||||||||
|
Other liabilities
|
||||||||||
(In millions of Korean won) |
December 31, 2024 |
December 31, 2025 |
||||||||
|
Chabot Mobility Co., Ltd. *
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Deposits
|
||||||||||
|
Wemade Connect Co., Ltd.
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Loans measured at amortized cost (gross amount)
|
||||||||||
|
Allowances for credit losses
|
||||||||||
|
Provisions
|
||||||||||
|
Deposits
|
||||||||||
|
Insurance liabilities
|
||||||||||
|
Other liabilities
|
||||||||||
|
Nextrade Co., Ltd.
|
Loans measured at amortized cost (gross amount)
|
|||||||||
|
Deposits
|
||||||||||
|
Other liabilities
|
||||||||||
|
TMAP Mobility Co., Ltd.
|
Loans measured at amortized cost (gross amount)
|
|||||||||
|
Allowances for credit losses
|
||||||||||
|
Deposits
|
||||||||||
|
Insurance liabilities
|
||||||||||
|
Other liabilities
|
||||||||||
|
Provisions
|
||||||||||
|
FutureConnect Co., Ltd. *
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Grinergy Co., Ltd.
|
Loans measured at amortized cost (gross amount)
|
|||||||||
|
Financial assets at fair value through profit or loss
|
||||||||||
|
Allowances for credit losses
|
||||||||||
|
Provisions
|
||||||||||
|
NexThera Co., Ltd.
|
Financial assets at fair value through profit or loss
|
|||||||||
|
FineKB Private Equity Fund No.1
|
Other assets
|
|||||||||
|
Paramark KB Fund No.1
|
Other liabilities
|
|||||||||
|
KB Social Impact Investment Fund
|
Other assets
|
|||||||||
|
Checkmate Therapeutics Inc.
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Insurance liabilities
|
||||||||||
|
Hibiscus Fund L.P.
|
Financial assets at fair value through profit or loss
|
|||||||||
|
Other assets
|
||||||||||
|
RMG-KB BioAccess Fund L.P.
|
Financial assets at fair value through profit or loss
|
|||||||||
|
RMG-KB BP Management Ltd.
|
Financial assets at fair value through profit or loss
|
|||||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||||
KB Co-Investment Private Equity Fund No.1 | Other assets | |||||||||
Spoonlabs Co., Ltd. * | Financial assets at fair value through profit or loss | |||||||||
Neuroptika Inc. | Financial assets at fair value through profit or loss | |||||||||
Bitgoeul Cheomdan Green 1st Co., Ltd. | Deposits | |||||||||
Bigwave Robotics Corp. | Loans measured at amortized cost (gross amount) | |||||||||
Financial assets at fair value through profit or loss | ||||||||||
Allowances for credit losses | ||||||||||
Deposits | ||||||||||
Provisions | ||||||||||
Other liabilities | ||||||||||
3D Interactive Co., Ltd. | Loans measured at amortized cost (gross amount) | |||||||||
Provisions | ||||||||||
Financial assets at fair value through profit or loss | ||||||||||
Deposits | ||||||||||
XL8 INC. | Financial assets at fair value through profit or loss | |||||||||
Elev8-Capital Fund I | Financial assets at fair value through profit or loss | |||||||||
New Daegu Busan Expressway Co., Ltd. | Loans measured at amortized cost (gross amount) | |||||||||
Allowances for credit losses | ||||||||||
Other assets | ||||||||||
Deposits | ||||||||||
Other liabilities | ||||||||||
Insurance liabilities | ||||||||||
AIM FUTURE, Inc. | Financial assets at fair value through profit or loss | |||||||||
Loans measured at amortized cost (gross amount) | ||||||||||
Allowances for credit losses | ||||||||||
Other assets | ||||||||||
Deposits | ||||||||||
Provisions | ||||||||||
Novorex Inc. | Financial assets at fair value through profit or loss | |||||||||
Loans measured at amortized cost (gross amount) | ||||||||||
Allowances for credit losses | ||||||||||
Other liabilities | ||||||||||
Provisions | ||||||||||
Deposits | ||||||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||||
Seokwang T&I Co., Ltd | Insurance liabilities | |||||||||
ADP Holdings Co., Ltd. | Deposits | |||||||||
Other liabilities | ||||||||||
ADPGREEN | Loans measured at amortized cost (gross amount) | |||||||||
Deposits | ||||||||||
Other liabilities | ||||||||||
Allowances for credit losses | ||||||||||
Provisions | ||||||||||
Insurance liabilities | ||||||||||
Logpresso Inc. | Financial assets at fair value through profit or loss | |||||||||
Loans measured at amortized cost (gross amount) | ||||||||||
Deposits | ||||||||||
Other liabilities | ||||||||||
Onheal Co., Ltd. | Financial assets at fair value through profit or loss | |||||||||
Deposits | ||||||||||
Ascent Global Fund III | Financial assets at fair value through profit or loss | |||||||||
DYNE MEDICAL GROUP Inc. | Financial assets at fair value through profit or loss | |||||||||
Loans measured at amortized cost (gross amount) | ||||||||||
Allowances for credit losses | ||||||||||
Provisions | ||||||||||
Other assets | ||||||||||
Deposits | ||||||||||
Other liabilities | ||||||||||
Insurance liabilities | ||||||||||
TriOar Inc. | Financial assets at fair value through profit or loss | |||||||||
Loans measured at amortized cost (gross amount) | ||||||||||
Deposits | ||||||||||
Other liabilities | ||||||||||
Coxwave Co., Ltd. | Financial assets at fair value through profit or loss | |||||||||
SDT Inc. | Financial assets at fair value through profit or loss | |||||||||
Yeoulhyulgangho | Financial assets at fair value through profit or loss | |||||||||
Deposits | ||||||||||
Other liabilities | ||||||||||
KB-VEP Contact Fund | Other assets | |||||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||||
Xpanner Inc. | Financial assets at fair value through profit or loss | |||||||||
Insurance liabilities | ||||||||||
SD Speed Co., Ltd. | Insurance liabilities | |||||||||
Allra Fintech Corp. | Loans measured at amortized cost (gross amount) | |||||||||
Allowances for credit losses | ||||||||||
Deposits | ||||||||||
Other liabilities | ||||||||||
Provisions | ||||||||||
GCSM Holdings Limited | Financial assets at fair value through profit or loss | |||||||||
KB Rejuvenation Fund | Other assets | |||||||||
Qoala * | Financial assets at fair value through profit or loss | |||||||||
FineKB Private Equity Fund No.2 | Other assets | |||||||||
Koru Pharma Co., Ltd. | Financial assets at fair value through profit or loss | |||||||||
Deposits | ||||||||||
Insurance liabilities | ||||||||||
WhaTap Laps Inc. | Loans measured at amortized cost (gross amount) | |||||||||
Financial assets at fair value through profit or loss | ||||||||||
Other assets | ||||||||||
Allowances for credit losses | ||||||||||
Provisions | ||||||||||
Deposits | ||||||||||
Other liabilities | ||||||||||
Streami Inc. | Financial assets at fair value through profit or loss | |||||||||
Lemontree Inc. | Financial assets at fair value through profit or loss | |||||||||
Deposits | ||||||||||
Provisions | ||||||||||
GAME TALES | Financial assets at fair value through profit or loss | |||||||||
HyperAccel Co., Ltd. | Financial assets at fair value through profit or loss | |||||||||
Aldaver | Financial assets at fair value through profit or loss | |||||||||
Deposits | ||||||||||
Other liabilities | ||||||||||
enParticle Co., Ltd | Financial assets at fair value through profit or loss | |||||||||
Deposits | ||||||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||||
ALL ROUND DOCTORS Inc. | Financial assets at fair value through profit or loss | |||||||||
Emocog Inc. | Financial assets at fair value through profit or loss | |||||||||
Deposits | ||||||||||
ANTIGRAVITY | Financial assets at fair value through profit or loss | |||||||||
Loans measured at amortized cost (gross amount) | ||||||||||
Allowances for credit losses | ||||||||||
Deposits | ||||||||||
ByL | Financial assets at fair value through profit or loss | |||||||||
Deposits | ||||||||||
Other liabilities | ||||||||||
KB a2z 2025 Fund | Other assets | |||||||||
Semicolon Susong REITs Co., Ltd. | Loans measured at amortized cost (gross amount) | |||||||||
Allowances for credit losses | ||||||||||
Other assets | ||||||||||
Insurance liabilities | ||||||||||
K-1 23rd yeoksam Real Estate Investment Trust company Ltd. | Insurance liabilities | |||||||||
IMT TECHNOLOGY CO., LTD. | Insurance liabilities | |||||||||
VP Inc. | Loans measured at amortized cost (gross amount) | |||||||||
Other liabilities | ||||||||||
Insurance liabilities | ||||||||||
Deposits | ||||||||||
eRoun & company Co., Ltd | Deposits | |||||||||
Other liabilities | ||||||||||
RUMIKEU Holdings Inc. | Deposits | |||||||||
Key management personnel | ||||||||||
Key management personnel | Loans measured at amortized cost (gross amount) | |||||||||
Allowances for credit losses | ||||||||||
Other assets | ||||||||||
Deposits | ||||||||||
Provisions | ||||||||||
Insurance liabilities | ||||||||||
Other liabilities | ||||||||||
Others | ||||||||||
Retirement pension | Other assets | |||||||||
Other liabilities | ||||||||||
| * | Excluded from the Group’s related party as of December 31, 2025, therefore, the remaining outstanding balances with those entities are not disclosed. |
(In millions of Korean won) | 2024 | |||||||||||||||
Beginning | Loan | Collection | Ending | |||||||||||||
Associates and joint ventures | ||||||||||||||||
Korea Credit Bureau Co., Ltd. | ₩ | ₩ | ₩ | ( | ) | ₩ | ||||||||||
Incheon Bridge Co., Ltd. | ( | ) | ||||||||||||||
Star-Lord General Investors Private Real Estate Investment Company No.10 | ||||||||||||||||
KB Cape No.1 Private Equity Fund * | ( | ) | ||||||||||||||
RAND Bio Science Co., Ltd. * | ( | ) | ||||||||||||||
Food Factory Co., Ltd. | ( | ) | ||||||||||||||
Big Dipper Co., Ltd. | ( | ) | ||||||||||||||
RMGP Bio-Pharma Investment Fund, L.P. | ||||||||||||||||
RMGP Bio-Pharma Investment, L.P. | ||||||||||||||||
Wyatt Co., Ltd. * | ( | ) | ||||||||||||||
Banksalad Co., Ltd. * | ( | ) | ||||||||||||||
UPRISE, Inc. | ( | ) | ||||||||||||||
Stratio, Inc. | ||||||||||||||||
Honest Fund, Inc. | ( | ) | ||||||||||||||
CellinCells Co., Ltd. * | ( | ) | ||||||||||||||
KB No.21 Special Purpose Acquisition Company * | ||||||||||||||||
KB No.22 Special Purpose Acquisition Company * | ( | ) | ||||||||||||||
KB No.25 Special Purpose Acquisition Company | ( | ) | ||||||||||||||
KB No.26 Special Purpose Acquisition Company * | ( | ) | ||||||||||||||
KB No.27 Special Purpose Acquisition Company | ( | ) | ||||||||||||||
KB No.28 Special Purpose Acquisition Company * | ||||||||||||||||
KB No.29 Special Purpose Acquisition Company | ||||||||||||||||
KB No.30 Special Purpose Acquisition Company | ||||||||||||||||
KB No.31 Special Purpose Acquisition Company | ||||||||||||||||
COSES GT Co., Ltd. * | ( | ) | ||||||||||||||
Channel Corporation | ||||||||||||||||
MitoImmune Therapeutics | ( | ) | ||||||||||||||
Bioprotect Ltd. | ||||||||||||||||
ASSEMBLE CORPORATION | ( | ) | ||||||||||||||
Go2joy Co., Ltd. | ||||||||||||||||
S&E Bio Co., Ltd. | ( | ) | ||||||||||||||
Bluepointpartners Inc. | ( | ) | ||||||||||||||
Xenohelix Co., Ltd. | ||||||||||||||||
Contents First Inc. | ( | ) | ||||||||||||||
KB-MDI Centauri Fund L.P. | ||||||||||||||||
OKXE Inc. | ||||||||||||||||
Checkmate Therapeutics Inc. | ||||||||||||||||
Newavel Co., Ltd. | ( | ) | ||||||||||||||
IMBiologics Corp. | ( | ) | ||||||||||||||
Spark Biopharma Inc. | ( | ) | ||||||||||||||
Pin Therapeutics Inc. | ( | ) | ||||||||||||||
Hibiscus Fund L.P. | ||||||||||||||||
SuperNGine Co., Ltd. | ( | ) | ||||||||||||||
Desilo Inc. | ||||||||||||||||
(In millions of Korean won) | 2024 | |||||||||||||||
Beginning | Loan | Collection | Ending | |||||||||||||
RMG-KB BioAccess Fund L.P. | ||||||||||||||||
RMG-KB BP Management Ltd. | ||||||||||||||||
IGGYMOB Co., Ltd. | ( | ) | ||||||||||||||
Turing Co., Ltd. | ( | ) | ||||||||||||||
Kukka Co., Ltd. * | ||||||||||||||||
ZIPDOC Inc. * | ( | ) | ||||||||||||||
Gushcloud Talent Agency | ( | ) | ||||||||||||||
Grinergy Co., Ltd. | ( | ) | ||||||||||||||
NexThera Co., Ltd. | ||||||||||||||||
Chabot Mobility Co., Ltd. * | ||||||||||||||||
TeamSparta Inc. * | ( | ) | ||||||||||||||
FutureConnect Co., Ltd. * | ||||||||||||||||
Wemade Connect Co., Ltd. | ( | ) | ||||||||||||||
TMAP Mobility Co., Ltd. | ( | ) | ||||||||||||||
Spoonlabs Co., Ltd. * | ( | ) | ||||||||||||||
Neuroptika Inc. | ||||||||||||||||
Bigwave Robotics Corp. | ( | ) | ||||||||||||||
Blinkers Inc. * | ( | ) | ||||||||||||||
3D Interactive Co., Ltd. | ( | ) | ||||||||||||||
XL8 INC. | ||||||||||||||||
Elev8-Capital Fund I | ||||||||||||||||
AIM FUTURE, Inc. | ||||||||||||||||
New Daegu Busan Expressway Co., Ltd. | ( | ) | ||||||||||||||
Novorex Inc. | ||||||||||||||||
Logpresso Inc. | ||||||||||||||||
Onheal Co., Ltd. | ||||||||||||||||
Ascent Global Fund III | ||||||||||||||||
DYNE MEDICAL GROUP Inc. | ||||||||||||||||
TriOar Inc. | ||||||||||||||||
Coxwave Co., Ltd. | ||||||||||||||||
SDT Inc. | ||||||||||||||||
Yeoulhyulgangho | ||||||||||||||||
ADPGREEN | ||||||||||||||||
Xpanner Inc. | ||||||||||||||||
GCSM Holdings Limited | ||||||||||||||||
Qoala * | ||||||||||||||||
Key management personnel | ||||||||||||||||
Key management personnel | ( | ) | ||||||||||||||
| * | Excluded from the Group’s related party as of December 31, 2024. |
(In millions of Korean won) |
2025 |
|||||||||||||||
Beginning |
Loan |
Collection |
Ending |
|||||||||||||
|
Associates and joint ventures
|
||||||||||||||||
|
Korea Credit Bureau Co., Ltd.
|
₩ | ₩ | ₩ | ( |
) | ₩ | ||||||||||
|
Incheon Bridge Co., Ltd.
|
( |
) | ||||||||||||||
|
Star-Lord General Investors Private Real Estate Investment Company No.10
|
( |
) | ||||||||||||||
|
Food Factory Co., Ltd.
|
( |
) | ||||||||||||||
|
Big Dipper Co., Ltd.
|
( |
) | ||||||||||||||
|
RMGP Bio-Pharma Investment Fund, L.P.
|
( |
) | ||||||||||||||
|
RMGP Bio-Pharma Investment, L.P.
|
( |
) | ||||||||||||||
|
Wyatt Co., Ltd. *
|
( |
) | ||||||||||||||
|
Banksalad Co., Ltd. *
|
( |
) | ||||||||||||||
|
UPRISE, Inc.
|
||||||||||||||||
|
Stratio, Inc.
|
||||||||||||||||
|
Honest Fund, Inc.
|
( |
) | ||||||||||||||
|
CellinCells Co., Ltd. *
|
( |
) | ||||||||||||||
|
KB No.21 Special Purpose Acquisition Company *
|
( |
) | ||||||||||||||
|
KB No.25 Special Purpose Acquisition Company
|
||||||||||||||||
|
KB No.26 Special Purpose Acquisition Company *
|
( |
) | ||||||||||||||
|
KB No.27 Special Purpose Acquisition Company
|
||||||||||||||||
|
KB No.28 Special Purpose Acquisition Company *
|
( |
) | ||||||||||||||
|
KB No.29 Special Purpose Acquisition Company
|
||||||||||||||||
|
KB No.30 Special Purpose Acquisition Company
|
||||||||||||||||
|
KB No.31 Special Purpose Acquisition Company
|
||||||||||||||||
|
KB No.33 Special Purpose Acquisition Company
|
||||||||||||||||
|
Channel Corporation
|
( |
) | ||||||||||||||
|
MitoImmune Therapeutics
|
( |
) | ||||||||||||||
|
Bioprotect Ltd.
|
||||||||||||||||
|
ASSEMBLE CORPORATION
|
( |
) | ||||||||||||||
|
Go2joy Co., Ltd.
|
||||||||||||||||
|
S&E Bio Co., Ltd.
|
( |
) | ||||||||||||||
|
Bluepointpartners Inc.
|
||||||||||||||||
|
Xenohelix Co., Ltd.
|
( |
) | ||||||||||||||
|
Contents First Inc.
|
( |
) | ||||||||||||||
|
KB-MDI Centauri Fund L.P.
|
( |
) | ||||||||||||||
|
OKXE Inc.
|
||||||||||||||||
|
Checkmate Therapeutics Inc.
|
||||||||||||||||
|
Newavel Co., Ltd.
|
( |
) | ||||||||||||||
|
IMBiologics Corp.
|
( |
) | ||||||||||||||
|
Spark Biopharma Inc.
|
( |
) | ||||||||||||||
|
Pin Therapeutics Inc.
|
( |
) | ||||||||||||||
|
Hibiscus Fund L.P.
|
||||||||||||||||
|
SuperNGine Co., Ltd.
|
( |
) | ||||||||||||||
|
Desilo Inc.
|
( |
) | ||||||||||||||
|
RMG-KB BioAccess Fund L.P.
|
||||||||||||||||
|
RMG-KB BP Management Ltd.
|
||||||||||||||||
|
Turing Co., Ltd.
|
||||||||||||||||
(In millions of Korean won) |
2025 |
|||||||||||||||
Beginning |
Loan |
Collection |
Ending |
|||||||||||||
|
Kukka Co., Ltd. *
|
( |
) | ||||||||||||||
|
Grinergy Co., Ltd.
|
||||||||||||||||
|
NexThera Co., Ltd.
|
||||||||||||||||
|
Chabot Mobility Co., Ltd. *
|
( |
) | ||||||||||||||
|
TeamSparta Inc. *
|
( |
) | ||||||||||||||
|
FutureConnect Co., Ltd. *
|
( |
) | ||||||||||||||
|
Wemade Connect Co., Ltd.
|
( |
) | ||||||||||||||
|
TMAP Mobility Co., Ltd.
|
( |
) | ||||||||||||||
|
Spoonlabs Co., Ltd. *
|
( |
) | ||||||||||||||
|
Neuroptika Inc.
|
||||||||||||||||
|
Bigwave Robotics Corp.
|
( |
) | ||||||||||||||
|
3D Interactive Co., Ltd.
|
( |
) | ||||||||||||||
|
XL8 INC.
|
( |
) | ||||||||||||||
|
Elev8-Capital Fund I
|
( |
) | ||||||||||||||
|
AIM FUTURE, Inc.
|
( |
) | ||||||||||||||
|
New Daegu Busan Expressway Co., Ltd.
|
( |
) | ||||||||||||||
|
Novorex Inc.
|
( |
) | ||||||||||||||
|
Logpresso Inc.
|
( |
) | ||||||||||||||
|
Onheal Co., Ltd.
|
||||||||||||||||
|
Ascent Global Fund III
|
( |
) | ||||||||||||||
|
DYNE MEDICAL GROUP Inc.
|
( |
) | ||||||||||||||
|
TriOar Inc.
|
( |
) | ||||||||||||||
|
Coxwave Co., Ltd.
|
||||||||||||||||
|
SDT Inc.
|
||||||||||||||||
|
Yeoulhyulgangho
|
||||||||||||||||
|
ADPGREEN
|
( |
) | ||||||||||||||
|
Xpanner Inc.
|
||||||||||||||||
|
GCSM Holdings Limited
|
( |
) | ||||||||||||||
|
Qoala *
|
( |
) | ||||||||||||||
|
Koru Pharma Co., Ltd.
|
||||||||||||||||
|
WhaTap Laps Inc.
|
||||||||||||||||
|
Lemontree Inc.
|
||||||||||||||||
|
GAME TALES
|
||||||||||||||||
|
Streami Inc.
|
||||||||||||||||
|
ANTIGRAVITY
|
( |
) | ||||||||||||||
|
HyperAccel Co., Ltd.
|
||||||||||||||||
|
Aldaver
|
||||||||||||||||
|
enParticle Co., Ltd
|
||||||||||||||||
|
ALL ROUND DOCTORS Inc.
|
||||||||||||||||
|
Emocog Inc.
|
||||||||||||||||
|
ByL
|
||||||||||||||||
|
Allra Fintech Corp.
|
||||||||||||||||
|
Nextrade Co., Ltd.
|
||||||||||||||||
|
VP Inc.
|
||||||||||||||||
|
Balhae Infrastructure Company
|
||||||||||||||||
|
Semicolon Susong REITs Co., Ltd.
|
( |
) | ||||||||||||||
|
Key management personnel
|
||||||||||||||||
|
Key management personnel
|
( |
) | ||||||||||||||
| * |
Excluded from the Group’s related party as of December 31, 2025.
|
(In millions of Korean won) | 2024 | |||||||||||||||||||
Beginning | Borrowing | Repayment | Others 1 | Ending | ||||||||||||||||
Associates and joint ventures | ||||||||||||||||||||
Korea Credit Bureau Co., Ltd. | ₩ | ₩ | ₩ | ₩ | ₩ | |||||||||||||||
Incheon Bridge Co., Ltd. | ( | ) | ||||||||||||||||||
Jungdo Co., Ltd. | ||||||||||||||||||||
Dae-A Leisure Co., Ltd. | ( | ) | ||||||||||||||||||
Iwon Alloy Co., Ltd. | ||||||||||||||||||||
Skydigital Inc. | ( | ) | ||||||||||||||||||
Aju Good Technology Venture Fund | ||||||||||||||||||||
KB-KDBC Pre-IPO New Technology Business Investment Fund | ( | ) | ||||||||||||||||||
WJ Private Equity Fund No.1 | ( | ) | ||||||||||||||||||
KB No.21 Special Purpose Acquisition Company 2 | ( | ) | ( | ) | ||||||||||||||||
KB No.22 Special Purpose Acquisition Company 2 | ( | ) | ||||||||||||||||||
KB No.25 Special Purpose Acquisition Company | ( | ) | ( | ) | ||||||||||||||||
KB No.26 Special Purpose Acquisition Company 2 | ( | ) | ( | ) | ||||||||||||||||
KB No.27 Special Purpose Acquisition Company | ( | ) | ( | ) | ||||||||||||||||
KB No.28 Special Purpose Acquisition Company 2 | ||||||||||||||||||||
KB No.29 Special Purpose Acquisition Company | ||||||||||||||||||||
KB No.30 Special Purpose Acquisition Company | ||||||||||||||||||||
KB No.31 Special Purpose Acquisition Company | ||||||||||||||||||||
RAND Bio Science Co., Ltd. 2 | ||||||||||||||||||||
Food Factory Co., Ltd. | ||||||||||||||||||||
Big Dipper Co., Ltd. | ||||||||||||||||||||
Wyatt Co., Ltd. 2 | ||||||||||||||||||||
CellinCells Co., Ltd. 2 | ( | ) | ||||||||||||||||||
COSES GT Co., Ltd. 2 | ( | ) | ||||||||||||||||||
ASSEMBLE CORPORATION | ( | ) | ||||||||||||||||||
S&E Bio Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||
4N Inc. | ( | ) | ||||||||||||||||||
Contents First Inc. | ( | ) | ||||||||||||||||||
Newavel Co., Ltd. | ( | ) | ||||||||||||||||||
Pin Therapeutics Inc. | ( | ) | ||||||||||||||||||
Spark Biopharma Inc. | ( | ) | ( | ) | ||||||||||||||||
SuperNGine Co., Ltd. | ||||||||||||||||||||
Desilo Inc. | ||||||||||||||||||||
Turing Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||
TMAP Mobility Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||
KY Global Cell & Gene Private Equity Fund 2nd 2 | ( | ) | ( | ) | ||||||||||||||||
Nextrade Co., Ltd. | ( | ) | ||||||||||||||||||
ZIPDOC Inc. 2 | ( | ) | ||||||||||||||||||
TeamSparta Inc. 2 | ( | ) | ||||||||||||||||||
Chabot Mobility Co., Ltd. 2 | ||||||||||||||||||||
Wemade Connect Co., Ltd. | ( | ) | ||||||||||||||||||
Channel Corporation | ( | ) | ( | ) | ||||||||||||||||
Bitgoeul Cheomdan Green 1st Co., Ltd. | ||||||||||||||||||||
(In millions of Korean won) | 2024 | |||||||||||||||||||
Beginning | Borrowing | Repayment | Others 1 | Ending | ||||||||||||||||
KB-FT Green Growth 1st Technology Investment Association | ( | ) | ||||||||||||||||||
Bigwave Robotics Corp. | ( | ) | ||||||||||||||||||
3D Interactive Co., Ltd. | ||||||||||||||||||||
AIM FUTURE, Inc. | ( | ) | ||||||||||||||||||
New Daegu Busan Expressway Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||
Novorex Inc. | ( | ) | ||||||||||||||||||
Xenohelix Co., Ltd. | ( | ) | ||||||||||||||||||
ADP Holdings Co., Ltd. | ( | ) | ||||||||||||||||||
ADPGREEN | ( | ) | ||||||||||||||||||
Logpresso Inc. | ( | ) | ||||||||||||||||||
DYNE MEDICAL GROUP Inc. | ( | ) | ||||||||||||||||||
Onheal Co., Ltd. | ||||||||||||||||||||
TriOar Inc. | ( | ) | ||||||||||||||||||
Yeoulhyulgangho | ||||||||||||||||||||
SDT Inc. | ( | ) | ||||||||||||||||||
Allra Fintech Corp. | ( | ) | ||||||||||||||||||
Key management personnel | ||||||||||||||||||||
Key management personnel | ( | ) | ( | ) | ||||||||||||||||
1 | Transactions between related parties, such as settlements arising from operating activities and deposits, are expressed in net amount. |
2 | Excluded from the Group’s related party as of December 31, 2024. |
(In millions of Korean won) | 2025 | |||||||||||||||||||
Beginning | Borrowing | Repayment | Others 1 | Ending | ||||||||||||||||
Associates and joint ventures | ||||||||||||||||||||
Korea Credit Bureau Co., Ltd. | ₩ | ₩ | ₩ | ₩ | ( | ) | ₩ | |||||||||||||
Incheon Bridge Co., Ltd. | ( | ) | ||||||||||||||||||
Jungdo Co., Ltd. | ||||||||||||||||||||
Iwon Alloy Co., Ltd. | ( | ) | ||||||||||||||||||
Skydigital Inc. | ( | ) | ||||||||||||||||||
Aju Good Technology Venture Fund | ( | ) | ||||||||||||||||||
KB-KDBC Pre-IPO New Technology Business Investment Fund | ||||||||||||||||||||
WJ Private Equity Fund No.1 | ( | ) | ||||||||||||||||||
KB No.21 Special Purpose Acquisition Company 2 | ( | ) | ( | ) | ||||||||||||||||
KB No.25 Special Purpose Acquisition Company | ( | ) | ||||||||||||||||||
KB No.26 Special Purpose Acquisition Company 2 | ( | ) | ( | ) | ||||||||||||||||
KB No.27 Special Purpose Acquisition Company | ( | ) | ( | ) | ||||||||||||||||
KB No.28 Special Purpose Acquisition Company 2 | ( | ) | ||||||||||||||||||
KB No.29 Special Purpose Acquisition Company | ( | ) | ( | ) | ||||||||||||||||
KB No.30 Special Purpose Acquisition Company | ( | ) | ( | ) | ||||||||||||||||
KB No.31 Special Purpose Acquisition Company | ( | ) | ( | ) | ||||||||||||||||
KB No.32 Special Purpose Acquisition Company | ||||||||||||||||||||
KB No.33 Special Purpose Acquisition Company | ||||||||||||||||||||
RAND Bio Science Co., Ltd. 2 | ( | ) | ||||||||||||||||||
Food Factory Co., Ltd. | ( | ) | ||||||||||||||||||
Big Dipper Co., Ltd. | ( | ) | ||||||||||||||||||
Wyatt Co., Ltd. 2 | ( | ) | ||||||||||||||||||
CellinCells Co., Ltd. 2 | ( | ) | ||||||||||||||||||
ASSEMBLE CORPORATION | ||||||||||||||||||||
S&E Bio Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||
4N Inc. | ( | ) | ||||||||||||||||||
Contents First Inc. | ( | ) | ||||||||||||||||||
Newavel Co., Ltd. | ||||||||||||||||||||
Pin Therapeutics Inc. | ( | ) | ( | ) | ||||||||||||||||
Spark Biopharma Inc. | ( | ) | ( | ) | ||||||||||||||||
SuperNGine Co., Ltd. | ( | ) | ||||||||||||||||||
Desilo Inc. | ( | ) | ||||||||||||||||||
Turing Co., Ltd. | ||||||||||||||||||||
TMAP Mobility Co., Ltd. | ( | ) | ||||||||||||||||||
Nextrade Co., Ltd. | ( | ) | ( | ) | ||||||||||||||||
ZIPDOC Inc. 2 | ( | ) | ||||||||||||||||||
(In millions of Korean won) | 2025 | |||||||||||||||||||
Beginning | Borrowing | Repayment | Others 1 | Ending | ||||||||||||||||
TeamSparta Inc. 2 | ( | ) | ( | ) | ||||||||||||||||
Chabot Mobility Co., Ltd. 2 | ( | ) | ( | ) | ||||||||||||||||
Wemade Connect Co., Ltd. | ( | ) | ||||||||||||||||||
Channel Corporation | ( | ) | ||||||||||||||||||
Bitgoeul Cheomdan Green 1st Co., Ltd. | ||||||||||||||||||||
Bigwave Robotics Corp. | ( | ) | ||||||||||||||||||
3D Interactive Co., Ltd. | ( | ) | ||||||||||||||||||
AIM FUTURE, Inc. | ( | ) | ||||||||||||||||||
New Daegu Busan Expressway Co., Ltd. | ( | ) | ||||||||||||||||||
Novorex Inc. | ||||||||||||||||||||
Xenohelix Co., Ltd. | ( | ) | ||||||||||||||||||
ADP Holdings Co., Ltd. | ( | ) | ||||||||||||||||||
ADPGREEN | ( | ) | ( | ) | ||||||||||||||||
Logpresso Inc. | ( | ) | ( | ) | ||||||||||||||||
DYNE MEDICAL GROUP Inc. | ( | ) | ( | ) | ||||||||||||||||
Onheal Co., Ltd. | ( | ) | ||||||||||||||||||
TriOar Inc. | ( | ) | ||||||||||||||||||
Yeoulhyulgangho | ( | ) | ||||||||||||||||||
Allra Fintech Corp. | ( | ) | ( | ) | ||||||||||||||||
Koru Pharma Co., Ltd. | ( | ) | ||||||||||||||||||
Emocog Inc. | ( | ) | ||||||||||||||||||
WhaTap Laps Inc. | ||||||||||||||||||||
Aldaver | ( | ) | ||||||||||||||||||
Lemontree Inc. | ||||||||||||||||||||
enParticle Co., Ltd | ||||||||||||||||||||
ANTIGRAVITY | ||||||||||||||||||||
FineKB Private Equity Fund No.1 | ( | ) | ||||||||||||||||||
ByL | ( | ) | ||||||||||||||||||
eRoun & company Co., Ltd | ||||||||||||||||||||
VP Inc. | ||||||||||||||||||||
RUMIKEU Holdings Inc. | ||||||||||||||||||||
Key management personnel | ||||||||||||||||||||
Key management personnel | ( | ) | ( | ) | ||||||||||||||||
1 | Transactions between related parties, such as settlements arising from operating activities and deposits, are expressed in net amount. |
2 | Excluded from the Group’s related party as of December 31, 2025. |
(In millions of Korean won) |
2024 |
2025 |
||||||||||||||
Equity investment and others |
Withdrawal and others |
Equity investment and others |
Withdrawal and others |
|||||||||||||
|
Balhae Infrastructure Company
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
POSCO-KB Shipbuilding Fund
|
||||||||||||||||
|
KB-KDBC Pre-IPO New Technology Business Investment Fund
|
||||||||||||||||
|
KB-SJ Tourism Venture Fund
|
||||||||||||||||
|
Korea Credit Bureau Co., Ltd.
|
||||||||||||||||
|
KB-UTC Inno-Tech Venture Fund
|
||||||||||||||||
|
KB-Solidus Global Healthcare Fund
|
||||||||||||||||
|
KB-Stonebridge Secondary Private Equity Fund
|
||||||||||||||||
|
KB SPROTT Renewable Private Equity Fund No.1
|
||||||||||||||||
|
KB-NAU Special Situation Corporate Restructuring Private Equity Fund
|
||||||||||||||||
|
2020 KB Fintech Renaissance Fund
|
||||||||||||||||
|
KB Material and Parts No.1 PEF *
|
||||||||||||||||
|
KB-TS Technology Venture Private Equity Fund
|
||||||||||||||||
|
KB-Brain KOSDAQ Scale-up New Technology Business Investment Fund *
|
||||||||||||||||
|
Aju Good Technology Venture Fund
|
||||||||||||||||
|
G payment Joint Stock Company
|
||||||||||||||||
|
KB-KTB Technology Venture Fund
|
||||||||||||||||
|
KB-SOLIDUS Healthcare Investment Fund
|
||||||||||||||||
|
Paramark KB Fund No.1
|
||||||||||||||||
|
FineKB Private Equity Fund No.1
|
||||||||||||||||
|
FineKB Private Equity Fund No.2
|
||||||||||||||||
|
KB No.21 Special Purpose Acquisition Company *
|
||||||||||||||||
|
KB No.22 Special Purpose Acquisition Company *
|
||||||||||||||||
|
KB-SP Private Equity Fund IV *
|
||||||||||||||||
|
KB-BridgePole Venture Investment Fund *
|
||||||||||||||||
|
KB-Kyobo New Mobility Power Fund *
|
||||||||||||||||
|
JS Private Equity Fund No.3
|
||||||||||||||||
|
Star-Lord General Investors Private Real Estate Investment Company No.10
|
||||||||||||||||
|
KB Co-Investment Private Equity Fund No.1
|
||||||||||||||||
|
POSITIVE Sobujang Venture Fund No.1
|
||||||||||||||||
|
History 2022 Fintech Fund
|
||||||||||||||||
|
KB-NP Green ESG New Technology Venture Capital Fund
|
||||||||||||||||
|
KB-Badgers Future Mobility ESG Fund No.1
|
||||||||||||||||
|
Lakewood-AVES Fund No.1 *
|
||||||||||||||||
|
MW-Pyco NewWave New Technology Investment Fund 4th
|
||||||||||||||||
|
KB No.26 Special Purpose Acquisition Company *
|
||||||||||||||||
|
Bitgoeul Cheomdan Green 1st Co., Ltd.
|
||||||||||||||||
|
KB-SUSUNG 1st Investment Fund
|
||||||||||||||||
|
KB-SUSUNG 2nd Investment Fund
|
||||||||||||||||
|
Friend 55 New Technology Business Investment Fund *
|
||||||||||||||||
|
DSIP-Pharos Bioenergy Fund *
|
||||||||||||||||
(In millions of Korean won) |
2024 |
2025 |
||||||||||||||
Equity investment and others |
Withdrawal and others |
Equity investment and others |
Withdrawal and others |
|||||||||||||
|
Shinhan-Eco Venture Fund 2nd
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
2023 JB Newtech No.2 Fund
|
||||||||||||||||
|
U-KB Credit No.1 Private Equity
|
||||||||||||||||
|
KB No.28 Special Purpose Acquisition Company *
|
||||||||||||||||
|
Timefolio Athleisure Investment Fund
|
||||||||||||||||
|
COMPA Global Scale-Up Fund No.3
|
||||||||||||||||
|
AKK Robotech Valueup New Technology Investment Fund *
|
||||||||||||||||
|
YG MCE PROJECT NO.1 Fund
|
||||||||||||||||
|
KB No.29 Special Purpose Acquisition Company
|
||||||||||||||||
|
KB No.30 Special Purpose Acquisition Company
|
||||||||||||||||
|
KB No.31 Special Purpose Acquisition Company
|
||||||||||||||||
|
KB No.32 Special Purpose Acquisition Company
|
||||||||||||||||
|
KB No.33 Special Purpose Acquisition Company
|
||||||||||||||||
|
THE CHAEUL FUND NO.1 *
|
||||||||||||||||
|
IMM global Secondary 1-1 Equity Private Fund
|
||||||||||||||||
|
Elohim-Bilanx aerospace No.1 Fund
|
||||||||||||||||
|
KB-CJ Venture Fund 1st
|
||||||||||||||||
|
HI YG Win-win Fund No.2
|
||||||||||||||||
|
KB-VEP Contact Fund
|
||||||||||||||||
|
Reboot Private Equity Fund
|
||||||||||||||||
|
LIB Material Investment Fund
|
||||||||||||||||
|
NOVORSEC-SJG Consumer Secondary Fund *
|
||||||||||||||||
|
Allra Fintech Corp.
|
||||||||||||||||
|
KB Global Commerce Private Equity Investment Fund *
|
||||||||||||||||
|
KB-SBI Global Strategic Capital Fund
|
||||||||||||||||
|
KB-Cyrus Tourism Venture Fund
|
||||||||||||||||
|
IBKS Design Fund
|
||||||||||||||||
|
NICE DATA INTELLIGENCE VENTURE FUND *
|
||||||||||||||||
|
Pectus Hanhwa Fund 2 *
|
||||||||||||||||
|
KB-IMM New Star Real Estate Private Fund I
|
||||||||||||||||
|
KB Rejuvenation Fund
|
||||||||||||||||
|
VIG Private Equity Fund V-3
|
||||||||||||||||
|
KOENTEC Co. Ltd. *
|
||||||||||||||||
|
E&I Holdings *
|
||||||||||||||||
|
YG AI Industrial Automation Solutions FUND
|
||||||||||||||||
|
KB-Novus Genesis Private Equity Fund
|
||||||||||||||||
|
Semicolon Susong REITs Co., Ltd.
|
||||||||||||||||
|
KB-LB Middle Market Enterprises Innovation Private Equity Fund
|
||||||||||||||||
|
ATP TP VC Fund No.1
|
||||||||||||||||
|
AIM-KB-DOUBLE Connected Future Investment Fund
|
||||||||||||||||
|
KB-IMM New Star Real Estate Private Fund II
|
||||||||||||||||
|
K-1 23rd yeoksam Real Estate Investment Trust company Ltd.
|
||||||||||||||||
(In millions of Korean won) |
2024 |
2025 |
||||||||||||||
Equity investment and others |
Withdrawal and others |
Equity investment and others |
Withdrawal and others |
|||||||||||||
|
IMM Korea Beauty Co-Invest Private Equity Fund
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
KB-GVA Premier Mezzanine Investment Fund
|
||||||||||||||||
|
KB-ANDA Deep Tech Venture Fund
|
||||||||||||||||
|
KB a2z 2025 Fund
|
||||||||||||||||
|
DAILY Fountainhead Blind Private Equity Fund II
|
||||||||||||||||
|
Meritz-Hyundai Investment Real Estate Strategy No.1 Private Equity Fund
|
||||||||||||||||
|
Smart Korea KB Future9-Sejong Venture Fund
|
||||||||||||||||
| * |
|
(In millions of Korean won or in a US Dollar or the Indonesian Rupiah) |
December 31, 2024 |
December 31, 2025 |
||||||||
Associates and joint ventures |
||||||||||
|
Balhae Infrastructure Company
|
Purchase of securities | ₩ | ₩ | |||||||
| Loan commitments in Korean won | ||||||||||
|
Korea Credit Bureau Co., Ltd.
|
Unused lines of credit for credit card | |||||||||
|
Incheon Bridge Co., Ltd.
|
Loan commitments in Korean won | |||||||||
| Unused lines of credit for credit card | ||||||||||
|
TeamSparta Inc. *
|
Loan commitments in Korean won | |||||||||
| Unused lines of credit for credit card | ||||||||||
|
3D Interactive Co., Ltd.
|
Unused lines of credit for credit card | |||||||||
|
Food Factory Co., Ltd.
|
Unused lines of credit for credit card | |||||||||
|
CellinCells Co., Ltd. *
|
Unused lines of credit for credit card | |||||||||
|
RAND Bio Science Co., Ltd. *
|
Unused lines of credit for credit card | |||||||||
|
Big Dipper Co., Ltd.
|
Unused lines of credit for credit card | |||||||||
|
ASSEMBLE CORPORATION
|
Unused lines of credit for credit card | |||||||||
|
COSES GT Co., Ltd. *
|
Unused lines of credit for credit card | |||||||||
|
Spark Biopharma Inc.
|
Unused lines of credit for credit card | |||||||||
|
Newavel Co., Ltd.
|
Unused lines of credit for credit card | |||||||||
|
IMBiologics Corp.
|
Unused lines of credit for credit card | |||||||||
|
SuperNGine Co., Ltd.
|
Unused lines of credit for credit card | |||||||||
|
IGGYMOB Co., Ltd.
|
Unused lines of credit for credit card | |||||||||
|
Pin Therapeutics Inc.
|
Unused lines of credit for credit card | |||||||||
|
Grinergy Co., Ltd.
|
Unused lines of credit for credit card | |||||||||
|
S&E Bio Co., Ltd.
|
Unused lines of credit for credit card | |||||||||
|
Wemade Connect Co., Ltd.
|
Unused lines of credit for credit card | |||||||||
|
TMAP Mobility Co., Ltd.
|
Unused lines of credit for credit card | |||||||||
|
Contents First Inc.
|
Unused lines of credit for credit card | |||||||||
|
Allra Fintech Corp.
|
Unused lines of credit for credit card | |||||||||
|
Bigwave Robotics Corp.
|
Unused lines of credit for credit card | |||||||||
|
New Daegu Busan Expressway Co., Ltd.
|
Unused lines of credit for credit card | |||||||||
|
AIM FUTURE, Inc.
|
Unused lines of credit for credit card | |||||||||
|
Novorex Inc.
|
Unused lines of credit for credit card | |||||||||
|
Xenohelix Co., Ltd.
|
Unused lines of credit for credit card | |||||||||
|
ADPGREEN
|
Unused lines of credit for credit card | |||||||||
|
Logpresso Inc.
|
Unused lines of credit for credit card | |||||||||
|
DYNE MEDICAL GROUP Inc.
|
Unused lines of credit for credit card | |||||||||
|
TriOar Inc.
|
Unused lines of credit for credit card | |||||||||
|
KB-CJ Venture Fund 1st
|
Purchase of securities | |||||||||
|
KB-Stonebridge Secondary Private Equity Fund
|
Purchase of securities | |||||||||
|
KB-NAU Special Situation Corporate Restructuring Private Equity Fund
|
Purchase of securities | |||||||||
|
All Together Korea Fund No.2
|
Purchase of securities | |||||||||
|
KB-SOLIDUS Healthcare Investment Fund
|
Purchase of securities | |||||||||
|
KB Co-Investment Private Equity Fund No.1
|
Purchase of securities | |||||||||
|
KB-Badgers Future Mobility ESG Fund No.1
|
Purchase of securities | |||||||||
|
KB-NP Green ESG New Technology Venture Capital Fund
|
Purchase of securities | |||||||||
|
FineKB Private Equity Fund No.1
|
Purchase of securities | |||||||||
|
KB-Solidus Global Healthcare Fund
|
Commitments on loss absorption priority | |||||||||
|
Paramark KB Fund No.1
|
Purchase of securities | |||||||||
|
Smart Korea KB Future9-Sejong Venture Fund
|
Purchase of securities | |||||||||
|
Shinhan-Eco Venture Fund 2nd
|
Purchase of securities | |||||||||
|
U-KB Credit No.1 Private Equity
|
Purchase of securities | |||||||||
(In millions of Korean won or in a US Dollar or the Indonesian Rupiah) |
December 31, 2024 |
December 31, 2025 |
||||||||
Associates and joint ventures |
||||||||||
|
KB-Cyrus Tourism Venture Fund
|
Purchase of securities | ₩ | ₩ | |||||||
|
KB-SBI Global Strategic Capital Fund
|
Purchase of securities | |||||||||
|
KB-IMM New Star Real Estate Private Fund I
|
Purchase of securities | |||||||||
|
VIG Private Equity Fund V-3
|
Purchase of securities | |||||||||
|
KB-IMM New Star Real Estate Private Fund II
|
Purchase of securities | |||||||||
|
IMM global Secondary 1-1 Equity Private Fund
|
Purchase of securities | |||||||||
|
KB-LB Middle Market Enterprises Innovation Private Equity Fund
|
Purchase of securities | |||||||||
|
KB-ANDA Deep Tech Venture Fund
|
Purchase of securities | |||||||||
|
DAILY Fountainhead Blind Private Equity Fund II
|
Purchase of securities | |||||||||
|
Meritz-Hyundai Investment Real Estate Strategy No.1 Private Equity Fund
|
Purchase of securities | |||||||||
|
Nextrade Co., Ltd.
|
Unused lines of credit for credit card | |||||||||
|
Aldaver
|
Unused lines of credit for credit card | |||||||||
|
ANTIGRAVITY
|
Unused lines of credit for credit card | |||||||||
|
Lemontree Inc.
|
Unused lines of credit for credit card | |||||||||
| Loan commitments in Korean won | ||||||||||
|
WhaTap Laps Inc.
|
Unused lines of credit for credit card | |||||||||
| Loan commitments in Korean won | ||||||||||
|
VP Inc.
|
Unused lines of credit for credit card | |||||||||
|
RMGP Bio-Pharma Investment Fund, L.P.
|
Purchase of securities | USD | USD | |||||||
|
RMGP Bio-Pharma Investment, L.P.
|
Purchase of securities | USD | USD | |||||||
|
RMG-KB BP Management Ltd.
|
Purchase of securities | USD | USD | |||||||
|
RMG-KB BioAccess Fund L.P.
|
Purchase of securities | USD | USD | |||||||
|
Elev8-Capital Fund I
|
Purchase of securities | IDR | |
IDR | |
|||||
|
Ascent Global Fund III
|
Purchase of securities | USD | USD | |||||||
|
Key management personnel
|
||||||||||
|
Key management personnel
|
Loan commitments in Korean won | |||||||||
| * |
Excluded from the Group’s related party as of December 31, 2025.
|
(In millions of Korean won) |
2023 |
|||||||||||||||
Short-term employee benefits |
Post-employment benefits |
Share-based payments |
Total |
|||||||||||||
|
Registered directors (executive)
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
Registered directors (non-executive)
|
||||||||||||||||
|
Non-registered directors
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
(In millions of Korean won) |
2024 |
|||||||||||||||
Short-term employee benefits |
Post-employment benefits |
Share-based payments |
Total |
|||||||||||||
|
Registered directors (executive)
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
Registered directors (non-executive)
|
||||||||||||||||
|
Non-registered directors
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
(In millions of Korean won) |
2025 |
|||||||||||||||
Short-term employee benefits |
Post-employment benefits |
Share-based payments |
Total |
|||||||||||||
|
Registered directors (executive)
|
₩ | ₩ | ₩ | ₩ | ||||||||||||
|
Registered directors (non-executive)
|
||||||||||||||||
|
Non-registered directors
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| ₩ | ₩ | ₩ | ₩ | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
(In millions of Korean won) |
Assets held as collateral
|
December 31, 2024 |
December 31, 2025 |
|||||||
|
Key management personnel
|
Time deposits and others
|
₩ | ₩ | |||||||
|
Real estate
|
||||||||||
(In millions of Korean won) | December 31, 2024 | December 31, 2025 | ||||||
Assets | ||||||||
Cash and due from financial institutions | ₩ | ₩ | ||||||
Financial assets at fair value through profit or loss | ||||||||
Loans at amortized cost | ||||||||
Investments in subsidiaries * | ||||||||
Banking subsidiaries | ||||||||
Nonbanking subsidiaries. | ||||||||
Other assets | ||||||||
Total assets | ₩ | ₩ | ||||||
Liabilities and shareholders’ equity | ||||||||
Borrowings | ₩ | ₩ | ||||||
Debentures | ||||||||
Other liabilities | ||||||||
Shareholders’ equity | ||||||||
Total liabilities and shareholders’ equity | ₩ | ₩ | ||||||
| * | Investments in subsidiaries were accounted at cost method in accordance with IAS No.27. |
(In millions of Korean won) | 2023 | 2024 | 2025 | |||||||||
Income | ||||||||||||
Dividends from subsidiaries | ₩ | ₩ | ₩ | |||||||||
Interest from subsidiaries | ||||||||||||
Other income | ||||||||||||
Total income | ||||||||||||
Expense | ||||||||||||
Interest expense | ||||||||||||
Non-interest expense | ||||||||||||
Total expense | ||||||||||||
Profit before income tax expense | ||||||||||||
Income tax benefit | ( | ) | ( | ) | ( | ) | ||||||
Profit for the year | ||||||||||||
Other comprehensive gain(loss) for the year, net of tax | ( | ) | ( | ) | ( | ) | ||||||
Total comprehensive income for the year | ₩ | ₩ | ₩ | |||||||||
(In millions of Korean won) | 2023 | 2024 | 2025 | |||||||||
Operating activities | ||||||||||||
Net income | ₩ | ₩ | ₩ | |||||||||
Reconciliation of net income to net cash provided by operating activities: | ||||||||||||
Other operating activities, net | ( | ) | ||||||||||
Net cash inflow from operating activities | ||||||||||||
Investing activities | ||||||||||||
Net payments from (to) subsidiaries | ( | ) | ||||||||||
Other investing activities, net | ||||||||||||
Net cash outflow from investing activities | ||||||||||||
Financing activities | ||||||||||||
Net increase (decrease) in borrowings | ( | ) | ||||||||||
Increases in debentures | ||||||||||||
Repayments of debentures and lease liabilities | ( | ) | ( | ) | ( | ) | ||||||
Issuance of hybrid securities | ||||||||||||
Redemption of hybrid securities | ( | ) | ( | ) | ||||||||
Cash dividends paid | ( | ) | ( | ) | ( | ) | ||||||
Acquisition of treasury shares | ( | ) | ( | ) | ( | ) | ||||||
Other financing activities | ||||||||||||
Net cash inflow (outflow) from financing activities | ( | ) | ( | ) | ( | ) | ||||||
Net increase (decrease) in cash and cash equivalents | ( | ) | ||||||||||
Cash and cash equivalents as of January 1 | ||||||||||||
Cash and cash equivalents as of December 31 | ₩ | ₩ | ₩ | |||||||||